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Arsenic trioxide (As2O3) has been proven to induce clinical remission in patients with 
acute promyelocytic leukaemia without severe side effects. Previously, Du and Ho 
showed that arsenical compounds were able to induce cytotoxicity and apoptosis in 
both cisplatin (Cddp)-sensitive and -resistant ovarian cancer cells (Du and Ho, 2001). 
In the present study, the potential use of As2O3 for ovarian cancer treatment, its 
mechanisms of action, the factors responsible for As2O3 resistance in OVCAR-3 cells 
and the combined use of As2O3 with histone deacetylase inhibitors (HDACIs) were 
evaluated. It was found that As2O3 displayed a similar pattern of cytotoxic effect with 
paclitaxel against various Cddp-sensitive and resistant ovarian cancer cell lines. This 
further reinforced its potential usefulness for the treatment of platinum refractory 
disease, especially in patients who cannot tolerate paclitaxel therapy. Investigations into 
the effects of As2O3 confirmed apoptosis induction. In OVCAR-3 cells, apoptosis 
induction was a late event that was time and concentration-dependent. It was 
accompanied by cell cycle arrest at either the G2/M or S phase that was again 
concentration-dependent. Cell death induced by As2O3 was found to be caspase- and  
oxidative stress independent. It was accompanied by the dissipation of the 
mitochondrial membrane potential and the mitochondria to nucleus translocation of 
caspase-independent apoptosis inducing factor in a fraction of arsenic-treated cells. In 
addition, As2O3 treatment was associated with the down-regulation of Bclxl gene and 
protein levels. Ectopic expression of Bclxl in OVCAR-3 cells not only completely 
blocked apoptosis but conferred a greater protection against cell death beyond 




apoptosis induction. This suggests that multiple complex modes of cell death processes 
might be involved in As2O3-mediated ovarian cancer cell death.    
Intracellular glutathione (GSH) levels were found to be correlated to the arsenic 
sensitivities of the ovarian cancer cell lines studied. Modulation of intracellular GSH 
levels using buthionine sulfoximine (BSO) resulted in a reactive oxygen species (ROS) 
independent augmentation of arsenic-induced cell death. It also caused a net increase in 
cellular arsenic levels, suggesting that transporter mediated efflux of arsenic-GSH 
conjugate may play a role in determining arsenic sensitivity of ovarian carcinoma cells. 
In this study, physiological level of ascorbic acid (AA), another reported GSH 
modulator, was unable to modulate the intracellular GSH levels of ovarian tumour 
cells. Likewise, pharmacological levels of AA did not bring about GSH reduction but 
increased arsenic-induced cell kill in part through ROS. 
  
Microarray analysis of gene expression patterns of parental OVCAR-3 cells after acute 
arsenic treatment further revealed the novel role of endoplasmic recticulum (ER) stress 
in arsenic-induced cell death. Accompanying the induction of ER stress, parental 
OVCAR-3 cells mounted a survival response to increase intracellular GSH levels. This 
formed another rationale with which BSO was able to effectively enhanced arsenic-
induced cell kill. It further revealed the existence of a complex crosstalk between the 
mitochondria and ER in response to acute As2O3 exposure. In arsenic-resistant 
OVCAR-3 (OVCAR-3/AsR) cells, gene expression analysis showed the involvement of 
multiple factors in mediating As2O3 chemoresistance. Of particular importance was the 




increased in IL1A signalling that could in turn modulate the gene expression of other 
genes to promote the continual growth and survival of OVCAR-3/AsR cells.  
 
Lastly, the combined use of HDACIs with As2O3 antagonized the cytotoxic effects of 
As2O3 while combined use of HDACIs with Cddp were able to enhance the apoptotic 
cell kill of the Cddp in Cddp-resistant ovarian cancer cells, OVCAR-3 and SKOV-3, in 
a sequence dependent manner. Overall, these results showed that in addition to As2O3, 
Cddp and HDACIs drug combination can be another novel way of overcoming 
platinum chemoresistance in ovarian carcinoma.  
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1.1 General Concepts of Cell Death Processes in Cancer Biology   
 
1.1.1 Cellular Homeostasis and Overview of Cell Death Processes 
 
Cells are fundamental units of life. Within the human body, some types of cells are 
capable of reproducing in response to the needs of the environment. For example, the 
bone marrow increases its production of oxygen-carrying red blood cells seven-fold or 
greater in response to bleeding or high altitude (Lodish et al., 2000). This process of 
cell reproduction or division is highly regulated under normal physiological conditions 
and is responsive to the needs of the body. In concordance with cellular replication, 
active cell death occurs constantly within complex multicellular organisms whereby 
scattered cells are subtly removed from the midst of living tissue without compromising 
overall tissue architecture and function (Jacobson et al., 1997; Baehrecke, 2002). It is a 
critical process and is required for proper development in areas such as sculpting of 
anatomical structures and organs, deletion of superfluous structures, regulation of cell 
numbers, elimination of abnormal cells and cell differentiation without organelles 
(Jacobson et al., 1997; Baehrecke, 2002).  
 
A delicate equilibrium exists between cellular replication and death which is essential 
and critical to normal development. This is the essence of cellular homeostasis of all 
tissues within multicellular organisms. A disruption of this balance has dire 
consequences and is the root of the pathobiology of numerous diseases including 
neurodegenerative disorders (Martinou, 1995), autoimmune diseases (Ameison et al., 
1995) and cancer (Bursch et al., 1992; Thompson; 1995, Nicholson, 1996; Fleisher, 
1997) (Figure 1-1).  
 




















Figure 1-1 Maintenance of cellular homeostasis 
(Adapted and modified from Thomadaki and Scorilas, 2006) 
 
Our knowledge of cell death processes has progressed considerably over the years. 
Along with this, different ways of grouping the various cell death processes have been 
devised and used by researchers. One method of classification is derived based on the 
mechanisms of mammalian cell death whereby cell demise is generally divided into 
programmed cell death (PCD) or accidental necrosis. PCD is now accepted as death 
that is reliant on signals or activities within the dying cell (Lockshin and Zakeri, 2001). 
Based on this model, PCD can be further classified into apoptosis, autophagy 
(Schweichel and Merker, 1973; Clarke, 1990), paraptosis (Sperandio et al., 2000), 
mitotic catastrophe (King and Cidlowski, 1995) and slow cell death (Blagosklonny, 
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  Figure 1-2 Classification of cell death based on mechanisms of cell death 
(Adapted from Broker et al., 2005) 
 
Another approach of classifying cell death relies on a more descriptive model whereby 
cell death is divided into four subclasses, according to their nuclear morphology during 
death (Broker et al., 2005). These four patterns of death are apoptosis, apoptosis-like 






















Figure 1-3 Classification of cell death based on nuclear morphology of the dying cell 
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In the latter model, apoptosis is delineated by stereotypical morphological changes 
evident by nuclear chromatin condensation into compact, simple globular or crescent-
shaped figures. Apoptosis-like PCD on the other hand is used to describe forms of PCD 
with chromatin condensation that is geometrically more complex and irregular shapes 
but are less compact or complete than in apoptosis (Stage I chromatin condensation) 
(Jaattela and Tschopp, 2003; Broker et al., 2005). Necrosis-like PCD such as autophagy 
and aborted apoptosis occur in the absence of chromatin condensation or is at best 
observed as clustering of chromatin into loose speckles (Jaattela and Tschopp, 2003;  
Broker et al., 2005). Accidental necrosis has been characterized by rapid plasma 
membrane lysis and organelle swelling and forms the conceptual counterpart of PCD 
(Jaattela and Tschopp, 2003; Broker et al., 2005). Regardless of the different 
nomenclature of the various cell death programs, it is now known that mammalian cell 
death is a highly sophisticated process involving dynamic cellular signalling. The 
different cell death pathways do not occur in isolation and can be concurrently 
exploited within a dying cell depending on the death stimuli.     
 
1.1.2 Definition, Morphological and Biochemical Characterization of Apoptosis, 
Autophagy and Necrosis  
 
Apoptosis or suicidal cell death is a molecularly regulated and genetically determined 
cellular mechanism that is complementary to cell proliferation. The pattern of events in 
apoptosis is highly regulated, proceeds in an orderly manner and is intrinsic to all cell 
types (Thompson, 1995; Fleisher, 1997; Staunton and Gaffney, 1998).  It was first 
described by Kerr and colleagues more than 30 years ago (Kerr et al., 1972) and is 
characterized by a series of well-defined morphological changes. These are cytoplasmic 




shrinkage, aggregation of compacted chromatin to the wall of the nuclear membrane 
and nuclear fragmentation with dispersion throughout the cytoplasm. Other changes 
that occur include the development of bubble-like blebs on the surface of cells, 
exposure of phospholipid phosphatidylserine (PS) on the outer surface of the plasma 
membrane, loss of microvilli and gap junctions as well as the breakdown of the 
mitochrondria with the release of cytochrome c in the final stages of apoptosis 
(Schwartz and Osborne, 1993; Fleisher, 1997; Lincz, 1998; Hacker, 2000; Kanduc et 
al., 2002). The cellular remnants are subsequently heterophagocytosed by phagocytes 
or neighboring cells and are removed by their lysosomes (Gozuacik and Kimchi, 2004). 
Cellular components are thus not released into the circulation and are therefore not 
available to elicit immune responses. 
 
In animals, autophagy has been a recently described form of non-apoptotic PCD. It 
occurs without chromatin condensation and is distinguished by the formation of 
multiple double-membrane cytoplasmic vacuoles or autophagosomes from 
encapsulation of bulk cytoplasm or cell organelles such as the mitochondria and 
endoplasmic reticulum (ER) (Gozuacik and Kimchi, 2004; Gozuacik and Kimchi, 
2007). The contents of the autophagosomes are subsequently destroyed by the 
lysosomal hydrolases after fusion of the autophagosomes with lysosomes within the 
same cell (Gozuacik and Kimchi, 2004; Gozuacik and Kimchi, 2007). Conditions of 
starvation such as deficiency in amino acids, hypoxia and high temperatures have been 
reported to trigger autophagy (Codogno and Meijer, 2005; Levine and Yuan, 2005). By 
undergoing this process of partial digestion, autophagy serves to maintain cell viability 
and prolong cell survival for short period of time under these conditions. 




Necrosis or cell death by injury is a non-apoptotic or non-autophagic form of cell death. 
It is a more chaotic way of cell death as a result of extracellular factors. It is a passive 
process that is not regulated. The mechanism of necrosis involves the generalized 
swelling of cells and their organelles with limited or no chromatin condensation. This is 
followed by disruption of the plasma membrane, thereby causing the release of 
intracellular components, subsequently leading to tissue inflammation and phagocytosis 
(Schwartz and Osborne, 1993; Lincz, 1998; Hacker, 2000; Kanduc et al., 2002). Table 
1-1 illustrates a summary of the biochemical and morphological differences between 





















Table 1-1 Biochemical differences between apoptosis and necrosis 
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1.1.3 Molecular Regulation of Apoptotic Cell Death 
  
In recent years, extensive research has revealed some of the pathways of apoptosis. 
Apoptosis is known to be divided into the four phases of initiation, commitment or 
decision, execution and postmortem (Figure 1-4) (Vaux and Strasser, 1996; Au et al., 
1997; Staunton and Gaffney, 1998). Initiation entails the receipt of death signals by 
cells. These signals can be triggered by a variety of intrinsic and extrinsic factors such 
as cell contact, cytokines, chemotherapeutic agents, viruses, radiation, free radicals, 
oncogenes, cytolytic T cells, ethanol, glucocorticoids, oxidants and agents that alter 
calcium homeostasis (Thompson 1995; Fleisher, 1997). Following this, the 
commitment or decision phase occurs whereby an irreversible commitment to death has 
been made and apoptotic signals are detected and passed on to downstream effectors 
such as nuclear and cytoplasmic target enzymes. The signalling molecules involved in 
this phase differ depending on the triggering stimulus. In the third stage or execution 
phase, the cell has arrived at the stage of no return where multiple cellular targets are 
acted upon by a family of cysteine proteases called the caspases, endonucleases and 
their positive and negative regulators, resulting in the destruction of the cell (Vaux and 
Strasser, 1996; Au et al., 1997). Following these, the apoptotic cells are phagocytosed 
and digested in the postmortem stage without causing damage to the neighbouring cells 







































Figure 1-4 Different stages of apoptosis 
(Adapted from Vaux and Strasser, 1996) 
Although a varied array of signals can induce apoptosis in various cell types, the final 
pathway of apoptotic cell death (commitment and execution phases) has been reported 
to be highly conserved from the nematode Caenorhabditis elegans to humans and is 
regulated by a number of evolutionally conserved genes (Thompson, 1995; Au et al., 
1997). At least three gene families including interleukin 1-β-converting enzyme (ICE)-
like proteases, Bcl2 family and the tumour suppressor gene p53, play important roles in 
regulating the apoptotic process.  
 
Caspases or ICE-like proteases are a family of cysteine proteases that cleave their 





INITIATION COMMITMENT   EXECUTION 






























apoptotic process. In mammals, at least fourteen members of the caspase family have 
been identified (Nicholson, 1999). Within most cells, caspases are synthesized as 
inactive  proenzymes. Each proenzyme is made up of a N-terminal prodomain followed 
by a region that contains both a small and large subunit with the catalytic domain. Upon 
receiving an apoptotic signal, the proenzymes are firstly proteolytically cleaved at 
specific aspartate residues between the two domains. This is followed by 
heterodimerization of the large and small subunits. Afterward, two heterodimers 
associate to form an active tetramer containing two catalytic sites (Nicholson, 1999; 
Kaufmann and Hengartner, 2001).  
 
In general these enzymes can be subdivided in three different groups namely, group I 
(WEHDases), group II (DExDase) and group III ([IVL]EXDases) based on their 
tetrapeptide recognition sequence with the exception of caspase 12 and 14 (Nicholson, 
1999; Strasser et al., 2000) (Figure 1-5). Apart from WHDases (caspase 1, 4, 5, 11, 13) 
that are involved in cytokine processing and inflammation, at least seven caspases 
(caspases 2, 3, 6, 7, 8, 9, 10) participate in cell death. The caspases that are involved in 
apoptotic signaling and execution can be further classified into initiator caspases 
(caspase 2, 8, 9, 10) and effector caspases (caspase 3, 6, 7).  Initiator caspases are 
caspases containing a long N-terminal prodomain. The long prodomain consists of 
specific protein-protein interaction motifs such as caspase recruitment domain (CARD) 
or a pair of death effector domains (DEDs) that binds similar motifs in adapter 
molecules (Strasser et al., 2000; Kumar, 2007). Upon recruitment by these adapter 
molecules, the procaspases undergo autocatalysis, thereby leading to caspase activation 
(Strasser et al., 2000; Kumar, 2007). 
 





























Figure 1-5 Nomenclature and substrate specificity of various mammalian caspases 
(Adapted from Strasser et al., 2000) 
 
On the other hand, the effector caspases lack a long N-terminal prodomain and are 
unable to self activate. Their procaspases are activated upon cleavage by activated 
initiator caspases (Strasser et al., 2000; Kumar, 2007). Once activated, the effector 
caspases proteolytically cleave various cellular targets including DNA and proteins 
involved in cell structure, signalling, cell cycle control and DNA repair (Strasser et al., 
2000; Kumar, 2007). For example, cleavage of the cytoplasmic inhibitory subunit of 
caspase-activated DNase (CAD) by caspase 3 release results in its activation, allowing 
its subsequent entry into the nucleus to catalyze DNA degradation into 
oligonucleosomal fragments. Cleavage of structural proteins such as fodrin (Martin et 
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al., 1995; Janicke et al., 1998) and gelsolin (Kothakota et al., 1997; Kamada et al., 
1998) leads to loss of the overall cell shape and membrane blebbing. 
 
Caspases can be activated by two separate pathways through either the extrinsic or 
intrinsic routes (Figure 1-6). The extrinsic pathway is initiated by the ligation of 
transmembrane death receptors (CD95, TNF receptor and TRAIL receptors) to activate 
membrane-proximal activator caspases 8 and 10 that in turn cleave and activate effector 
caspases 3 and 7. This pathway is regulated by c-FLIP through its inhibition of 
activator caspases and inhibitor of apoptosis proteins (IAPs) that act on both the 
activator and effector caspases (Thompson, 1995; Au et al., 1997; Nunez et al., 1998; 
Roy and Nicholson, 2000). The intrinsic pathway, which can be activated by cytotoxic 
insults, direct DNA damage, hypoxia and oncoproteins, proceeds via the loss of the 
mitochondrial membrane potential (ΔΨ) and mitochondria dysfunction. This could in 
turn trigger the opening of the mitochondrial permeability transition pore (PTP), 
thereby increasing the permeability of certain ions across the mitochondrial membrane, 
resulting in mitochondrial swelling and rupture of the mitochondrial outer membrane. 
The disruption of the mitochrondria membrane leads to the release of mitochrondria 
proteins such as Smac/DIABLO and cytochrome c. Cytochrome c complexes with 
apoptosis activating factor-1 (Apaf-1) to activate the activator caspase in this pathway, 
caspase 9, which acts on other downstream effector caspases. The permeation of the 
mitochrondria membrane is in turn regulated by the opposing effects of members of the 
Bcl2 family (Thompson, 1995; Au et al., 1997; Nunez et al., 1998; Roy and Nicholson, 
2000).    
 
 






































Figure 1-6 Extrinsic and intrinsic pathways of caspase activation 
(Adapted from Roy and Nicholson, 2000) 
 
The Bcl2 family represents a unique class of proto-oncogene homologous apoptosis 
regulators. Its founding member, Bcl2 was originally used to describe the product of 
t(14,18) translocation in follicular non-Hodgkin’s lymphoma (Tsujimoto et al., 1984). 
It is a 25 kDa oncoprotein which is predominantly localized to the mitochrondria. To 
date at least twenty members of the family have been identified within mammalian 



























Bcl2-homology domains or BH domains (BH1-BH4) (Adams and Cory, 1998; Cory  
and Adams, 2002; Thomadaki and Scorilas, 2006). These domains correspond to an α - 
helical configuration and are necessary for the activities and interaction with other 
proteins (Adams and Cory, 1998; Cory and Adams, 2002; Thomadaki and Scorilas, 
2006). In addition, a hydrophobic C terminal domain (HCD) also known as the 
transmembrane domain (TM) can be found in some members. This domain is 
postulated to be required for interaction of these proteins with lipid membranes (Figure 













Figure 1-7 Apoptotic and antiapoptotic members of the Bcl2 family proteins 
(Adapted from Adams and Cory, 2002) 
 
 
Members of the Bcl2 family either promote or prevent apoptosis (Figure 1-7) (Adams 
and Cory, 1998; Cory and Adams, 2002). The antiapoptotic Bcl2 and Bclxl contain all 
four BH domains while other antiapoptotic members have at least BH1 and BH2 
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domains. These members are capable of inhibiting apoptotic signals triggered by 
numerous insults such as gamma- and UV-irradiation, cytokine withdrawal, 
dexamethasone and some cytotoxic drugs, thus promoting tumour genesis by 
preventing cell death (Ning and Knox, 1999; Pourzand et al., 1997; Baffy et al., 1993; 
Gazitt et al., 1998; Haarman et al., 1999). Bcl2 and several antiapoptotic proteins 
associate with the mitochondrial outer membrane, the ER and nuclear envelope thereby 
maintaining the integrity of these cellular organelles.  They function to stabilize the 
mitochondrial membrane and inhibit the release of cytochrome c and its subsequent 
binding to Apaf-1 (Adams and Cory, 1998; Cory and Adams, 2002; Thomadaki and 
Scorilas, 2006). It has also been reported that the BH4 domain of Bcl2 and Bclxl can 
directly bind to the C terminal portion of Apaf-1 leading to a complex formation that 
prevents the activation of caspase 9 (Huang et al., 1997; Hu et al., 1998; Pan et al., 
1998). More recently, evidence suggest that antiapoptotic members such as Bcl2 and 
Bclxl play a role in regulating caspase-independent cell death through blocking the 
mitochondrial release of apoptosis inducing factor (AIF) (Susin et al., 1996; Otera et 
al., 2005). 
 
For the proapoptotic members, they can be further divided into either Bax/Bak-like 
multidomain containing proteins which resemble Bcl2 closely or short BH3 domain-
only killers that are structurally diverse (Adams and Cory, 1998; Cory and Adams, 
2002).  Bax/Bak-like proteins are important downstream factors within the apoptotic 
signalling cascade at the level of mitochondria whereas BH3-only proteins are cell 
death signal sensors and direct antagonists of the prosurvival proteins. They are 
responsible for transducing death signals from the cytosol to the mitochondria and 
subsequent activation of multidomain proapoptotic members such as Bax and Bak 




(Adams and Cory, 1998; Cory and Adams, 2002). Under normal circumstances, these 
proteins are contained by numerous mechanisms such as sequestration onto the 
cytoskeleton or binding with scaffold proteins (Adams and Cory, 1998; Cory and 
Adams, 2002).  
 
Within this family, the proapoptotic and antiapoptotic members can form homo- or 
hetero-dimers with each other (Oltvai et al., 1993; Yang et al., 1995). This association 
is brought about by the dimerization of the BH3-only domain with the hydrophobic 
cleft formed by BH1, BH2 and BH3 domains containing antiapoptotic members. Due to 
this neutralizing competition between these proteins, the relative concentrations of 
proapoptotic and antiapoptotic Bcl2 family members are thus thought to be an important 
factor arbitrating the life-or-death of a cell (Tsujimoto, 1998). 
 
Bcl2 family members are transcriptionally or postranslationally regulated by cytokines 
(Moreb and Schweder, 1997).  In interleukin-3 treated haematopoetic cells, Bad is 
phosphorylated and the product is sequestered in the cytosol by 14-3-3 proteins, 
therefore preventing its inhibition of Bclxl (Datta et al., 1997). For antiapoptotic 
members, phosphorylation may both enhance and suppress activity. A known region 
for phosphorylation and activity-regulation is within the nonconserved flexible loop in 
Bcl2 and Bclxl. Loop-deletion mutants of these proteins have shown an increased 
antiapoptotic function. In contrast, Bcl2 may be inactivated by phosphorylation of 
several loop sites (Chang et al., 1997; Basu and Haldar, 1998).  
 
Among the death-survival signal regulated control of Bcl2 family members, the most 
studied is the induction of Bax as part of cellular DNA damage reaction mediated by 




p53 (Miyashita and Reed, 1995; Han et al., 1996). The p53 DNA binding sequence has 
been found in the Bax gene promoter suggesting that Bax may be part of p53-
dependent apoptosis in some instances (Miyashita and Reed, 1995; Han et al., 1996).  
In addition, overexpression of the p53 protein or the induction of the p53 gene by 
DNA-damaging agents has been reported to down-regulate the expression of Bcl2 and 
up-regulate the IAPs (Bartke et al., 2001; Ryan et al., 2001; Hoffman et al., 2002).  
 
The p53 is a tumour suppressor protein that plays a critical role in inhibiting cancer 
formation. It acts as the cellular gatekeeper for cell cycle regulation and apoptosis. 
Within a normal cell, the p53 network is typically not activated and non-functional. But 
upon DNA damage and when triggered by other signals, cellular p53 content is 
induced, thereby activating cell cycle arrest and/or apoptosis. By doing so, p53 prevents 
the replication of the damaged DNA and hence eliminates the damaged cells (Levine, 
1997). As such, cells defective of functional wild-type p53 continue to proliferate, 
resulting in tumour formation (Levine, 1997).   
 
The majority of p53 function occurs through its role as a sequence-specific nuclear 
transcription factor. It binds to specific consensus sites within cellular DNA and affects 
the transcription of a number of genes (El-Deiry, 1998). This is achieved either through 
transcriptional activation (Murphy et al., 1999) or by modulating other protein 
activities by direct binding (Guimaraes and Hainaut, 2002). p53 transcriptionally 
activates both the CD95 and TRAIL receptor 2, thus sensitizing cells to the intrinsic 
pathway of apoptosis (El-Deiry, 1998; Gottlieb and Oren, 1998). p53 can also 
transcriptionally activate PTEN, Apaf-1 and genes that lead to increase in reactive 
oxygen species (ROS) which in turn transactivate other genes that may contribute to 




apoptosis (Hwang et al., 2001; Moroni et al., 2001; Stambolic et al., 2001). By 
affecting these genes that mediate DNA damage repair, growth arrest and apoptosis, 
p53 effectively keeps cell growth and proliferation in check. 
 
The cancer-related genes mentioned above are closely associated with and are often 
mutated in malignancies. For example, the p53 tumour suppressor gene has been 
reported to be mutated in 50% of all tumours (Levine et al., 1991; Carson, 1995) while 
Bcl2 expression is often increased in tumours displaying a more malignant phenotype 
(Herbst and Frankel, 2004). More importantly, these changes have been associated with 
resistant to apoptosis and thus poor response to treatment with majority of 
chemotherapeutic agents (Lowe et al., 1993). The understanding of the role of these 
important regulators of apoptotic cell death and ways in which they are dysregulated 
within tumour cells is therefore critical and aids in the identification of novel 
therapeutic agents that can be used to combat oncogenic cell growth.            
 
1.1.4 Death Programs Beyond Caspases: Caspase-Independent Cell Death  
 
Current research supports the idea of plasticity within cellular death programming, 
implying that caspase activation is not the sole determinant of life and death decisions 
in PCD (Vercammen et al., 1998; Chautan et al., 1999; Yuan et al., 2003; Levine and 
Klionsky, 2004; Golstein and Kroemer, 2005). Increasing evidence promulgates the 
existence of alternative forms of cell death that are caspase-independent. The first 
indication of such cell death pathways was demonstrated by Xiang et al (Xiang et al., 
1996). In this landmark paper, inhibition of caspase activities in Jurkat cells did not 
inhibit Bax-induced cell death but merely changed the apoptotic morphology of the 
dying cells (Xiang et al., 1996). Following this, more reports have confirmed that PCD 




can be executed in the complete absence of caspases or when they are inhibited (Borner 
and Monney, 1999; Kitanaka and Kuchino, 1999; Nylandsted et al., 2000, Joza et al., 
2001; Carter et al., 2003).  
 
Caspase-independent mode of PCD can take the form of apoptotic-like PCD whereby 
cellular changes seen are similar to the classical features witnessed in apoptosis. This 
includes externalisation of PS, loss of mitochondrial membrane potential, condensation 
of chromatin and internucleosomal DNA degradation (Leist and Jaattela, 2001). 
Alternatively, they can display necrotic-like PCD with features such as intact nuclei, 
vacuolation of the cytoplasm and mitochondrial swelling (Leist and Jaattela, 2001). 
Such cell death programs might have evolved to complement and fulfill the same 
purpose as classical apoptosis, ensuring a safe and non-inflammatory removal of dead 
cells (Leist and Jaattela, 2001). Currently, increasing number of model systems have 
been reported to exhibit these types of caspase-independent PCD (Table 1-2). Such 
programs have been found to be getting more apparent in cancer cells as they often 















Table 1-2 Caspase-independent cell death triggered by cytotoxic agents 
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Reference 
Camptothecin Hepatocytes Cathepsin D Roberts et al., 1999 
 
Cladribine Human leukaemic 
cells 
AIF Marzo et al., 2001; 
Perez-Galan et al., 
2002 
 



















et al., 2002 
 
Lim et al., 2004 
















Ahn et al., 2004 
 
Arsenic trioxide Myeloma cells 
 
 











Michel et al., 2003 










Cathepsin D, AIF 
Gallego et al., 2004 
 
Johansson et al., 2003 
 
Bidere et al., 2003 
Flavopiridol Glioma cells 
 
AIF Alonso et al., 2003 
Vitamin D Breast cancer cells Calpains Mathiasen et al., 
1999; Mathiasen et 
al., 2002 
Quinolone antibiotics Several human and 
mice cells 





Boya et al., 2003 
 




As with apoptosis, caspase-independent cell death programs can be activated by either 
death receptors or by mitochondrial alterations (Leist and Jaattela, 2001). These 
programs are subsequently executed by non-caspase proteolytic enzymes such as 
cathepsins, calpains and other serine proteases (Leist and Jaattela, 2001). Several 
members of the tumour necrosis factor receptor (TNFR) superfamily including Fas and 
TNFR1 have been reported to efficiently initiate caspase-independent PCD (Leist and 
Jaattela, 2001). They include both caspase-independent apoptotic-like PCD and 
caspase-independent necrotic-like PCD.     
 
An example of caspase-independent apoptotic cell death mediated by the death 
receptors include tumour necrosis factor alpha (TNFα)-induced cell death mediated by 
cathepsin D following activation of TNFR1 (Foghsgaard et al., 2001). In addition, two 
different groups of researchers reported the recruitment of Daxx, a nuclear protein, to 
the Fas receptor following Fas activation. (Charette et al., 2000; Ko et al., 2001). This 
triggers the subsequent activation of apoptosis-stimulating kinase (ASK1) and Jun 
amino-terminal kinases (JNKs) (Charette et al., 2000; Ko et al., 2001). This pathway 
was believed to be caspase-independent as ASK1 possessed caspase-independent 
kinase activity which was activated after interaction with Daxx (Charette et al., 2001). 
However, further studies by other groups cast a doubt on this Daxx-ASK1-JNK 
pathway as it was not inhibited by pan-caspase inhibitors in many cells (Charette et al., 
2000). Lately, it has been reported that TNFα triggered apoptosis in fibroblasts requires 
ROS and involves ASK1 signalling (Tobiume et al., 2001). The requirement of 
caspases for this TNFR1-ROS-ASK1 pathway remains to be determined. For the 
necrotic-like PDC induced by death receptors, the Fas associated death domain protein 
(FADD), the kinase activity of the receptor-interacting protein (RIP) and generation of 




ROS have been reported to be involved (Vercammen et al., 1998; Holler et al., 2000; 
Matsumura et al., 2000).  
 
In addition to the death receptor-mediated caspase-independent cell death, emerging 
data have shown that mitochondrial dysfunction can lead to a form of necrotic-like 
PCD without the requirement for caspase activation. In L929 and WEHI 164 clone 13 
mouse fibrosarcoma cells, mitochondria derived ROS triggers TNFα-induced necrosis-
like PCD that can be inhibited by various antioxidants (Schulze-Osthoff et al., 1992). 
 
From another perspective, various cytotoxic insults can cause caspase-independent cell 
death via the release of AIF from the mitochondria intermembranous space (Susin et 
al., 1999; Kroemer and Reed, 2000; Joza et al., 2001). AIF is an evolutionarily 
conserved mitochondrial flavoprotein which translocates to the nuclei after being 
released from the mitochondria. It results in the formation of large-scale DNA 
fragmentation of more than 50 kilobase pairs in a caspase-independent manner (Susin 
et al., 1999; Kroemer and Reed, 2000; Joza et al., 2001). The release of these 
mitochondria-derived AIF could in turn be prevented by the overexpression of Bcl2 or 
Bclxl (Otera et al., 2005; Kluck et al., 1997; Finucane et al., 1999). Apart from AIF, 
the mitochondria also harbour other caspase-independent cell death effectors including 























Figure 1-8 Caspase-independent pathways associated with mitochondrial dysfunction 
(Adapted from Grimm, 2003) 
 
1.1.5 PCD: Significance in Cancer Development and Treatment  
 
As mentioned earlier, triggering PCD within multicellular organisms is a process for 
eliminating unwanted, transformed or damaged cells. PCD or other types of active cell 
death play a major role in various stages of carcinogenesis. When PCD is dysregulated, 
for example in the presence of cellular defects in apoptotic regulation, cells that are 
normally destined to die, continue to survive. Together with an enhanced cellular 
proliferation, they contribute to the development and progression of various cancers 
(Jacobson et al., 1997).  
 
On the contrary, PCD is also a key variable in cancer therapy whereby the usual 
approach in management is either surgical debulkment of the tumour or induction of 
cell death in neoplastic cells by radiation, toxic chemicals, antibodies or a combination 













carcinogenic chemicals that are capable of inhibiting growth and inducing various 
modes of cell death (Newlands, 1978; Neilan, 1983). When they are utilized in an 
appropriate manner, active cell death can be induced, by internal and exogenous 
signals, in preneoplastic, neoplastic and malignant cells while minimizing toxicity to 
normal cells. This can result in a reversal of tumour initiation and promotion and may 
even lead to tumour regression (Newlands, 1978; Neilan, 1983).  
 
Defects of the PCD machinery are a major obstacle to successful cytotoxic 
chemotherapy. Many cancer cells have been reported to carry mutations in the classical 
apoptotic genes such as p53, Bcl2 family proteins or those affecting caspase signalling, 
thus rendering treatment with traditional chemotherapeutic agents ineffective (Hollstein 
et al., 1994; McCurrach et al., 1997; Kondo et al., 2000; Devarajan et al., 2002; Lowe, 
1995; Soengas and Lowe, 2003). Under such situations, the triggering of alternative 
caspase-independent death pathways could therefore be an alternative approach to 
eradicate these tumour cells. Thus, a better understanding of the relationship between 
PCD and cancer developmental therapies and treatment could possibly create new 
conceptual paradigms for future cancer treatment. 
 
 
1.2  Cellular Antioxidant System and Glutathione 
 
1.2.1 Cellular Redox Regulation and Chemotherapy 
  
Within our aerobic environment, oxidants are universally present. In mammalian cells, 
oxidants in the form of chemically active ROS are by-products which are continuously 
generated during normal cellular metabolism within the cellular mitochondria (Richter 
et al., 1995; Halliwell and Gutteridge, 2003). They include the superoxide anion radical 
(O2•-) and the hydroxyl radical (•OH). The overproduction of ROS can subject 




mammalian cells to undue oxidative stress and cause potential biological damages to 
cellular lipids, proteins and DNA. For example, hydroxyl radicals are known to react 
with all components of the DNA molecule, damaging the purine and pyrimidine bases 
and also the deoxyribose backbone (Halliwell and Gutteridge, 2003). When this occurs, 
the normal functions of these macromolecules are impaired. As a consequence, ROS is 
implicated in a number of human diseases such as cancer, Alzheimer's disease, 
Parkinson's disease and reperfusion injury as well as in the ageing process (Droge, 
2002). Therefore, over the course of evolution, cells have developed a tightly regulated 
antioxidant defence system to keep the beneficial and harmful effects of these free 
radicals in check.  
 
In eukaryotic cells, this redox balance regulating network is made up of antioxidants 
comprising small molecules and several enzymes. Antioxidant molecules can be both 
exogenous and endogenous. They include ascorbic acid (AA), α-tocopherol (Vitamin 
E), glutathione (GSH), carotenoids, flavonoids, and other antioxidants (Halliwell and 
Gutteridge, 2003). These molecules effectively compete with other oxidizable 
substrates within the cells at very low concentrations, thereby delaying or inhibiting the 
oxidation of these substrates (Halliwell and Gutteridge, 2003).  
 
In a similar manner, the enzymatic defence system consists of enzymes such as 
superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx). These 
enzymes directly scavenge and inactivate noxious ROS, alleviating the toxic and 
deleterious effects of the ROS. They work in concert with SOD catalyzing the 
conversion of superoxide anions into hydrogen peroxide (H2O2) which is further 




eliminated at low and high concentrations, by CAT or GPx, respectively (Halliwell and 
Gutteridge, 2003).    
 
On the contrary to its harmful effects, ROS can also be beneficial to the organism 
(Valko et al., 2006). At low or moderate concentrations, ROS act as secondary 
messengers in various physiological processes including cellular defence against 
infectious agents (Keisari et al., 1983), induction of mitogenic responses to various 
stimuli (Preeta and Nair, 1999) and activation of numerous cell signal transduction 
pathways during PCD (Murrell et al., 1990; Buttke and Sandstrom, 1994; Fuchs et 
al.,1994; Green and Reed, 1998; Droge, 2002). The latter is particularly useful during 
cancer treatment.  
 
Cancer cells generally exist in a pro-oxidant state (Kokoglu et al., 1989; Szatrowski   
and Nathan, 1991; Toyokuni et al., 1995). This is required to sustain continuous 
cellular proliferations and cell survival. The higher cellular oxidative status leads to 
increase DNA mutational damage that is beneficial to these cells (Pelicano et al., 2004). 
The enhanced cellular redox signalling which in turn favours the inactivation of some 
transcription factors that limit cell proliferation such as p53 (Cobbs et al., 2003), 
thereby facilitating cancer progression.  
 
Despite this, increasing evidence illustrates that cancer cells exhibit greater 
susceptibility to free radical damage compared to their normal cells (Pelicano et al., 
2004). In several human cancer cell lines, increased H2O2 production had been reported 
(Szatrowski and Nathan, 1991). This is the basis of cytotoxic kill by numerous 
chemotherapeutic drugs for example doxorubicin, bleomycin and arsenic trioxide 




(As2O3) in certain tumour cells (Doroshow, 1983; Wallach-Dayan et al., 2006; Gupta et 
al., 2003; Woo et al., 2004). Exposure to such chemicals brings about an increase in 
cellular ROS way beyond the usual threshold tolerance of these cells. It ultimately 
overwhelms their antioxidant capacity, leading to irreversible damage and cell death 
(Kong et al., 2000). The complex relationship between mitochondria ROS production 
and PCD thus presents a unique opportunity for cancer chemotherapy and therapeutic 
selectivity.                         
 
 
1.2.2 Cellular GSH System – Biochemistry and Cellular Regulation 
 
GSH or L-γ-glutamyl-L-cysteinyl-glycine is a ubiquitous intracellular tripeptide found 
in virtually all animal cells. It forms the most prevalent cellular thiol and the most 
abundant low-molecular weight peptide in many cells (Meister, 1994; Lomaestro and 
Malone, 1995). Cellular GSH plays numerous key functions. It acts both as a reducing 
and oxidizing agent. Widely hailed as the most important cellular antioxidant, this 
peptide is critical in protecting against tissue damage induced from exposure to 
oxidizing environment including hypoxia, hyperbaric oxygen and ozone, as well as, 
against the harmful effects of free radicals and reactive electrophiles generated by 
radiation and ultraviolet light (Meister, 1994).  
 
Apart from this, GSH serves as a reservoir for cysteine and participates in the phase II 
detoxification reactions for xenobiotics and metabolism of numerous cellular 
compounds. It has also been reported to be involved in cell cycle regulation, 
thermotolerance, eicosanoids metabolism, synthesis of DNA precursor and DNA repair. 
Other reactions include enzyme activation, enhancement of immune system function, 




maintenance of thiol moieties of proteins and reduced form of other molecules such as 
co-enzyme A and AA (Meister, 1994; Lomaestro and Malone, 1995).    
        
In all mammalian cells, GSH is synthesized de novo from its precursor non-essential 
amino acids, L-glutamate, L-cysteine and glycine, in two consecutive ATP-dependent 
reactions (Figure 1-9) (Meister, 1994; Lomaestro and Malone, 1995; Sies, 1999). The 
first reaction is catalyzed by the enzyme γ-glutamyl-cysteine synthase. It is the control 
point in GSH synthesis and is rate-limited by GSH biofeedback (Lomaestro and 
Malone, 1995; Deneke and Fanburg, 1989). The second step in GSH formation 
involves GSH synthase that is not subjected to negative feedback by GSH. Once GSH 
is formed, it is transported to other intracellular compartments, such as the 
mitochrondria and the ER, and also to the extracellular spaces where it is utilized 
(Hammond et al., 2001). Consumption of GSH results in the loss of feedback inhibition 
and the availability of cysteine as a precursor thus becomes a rate-limiting factor for 
GSH synthesis (Lomaestro and Malone, 1995). 
                L-cysteine  ­ L-glutamate 
γ-glutamyl-cysteine synthase 
            Inhibited by  GSH feedback    
   γ-glutamyl-cysteine      ­ L-glycine 
                    GSH synthase 
                                                                     No GSH feedback inhibition 
 
                                                                            GSH 
 
Figure 1-9 Synthesis of GSH  
(Adapted from Lomaestro and Malone, 1995) 
 
GSH is catabolized and metabolically utilized via several pathways (Figure 1-10). 
Under normal physiological conditions, catabolism of GSH, GSH S-conjugates and 
GSH-complexes are initiated extracellularly by the plasma membrane bound enzyme, 




γ-glutamyl transpeptidase or γ-glutamyl transferase (γGT). This leads to the formation 
of γ-glutamyl amino acids and cysteinyl-glycine (γ-glutamyl cycle) (Meister, 1994). γ-
glutamyl amino acids are acted upon by γ-glutamyl cyclotransferase to 5-oxoproline 
which is subsequently converted to glutamate by 5-oxoprolinase. Cysteinyl-glycine is 
split extracellularly by dipeptidases to cysteine and glycine which are necessary for the 
recycling of GSH. In another pathway, the mercapturate pathway, GSH is broken down 
by GSH S-transferases to yield γ-glutamyl amino acids and cysteinyl-glycine S-
conjugates which are metabolically degraded in the same manner as described above 
(Meister, 1994). A dynamic balance thus occurs in a typical cell between the rate of 
GSH synthesis and the rate of GSH consumption to maintain intracellular GSH at 


























Figure 1-10 Overall pathway of GSH metabolism 
(Adapted from Meister, 1994) 
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1: γ-glutamylcysteine synthetase; 2: GSH synthetase; 3: γ-glutamyl transpeptidase; 
4: cysteinly glycine hydrolases; 5: γ-glutamyl cyclotransferase; 6: 5-oxoprolinase;  
7: GSH S-transferases; 8: transport and reduction of γ-Glu-(Cys)2; 9: oxidation reduction pathways 




Cellular, tissue and plasma GSH are present in several other forms (Sies, 1999). The 
thiol-reduced form (GSH) predominates and accounts for more than 98% of total GSH 
(GSH and oxidized glutathione (GSSG)). Other minor forms of GSH are the thiol-
oxidized GSSG, thioether, mercaptide and other thioester forms (GSH conjugates) 
(Hammond et al., 2001). GSSG is formed in antioxidant reactions involving GSH and 
accumulates with increased oxidative processing in cells (Lomaestro and Malone, 
1995). GSSG is toxic and is rapidly used to regenerate GSH under normal 
circumstances. This reaction is catalyzed by GSH reductase and requires the presence 
of reduced nicotinamide adenine dinucleotide phosphate (NADPH) as a hydrogen 
donor (Lomaestro and Malone, 1995). Hence, GSH and GSSG are interlinked in a 
redox cycle and the ratio of GSH/GSSG is usually maintained at about 100:1 (Pastore 
et al., 2003).      
 
Cellular regulation of GSH is also known to be interlinked with another water-soluble 
antioxidant, AA via redox coupling reactions (Figure 1-11). A tight connection has 
been postulated between these two compounds suggesting mutual regulation in 
synthesis. In animal cells, AA is oxidized to dehydroascorbic acid (DHA) either by 
one-electron oxidation of ascorbate to semidehydroascorbate radical followed by 
further oxidation to dehydroascorbate or by very rapid disproportionation to 
dehydroascorbate and ascorbate (Coassin, 1991). Dehydroascobate formed can be 
reduced back to AA enzymatically (Wells et al., 1990; Wells and Xu, 1994; Maellar et 
al., 1994) or non-enzymatically (Szent-Györgyi, 1928). In the enzyme-dependent 
recycling, the reduction of dehydroascorbate to ascorbic acid is performed in the 
presence of glutaredoxin (thiotransferase) (Wells et al., 1990; Wells and Xu, 1994; 




Maellar et al., 1994). Both reactions occur at the expense of GSH, leading to a decrease 
















Figure 1-11 Relationship between GSSG, GSH and ascorbate recycling 




1.2.3 The Role of GSH in Oxidative Stress, Detoxification and PCD  
 
GSH provides a first line of defence against ROS, as it can scavenge free radicals and 
reduce H2O2. It participates in reductive detoxification of H2O2 and lipid peroxides via 
several forms of GSH peroxidases present in tissues (Lomaestro and Malone, 1995) and 
in phase II of detoxification leading to sequential modification, biliary excretion and 
inter-organ transport for final excretion (Sies, 1999). In the presence of reactive 
endogenous and exogenous peroxides, mGSH peroxidases and related enzymes utilise 
GSH as a substrate to convert these reactive species into less harmful fatty acids, water 
and GSH disulfide or GSSG. In doing so, GSH protects the cell by preventing cell 
membrane lipid peroxidation and its subsequent deleterious effects on cellular functions 
(Lomaestro and Malone, 1995). Under normal circumstances, the GSSG formed is 
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AA: ascorbic acid; DHA: dehydroascorbic acid; GSH: glutathione; GSSG: glutathione 
disulfide; G-6-P: glucose-6-phosphate  




rapidly reduced back to GSH via the NADPH dependent GSSG-GSH recycling 
pathway mentioned in the previous section. This is achieved by maintaining a high 
GSH/GSSG ratio within the cells (Lomaestro and Malone, 1995). When tissues are 
exposed to excessive amounts of certain drugs or metabolites, X-ray or ultraviolet 
radiation, the capacity of GSH synthesis may become insufficient to maintain a high 
tissue GSH concentration. This results in GSH depletion and increased toxicity with 
these compounds leading to increased morbidity or even death. A classical example of 
such a scenario is exemplified by acetaminophen induced-hepatotoxicity (Lomaestro 
and Malone, 1995).                  
  
GSH has a role in signal transduction and apoptosis (Sies, 1999). Recent studies 
demonstrate that GSH regulates cell death pathways in apoptosis by modulating the 
redox state of specific thiol residues of target proteins. These would include stress 
kinases, transcription factors, and caspases that are sensitive to the cellular redox 
environment (Fernandez-Checa, 2003). Mitochrondria GSH has been implicated in 
maintaining the integrity of mitochondrial proteins and lipids and plays a vital role in 
the permeabilization of mitochondrial membranes and release of proapoptotic factors 
(Fernandez-Checa, 2003). Cells undergoing apoptosis appear to rapidly and selectively 
release GSH into the extracellular space, thus providing an efficient mechanism to 
circumvent the protective effects of intracellular GSH and allowing apoptosis to 
proceed (Hammond et al., 2001). 
 
In addition, numerous investigations have linked the susceptibility to apoptosis with 
intracellular GSH levels. Low GSH levels enhance cell death while high intracellular 
GSH levels prevent this (Hammond et al., 2001). GSH depletion almost invariably 




predisposes cells to apoptosis by other proapoptotic stimuli or may activate apoptosis in 
the absence of other stimuli or may lead to necrosis in cells that would otherwise 
undergo apoptosis (Hammond et al., 2001). Low GSH levels are frequently associated 
with mitochondrial dysfunction, activation of apoptosis through mitochondrial 
pathways, and production of sphingomyelin metabolites that can signal apoptosis. 
Replenishing GSH generally prevents apoptosis (Hammond et al., 2001). Thus, a 
complex relationship exists between GSH and apoptotic pathways that remain to be 
fully elucidated.  
 
 
1.2.4 The Role of GSH in Disease and Cancer Chemotherapy     
 
GSH and its related enzymes have been implicated in various pathology including liver 
disease, AIDS, Alzheimer’s disease, lung diseases, rheumatoid arthritis and cancer 
(Hadi et al., 1999; Pirmohamed et al., 1996; Cecchi et al., 1999; Rahman and MacNee, 
2000; Lomaestro and Malone, 1995). The key involvement of GSH in these conditions 
is its protective role against oxidative stress and cellular detoxification. Detoxification 
can be achieved either by enzymatic conjugation through the GSH S-transferase family 
of proteins or by nonenzymatic conjugation reactions which is common for cytotoxic 
compounds.  
 
In cancer, GSH acts to prevent carcinogenesis by detoxifying chemical carcinogens into 
less toxic or inactive metabolites. Promotion of carcinogen binding to DNA has been 
described when GSH levels are depressed. Furthermore, GSH has been suggested to be 
essential in steps closely involved in DNA synthesis (Liu et al., 1994). Thus, the 
anticarcinogenic protective mechanisms of GSH include its direct antioxidant function, 




indirect maintenance of other antioxidants, mediation of DNA synthesis and repair and 
ability to bind with cellular mutagens (Deneke and Fanburg, 1989).    
 
Several reports have demonstrated that GSH levels are elevated in various human 
cancer tissues such as breast, colon, lung, bone marrow, ovary and larynx as compared 
with normal tissues in these regions (Schnelldorfer et al., 2000). Elevation of GSH 
levels in tumour tissues has been linked to resistance to chemotherapy, radiation and 
oxidative effects. For example, elevated levels of GSH render some cancer cells to 
become resistant against well-known platinum anticancer drugs such as cisplatin 
(Cddp) and carboplatin (Godwin et al., 1992). Platinum complexes are often very 
reactive towards the cysteine residue of GSH, which detoxifies these compounds by 
rapid binding mechanisms (Eastman, 1987). 
 
It is of interest to note that certain tumour cells that have become resistant to radiation 
and to some anticancer agents due to increased intracellular GSH have been re-
sensitized to these treatments when cellular GSH is reduced (Biaglow et al., 1984; van 
der Schans et al., 1986, Astor et al., 1984, Lehnert et al., 1990). With these findings, 
the application of GSH depletion in the treatment of tumours has generated much 
interest within the scientific community and various approaches have been utilized in 
intracellular GSH depletion. The first being direct complexation of GSH to an 
electrophilic agent such as diethyl-maleate (DEM), bromobenzene or phorone via the 
GSH transferase reaction. Another method involves the use of buthionine sulfoximine 
(BSO), a γ-glutamyl-cysteine synthase inhibitor. A third method exists by subjecting 
the cells to oxidative stress in the presence of a GSH reductase inhibitor such as N,N-2-
chloroethyl-N-nitrosurea. To date, the use of BSO for GSH depletion has been most 




widely employed as it results in more sustained GSH depletion and is less toxic 
compared to DEM (Deneke and Fanburg, 1989).  
 
Recent research on AA has investigated its use in relation to the reduction of GSH 
levels. AA was successfully employed as a GSH depletor in vitro to enhance the 
sensitivity of leukaemic and multiple myeloma cell lines to the cytotoxic effects of 
As2O3 (Dai et al., 1999; Grad et al., 2001). It is thus evident that modulation of GSH 
metabolism may allow the selective protection and apoptosis of cells. 
 
 
1.3 Ovarian Cancer      
  
1.3.1 Ovarian Cancer and Chemotherapy 
 
Ovarian cancer is a common gynaecological malignancy and is the fourth leading cause 
of cancer mortality in women (Jemal et al., 2006). In the United States alone, an 
estimate of over 20 180 new cases of ovarian carcinoma has been forecasted to be 
diagnosed in the year 2006 (Jemal et al., 2006). Although this is a relatively low 
percentage compared to the overall number of female cancer cases, it will amount to 15 
310 deaths, which is more than half of all cancer deaths in the female population (Jemal 
et al., 2006). The high mortality rate is a major concern and is commonly attributed to 
its insidious onset and frequent late detection as a result of poor symptomatic warning. 
Approximately 75% of all ovarian cancer cases were diagnosed at an advanced stage, 
with disease metastasis beyond the pelvis at the time of diagnosis (Runowicz, 1992; 
Ries, 1993). Indeed, fewer than 25% of ovarian cancers are identified at an early 
curable stage (NIH consensus, 1995) and less than 20% of patients with stage III 
disease. Stage III being the most common stage at diagnosis with median survival of 
five years (Dietl and Marzusch, 1993).     




In general, the histopathology of ovarian carcinoma can be divided into three major 
categories. These are epithelial, stromal cell and germ cell tumours. Each cell type has 
different aetiologies and behaviours. Among them, ovarian epithelium-derived tumour 
is the most common; accounting for approximately 80-90% of adult ovarian tumours 
diagnosed. Ovarian cancer commonly leads to ascites in the abdomen and leads to the 
failure of organs in the pelvis and the upper part of the body (Feldman and Knapp, 
1974). 
 
Owing to the aggressive nature of the disease, the treatment for most patients 
presenting with advanced disease includes a combination of cytoreductive surgery 
followed by neoadjuvant chemotherapy (Cannistra, 1993). Thus, chemotherapy is a 
cornerstone in the management of ovarian cancer. Over the past three decades, first-line 
chemotherapeutic agents have evolved drastically from the initial use of the single 
agent melphalan to a combination of cyclophosphamide and doxorubicin in the 1970’s 
and subsequently to platinum-based (Cddp and carboplatin) chemotherapeutic regimen 
in the 1980’s. Platinum-based chemotherapeutic regimens, commonly termed the “holy 
grail” in ovarian carcinoma, are by far one of the most effective treatments of advanced 
disease (Agarwal and Kaye, 2003).  
 
Presently, the standard chemotherapeutic regimen for newly-diagnosed advanced 
ovarian carcinoma following surgical bulk reduction consists of a platinum-containing 
compound and a taxane (Bristow et al., 2002). In the United States, the most commonly 
used regimen is a combination of intravenous carboplatin and paclitaxel. The addition 
of paclitaxel to platinum-based chemotherapeutic regimen resulted in an improved 
survival for ovarian cancer patients as reported by the Gynaecological Oncology Group 




(GOG) and the European-Canadian Study (McGuire et al., 1996). Initial response rates 
were as high as 85% in primary ovarian epithelial carcinoma with up to 60% of patients 
showing complete clinical remission (Agarwal and Kaye, 2003).  
 
Despite advances in cytotoxic therapies, about 70% of patients with advanced ovarian 
cancer suffer relapse. There is eventual mortality due to platinum-resistant disease 
(Cannistra, 1993). Currently, treatment options are limited as second-line 
chemotherapeutic regimens are few due to low therapeutic response rates and toxicity 
issues. Hence, in the quest to combat ovarian cancer, an understanding of the 
mechanisms of action of Cddp and factors contributing to its resistance in ovarian 
tumours is needed. 
 
1.3.2 Cddp: Mode of Cytotoxic Action and Mechanisms of Resistance  
 
Diamminedichloroplatinum was first synthesized by chemist, Michele Peyrone, in 1845 
and known as Peyrone’s chloride (Kartalou and Essigmann, 2001). In 1965, Barnett 
Rosenberg at Michigan State University observed the antiproliferative properties of 
platinum coordination complexes in Escherichia coli. Following this observation, the 
antitumour activities of several platinum compounds were tested to be effective against 
murine sarcoma 180 and L1210 leukaemia (Kartalou and Essigmann, 2001). cis-
Diamminedichloroplatinum (II) or Cddp, the cis isomer of a heavy metal complex of 
platinum, chlorine and ammonia (Figure 1-12), was among the compounds tested and 

















Figure 1-12 Molecular structure of Cddp 
 
Cddp has been successfully utilized in cancer chemotherapy for more than 25 years and 
is widely recognized to be an effective chemotherapeutic agent for the treatment of a 
wide variety of malignant tumours including the ovary, cervix, bladder, lung, head and 
neck, oesophagus and testis (Kartalou and Essigmann, 2001). While the precise 
mechanism of Cddp is still unclear, it is thought to act primarily by interacting with 
macromolecules such as DNA, RNA, proteins, forming DNA-strand linkages (Reedijk 
and Lohman, 1985; Siddik, 2003). This occurs upon the entry of the drug into the cell 
where its chloride ligands are replaced by water molecules through a series of 
spontaneous aquation reactions, generating a positively charged aquated species that 
can react with nucleophilic groups containing oxygen, nitrogen or sulphur atoms with 
unpaired electrons. Within the DNA molecule, the aquated platinum molecule interacts 
with the nucleophilic N7-sites of purine bases. As a consequence, normal transcription 
and DNA replication are impaired. If left unrepaired, the DNA damage eventually leads 
to cell death (Siddik, 2003).      
 
Cell death following Cddp-induced nuclear lesions is likely to be attributed to 
activation of various molecular signalling pathways. One pathway leads to a temporary 
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to inhibition of Cdc2-cyclin A or B checkpoint kinase (Sorenson and Eastman, 1988a; 
1988b; 1990). In addition, Cddp-induced DNA damage has been known to trigger 
apoptosis in vitro via two distinct routes. One involves the tumour-suppressor protein 
p53, the other is mediated by the p53-related protein p73 (Allday et al., 1995; Gong et 
al., 1999). The activation of p53 in turn affects the expression of other downstream 
genes associated with apoptosis (such as  Bax, DR5,  NOXA,  PUMA) and cell cycle 
control (such as p21Waf1/Cip1, Gadd45, Mdm2, PCNA) (Siddik, 2003). These induced 
proteins control critical cellular functions including the levels of the p53 protein itself, 
progression through the cell cycle, and cellular apoptosis, thereby inducing tumour cell 
death.  In a p53-independent manner, following Cddp treatment, DNA damage signals 
activate c-Abl tyrosine kinase which stabilises p73 protein, resulting in the up-
regulation of p73. The p73 gene encodes several proteins, as a result of alternative 
splicing, which can induce apoptosis (Gong et al., 1999).   
 
Although Cddp is a very potent anticancer agent, tumour drug resistance often develops 
and is a significant impediment to successful chemotherapy. With the development of 
Cddp resistance, drug doses must be increased, leading to a resultant increase in 
toxicities such as intractable vomiting, deafness and failures of the kidneys and bone 
marrow (Kartalou and Essigmann, 2001). Cddp resistance can be divided into two 
forms. Acquired resistance occurs when a drug that is initially beneficial becomes 
ineffective over time. Intrinsic resistance on the other hand, occurs when a drug is 
ineffective from the outset (Kartalou and Essigmann, 2001). It is a complex 
phenomenon associated with many cellular and molecular mechanisms such as 
perturbation of Cddp transport, increased intracellular levels of sulphur-containing 




antioxidant molecule GSH, increased DNA repair, mutation in p53 and elevated levels 
of antiapoptotic Bcl2 and Bclxl proteins (Kartalou and Essigmann, 2001; Siddik, 2003). 
 
As described earlier, the cytotoxic activity of Cddp is brought about by the positively 
charged aquated species upon entry of the drug into the tumour cells. Cddp can enter 
the cells either by passive diffusion or active transport (Andrews et al., 1988; Gately 
and Howell, 1993; Yoshida et al., 1994; Kelland, 2000). A reduction in Cddp 
accumulation is a major method by which resistant cancer cells overcome its 
antitumour effects. This is due to either to an inhibition of drug uptake or an increase in 
drug efflux or both (Mann et al., 1990). It appears that a defect in the uptake is the 
dominant method although the exact mechanism remains to be defined. In human 
ovarian cancer cell line OV2008, decreased Cddp accumulation has been found to be 
due to decreased influx (Mann et al., 1990). Enhanced drug efflux has also been 
documented in Cddp-resistant ovarian tumour cells over their drug sensitive counterpart 
(Mann et al., 1990). Efflux transporters that mediate Cddp resistance include multi-
drug resistance protein 2 (MRP2) or cMOAT (Kool et al., 1997; Koike et al., 1997; Cui 
et al., 1999) and copper transporting pump ATP7B (Komatsu et al., 2000; Katano et 
al., 2002). 
 
Within the cell, active aquated species of Cddp is inactivated by nucleophilic GSH 
(Ishikawa and Ali-Osman, 1993) and cysteine-rich metallothionein (Sharma and 
Edwards, 1983; Zelazowski et al., 1984). Following chronic exposure to Cddp, drug 
resistance is acquired by increasing cellular thiol-containing molecules (Kartalou and 
Essigmann, 2001; Siddik, 2003). In Cddp-resistant ovarian tumour models, resistance 
has been correlated to marked elevation of intracellular GSH levels (Kelland, 1993) 




which is mediated by an increased in cellular γ-glutamylcysteine synthethase (γ-GCS) 
gene brought about by the up-regulation of transcription factor c-JUN (Pan et al., 
2002).            
 
A further means by which cells can become resistant to Cddp is to develop a phenotype 
with the ability to cope with the platinum DNA lesions. One way is via changes in 
proteins within the nucleotide excision repair (NER) system that are responsible for 
repairing the platinum DNA lesions (Chaney and Sancar, 1996; Furuta et al., 2002). 
Within the NER system, up-regulation of the ERCC1-XPA protein increases the 
excision activity of Cddp-resistant C200 cells compared to corresponding Cddp-
sensitive A2780 cells (Ferry et al., 2000). These cells have an increased ability to 
remove Cddp-DNA adducts and to repair Cddp-induced lesions within the DNA, so 
that similar levels of drug DNA lesions do not produce equivalent cytotoxicity 
compared to their drug sensitive counterparts (Ferry et al., 2000). Cddp resistance can 
also be achieved through the mismatch repair (MMR) pathway. This is responsible for 
repairing the mismatched base opposite the platinum DNA lesion. By leaving the lesion 
intact, the MMR system results in an augmentation of the toxicity of DNA-damaging 
agents such as Cddp (Vaisman et al., 1998). Allelic loss of the hMLH1 or hMSH2 
genes within this pathway has been known to contribute to decrease Cddp sensitivity in 
HCT-116 colon and HEC59 endometrial tumour cell lines (Aebi et al., 1996; Fink et 
al., 1996; Vaisman et al., 1998). In like manner, MMR-deficient A2780/CP70 ovarian 
carcinoma cells demonstrate marked resistance to Cddp compared to MMR-proficient 
A2780 cells (Parker et al., 1991).    
 




At the molecular level, decreased susceptibility to the induction of apoptosis is a way in 
which tumour cells manifest tolerance to Cddp. This can occur in the form of either a 
gene mutation or an overexpression of antiapoptotic genes within the apoptotic 
signalling cascade. Important molecular targets affected by such alterations are p53, 
Bcl2 and Bclxl genes (Eliopoulos et al., 1995). In this regard, tumour cells escape 
Cddp-induced cytotoxicity through mutations of the p53 tumour suppressor gene, thus 
rendering an ineffective execution of the apoptotic response (Anthoney et al., 1996). 
The p53 mutation represents the most common molecular alterations in ovarian 
carcinoma with as much as 50% of patients with advanced disease harbouring such 
genetic defects (McManus et al., 1996). In Cddp-resistant ovarian cancer tumour cells, 
increased levels of Bcl2 and Bclxl proteins have been observed (Kassim et al., 1999; 
Williams et al., 2005). Taken together, these cellular and molecular factors form a 
complex interacting network rendering the cancer cells resistant to Cddp treatment.   
 
1.3.3 Paclitaxel: Mode of Cytotoxic Action and Related Toxicity Issues  
 
Paclitaxel (Figure 1-13) also known as Taxol® is an alkaloid ester derived from the 
fermentation of the bark of the Western yew, Taxus brevifolia and the European yew, 
Taxus baccata. It was discovered by the National Cancer Institute in United States as 
part of its drug development program in the late 1960s and early 1970s. Its unique 
mechanism of action and broad spectrum of activity led to its clinical development 
(Rowinsky and Donehower, 1995).  
   







Figure 1-13 Molecular structure of paclitaxel 
 
As a chemotherapeutic agent, paclitaxel acts primarily as a mitotic spindle poison. It is 
a potent inhibitor of cell replication by promoting microtubule assembly and stabilizing 
tubulin polymers against depolymerisation by binding to the β-subunit of tubulin 
(Jordan and Wilson, 1998; Dumontet and Sikic, 1999). More recently, paclitaxel has 
been reported to exert other cellular and molecular effects. These include activation of 
signal transduction pathways, effects on tumour suppressor genes and induction of 
cytokines such as TNFα (Williams et al., 1992; Blagosklonny and Fojo, 1999; 
Ganansia-Leymarie et al., 2003). Following exposure to paclitaxel, the induced cell 
death exhibited characteristic features of classical apoptosis including DNA 
fragmentation, cell volume shrinkage and formation of apoptotic bodies (Ganansia-
Leymarie et al., 2003). More recently, ovarian carcinoma and non-small cell lung 
cancer (NSCLC) cells treated with paclitaxel have been reported to mediate caspase-
independent cell death (Ahn et al., 2004; Broker et al., 2004).   
 
Currently, paclitaxel is particularly important in the therapy of ovarian carcinoma 
(Bristow et al., 2002), advanced breast cancer (Dang and Hudis, 2006) and NSCLC 
(Choy, 2001). It is also a constituent of commonly used chemotherapeutic regimens for 




head and neck cancer, oesophageal cancer, bladder cancer, germ cell tumours and 
cancer of unknown primary origin (Schwartz et al., 1998; Choy, 2001). Despite its 
superior efficacy, the use of paclitaxel can be limited by the development of severe 
dose-limiting toxicities such as febrile neutropenia and significant neurological toxicity 
(Rowinsky and Donehower, 1995).      
 
Febrile neutropenia is a principal toxic effect of paclitaxel. It is dose and schedule 
dependent. Its onset is usually on days 8 to 10 after treatment and recovery is normally 
complete by days 15 to 21 (Rowinsky and Donehower, 1995).  Development of febrile 
neutropenia during chemotherapy presents problems for the patient. The patient is at 
increased risk of life-threatening opportunistic infections with resulting morbidity and 
mortality that may further compromise treatment outcomes due to accompanying 
chemotherapy dose reductions and delays (Rowinsky and Donehower, 1995). In one 
study, it was found that in hospitalized patients undergoing chemotherapy, the mortality 
associated with febrile neutropenia approached 10% (Crawford et al., 2004). 
 
Treatment with paclitaxel has been associated with the development of neurotoxicity 
due to its effects on the axonal microtubules (Rowinsky and Donehower, 1995). It is 
usually manifested as peripheral neuropathy displaying progressive paraesthesia, 
numbness and sometimes pain in the feet. This can be problematic as it results in 
difficulties with activities of daily living for the patient (Rowinsky and Donehower, 
1995). Such side effects are dose-related and cumulative. Their severity can increase 
particularly when used in combination with other neurotoxic agents such as Cddp 
(Markman, 2003). Symptomatic management of these adverse events consists mainly 




of changes in dosing schedule and cumulative dose-reduction which may compromise 
treatment outcomes (Rowinsky and Donehower, 1995; Markman, 2003).   
 
Another common side effect related to paclitaxel use is the manifestation of severe 
hypersensitivity reactions (Rowinsky and Donehower, 1995). This is known to be due 
to the presence of Cremophor EL, the solvent found in traditional paclitaxel 
formulation. Such side effects can be prevented using antihistamines and 
corticosteoroids as pre-medication prior to paclitaxel infusion (Rowinsky and 
Donehower, 1995). Currrently, several cremophor-free formulations such as Genexol-
PM® (a polymeric micelle loaded paclitaxel) (Kim et al., 2004; Lee et al., 2007) and 
Abraxane® (an albumin-bound paclitaxel formuation) (Micha et al., 2006) have shown 
reduced hypersensitivity reactions in clinical trials.   
 
Apart from these, a myriad of other less severe side effects has been documented with 
paclitaxel chemotherapy. They include nausea and vomiting, alopecia, arthralgia, 
myalgia, diarrhea and disturbances to cardiac rhythms (Rowinsky and Donehower, 
1995; Markman, 2003). The side effects associated with paclitaxel use necessitate 
meticulous management and patient care whilst undergoing paclitaxel chemotherapy. It 
also underlies the need for safer and more tolerable agents or formulations particularly 
in patients who are unable to tolerate paclitaxel therapy either alone or in combination 
with a platinum compound.       
 
 1.3.4 Investigational Agents for Ovarian Cancer Chemotherapy 
In patients who suffer a relapse following initial chemotherapy for ovarian cancer and 
present with platinum-resistant disease, effective standard chemotherapeutic options 




remain limited. Although several newer anticancer agents such as oral etoposide, 
pegylated liposomal doxorubicin, topotecan, vinorelbine and gemcitabine have shown 
some promise for ovarian cancer treatment, their overall response rates has been 
confined to less that 20% in phase II trials (Markman, 2007). Therefore, new treatment 
approaches and agents are still required for the management of platinum-resistant 
disease.  
 
Recent advances in the development of molecular biology have dramatically improved 
our understanding of ovarian cancer biology, its mechanism, progression and factors 
contributing to chemoresistance in relapsed patients. Along with the greater knowledge,   
multiple novel molecular targets, important signal transduction pathways and 
epigenetic changes in ovarian tumours have been identified. This information has led to 
the development of possible new cytotoxic agents and molecular-targeted therapies that 
are currently in various stages of preclinical development or clinical trials. These 
investigational agents include new taxanes, histone deacetylase inhibitors, signal 
transduction inhibitors, antiangiogenesis agents, and immunotherapeutic agents. 
 
Several new taxanes and paclitaxel analogues are currently being evaluated for ovarian 
cancer treatment. BMS-247550, a derivative of the natural product epothilone B, is able 
to induce cytotoxic cell death in paclitaxel-resistant cancer cells and is active against 
human tumour xenografts in mouse and rat models. It is currently being evaluated in 
phase I/II trials (Lee et al., 2001; See and Kavanagh, 2004). BMS-275183 is a novel 
oral taxane demonstrating comparable antitumor activity with intravenous paclitaxel in 
preclinical studies (See and Kavanagh, 2004). Taxoprexin, a docosahexaenoic acid 
conjugated paclitaxel and poliglumex, a poly-L-glutamic acid conjugated paclitaxel, are 




being evaluated in Phase II and Phase III trials for ovarian cancer, respectively 
(Lorusso et al., 2007). 
 
A common characteristic of many cancers is the silencing of genes involved in the 
suppression of malignant transformation. These can occur by genetic changes such as 
nucleotide substitution and by epigenetic modifications such as DNA methylation 
(Cheng et al., 1997). It is now widely recognized that epigenetic alterations are early 
important events in ovarian tumour development (Cheng et al., 1997). Important 
enzymes controlling epigenetic modifications include DNA methyltransferases and 
histone deacetylases (HDAC). A rapidly emerging class of anticancer agents is the 
histone deacetylase inhibitors (HDACIs). They have shown potential for treatment of 
both solid and haematological malignancies (Mehnert and Kelly, 2007). In preclinical 
ovarian tumour models, treatment with HDACIs including valproic acid and 
suberoylanilide bishydroxamine (SAHA) resulted in inhibition of cell proliferation and 
induction of apoptosis (Takai et al., 2004). Various HDACIs are now in clinical trials 
for ovarian cancer (Daud et al., 2001)  
 
In recent years, numerous novel signal transduction inhibitors targeted against various 
molecular abnormalities in ovarian cancer have been developed. Epidermal growth 
factor receptor (EGFR) inhibitors Gefitinib and Erlotinib have been tested in Phase II 
trials (Sewell et al., 2002; Ranson et al., 2002; Mendelsohn, and Baselga, 2003). 
Concurrent use of farnesyltransferase inhibitors R115777 and SCH66336 with 
paclitaxel have resulted in synergistic cell death in vitro. These inhibitors are currently 
in clinical trials (Haluska et al., 2002; Adjei et al., 2003). Rapamycin analogues, CCI 
779 and RAD 001, targeting the mammalian target of rapamycin in the 




phosphoinositide 3-kinase tumour survival pathway are now in Phase I trials (Hidalgo 
and Rowinsky, 2000). 
 
Vascularisation is an important requirement for the progression and distant metastasis 
of tumour cells. In ovarian tumours, numerous angiogenic factors and 
metalloproteinases play critical roles in the regulation of tumour vascularisation and 
metastasis. Investigators have examined angiogenesis inhibition for ovarian cancer 
therapy (Heath et al., 2001). For example, SU6668 inhibits VEGFR, PDGFR, and 
fibrinogen growth factor receptor. Thalidomide has been reported to be able to suppress 
several angiogenic growth factors and BAY 12-9566, inhibits MMP-2, MMP-3, and 
MMP-9 (Heath et al., 2001). 
 
It has been long known that the immune system is important in the defence against 
cancer. Proteins expressed on the surface of cancerous cells are often different from 
that on their normal counterparts and can trigger the body’s immune reaction to destroy 
these damaged cells. For ovarian cancer, this form of immune-mediated approach is 
currently under investigation for possible use in its treatment. Investigational therapies 
that are currently in clinical trials employ the use of monoclonal antibodies against 
ovarian cancer associated antigens such as CA125 and VEGF-A. Oregovomab, a 
photoactivated nonradiolabelled murine monoclonal antibody against CA125, has been 
shown to induce immunological responses in patients Phase II trial and is currently 
being further evaluated (Ehlen et al., 2005), while Bevacizumab (Avastin®), a 
humanized monoclonal antibody reactive with VEGF-A, is now in Phase II trials (See 
and Kavanagh, 2004). 
 




1.4 Arsenic Trioxide and Cancer Chemotherapy  
 
1.4.1 Arsenical Compounds, Their Reactivity, Biotransformation and Cellular 
Uptake  
 
Arsenical compounds have a long and complex history dating back to the thirteenth 
century. The word Arsenic is derived from the Greek term for potent, is a naturally 
occurring metalloid found in the soil, water and air (Miller et al., 2002). Within the 
environment, it is commonly complexed with sulfur as realgar (As2S2), orpiment 
(As2S3) and arsenopyrite (FeAsS). These complexes are unusual covalent compounds 
retaining native metallic arsenic properties (Waxman and Anderson, 2001).     
 
Arsenic can exist in both inorganic and organic forms with three possible oxidation 
states namely elemental (0), trivalent (+3 or -3) and pentavalent (+5) (Basu et al., 
2001). The majority of inorganic arsenic exists as trivalent meta arsenite (As3+) and the 
pentavalent arsenate (As5+) while organic arsenic includes methylated metabolites such 
as monomethylarsonic acid (MMA), dimethylarsinic acid (DMA) and trimethylarsine 
oxide (TMAO) (Basu et al., 2001). Depending on their valency states, arsenical 
compounds possess different properties. The trivalent forms of arsenic such as As2O3 
and sodium arsenite are capable of reacting with many sulphur-containing enzymes and 
their cofactors while pentavalent arsenates uncouple mitochondria oxidative 
phosphorylation (Crane and Lipmann, 1953; Ter Welle and Slater, 1967). Inorganic 
forms of arsenic are also known to be generally more toxic than the organic forms 
(Basu et al., 2001).    
 
Inorganic arsenical compounds are primarily metabolized by methylation reactions in 
the kidneys, testes and lungs (Styblo et al., 1995; Vahter, 2000) (Figure 1-14). 




Pentavalent forms of inorganic arsenic are first reduced in the presence of GSH to 
trivalent arsenite (Delnomdedieu et al., 1994). Arsenite is subsequently methylated to 
MMAv followed by DMAv using the methyl groups donated by S-adenosylmethionine 
(SAM) in the presence of arsenite methyltransferase (Vahter and Marafante, 1983). A 
trivalent intermediate, monomethylarsonous acid (DMAIII), is formed during the 
methylation reactions. This intermediary compound is found to be more toxic than 
arsenite and arsenate in in vitro cytotoxicity studies using human hepatocytes (Petrick 
et al., 2001). However, the stable organic metabolites (MMAv and DMAv) have been 
found to less toxic compared to their parent inorganic arsenite or arsenate (Buchet et 
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Figure 1-14 Metabolism of inorganic arsenic 
(Adapted from Chowdhury et al., 2006) 




In solution at neutral pH, As2O3 is in equilibrium with the oxyanion arsenite, and is 
fully protonated (Liu et al., 2004). Extended X-ray absorption fine structure 
spectroscopy has shown trivalent As(OH)3 as the predominant species at neutral pH 
(Liu et al., 2004).  In mammalian cells, As(OH)3 has been reported to be taken into 
cells by aquaglyceroporins in particular aquaglyceroporin 7 and aquaglyceroporin 9 
(Sanders et al., 1997; Liu et al., 2002 ; Wysocki et al., 2001). In the K562 leukaemic 
cell line, transfection with the aquaglyceroporin 9 gene increased its sensitivity to 
As2O3 due to an increased rate of arsenite uptake (Bhattacharjee et al., 2004). More 
recently, aquaglyceroporin 3 has been reported to mediate arsenite accumulation in 
lung adenocarcinoma cells (Lee et al., 2006). Apart from these, GSH conjugates of 
arsenite can be taken up by cells via organic anion transporting polypeptide C (Lu et 
al., 2006) and hexose permeases (Liu et al., 2004). On the other hand, pentavalent 
arsenic has been reported to be transported into cells via phosphate transport systems 
(Willsky and Malamy, 1980; Bun-ya et al., 1996).  
 
 
1.4.2 Carcinogenic Effects and Therapeutic History of Arsenical Compounds 
 
Traditionally, inorganic arsenicals have been known as poisons and potent human 
carcinogens (Basu et al., 2001). Their colourless and odourless characteristics made 
them ideal for sinister purposes in the past. Until today, chronic arsenic exposure 
through ingestion of food and water has been associated with neurotoxicity, liver 
injury, peripheral vascular disease and a variety of cancers, such as the skin and other 
internal organs including the bladder, liver, kidney or the lung (Basu et al., 2001; Bode 
and Dong, 2002). In some countries, widespread human exposure to arsenic through 
drinking water is still a major health concern.   
 




Much of the evidence suggesting that arsenic can promote cell transformation and 
tumour development comes from in vitro data. Exposure of JB6C141 cells to arsenite 
has been reported to induce cell transformation in soft agar (Huang et al., 1999). 
Enhanced blast transformation and DNA synthesis have also been reported in human 
lymphocytes exposed to arsenite or arsenate (Meng and Meng, 2000). Chronic 
exposure to low levels of arsenic has led to irreversible phenotypic changes that have 
been associated with arsenic-induced cell transformation or tumour development 
(Romach et al., 2000). Despite this evidence, arsenic has not been conclusively shown 
to initiate or promote carcinogenesis in animals, although its effects have been 
recognized to be irreversible. The present scientific evidence has yet to conclusively 
confirm that arsenic is indeed a mutagen in vivo even though arsenic has been shown to 
interact with DNA in vivo.    
 
Despite their nefarious uses and effects, arsenical compounds have also been utilized as 
therapeutic agents for over 2400 years (Table 1-3) (Waxman and Anderson, 2001). The 
medicinal use of these compounds began in the 15th century and had been the mainstay 
in the Material Medica in the 19th century (Waxman and Anderson, 2001). They had 
been used as remedies to cure anorexia and other nutritional disturbances, neuralgia, 
rheumatism, asthma, tuberculosis, diabetes, intermittent fever, skin disorders, 
haematologic abnormalities, malaria and syphilis (Winship, 1984; Klaassen, 1996). 
Over the years, arsenical compounds continue to remain important in the chemotherapy 
of trypansomal infections (Bouteille et al., 2003). However, most of the other medicinal 
uses of arsenic have been replaced by safer and more effective therapeutic agents 
(Bouteille et al., 2003).  
 




Table 1-3 Key events in the medicinal use of arsenic 
(Adapted from Miller et al., 2002) 
 
 
The revival in the medicinal use of arsenic as anticancer agents was led by Chinese 
physicians from Harbin in the early 1970s when they used white arsenic in the 
management of several cancers such as oesophageal carcinoma, malignant lymphoma 
and leukaemia (Wang, 2001). Long-term clinical trials completed in the last few years 
have indicated that low plasma concentrations of As2O3 (1-2 μM) are effective in the 
treatment of acute promyelocytic leukaemia (APL) involving the translocation t(15:17) 
(Dai et al., 1999) even in patients resistant to all trans-retinoic acid (ATRA) or 
conventional chemotherapy (Shen et al., 1997). Complete remission rates (CR) 
between 85-93% have been reported in newly diagnosed and relapsed patients with 
APL (Sun et al., 1992; Zhang et al., 1996; Shen et al., 1997; Niu et al., 1999). More 
Year Key events 
400 BCE Hippocrates used realgar (As2S2) and orpiment (As2S3) as remedies for ulcers 
 
50 AD  Dioscorides used orpiment as a depilatory 
 
14th century Angelus Salva used arsenic against the plague 
 
16th century Jean de Gorris used arsenic as a sudorific 
 
17th century Lentilius and Friceius used arsenic as a treatment for malaria 
 
18th century Arsenic preparations were used therapeutically: Aiken’s Tonic Pills, Andrew’s 
Tonic, Arsenauro, Gross’ Neuralgia Pills, Cholor-Phosphide of Arsenic, 
Sulphur Compound Lozenges 
These were still in circulation at the end of the 19th century 
 
19th century Arsenic was a mainstay of the materia medica 
Fowler’s Solution (potassium arsenite) was praised for its success in treating 
asthma, chorea, eczema, Hodgkin’s disease, pemphigus, pernicious anemia, 
and psoriasis 
 
20th century Ehrlich discovered an organic arsenical (salvarsan) that cured syphilis and was 
used to treat trypanosomiasis 
Used in traditional Chinese medicine for hundreds of years, arsenic derivatives 
are still used to devitalize the pulp of diseased teeth and in regimens for 
psoriasis, rheumatic diseases, and syphilis 
 




importantly, the toxic effects experienced during arsenic treatment were mild and 
responded to symptomatic treatment or resolved with dose reduction while other severe 
toxic effects, such as myelosuppression associated with conventional chemotherapy, 
were lacking (Sun et al., 1992; Zhang et al., 1996; Shen et al., 1997; Niu et al., 1999). 
Some of the acute toxicities reported by APL patients undergoing As2O3 chemotherapy 
are summarized in Table 1-4 (Evens et al., 2004). 
 
Table 1-4 Acute toxicities associated with APL patients undergoing As2O3 
chemotherapy 
(Adapted from Evens et al., 2004) 
 
Common (>20%) Infrequent (<15–20%) Rare 
 
QTc prolongation (with 
ventricular arrhythmias) 
 




APL differentiation syndrome Fatigue 
 
Pseudotumour cerebri 
Skin reactions Oral haemorrhage 
 
Liver failure/necrosis 
Peripheral neuropathies Facial edema 
 
Sudden cardiac death 






Hepatic dysfunction (enzyme 
changes) 
 
Oral ulcers  
Gastrointestinal reactions Toothache 
 
 
Abbreviations: APL: acute promyelocytic leukaemia; QTc: QT heart rate corrected interval; CNS: 
central nervous system 
 
 
These heartening data accelerated the approval of As2O3 injection (TrisenoxTM Cell 
Therapeutics) by the Food and Drug Administration of the United States of America in 
the year 2000 for induction of remission and consolidation of adult patients with 
relapsed or refractory APL (Bradley, 2000). Presently, As2O3 alone or in combination 




with other chemotherapeutic agents is being evaluated for the treatment of newly 
diagnosed, previously untreated APL and other malignant disorders including chronic 
lymphocytic leukaemia (CLL) (Murgo, 2001), multiple myeloma (Murgo, 2001; Bahlis 
et al., 2002) and myelodysplastic syndromes (Douer and Tallman, 2005). Its use is also 
being investigated in numerous solid tumours such as prostate, metastatic renal 
carcinoma and advanced liver and gallbladder cancers (Douer and Tallman, 2005). 
 
1.4.3 Anticarcinogenic Mechanisms of As2O3          
 
The therapeutic efficacy of As2O3 in APL had fuelled research into the mechanisms of 
action of As2O3. In recent years, significant progress has been made in our 
understanding of the mechanisms of action of arsenic derivatives. As2O3 targets 
multiple signal transduction pathways, resulting in diverse cellular effects such as 
partial cytodifferentiation, induction of apoptosis, inhibition of proliferation and 
inhibition of angiogenesis (Bode and Dong, 2002). Responses vary depending on cell 
type and the form of arsenic used.  
 
Initial research to investigate the mechanism of action of As2O3 has centered around 
APL. In APL, a large proportion of cases are characterized by t(15;17) translocation. 
This translocation generates a fusion between the promyelocytic leukemia gene (PML) 
and the retinoic acid receptor alpha (RARα) gene which encodes a transcription factor. 
The resulting fusion protein PML- RARα blocks the expression of genes required for 
normal myeloid differentiation. As2O3 is proposed to exert its antileukaemic effects by 
its ability to induce relocation and differentiation of promyelocytic leukemia gene in 
addition to degradation of the fusion protein in APL (Chen et al., 1996; Shao et al., 




1998). This ability to induce cellular differentiation is critical for its clinical efficacy in 
APL. 
 
In various leukaemic and solid tumour cell lines, there is evidence to suggest that As2O3 
treatment results in cell arrest and growth inhibition. At low As2O3 concentrations of 
less than 2 µM, cell cycle arrest did not contribute to its cell growth inhibitiory effects 
(Rojewski et al., 2004). On the contrary, p53 independent G2/M cell cycle arrest and 
upregulated cyclin D1 mRNA expression results in its cell growth inhibitory effects at 
higher As2O3 concentrations (Rojewski et al., 2004).  
 
Apart from its cell growth inhibitory and differentiation effects, As2O3 has been 
reported to induce apoptosis in NB4 cells, an APL cell line, at the concentration range 
of 1-2 μM (Chen et al., 1996). Since then, an overwhelming amount of evidence has 
accumulated providing the basis that arsenic induces apoptosis in many cell types 
comprising of both haematological and solid malignancies (Akao et al., 1999; Zhang et 
al., 1999; Bahlis et al.; 2002; Woo et al., 2002). Several characteristics appear to be 
commonly associated with arsenic-induced apoptosis. They include an increase in 
oxidative stress, changes in mitochrondrial membrane potential, caspase activation and 
Bcl2 down-regulation and reciprocal regulation of Bax and Bcl2/Bclxl expression (Bode 
and Dong, 2001).  
 
Arsenic disturbs the natural oxidation and reduction equilibrium through various 
mechanisms related in complex redox reactions with endogenous oxidants and cellular 
antioxidants systems. The redox capacities of many proteins reside in the sulphydryl 
groups of cysteines. Both the toxic and therapeutic effects of arsenic are mediated 




through reactions with closely spaced cysteine residues on critical redox sensitive 
proteins and enzymes, notably redox sensitive signalling molecules such as activator 
protein-1 (AP-1), nuclear factor-kappa B (NFκB), inhibitor of κB (IκB), p53 and p21ras 
and the GSH redox system (Bode and Dong, 2001).   
 
ROS generated in response to arsenic exposure leads to an accumulation of intracellular 
H2O2 resulting in the disruption of the ΔΨm with the release of cytochrome c and 
subsequent caspase activation which ultimately cumulates with the induction of 
apoptosis. Changes in the ΔΨm from the opening of the mitochrondrial permeability 
transition complex occur following the oxidation of thiols by arsenic. The effect can be 
diminished by free radical scavengers such as the GSH that regulate the level of ROS 
and protect the cells from arsenic-induced damage. Some investigators have observed 
that arsenic-induced apoptosis has been associated with changes in GSH levels (Jing et 
al., 1999). GSH thus appears to be a key player in determining whether apoptosis will 
occur following arsenic exposure. The sensitivity of various cells has also been shown 
to be inversely related to intracellular GSH concentrations (Akao, 2000), suggesting 
that GSH levels is a good indicator for determining sensitivity to arsenic-induced 
cytotoxicity.  
 
Besides involvement of ROS, activation of JNKs/AP-1 pathway and the inhibition of 
dual specific phosphatases have been implicated in the induction of arsenic mediated 
apoptosis (Bode and Dong, 2001). Activation of JNKs is important for the 
phosphorylation of many transcription factors that enhance gene expression in early 
intermediate genes. Its activation could phosphorylate c-Jun which is part of the 
transcription factor complex AP-1 (Bode and Dong, 2001). Consequently, the action of 




arsenic on JNKs leads to the activation of AP-1 which has been associated with 
numerous cellular effects, such as cell growth, transformation and apoptosis.    
 
More recently, As2O3 has been reported to induce various forms of caspase-
independent and autophagic cell death (McCafferty-Grad et al., 2003; Michel et al., 
2003; Kang et al., 2004; Scholz et al., 2005; Kanzawa et al., 2005; Qian et al., 2007). 
In APL cell lines, in addition to classical apoptosis induction, As2O3 induces a necrotic 
like caspase-independent mode of cell death via the mitochondria (Scholz et al., 2005). 
In human cervical carcinoma cells, As2O3 treatment triggers ROS-mediated AIF 
dependent caspase-independent apoptosis (Kang et al., 2004). Further, As2O3 deploys 
autophagy as a unique mechanism of cell death in leukaemic and malignant glioma 
cells via upregulation of Beclin-1 and mitochondrial BNIP3, respectively (Kanzawa et 
al., 2005; Qian et al., 2007).  
 
Numerous other antitumour effects of As2O3 have been reported. These include 
inhibition of angiogenesis, disruption of microtubule function by binding to cysteine 
residues, and its effects on the cytoskeleton and receptors (Bode and Dong, 2001; 
Miller et al., 2002). Indeed, the enigma of arsenic continues. A better understanding of 
the mechanisms involved in arsenic-based treatment will help to guide the development 
of new treatment regimens directed at realizing the synergistic potential between 









1.5 Statement of Purpose 
 
As discussed under section 1.3.2, cellular resistance to Cddp in patients with relapsed 
ovarian cancer is a major cause of treatment failure in clinical practice. Although 
paclitaxel is a valuable agent in the presence of Cddp resistance, its numerous toxicities 
frequently hamper its usefulness. Despite a plethora of second-line treatment modalities 
available, their efficacy remains limited in platinum-resistant disease (Eltabbakh and 
Awtrey, 2001). This spells out an urgent and important problem substantiating the 
critical need to explore novel chemotherapeutic agents and alternative anticancer drug 
combinations for the management of this deadly illness. 
 
In the 1990s, numerous reports documented the successful use of As2O3 in the 
treatment of patients with relapsed APL (Shen et al., 1997; Soignet et al., 1998). While 
demonstrating remarkable efficacy, the use of As2O3 was further associated with 
limited haematological toxicity (Shen et al., 1997; Soignet et al., 1998). Encouraged by 
these reports, it was hypothesized that arsenical compounds may be effective against 
ovarian tumour cells. This hypothesis was subsequently confirmed in previous research 
whereby arsenical compounds, As2O3 and As2S3, selectively induced cellular 
cytotoxicity in both Cddp-sensitive and -resistant ovarian cancer cells at clinically 
achievable concentrations with little effect on normal cells (Du and Ho, 2001). In line 
with this study, numerous other groups have also reported the efficacy of As2O3 in 
several other forms of solid tumour (Shen et al., 1999; Akao et al., 1999; Maeda et al., 
2001; Chow et al., 2004).  
 
Investigations into the mechanisms of action of As2O3 revealed that it influences a 
complex network of intracellular signalling pathways and cellular targets as reviewed 




in section 1.4.3. These effects however, appear to be cell-type specific. Consequently, 
there is a need to understand the action of As2O3 in ovarian cancer cells. This forms the 
basis for the overall objectives of this doctoral thesis.  
 
The principal aims were:  
(i) to study the mechanisms of action of As2O3 in ovarian cancer cells 
(ii) to study the molecular determinant of resistance of As2O3 in ovarian cancer 
cells  
(iii) to explore the effects of investigational agents when used in tandem with 
As2O3 
 
These principal aims could be further divided into the following specific objectives:  
1. To compare the cytotoxic profiles of As2O3 with paclitaxel in human ovarian 
    cancer and normal cell lines 
2. To confirm the induction of apoptosis in arsenic-treated ovarian cancer cells  
3. To investigate the roles of antioxidant, caspases, Bcl2, Bclxl, Bax, mitochondria  
    and mitochondria AIF in arsenic-induced cell death in human ovarian cancer cells 
4. To study the relationship between the GSH content and arsenic sensitivity in ovarian 
    cancer cells 
5. To modulate the sensitivity of As2O3 in ovarian cancer cells using GSH depleting  
    agents and compare their efficacy as suitable modulating agents 
6. To examine the gene expression changes during acute As2O3 exposure in 
    OVCAR-3 cell line using microarray technology.  
7. To develop an As2O3 resistant OVCAR-3 cell line (OVCAR-3/AsR) that will be    
    used to explore the possible factors mediating arsenic resistance 




8. To investigate the effects of synergistic and antagonistic drug combinations of As2O3       
and Cddp in ovarian cancer cell lines 
 
Specific objectives one and two were covered in chapter 2. They served to give 
important information with regards to the cross resistant profiles of As2O3 and 
paclitaxel. A demonstration of parallel cytotoxicity profiles will support the hypothesis 
that As2O3 will be useful as a second line clinical utility for patients who cannot 
tolerate the side effects of paclitaxel chemotherapy. Meanwhile, a confirmation of the 
induction of apoptosis provided guidance for further exploration of the mechanisms of 
As2O3 in ovarian carcinoma cells. This formed the core focus of Chapter 3 which was 
devoted to the studies listed under specific objective three. The results obtained may 
shed light into the roles of key important molecules in As2O3 mediated ovarian cancer 
cell death. They may further confirm whether the efficacy of As2O3 against Cddp 
resistant ovarian cancer was mediated through an unconventional mode of cell death, 
distinct from that of Cddp. 
 
Specific objectives four and five served to investigate the role of GSH in the sensitivity 
ovarian cancer cells to As2O3 therapy. The results as presented in Chapter 4 could 
further lead to the use of suitable GSH modulating agent that can effectively and safely 
manipulate the more arsenic resistant cell line to a therapeutic level of As2O3 that 
would be comparable to that used in APL while maintaining specificity for normal cell 
lines. The significance of these objectives once achieved can further support the role for 
development and investigations for the clinical use of As2O3 in ovarian cancer.   
 




Specific objectives six and seven allow for a further global overview of the effects of 
As2O3 in ovarian cancer cells both acutely and chronically. This is important and 
necessary as As2O3 has been known to affect multiple targets. Identification of new 
molecular targets that mediates its efficacy and chemoresistance can lead to better 
therapeutic combinations being devised that can allow for optimal cancer eradication 
while reducing the occurrence of chemoresistance.  
 
Lastly, specific objective eight served to identify novel drug combinations of As2O3 
and Cddp that can further enhance the therapeutic selectivity and efficacy of As2O3 
drug regimens and also possible drug combination that can improve the sensitivity of 
Cddp resistance ovarian cancer cells to novel Cddp drug combinations. Identification of 
these drug combinations is important as chemotherapy in synergistic combinations that 
act on different cellular targets can bring about a more complete eradication of the 
tumour volume.  
 
In combination, the expected results obtained from the listed specifics will provide 
guidance into the rationale design of future chemotherapeutic regimens involving 
As2O3 for ovarian cancer treatment. They also served as a platform to further study and 
confirm the effects of As2O3 in future in vivo animal models and subsequent Phase II 
clinical trials.   




Comparison of the Cytotoxicity Profiles of As2O3 and Paclitaxel in 
Ovarian Cancer and Normal Cells and Investigation of the Apoptotic 
and Cell Cycle Effects of As2O3 in Ovarian Cancer Cells  
2.1 Introduction 
As2O3 has been successfully utilized for the treatment of patients with APL with 
remarkable efficacy and limited hematological toxicity (Shen et al., 1997; Soignet et 
al., 1998). In vivo and in vitro studies demonstrated that As2O3 (Shen et al., 1997; 
Soignet et al., 1998) induced partial differentiation of leukaemic cells through 
degradation of PML-RARα at low drug concentrations of between 0.1 - 0.25 µM (Chen 
et al., 1996). At higher doses of 0.5 - 2 µM, As2O3 caused inhibition of cell growth, cell 
cycle arrest and induction of apoptosis in both leukaemic and solid tumour cells such as 
oesophageal, neuroblastoma, prostate and breast carcinoma cells (Shen et al., 1999; 
Akao et al., 1999; Maeda et al., 2001; Chow et al., 2004).  
 
Previous research has shown that arsenical compounds, As2O3 and As2S3, effectively 
kill both Cddp-sensitive and -resistant ovarian cancer cells at clinically comparable 
concentrations to that used in leukaemia (Du and Ho, 2001). This highlighted its 
potential as a novel agent against Cddp-resistant ovarian cancer. At present, there are 
few effective second-line agents available for the treatment of this deadly disease, with 
the most effective being paclitaxel. The suitability of paclitaxel as a second-line agent 
is partly attributed to its collateral sensitivity against Cddp-resistant cell lines in vitro 
(Perego et al., 1998). In patients refractory to Cddp chemotherapy, multicenter trials of 
paclitaxel showed response rates of between 14% and 24%, depending on the dose and 
schedule (Eisenhauer et al., 1994). 




Comparison of in vitro cell cytotoxicity patterns to different chemotherapeutic drugs 
provides for a convenient and useful method for identifying drug cross-resistance, 
identifying prospective therapeutic utility and designing chemotherapeutic 
combinations. Numerous methods have been used to date for the measurement of 
cellular cytotoxicity in vitro. These methods primarily evaluate the amount of cell death 
irregardless of the death mechanisms. Some commonly utilized methods include 
measurement based on the alterations of plasma membrane permeability and the 
consequent leakage of cytoplasmic enzymes into the supernatant.  
 
The fluorometric microculture cytoxocity assay (FMCA) is a cell membrane integrity 
assay used to provide a simple, rapid, reliable and sensitive method of evaluating cell 
proliferation and cytotoxicity (Kramer and Guilbault, 1963; Du and Ho, 2001). 
Fluorescence diacetate (FDA) is an electrically neutral non-fluorescent molecule with 
which viable cells accumulate (Kramer and Guilbault, 1963). Intracellular FDA is 
hydrolyzed by esterases to liberate its parent compound, fluorescein, which is highly 
fluorescent (Kramer and Guilbault, 1963). Anionic fluorescein accumulates within the 
live cells for a short period of time, causing them to become fluorescent, thus enabling 
the measurement of fluorescence and the differentiation between viable and non-viable 
cells, as the latter lack the ability to accumulate and hydrolase FDA (Kramer and 
Guilbault, 1963). Following cytotoxic drug treatment resulting in PCD or necrosis, the 
reduction in cell number can thus be proportionally approximated using the FMCA.  
 
The focus of this chapter was to compare the cytotoxic profiles of As2O3 and paclitaxel 
using FMCA assay. This served to further evaluate the suitability of As2O3 for use in 
the treatment of Cddp-resistant ovarian cancer which could be particularly beneficial to 




patients who cannot tolerate the side effects of paclitaxel chemotherapy. Additionally, 
apoptosis induction and effects of As2O3 on cell cycle were confirmed using OVCAR-3 
cells as prototype cells since the apoptotic mode of cell death is a kinetic event of 
variable duration depending on the type of inducer and tumour cell type studied 
(Wolbers et al., 2004). 
 
2.2 Materials and Methods 
2.2.1 Materials  
As2O3, fluorescein diacetate and ribonuclease A (RNase A) were purchased from 
Sigma Co. (St Louis, MO, USA). Paclitaxel powder was obtained from Institute of 
Material Medica, Chinese Academy of Science (Shanghai Medical Institute, China). 
Triton X 100 was purchased from Biorad (Hercules, CA, USA). Fetal bovine serum 
(FBS), penicillin/streptomycin solution, trypsin/EDTA, Roswell Park Memorial 
Institute-1640 (RPMI-1640) medium and Dulbecco’s modified Eagle’s medium 
(DMEM) were from HyClone Laboratories Inc. (Logan, UT, USA). Popidium iodide 
(PI) was from Molecular Probes (Grand Island, NY, USA).  As2O3 and paclitaxel were 
dissolved as 1.0 mmol/L stock solutions in phosphate-buffered saline (PBS) and 
dimethylsulphoxide (DMSO), respectively. Both stock solutions were stored at 4°C and 
diluted to required working concentration with culture medium before use. The 
working concentrations of As2O3 of between 0.1 µM to 20 µM and paclitaxel of 
between 0.1 nM to 50 nM were selected as these concentrations showed a good 
representation of the dose response profiles of the various cell lines tested from 
preliminary experiments. Final concentration of DMSO in the cell culture medium was 
always maintained at less than 0.01% (v/v).  
 




2.2.2 Cell Lines and Cell Culture  
Four human ovarian cancer cell lines, CI80-13S, OVCAR, OVCAR-3 and JAM were 
used. CI80-13S, OVCAR and JAM cell lines were previously characterized (Dong et 
al., 1997) and kindly supplied by the Queensland Institute of Medical Research, 
Australia. OVCAR-3 cells were purchased from American Type Culture Collection 
(ATCC) (Manassas, VA, USA).  Human dermal fibroblasts (HF) cell line (Skin Culture 
Laboratory, Singapore General Hospital, Singapore) and lung fibroblast cell line 
(MRC-5) (ATCC, Manassas, VA, USA) were used as normal controls. All human 
ovarian cancer cell lines were grown as monolayers in RPMI-1640 medium and HF and 
MRC-5 cells were grown in DMEM, supplemented with 1% (w/v) 
penicillin/streptomycin (Invitrogen Gibco, Carlsbad, California, USA)   and 10% (v/v) 
FBS (HyClone Laboratories, Logan, Utah, USA) at 37°C in a 5% CO2 humidified 
atmosphere. All cells were grown till 80% confluency before each experiment and cell 
viability of stock cultures used was always above 95% as judged by the trypan blue 
exclusion test. 
 
2.2.3 Growth Inhibition and Cytotoxicity Measured by FMCA  
 
2.2.3.1 Correlation Between Cell Numbers and Fluorescence Intensity  
Ovarian cancer (CI80-13S, OVCAR, OVCAR-3 and JAM) and normal fibroblast (HF 
and MRC-5) cells were seeded at a density of 500 to 30, 000 cells, into each well of 96-
well microtiter plates (Nalge Nunc International Co., Rochester, NY, USA). After 24 
hrs of incubation at 37°C in an atmosphere containing 5% CO2, cell culture medium 
was removed and adherent cells were rinsed with PBS. 200 µl of 2 ng/ml of FDA 
solution was added into each well and the microtiter plate was incubated for 30 mins. 
Fluorescence intensity was measured using microtiter plate reader (Spectrafluor, Tecan, 




Austria). The Spectrafluor was equipped with broadband interference filters and the 
excitation filter for fluorescence at 485 nm for FDA. The emitted light from a vertical 
light path on each of well of the 96-well microtitre plate was sequentially read at 535 
nm for FDA. The correlation between cell number of the individual cell line and 
fluorescence intensity was determined.   
           
2.2.3.2 FMCA  
The cell proliferation and cytotoxicity following drug treatment were determined using 
previously described FMCA (Du and Ho, 2001). Briefly, the cells (1 x 104) were 
seeded into 96-well microtitre plates. The plates were incubated at 37°C overnight to 
allow the cells to adhere to the bottom of the plates. After that, the medium of the plates 
was replaced with 200 µl of medium containing the test compounds (As2O3 0.1 µM to 
20 µM and paclitaxel 0.1 nM to 20 nM) or the vehicle for the test compounds as 
control. After 72 hrs of incubation, the plates were washed with PBS. 200 µl of FDA 
solution (2 ng/ml) was then added into the control, experimental and blank wells. The 
plates were incubated for 30 min at 37°C and the fluorescence generated from each 
well was measured using Spectrafluor at an excitation λ = 485 nm and emission λ = 






where by  Fdrug-treated cells represents fluorescence generated from drug-treated wells  
                 Fcontrol represents fluorescence generated from control untreated wells 
                 Fblank represents fluorescence generated from blank wells without cells  
 
 
Survival Index (SI) =                                        x 100% 
Fdrug-treated cells- Fblank 
      Fcontrol - Fblank 




The inhibitory concentration 50% (IC50) was defined as the drug concentration giving a 
SI of 50% of the control at the end of the treatment period.  
 
2.2.4 Cell Morphology Evaluation 
Morphological changes in cellular structures following drug treatment were evaluated 
using phase contrast microscopy and confocal microscopy.  
 
2.2.4.1 Phase Contrast Microscopy 
 
Ovarian cancer cells (CI80-13S, OVCAR, OVCAR-3 and JAM) and normal fibroblast 
controls (HF and MRC-5) were seeded into 24-well plates (Nalge Nunc International 
Co., Rochester, NY, USA) and incubated overnight. Control medium or medium 
containing various concentrations of As2O3 (1 µM to 3 µM) were added into the 
respective wells the following day and incubated for 72 hrs. This concentrations were 
selected as they provide a good representation of the selective cell kill effects of As2O3 
in the arsenic sensitive ovarian cancer cell lines (CI80-13S, OVCAR, OVCAR-3) 
against the normal fibroblast cells (HF and MRC-5). Medium containing floating cells 
were subsequently removed and the adherent cells were washed with PBS at 37°C. 500 
µl of PBS were added into respectively wells and adherent cells were observed by 
phase contrast microscopy. Photographs of the adherent cells were taken using a phase 
contrast microscope (Nikon Eclipse, TE 2000).  
 
2.2.4.2 Confocal Microscopy 
 
The nuclear morphological changes in untreated and As2O3 treated cells were further 
observed using confocal microscopy after nuclear staining with PI. Briefly, CI80-13S, 
OVCAR-3, OVCAR human ovarian cancer cells were treated with 2 µM of As2O3 for 




72 hrs. Afterwhich, adherent and floating cells were harvested separately and washed 
twice with PBS. The cells were fixed in 70% (v/v) ice-cold ethanol overnight, washed 
twice with ice-cold PBS and stained with PI (Molecular Probes)/Triton X-100 staining 
solution (20 µg of PI per ml of  0.1% (v/v) of Triton X-100 in PBS) containing 0.2 
mg/ml of  DNAse-free RNAse A  (Sigma, St. Louis, MO, USA) for 30 min at 37°C. 
Samples were brought on microscope glass slides and analyzed under confocal 
microscope (Olympus, FV1000) under 600x magnification and the images were taken. 
Apoptotic cells were identified by the shrinking cytoplasm, condensed chromatin and 
nuclear fragmentation with intact cell membrane.  
 
2.2.5 Analysis of Apoptosis Rate and Cell Cycle Distribution by Flow Cytometry 
Apoptosis rate was identified and quantified by flow cytometry. Briefly, control and 
treated cells were fixed in 70% (v/v) ice-cold ethanol at -20°C for 2 hrs. Cells were 
then washed with PBS and incubated in 1 ml of PI (Molecular Probes)/Triton X-100 
staining solution (20 µg of PI per ml of  0.1% (v/v) of Triton X-100 in PBS) containing 
0.2 mg/ml of  DNAse-free RNAse A  (Sigma, St. Louis, MO, USA) for 30 min at 37°C. 
Samples were filtered through a 40 µM pore nylon mesh and the percentage of 
apoptotic cells were measured with a FACScan flow cytometer (Altra™, Beckman-
Coulter Inc., Germany). The excitation wavelength for PI was 488 nm. At least 10,000 
cells were collected for each sample. DNA histograms were subsequently analyzed 
using WINMDI Software (Scripps Institute, La Jolla, CA, USA). Cells with DNA 









Results were presented as the mean ± SD of at least three independent experiments. 
Data was analysed by ANOVA with Tukey’s posthoc analysis for comparison with 
three or more groups (Graphpad Prism 4 Software, Graphpad Software Inc., San Diego, 
CA, USA). A p value of < 0.05 was considered to be statistically significant.  
 
2.3 Results 
2.3.1 Linear Relationship Between FDA Fluorescence and Cell Number  
To ensure accurate correlation of changes in cell proliferation following drug treatment, 
a linear relationship between the cell number and fluorescence emitted had to be first 
established. Healthy cells from each ovarian cancer and normal fibroblast cell lines 
with viabilities of more than 95% were harvested, seeded at different densities in 
microtitre wells of 96-well plates and tested under the optimized FDA assay conditions 
(Du and Ho, 2001). All cell lines tested exhibited a linear proportional relationship (r2 > 
0.99) between the fluorescence emitted and the cell number (Figure 2-1). The 
difference in the fluorescence reading for equal number of cells among the different 
cell types reflects the inherent differences in cell volume and level of hydrolytic 
enzymes activities within each cell type. The results showed that accurate 
quantification of as little as 1000 cells per well for each cell line could be achieved, 























































































































































Figure 2-1 Linear correlation between cell numbers and fluorescence emitted by  











2.3.2 Cytotoxicity Profiles of As2O3 and Paclitaxel in Ovarian Tumour and 
Normal Cell Lines  
 
 
The dose-dependent growth inhibition profiles of As2O3 on ovarian cancer cell lines 
CI80-13S, OVCAR, OVCAR-3, JAM, normal skin and lung fibroblast HF and MRC-5 
cells were performed by treating 10 000 cells from each cell line with 0.1 – 20 µM of 
As2O3 solutions for 72hrs. Drug-induced cytotoxicities were measured using FMCA. 
As2O3 exerted different effects on cell survival and proliferation of the ovarian cancer 
cell lines as illustrated by their dose-response curves (Figure 2-2). The order of their 
sensitivities in a decreasing manner was CI80-13S ≥ OVCAR-3 ≥ OVCAR > JAM > 
MRC-5 ~ HF. This result was confirmed by their IC50 values ranging from between 
1.10 µM to 7.89 µM for ovarian cancer cells and 9.01 µM to 9.65 µM for normal 
fibroblast cells (Table 2-1).  
 
Similarly, the cytotoxicity profiles of paclitaxel in the different cell lines were 
determined following treatment with 0.1-50 nM of paclitaxel in DMSO. The final 
concentration of DMSO in the cell culture medium was constantly maintained at less 
than 0.01% (v/v) such that it has minimal cytotoxic effects on the cells tested. The 
cytotoxicity profiles of the cell lines and IC50 values for paclitaxel were shown in 
Figures 2-2 and Table 2-1, respectively. As with As2O3, the ovarian cancer cell lines 
showed different sensitivities to paclitaxel. The order of sensitivity obtained was 
similar to that of arsenic with CI80-13S being the most sensitive, followed by OVCAR-
3, OVCAR and subsequently the JAM cell line. As with As2O3, paclitaxel was less 
toxic to normal fibroblast cells, MRC-5 and HF, as shown by the higher survival 
indices within the tested concentration range. These results obtained illustrated that 




both drugs exhibited similar cytotoxic profiles for the selected panel of ovarian cancer 































































Figure 2-2 Cytotoxicity profiles of (A) As2O3 and (B) paclitaxel on ovarian cancer and 
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Table 2-1 IC50 values of As2O3, paclitaxel and Cddp in in vitro growth inhibition assay 
in ovarian cancer cell lines and normal human fibroblast cells 
 
           
          Cell Line                                       IC50 values (Mean ± SD) 
 
                                            As2O3 (μM)             Paclitaxel (nM)         Cddp (μg/ml)                                 
 
                 
CI80-13S 
           
1.10 ± 0.69                2.00 ± 0.32                7.74 ± 1.70+ 
OVCAR 
 
1.96 ± 0.67               6.98 ± 0.82              1.00 ± 0.18+ 
OVCAR-3 
 
1.48 ± 0.41                4.83 ± 0.43                1.84 ± 0.25# 
JAM         
                      
7.89 ± 0.84                8.03 ± 2.61                5.53 ± 1.27+ 
MRC-5     
                     
9.01 ± 0.10              23.08 ± 1.52              ND 
HF 
 
9.65 ± 0.89                         * 3.10 ± 0.35+ 
 
   *IC50 could not be reached in the tested dosage range. + Data was obtained from Du and Ho, 2001. 




2.3.3 Reduction in Cell Number and Apoptosis Induction in As2O3 Responsive 
Ovarian Tumour Cells  
 
Cell morphological studies were performed to observe the effects of As2O3 in ovarian 
cancer and normal fibroblast cells. Under the phase contrast microscope, increasing 
As2O3 concentration of up to 3 µM resulted in extensive detachment of As2O3 
responsive cells, CI80-13S, OVCAR and OVCAR-3, from the cell culture substratum 
resulting in a visible reduction in cell numbers after 72 hrs of drug incubation (Figures 
2-3 to 2-5). In parallel, xstudies on the less arsenic responsive cell line, JAM, and 
normal fibroblast cells, MRC-5 and HF, concentrations of As2O3 less than 3 µM 
resulted in no observable detachment and reduction in cell numbers (Figures 2-6 to 2-
8), indicating the greater cytotoxic selectivity of As2O3 for CI80-13S, OVCAR and 
OVCAR-3 cells.  
 




Previously Du and Ho (Du and Ho, 2001) have reported apoptosis induction in a panel 
of arsenic sensitive ovarian cancer cell lines (Du and Ho, 2001). To confirm this 
observation, the occurrence of apoptosis was further verified using PI staining. Arsenic-
treated cells showed chromatin condensation and nuclear fragmentation (Figure 2-9) 































       
                 Control       As2O3 1 μM  
               
 As2O3 2 μM                                                            As2O3 3 μM 
      
Figure 2-3 Effects of As2O3 on cell number of CI80-13S cells 
 
Adherent cells were washed once with PBS and visualized using phase contrast microscope. Original 





















       
                  Control      As2O3 1 μM         
                 
    As2O3 2 μM                 As2O3 3 μM  
 
Figure 2-4 Effects of As2O3 on cell number of OVCAR cells 
 
Adherent cells were washed once with PBS and visualized using phase contrast microscope. Original 






















       
                    Control       As2O3 1 μM         
           
   As2O3 2 μM                                                        As2O3 3 μM     
 
Figure 2-5 Effects of As2O3 on cell number of OVCAR-3 cells 
 
Adherent cells were washed once with PBS and visualized using phase contrast microscope. Original 






















       
                 Control       As2O3 1 μM  
                 
     As2O3 2 μM                                                       As2O3 3 μM           
 
Figure 2-6 Effects of As2O3 on cell number of JAM cells 
 
Adherent cells were washed once with PBS and visualized using phase contrast microscope. Original 























       
                   Control      As2O3 1 μM  
                 
    As2O3 2 μM      As2O3  3 μM  
 
Figure 2-7 Effects of As2O3 on cell number of MRC-5 cells 
 
Adherent cells were washed once with PBS and visualized using phase contrast microscope. Original 























       
                   Control       As2O3 1 μM  
                 
   As2O3 2 μM                                                        As2O3 3 μM   
      
 
Figure 2-8 Effects of As2O3 on cell number of HF cells 
 
Adherent cells were washed once with PBS and visualized using phase contrast microscope. Original 
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Figure 2-9 Apoptosis Induction in CI80-13S, OVCAR and OVCAR-3 cells in response 
to As2O3 
Untreated and As2O3-treated cells were collected after 72 hrs, stained with PI and observed under 
confocal microscope. Original magnification 600X.   




2.3.4 Time- and Concentration-Dependent Increase in Apoptotic Effects of As2O3 
in OVCAR-3 Cells  
 
OVCAR-3 cell line was chosen as a representative cell line to investigate the kinetics of 
As2O3-mediated apoptotic effects in ovarian cancer cells. The percentage of apoptosis 
was determined by measuring the sub-G1 DNA content, an indication of apoptosis, of 
PI stained untreated and arsenic-treated cells using flow cytometry. OVCAR-3 cells 
were cultured with different As2O3 concentrations for different time intervals up to 120 
hrs. There appeared to be a very small increase in the apoptotic rate at 24 hrs of 
treatment (Figure 2-10). As the As2O3 incubation period was prolonged, a greater 
percentage of apoptotic cell population was observed. Apoptotic rates at 48 hrs after 
incubation with 2 µM, 3 µM and 5 µM of As2O3,  respectively were 8.58 ± 1.34% (p > 
0.05), 11.65 ± 1.97% (p < 0.05) and 14.03 ± 2.48% (p < 0.05). Further significant 
increase in apoptotic rates (p < 0.05) were observed for cells treated with 2 µM, 3 µM 
and 5 µM of As2O3 for 120 hrs when compared to untreated cells (0 hr). These results 
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Figure 2-10 Time- and concentration-dependent induction of apoptosis in arsenic-
treated OVCAR-3 cells 
 
(* p < 0.05 between 48 or 120 hrs versus 0 hrs; ** p < 0.05 between As2O3 2 µM at 120 hrs versus  
As2O3 5 µM at 120 hrs; *** p<0.05 between  As2O3 3 µM at 120 hrs versus As2O3 5 µM at 120 hrs using 
ANOVA and Tukey’s posthoc test) 
 
 
2.3.5 Low Concentrations of As2O3-Induced G2/M Phase Cell Cycle Arrest in 
OVCAR-3 Cells  
 
The effects of As2O3 on cell cycle progression of OVCAR-3 cells were analyzed by 
flow cytometry after PI staining following 48 hrs of exposure to varying concentrations 
of As2O3. The cell cycle effects of As2O3 on OVCAR-3 cells were arsenic 
concentration-dependent. At lower concentrations of As2O3, 2 µM and 3 µM, a 
significant increase in the proportion of cells in the G2/M phase of the cell cycle was 
seen (p < 0.05) (Figure 2-11) when compared to control untreated cells. This was 
accompanied by a reduction in the cells formerly present in G1 phase. When the 
concentration of As2O3 was increased further to 5 µM, no G2/M phase arrest was 
observed at 48 hrs of As2O3 exposure. Instead a slightly greater proportion of cells was 
arrested at the S phase of the cell cycle (15.36 ± 2.02% for 5 µM of As2O3 versus 8.81 
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± 1.20% for control cells; p < 0.05) (Figure 2-11) while the rest of the cells underwent 
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Figure 2-11 Effect of As2O3 on cell cycle of OVCAR-3 cells 
 
(* p < 0.05 between control versus As2O3 2 µM or As2O3 3 µM; ** p < 0.05 between control versus 





The 5-year survival rate for ovarian cancer patients has been reported to be limited to 
less than 30%, making the disease one of the most fatal gynaecological malignancies 
(Jemal et al., 2004). This was attributed mainly by its insidious onset and the 
manifestation of Cddp-resistant disease despite their initial response to Cddp 
chemotherapy. While the impressive antitumour activities of paclitaxel offers some 
hope for patients with Cddp chemoresistance, its potential side effects and toxicities, 
such as life-threatening neutropenia, frequently hamper its usefulness, thus 
necessitating the evaluation of other effective therapeutic agents, with less severe side 
effect profiles, as alternative treatment options (Rowinsky and Donehower, 1995).  
 
Control        As2O3 2 µM     As2O3 3 µM     As2O3 5 µM 












The re-emergence of As2O3 for the treatment of APL (Shen et al., 1997; Soignet et al., 
1998) and its potential efficacy in other solid tumour cells (Shen et al., 1999; Akao et 
al., 1999; Maeda et al., 2001; Du and Ho, 2001) offer promising prospects in the battle 
against cancer. In this study, the suitability of As2O3 for ovarian cancer treatment was 
further evaluated. It was shown that As2O3 has a similar cytotoxic profile with 
paclitaxel in the panel of ovarian cancer cell lines tested. These dose response profiles 
do not have a similar cross-resistant pattern as that of Cddp. It was also observed that 
the therapeutic selectivity of As2O3 for normal fibroblast cells was reduced against the 
more arsenic resistant JAM cell line when compared to paclitaxel, suggesting that when 
higher concentrations of As2O3 are being used, there can be a potential of greater 
toxicity of As2O3 compared to paclitaxel. This however have to be carefully interpreted 
as As2O3 did not show the myleosuppressive effects, neuropathy and hypersensitivity 
episodes in clinical practice when As2O3 is being used at a concentration equivalent to  
of 1-2 µM in vitro (Shen et al., 1997; Soignet et al., 1998). At these concentrations 
As2O3 chemotherapy is well tolerated with careful hydration and electrolyte monitoring 
(Shen et al., 1997; Soignet et al., 1998). This suggests that As2O3 chemotherapy could 
still be feasible in a more arsenic responsive subset of Cddp-resistant patients who 
cannot tolerate paclitaxel chemotherapy. In addition, further studies exploring the use 
of synergistic agents with As2O3 should be conducted to achieve IC50 of As2O3 to be 
around 1-2 µM in the more arsenic resistant JAM cell line. Such therapeutic 
combinations when identified would allow for a safer use of As2O3 in Cddp-resistant 
patients with a less arsenic responsive subset of tumour.     
 
The arsenical-induced cytotoxicity and apoptosis in several gynaecological cell lines 
have been previously reported (Du and Ho, 2001). In this study, apoptosis induction 




was confirmed in CI80-13S, OVCAR and OVCAR-3 cells at As2O3 concentrations of 
about 2 µM which is comparable to that for the clinical treatment of APL. In addition, 
the induction of apoptosis in OVCAR-3 cells was shown to be a time- and 
concentration- dependent event. Further, the results revealed that concurrent with 
apoptosis induction, arsenic-treated OVCAR-3 cells were arrested at various phases of 
the cell cycle that was dependent on the concentration of As2O3 used. The latter is in 
agreement with other reports whereby low concentrations of As2O3 slowed down the 
progression of the cells through the S phase of the cell cycle and caused G2/M phase 
arrest (McCollum et al., 2005) while higher As2O3 concentration induced S phase cell 
cycle arrest (Hernandez-Zavala et al., 2005; Han et al., 2007). Since the S phase cell 
cycle checkpoint seemingly acts to prevent cell replication in the presence of significant 
DNA damage (Paulovich and Hartwell, 1995), a plausible explanation for the slightly 
greater proportion of the cell arrested in the S phase of the cell cycle with 5 µM of 
As2O3 treatment could be the greater amount of DNA damage induced by the higher 
As2O3 concentration.   
 
PCD in the form of apoptosis induction is currently the best understood mode of cell 
death. Induction of apoptosis is an important mechanism by which most conventional 
anticancer therapies exert their tumour killing effects (Thompson 1995; Fleisher, 1997). 
In tumour cells, a strong selection pressure exists to suppress apoptosis induction. 
Simultaneously, these cells develop the ability to bypass cell-cycle checkpoint controls 
to ensure continuous proliferation (Nojima, 1997). The dual ability of As2O3 to 
modulate alternative apoptotic related pathways distinct from that of Cddp and to cause 
cell cycle arrest in Cddp-resistant OVCAR-3 cells suggest that the mechanisms of 
As2O3 induced cytotoxicity in these cell lines may be unique. Indeed recent reports of 




the effects of As2O3 suggest that As2O3 works in p53 independent manner (Rojewski et 
al., 2004) and may use the mitochondrial route of apoptosis associated with modulation 
of molecules such as Bcl2 (Bode and Dong, 2001). The latter can be further explored to 
provide a better understanding of the therapeutic mechanisms of As2O3 in ovarian 
cancer cell lines. Overall, the results of this chapter showed that As2O3 may be a 
potentially promising agent to improve the efficacy of chemotherapy in platinum-






The Role of Caspases, Antioxidants, Bcl2, Bclxl, Bax, Mitochondria 




The established effectiveness of As2O3 for APL treatment has led to numerous 
investigations into its mechanisms of action, both in APL and in other types of cancers 
(Gazitt and Akay, 2005). These studies revealed that As2O3 mediates an intricate 
network of effects on numerous cellular targets and signal transduction pathways 
(Gazitt and Akay, 2005). It has since been labelled as a potent anticancer agent and is 
becoming an increasingly useful agent not only for the treatment of APL but also other 
diseases (Gazitt and Akay, 2005). Some of the factors identified to be important in 
As2O3-mediated apoptosis and cell death include caspase activation (Akao et al., 
1999), generation of ROS (Maeda et al., 2001), opening of the PTP (Tian et al., 2005) 
and down-regulation of Bcl2 expression (Chen et al., 1996). These effects, however, 
appear to be cell-type specific, thus necessitating the study of the action of As2O3 in 
individual cell types.        
 
As discussed in Chapter 1, cellular apoptosis is an important process in a wide variety 
of different biological systems and in chemotherapy-induced cell death. It can be 
mediated by caspase proteases and can proceed through several different cell death 
signalling pathways that converge at the mitochondria (Thompson, 1995; Au et al., 
1997; Nunez et al., 1998; Roy and Nicholson, 2000). The mitochondria-mediated cell 
death can in turn be elicited by several factors. The first being excessive oxidative 
stress generated by cytotoxic insults. This oxidative stress can in turn play an important 





death by several chemotherapeutic drugs (Doroshow, 1983; Wallach-Dayan et al., 
2006; Gupta et al., 2003; Woo et al., 2004; Kang et al., 2004).  
 
Other important factors involved in the mitochondria-mediated cell death include the 
Bcl2 family members and caspase independent factors such as AIF. In leukaemic (Jing 
et al., 1999; Dai et al., 1999) and several solid tumour cells (Woo et al., 2002; Shen et 
al., 2002; Haga et al., 2005), induction of proapoptotic members and/or down-
regulation of antiapoptotic Bcl2 family members plays an important role in their 
cytotoxic effects. In APL, As2O3 has been shown to down-regulate Bcl2 protein (Chen 
et al., 1996). Bcl2 (Kassim et al., 1999) and Bclxl (Williams et al., 2005) have also 
been shown to play an important role in Cddp resistance in ovarian cancer cells.  
Furthermore, AIF has been reported to induce condensation of the chromatin in a 
caspase independent manner in cervical cancer cells after As2O3 treatment (Kang et al., 
2004). Taken together, current evidence implies that the mitochondrial and the 
molecules it habour play an important role in As2O3 mediated cytotoxicity.  
 
Although As2O3 has been reported to induce cytotoxicity and apoptosis in ovarian 
cancer cell lines (Uslu et al., 2000; Du and Ho, 2001), the cellular factors mediating its 
effects in these cells remain largely unknown. In the present chapter, the contribution of 
caspases, oxidative stress, mitochondria, selected members of the Bcl2 family namely, 
Bax, Bcl2, Bclxl and AIF, in As2O3-induced apoptosis and cell death in selected 
arsenic-sensitive and -resistant ovarian cancer cells were investigated.    





3.2 Materials and Methods 
 
3.2.1 Materials  
    
As2O3, t-butyl-hydroxyanisole (BHA), CAT, FDA and Bradford reagent were 
purchased from Sigma (St. Louis, MO, USA).  Caspase inhibitors, benzoyloxy-
carbonyl-Val-Ala-Asp-fluoromethylketone (z-VAD-FMK) and acetyl-Asp-Glu-Val-
Asp-aldehyde (Ac-DEVD-CHO) were from Promega, USA. Mouse monoclonal anti-
Bcl2 antibody was from NeoMark’ers (Fremont, CA, USA). Anti-Bax antibody, mouse 
monoclonal c-Myc and AIF antibodies were from Santa Cruz Biotechnology Inc. 
(Santa Cruz, CA, USA). Rabbit anti-Bclxl antibody was from Cell Signalling 
Technology (Beverly, MA, USA). Anti-actin antibody was from Sigma (St. Louis, MO, 
USA). Horseradish peroxidase-conjugated anti-mouse and anti-rabbit secondary 
antibodies were from Abcam (Clearbrook, IL, USA) and DAKO (Carpinteria, CA, 
USA), respectively.    
 
3.2.2 Cell Culture and Transfection 
 
CI80-13S, OVCAR-3 and JAM cells were used. All cells were grown as monolayers in 
RPMI-1640 medium supplemented with 10% (v/v) heat inactivated FBS (HyClone 
Laboratories, Logan, Utah, USA) and 1% (w/v) penicillin/streptomycin (Gibco 
Invitrogen, Carlsbad, CA, USA) at 37C in a humidified atmosphere of 95% air and 5% 
CO2. Cell viability was assessed by the trypan blue dye exclusion assay. The viability 
of the cells used for subsequent experiments was always ensured to be above 95%. 
 
OVCAR-3 cells were transfected with a pIRESNeo Myc-tagged Bclxl vector or 
pIRESNeo Myc-tagged empty vector using the Amaxa Nucleofector System (Amaxa 





established by continuous culture with G418 (Life Technologies Inc., Grand Island, 
NY, USA).    
 
3.2.3 Quantification of Cell Death  
 
Cell death and cytotoxicity were assessed using FMCA as described in Chapter 2.  For 
all experiments, cells were seeded at 1 x 105 cells per well of 96-well plates. For the 
caspase inhibitor experiments, pan-caspase inhibitor (z-VAD-FMK) or caspase 3 
inhibitor (Ac-DEVD-CHO), were applied 2 hrs before As2O3 treatment and replenished 
every 24 hr until the treatment was terminated. For the antioxidant experiments, the 
cells were treated with As2O3 simultaneously with either BHA or CAT until 
experiments were terminated following 48 hrs of drug incubation. Cell survival was 
presented as SI and IC50 values were calculated as previously described in Section 
2.2.3.2.  
 
3.2.4 Measurement of Caspase 3 Activity 
 
Caspase 3 activity in response to arsenic treatment was determined using a 
CaspaseACETM assay kit (Promega, Madison, WI, USA) according to the 
manufacturer’s instruction. Briefly, 3 x 106 cells were lysed in lysis buffer (25 mM 
HEPES (pH = 7.5), 5 mM MgCl2, 5 mM EDTA, 5 mM DTT, 2 mM PMSF, 10 µg/ml 
pepstatin, 10 µg/ml leupeptin) and the supernatant fractions were collected by 
centrifugation (16 000 g) for 20 min. Caspase 3 activity was detected in the 
supernatants (50 µg of protein) by measuring the proteolytic cleavage of the 
fluorogenic substrates Ac-DEVD-AMC (where AMC is the fluorochrome 7-amino-4-
methyl coumarin) (Dimmeler et al., 1997). The generated AMC fluorescence was 





emission wavelength of 460 nm. All the reactions were performed in duplicate. The 
activity was calculated as the fluorescence intensity/mg protein and represented as % of 
the activity from the untreated control cells. The protein concentration was measured 
by protein determination assay kit (Sigma, St. Louis, MO, USA), with bovine serum 
albumin as standard for calibration.  
 
3.2.5 Western Blotting 
 
Bax, Bcl2 and Bclxl protein levels were determined using western analysis. Control and 
treated cells were collected by centrifugation, washed with PBS and lysed in lysis 
buffer (10 mM Tris-Cl (pH = 7.4), Triton X 0.1% (v/v), 5 mM EDTA (pH = 8.0) and 
0.15 M NaCl) supplemented with protease inhibitor cocktail (Roche, Indianapolis, IN, 
USA). Lysates (30-40 µg total protein) were electrophoretically separated by sodium 
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and blotted onto 
nitrocellulose membrane. Antibody dilutions were carried out as per data sheet 
provided by the manufacturer. Blots were developed by horseradish peroxidase-
conjugated secondary antibodies and visualized using an enhanced chemiluminescence 
detection system (Perkin Elmer Life Sciences, Wellesley, MA, USA). Results were 
quantified by densitometric analysis using an Alpha Inotech densitometer 
(FluorChemTM 9900, Alpha Inotech, San Leandra, CA, USA). The data were 
normalized by actin and presented as a ratio of the control protein levels within each 
group.  
 
3.2.6 Isolation of RNA and Quantitative Polymerase Chain Reaction 
 
Total RNA was prepared using RNeasy Mini kit obtained from Qiagen (Valencia, CA, 





transcription reagents (Applied Biosystems, Foster City, CA, USA) according to 
manufacturer’s protocol. Gene expression was quantified using the ABI PRISM  7500 
(Applied Biosystems) Sequence Detection System instrument. Assays on demand gene 
expression products consisting of unlabelled PCR primers and FAM labelled, TaqMan 
probes were from Applied Biosystems. The assay identifications for the probes were 
Hs00180269_m1, Hs00608023_m1, Hs00236329_m1 and Hs99999905_m1 for Bax, 
Bcl2, Bclxl and GAPDH genes, respectively. Amplification reactions were done with 
the Universal Taqman PCR Master Mix (Applied Biosystems) in quadruplicates for 
each cDNA sample with the following thermal cycling conditions: 50C for 2 min, 
95C for 10 min and 40 cycles of 95C for 15 s and 60C for 1 min. Normalization of 
samples was performed by dividing the value of the unknown gene by the value of the 
endogenous reference gene (GAPDH). Relative expression was calculated for each 
gene using the 2- CT method (Livak and Schmittgen, 2001). Values reported have a 
95% confidence interval as determined by the ABI RQ software.    
 
3.2.7 Measurement of m   
Mitochondria were labelled using a mitochondria specific dye, tetramethylrhodamine 
ethyl ester perchlorate (TMRE) (Sigma, St Louis, MO, USA). TMRE is a cationic dye 
with an affinity for intact mitochrondria. When the mitochondria are depolarized by 
cytotoxic agents, they have a less affinity for the dye and thus they retain a lower 
amount of TMRE. The difference in the TMRE fluorescence between control and 
treated cells can in turn be measured and thus provides an indication of the amount of 
mitochondrial depolarization that has taken place. The control (untreated) and treated 





for 30 mins at 37ºC in PBS buffer containing 100 nM of TMRE. Cells were then 
washed with ice-cold PBS, trypsinized and analyzed by flow cytometry.  Cells treated 
with the mitochondrial uncoupler, carbonyl cyanide m-chlorophenyl-hydrazone 
(CCCP) (Sigma, St Louis, MO, USA) were used as the positive control.     
   
3.2.8 Localization of AIF by Immunofluorescence 
 
Control and treated cells were grown on coverslips, washed with PBS, fixed with 
paraformaldehyde and permeabilized with 0.2% (v/v) Triton X-100 at room 
temperature before incubation with mouse anti-AIF (Santa Cruz, CA, USA) overnight 
at 4C. After three washes in PBS, cells were incubated with Alexa Fluor 488 
conjugated secondary antibody (Molecular Probes, MO, USA) for 2 hrs at room 
temperature. Cells were washed three times with PBS, nuclei were stained with 4',6-
diamidino-2-phenylindole (DAPI) (0.1 µg/ml) for 5 mins before mounting with 






Results were presented as the mean  SD of at least three independent experiments. 
Statistical analysis was performed using Graphpad Prism 4 Software (Graphpad 
Software Inc., San Diego, CA, USA). p values were calculated according to Student’s t 
test for comparison between two groups and ANOVA with Tukey’s posthoc test for 
comparison between three or more groups. A p value of < 0.05 was considered to be 








3.3.1 Cell Death Induced by As2O3 Is Caspase-Independent  
 
The activation of caspase-3 in As2O3 induced cytoxocity in ovarian cancer cells was 
examined in arsenic sensitive CI80-13S and OVCAR-3 cells after arsenic treatment. 
Treatment with various concentrations of As2O3 resulted in a significant increase in 
caspase 3 activity in OVCAR-3 cells (Figure 3-1) (Du and Ho, unpublished data), with 
highest activity detected at 2 µM of As2O3.  However, in CI80-13S cell line, no 
activation of caspase 3 was observed despite its sensitivity to As2O3 (Figure 3-1) (Du 
and Ho, unpublished data). This result implied that caspase 3 might not be required for 
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Figure 3-1 As2O3-induced selective caspase 3 activation in OVCAR-3 cells  
 
(* p < 0.05 when compared to control using Student’s t test) 
 
 
To further understand the relevance of caspase 3 in arsenic-induced cell death, cell kill 
after exposure of OVCAR-3 and CI80-13S cells to As2O3 in the presence and absence 
of a caspase 3 inhibitor (Ac-DEVD-CHO) was assessed. As shown in Figure 3-2, cell 





DEVD-CHO, confirming that caspase 3 was not crucial for arsenic-mediated cell death 
of ovarian cancer cells. To evaluate the importance of other caspases, the ability of a 
pan-caspase inhibitor (z-VAD-FMK) to attenuate arsenic-induced cell death was 
examined. As with Ac-DEVD-CHO, z-VAD-FMK did not affect the cell viability of 
arsenic-induced cell death (Figure 3-2). The inability of caspase inhibitors to block 
arsenic-induced cell death was not due to the use of a suboptimal concentration of 
inhibitors as they were able to partially protect against Cddp-induced cell death in 
similarly treated cells (Figure 3-2). These results highlight that cell death following 
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Figure 3-2 Effect of caspase inhibitors on As2O3 and Cddp-induced cell death in    
(A) CI80-13S cells 
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Figure 3-2  Effect of caspase inhibitors on As2O3 and Cddp-induced cell death in  
(B) OVCAR-3 cells (Continued)  
 
(* p < 0.05 between Cddp 3 M versus Cddp 3 M + z-VAD-FMK 100 M; ** p < 0.05 between Cddp 
3 M versus Cddp 3 M + Ac-DEVD-CHO 150 M using Student’s t-test) 
 
 
3.3.2 As2O3-Mediated Cell Kill Occurred Independently of ROS in Ovarian 
Cancer Cells  
 
ROS has been reported to be involved in As2O3-mediated apoptosis and cell kill 
(Maeda et al., 2001). To determine whether ROS was essential to As2O3-mediated 
cytotoxicity of ovarian cancer cells, antioxidants were used to probe the involvement of 
ROS in the death process. In the presence of the H2O2 scavenger CAT, arsenic-





0.05) (Figure 3-3). When BHA, a lipophilic antioxidant with superoxide radical 
scavenging activity was used, it was unable to confer protection to As2O3-mediated 
cytotoxicity (Figure 3-4). Taken together, these results provided evidence to suggest 


































































































































































































































































































































































































































































































































3.3.3 Both Bclxl Protein and Gene Expression Were Consistently Down-Regulated 
In Arsenic Sensitive Cell Lines While Bcl2 and Bax Protein and Gene Expression 
Remained Unchanged In Response to Low As2O3 Concentration 
 
The effects of As2O3 on Bcl2, Bclxl and Bax proteins in ovarian cancer cell lines were 
examined. Bclxl protein was dose-dependently decreased in OVCAR-3 and CI80-13S 
cells following exposure to As2O3 (Figure 3-5).  In both cell lines, no increase in 
proapoptotic Bax protein level was observed. Bcl2 protein level again remained 
unchanged in OVCAR-3 cells at low arsenic concentrations and was slightly down-





Interestingly, in CI80-13S cells, no Bcl2 protein was constitutively detectable. For JAM 
cells which were less responsive to arsenic treatment, there was an increase in Bclxl 
protein level at low arsenic concentrations (1 to 3 µM) followed by down-regulation 
towards basal level with higher As2O3 concentration of 5 µM. The level of Bcl2 was 
only slightly down-regulated at 5 µM of As2O3, while no up-regulation of proapoptotic 
Bax was observed.  
 
Bcl2, Bclxl and Bax gene expressions in arsenic-treated cells were further examined 
using real time PCR (Figure 3-6). Bclxl gene expression was dose-dependently down-
regulated in OVCAR-3 and CI80-13S cells, whilst the levels of Bax gene remained 
unchanged. In OVCAR-3 cells, Bcl2 gene expression was not affected at low arsenic 
concentrations. In JAM cells, Bclxl gene expression was up-regulated with lower 
concentration of As2O3, but was again down-regulated towards basal level when higher 
As2O3 concentration was used. In this cell line, Bcl2 gene expression was slightly 
down-regulated by 3 µM and 5 µM of As2O3, while Bax gene expression was also 
slightly down-regulated at 5 µM of As2O3. Overall, these results suggest that As2O3 
may affect Bclxl expression either at the transcriptional or at the mRNA stability level 
and it is possible that Bclxl may play a more important role in regulating the effects of 















          
  










































Figure 3-5 Effects of As2O3 treatment on Bclxl, Bcl2 and Bax protein levels in  
(A) CI80-13S, (B) OVCAR-3 and (C) JAM cells 
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3.3.4 Bclxl Overexpression Partially Protected Against Arsenic-Induced 
Cytotoxicity  
 
To confirm the importance of Bclxl in As2O3-induced cell death in ovarian cancer 
cells, Bclxl protein was selectively overexpressed in OVCAR-3 cells. This cell line was 
transfected on a stable basis with a Myc-tagged vector encoding a neomycin-resistance 
gene, namely, Myc-tagged neo-vector control or Myc-tagged Bclxl. The transfected 
clones 1 and 2 were characterized and shown by western blotting to overexpress Myc-
tagged Bclxl protein as compared with the empty vector control (Neo-vector control) 











Figure 3-7 Western blot of untransfected and transfected OVCAR-3 cells 
 
 
As shown in Figure 3-8, overexpression of Bclxl protein only resulted in a partial 
protection from arsenic-induced cell death in OVCAR-3 cells. In comparison, Bclxl 
overexpression afforded complete protection against As2O3-induced apoptosis in 
transfected clones (Figure 3-9). These findings suggest that other pathways in addition 
to apoptosis may contribute to As2O3-induced cell death of ovarian tumour cells which 
may be partially inhibited by ectopically expressed Bclxl.     
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Figure 3-9 Effect of Bclxl transfection on As2O3-induced apoptosis in OVCAR-3 cells 
(M1 marker represents the proportion of cells in the sub-G1 phase of the cell cycle) 
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3.3.5 Depolarization of m in a Fraction of OVCAR-3 Cells After As2O3 
Treatment 
 
Given that the antiapoptotic Bclxl protein was able to partially blunt the induction of 
cell death by As2O3 and that it was an important regulator of mitochondria pathway of 
cell death, changes in the cellular m after arsenic treatment were examined. 
Measurement of the changes in m was facilitated by loading control and treated 
cells with the m sensitive fluorescent probe TMRE. As illustrated in Figure 3-10, 
the marker M1 indicates the proportion of cells displaying low TMRE fluorescence, 
thus demonstrating that m has occurred in these cells. In the presence of the 
mitochondrial uncoupler, CCCP, a significant amount of cells underwent m, as 
evidenced by the large number cells (57.23%) showing low TMRE retention when 
compared to only 13.66% of control untreated cells. With As2O3 treatment, relatively 
smaller portion of OVCAR-3 cells (27.76%) underwent m after 48 hrs of 
incubation. This was further increased to 37.50% after 72 hrs of incubation (Figure 3-
10). 
     
 
M1   
Figure 3-10 Loss of m in a fraction of OVCAR-3 cells after As2O3 treatment 
Control (Untreated Cells) (% of Total) 
 Control (Untreated Cells)  13.66 O  2 μM for 48 hr As2 3
 As O  2 μM for 48 hr 27.76 2 3 O  2 μM for 72 hr As2 3
As O  2 μM for 72 hr 37.50  2 3






3.3.6 AIF Translocation in a Fraction of OVCAR-3 Cells After As2O3 Treatment 
 
Since As2O3-induced cell death was caspase-independent and involved the disruption 
of m, confocal microscopy was used to investigate whether AIF was involved in 
As2O3-induced apoptotic cell death. In control untreated cells, all the AIF showed a 
punctuate localization (green fluorescence) outside the nucleus which was stained blue 
by nuclear dye, DAPI (Figure 3-11). In As2O3-treated cells, it was observed in a 
fraction of cells that AIF had translocated from the cytoplasm to the nucleus, as evident 
by the co-localization of both the green and blue fluorescence (Figure 3-11). Overall, 
these results demonstrate that arsenic-induced caspase-independent cell death may be 
partly attributed by the mitochondrial route involving AIF. 
Control  
            AIF      DAPI         OVERLAY 
 
 
2 µM of As2O3 treatment for 48 hr  
 
                    AIF                             DAPI         OVERLAY    
 
 
Figure 3-11 Mitochondria to nuclear translocation of AIF in a fraction of OVCAR-3 
cells after As2O3 treatment  
 









     
In recent years, significant progress has been made in understanding the complex 
actions of As2O3 in APL. Despite these advances, much remains unknown about the 
molecular factors governing its effects in ovarian cancer cells. In this study, the 
contribution of several factors in As2O3–mediated cytotoxicity of Cddp-resistant 
ovarian carcinoma cells was investigated. While most traditional chemotherapeutic 
drugs such as Cddp induce tumour cell death by activation of caspases leading to 
subsequent induction of apoptosis, we found that an alternative non-classical caspase-
independent pathway was instrumental in the cell killing effect of As2O3 in ovarian 
tumour cells.  This was supported by the selective activation of caspase 3 in arsenic-
treated OVCAR-3 cells but not in similarly treated CI80-13S cells, even though both 
cell lines were equally responsive to arsenic therapy, displaying apoptosis induction 
with almost comparable IC50 values. This data was further corroborated by the inability 
of Ac-DEVD-CHO and z-VAD-FMK to confer substantial protection against arsenic 
treatment in both cell lines.  
 
It has become increasingly evident that although caspase proteases have been 
traditionally identified as key players in regulating apoptosis, their function may not 
always be essential in mediating cell demise, as pan-caspase inhibitors failed to prevent 
cell death in some cell death programs (Xiang et al., 1996; Borner and Monney, 1999; 
Kitanaka and Kuchino, 1999; Nylandsted et al., 2000, Joza et al., 2001; Leist et al., 
2001; Carter et al., 2003). This mode of cell demise frequently serves as a backup cell 
death machinery which is particularly important in various pathological conditions 
(Leist and Jaattela, 2001). In recent years, numerous potential anticancer agents 





independent cell death (McCafferty-Grad et al., 2003; Kang et al., 2004; Liang et al., 
2004; Yim et al., 2005; Nakamura et al., 2006). It is believed that the ability of these 
agents to trigger these caspase-independent mechanisms helps them circumvent the 
apoptotic resistance of cancer cells that are insensitive to conventional apoptosis 
inducing chemotherapeutic agents. This is also a likely contributing factor explaining 
the effectiveness of As2O3 in mediating cell death in Cddp-resistant ovarian cancer.   
 
While several other investigators have reported the occurrence of caspase-independent 
cell death following As2O3 therapy (McCafferty-Grad et al., 2003; Michel et al., 2003; 
Karlsson et al., 2004; Akay et al., 2004; Kang et al., 2004), initial reports of this form 
of cell death in multiple myeloma by McCafferty-Grad et al (McCafferty-Grad et al., 
2003) and in cutaneous T cell lymphoma cells (Michel et al., 2003) did not identify the 
caspase-independent molecular factor responsible for this mode of cell kill. 
Subsequently, Karlsson et al (Karlsson et al., 2004), Akay et al (Akay et al., 2004) and 
Kang et al (Kang et al., 2004) reported the involvement of AIF in As2O3 mediated 
caspase-independent cell kill in neuroblastoma, multiple myeloma and cervical cancer 
cells, respectively. As with the latter two groups, similar results of loss of m and 
mitochondria to nuclear translocation of AIF in a proportion of As2O3-treated cells 
were observed, confirming the partial contribution of the mitochondrial route in the cell 
death response induced by As2O3 in ovarian tumour cells.       
 
Numerous studies have indicated that As2O3 induces apoptosis, DNA damage and cell 
death through the generation of ROS (Jing et al., 1999; Dai et al., 1999; Li et al., 2001; 





that antioxidants were unable to abrogate cell death induced by As2O3. This implied 
that As2O3-induced ovarian cancer cell death occurred independently of ROS.  
 
Members of the Bcl2 proto-oncogene family encode proteins that function either to 
promote or to inhibit apoptosis (Lowe and Lin, 2000). Antiapoptotic products of this 
gene family, such as Bcl2 and Bclxl, prevent cell death in response to a wide variety of 
stimuli including traditional chemotherapeutic agents (Simonian et al., 1997) and 
radiation (Datta et al., 1995). In ovarian tumours resistant to chemotherapy, these two 
members have been reportedly up-regulated (Kassim et al., 1999; Williams et al., 
2005). As2O3 was able to down-regulate both Bclxl gene and protein expression levels 
in the more arsenic responsive cells CI80-13S and OVCAR-3 which were Cddp 
resistant. These results were in agreement with previous studies in renal cell carcinoma 
(Hyun Park et al., 2003) and human myeloid leukaemia cells (Kerbauy et al., 2005). 
While selective overexpression of Bclxl in OVCAR-3 cells afforded a complete 
protection against As2O3-induced apoptosis, it could only partially protect against the 
overall cell death. This indicated the presence of other enigmatic non-apoptotic 
caspase-independent mechanisms which can and cannot be overcome by ectopic 
expression of Bclxl.  
 
Bclxl resides in other sites outside the mitochondria including the nuclear envelope, 
extra-nuclear membranes and the cytosol (Gonzalez-Garcia et al., 1994; Hsu et al., 
1997). Thus, it can also act at sites other than the mitochondria, including the ER and 
downstream of mitochondria (Walter et al., 2005). In addition, Bclxl has been reported 
to modulate autophagic or type II programmed cell death in TNF-α treated transformed 







evidence has indicated As2O3 can induce other forms of cell death including autophagic 
cell death in maglinant glioma cells (Kanzawa et al., 2003; Kanzawa et al., 2005), 
human T-lymphocytic leukaemia and myelodysplastic syndrome cells (Qian et al., 
2007) as well as a necrotic-like caspase-independent cell death in leukaemic cells 
(Scholz et al., 2005). It might be likely that some of these non- conventional pathways 
of cell death could play a role in As2O3-induced cell death which could be partially 
overcome by ectopic Bclxl overexpression.     
 
Taken together, these results reveal that As2O3-induced ovarian cancer cell death is 
multifaceted in nature and proceeds not only via caspase-independent apoptosis but by 
other caspase-independent non-apoptotic mechanisms that may circumvent the 
apoptotic resistance of Cddp-resistant in ovarian cancer cells. This evidence supports 
the potential clinical application of As2O3 in Cddp-resistant ovarian carcinomas, 





Correlation of Intracellular GSH Levels to Arsenic-Induced Cell 
Death And Effects of GSH Modulating Agents in Enhancing The 
Cytotoxicity of As2O3          
 
4.1 Introduction 
The GSH redox detoxification system is known to be involved in numerous 
fundamental biological processes. These include cellular metabolism, defense 
mechanisms against a variety of internal and external stresses as well as synthesis of 
DNA and proteins and transport of certain amino acids (Meister, 1994; Lomaestro and 
Malone, 1995). In particular, GSH plays a pivotal role in cellular protection against the 
harmful toxicities brought about by heavy metals including arsenicals and related 
metal-containing compounds (Meister, 1994; Lomaestro and Malone, 1995).    
  
The high affinity of As2O3 for GSH is attributed to its ability to interact with the vicinal 
SH group of cysteine within the tripeptide GSH molecule. Based on this action, 
numerous cancer cells develop tolerance and resistance to As2O3 treatment by 
increasing their intracellular GSH concentrations and related enzymes activities. In 
leukaemia, multiple myeloma and some solid tumour cells, intracellular GSH levels 
have been associated to their sensitivity to As2O3 in vitro (Yang et al., 1999). Research 
on ovary cells from Chinese hamsters have shown an inverse relation between arsenite 
sensitivity and intracellular GSH levels (Huang et al., 1993). The resistance of these 
cells to arsenite was in turn, linked to a high level of intracellular GSH concentration, 
elevated GSH-S-transferase activity and increased arsenite efflux by the direct 
conjugation of GSH to arsenic and exclusion by way of the GSH-conjugate export 





High intracellular GSH levels in resistance cells have been modulated by the use of 
various GSH reducing agents. In leukaemic and other neoplastic cells, concurrent 
treatment of As2O3 with GSH modulators such as BSO and physiological level of AA 
(100 µM) have been reported to be able to modulate the cytotoxicity of As2O3 in 
leukaemic and multiple myeloma cell lines (Dai et al., 1999; Grad et al., 2001).  
 
Currently, the role of GSH on the sensitivity of As2O3 in ovarian cancer cells remains to 
be defined. This chapter defines the possible links between the cellular GSH content of 
human ovarian cancer cells to their response to As2O3. Further, the use of GSH 
modulators in modifying the sensitivity of ovarian cancer cells to As2O3 was 
investigated.  
 
4.2 Materials and Methods 
4.2.1 Chemicals   
 
As2O3, AA, FDA, 5,5'-dithiobis-(2-nitrobenzoic) acid (DNTB), reduced GSH, GSH 
reductase (GR), NADPH, Hank’s balanced salt solution (HBSS), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), dithiothreitol (DTT), N-acetylcysteine (NAC), 
5-sulfosalicylic acid (SSA) and Bradford reagent were purchased from Sigma (St. 
Louis, MO, USA).  Rabbit monoclonal anti-CAT antibody was from Calbiochem, 
Darmstadt, Germany. Mouse monoclonal anti-actin antibody was from Sigma (St. 
Louis, MO, USA). Horseradish peroxidase-conjugated anti-mouse and anti-rabbit 
secondary antibodies were from Abcam (Clearbrook, IL, USA) and DAKO 






4.2.2 Cell Lines  
 
Three human ovarian carcinoma cell lines (OVCAR, OVCAR-3 and JAM) were used. 
HF cells and MRC-5 were employed as normal controls. Human multiple myeloma cell 
line, U266, was used as a positive control for the experiment involving physiological 
concentration of AA at 100 µM. All ovarian cancer and U266 cells were maintained in 
RPMI-1640 media supplemented with 10% (v/v) heat inactivated FCS (HyClone 
Laboratories, Logan, Utah, USA) and 1% penicillin/streptomycin at 37°C in a 
humidified atmosphere of 95% air and 5% CO2. MRC-5 and HF cells were grown in 
DMEM-FCS. Cell viability was assessed by trypan blue dye exclusion assay and the 
viability of the cells used for subsequent experiments was ensured to be above 95%.  
 
4.2.3 3H-Thymidine Uptake Study 
 
Proliferation and cytotoxicity of U266 cells were assessed using 3H-thymidine 
incorporation study after treatment with various concentrations of As2O3 and 100 µM 
of AA alone and in combination. The cells in logarithmic growth phase were plated in 
96-well plates at a density of 104 cells per well and cultured at 37°C and 5% CO2 in 
RPMI medium with and without the test compounds. [Methyl-3H]-thymidine (0.5 µCi 
per well, specific activity 2 Ci/mmol; Amersham Biosciences, Piscataway, NJ, USA) 
was added during the final 18 hrs of incubation. At the end of incubation, samples were 
harvested using Harvester 96 (Tomtec, Humden, Connecticut, USA) and analyzed 
using a 1450 Microbeta microplate β-scintillation counter (Perkin Elmer, Gaithersburg, 
MD, USA). Cell survival was presented as SI, which was defined as the mean count of 
the drug-treated cells as a percentage of control untreated cells. IC50 was defined as the 






4.2.4 Determination of Intracellular GSH Content 
 
Untreated or treated cells were collected, washed twice with ice-cold PBS and lysed 
with 200 µl of 10 mM HCl. A 40 µl of the lysate was kept for protein determination 
using the Bradford Assay (Sigma Chemical Co., St Louis, USA). The remaining cell 
lysate (160 µl) was protein-precipitated by adding 40 µl of 5% (w/v) SSA, cooled on 
ice for 10 min and centrifuged at 8000 × g at 4°C for 15 min. Supernatants were 
transferred to a new tube and stored at –80°C until tested for total GSH contents.  
 
In order to determine total GSH contents, a modified DNTB-enzyme recycling assay 
that was based on the method described by Baker et al was used (Baker et al., 1990).   
A pipette was used to fill each well of a 96-well microtitre plate with 20 µl of either 
standards, samples or blanks in triplicates. 5 ml of 1 mM DNTB, 5 ml of 1 mM 
NADPH, 5.75 ml of phosphate buffer (100 mM Na3PO4, 1 mM EDTA, pH = 7.4) and 
0.1 ml of GR were thoroughly mixed. A 100 µl of the reaction mixture was 
immediately added into each well.  The absorbance generated in each well was read at 
405 nm using a microplate reader (SPECTRAFLUOR; Tecan Instruments Inc., 
Research Triangle Park, NC, USA). The concentration of GSH in the samples was 
determined with reference to the standard curve (GSH 0.5 - 20 µM) generated with 
each batch of samples. Intracellular GSH content was expressed as nmols per mg of 




4.2.5 Assay For Cellular GPx Level  
 
Cells were collected and homogenized in ice cold buffer containing 50 mM Tris HCl 





10,000 × g for 20 min at 4 °C. Supernatants were transferred to clean microcentrifuge 
tubes and store at -80 °C until analyzed. All samples were assayed within a month of 
harvesting. 
 
Cellular GPx level was assayed using a commercially available kit from Cayman 
Chemical (Ann Arbor, MI, USA). GPx activity was determined from the supernatants 
by an indirectly coupled reaction with GR. GPx present within the samples catalyzed 
the reduction of hydroperoxide to oxidized GSH (GSSG). The GSSG produced was 
recycled to its reduced state by GR and NADPH. The oxidation of NADPH to NADP+ 
was accompanied by a decrease in absorbance at 340 nm.  Under conditions of the 
assay, the rate of decrease in the absorbance at 340 nm was directly proportional to the 
GPx activity in the sample. GPx activity of each sample was normalized to protein 
concentration of the sample using the Bradford Reagent (Sigma, St Louis, MO, USA). 
One unit of GPx was defined as the amount of enzyme causing the oxidation of 1 nmol 
of NADPH per minute per milligram of protein.  
 
 
4.2.6 Western Blotting for Cellular CAT Level  
 
CAT protein level was determined using western blot analysis. OVCAR, OVCAR-3 
and JAM cells were collected by centrifugation, washed with PBS and lysed in lysis 
buffer (10 mM Tris-Cl pH = 7.4, Triton X 0.1% (v/v), 5 mM EDTA pH = 8.0 and 0.15 
M NaCl) supplemented with protease inhibitor cocktail (Roche Diagnostics, 
Indianapolis, IN, USA). Lysates (30 µg total protein) were separated by electrophoresis 
using sodium dodecyl sulfate (SDS)-polyacrylamide gel and then blotted onto 
nitrocellulose membrane. The membrane was subsequently incubated with anti-CAT 





MO, USA), washed three times with tris-buffered saline containing 0.1% Tween 20, 
followed by incubation with a peroxidase-conjugated anti-rabbit secondary antibody 
(Dako, Glostrup, Denmark) or anti-mouse secondary antibody (Abcam, Clearbrook, IL, 
USA), respectively.  All antibody dilutions were carried out as per data sheet provided 
by the manufacturer. The western blots were visualized using an enhanced 
chemiluminescence detection system (Perkin Elmer Life Sciences, Wellesley, MA, 
USA). Results were quantified by densitometry analysis using an Alpha Inotech 
densitometer (FluorChemTM 9900). The data were normalized by actin and presented as 
fold which is defined as a ratio of the CAT/actin ratio of the respective cell line over 
that of OVCAR cells.   
 
4.2.7 Measurement of Cellular AA Uptake   
 
OVCAR, OVCAR-3 and JAM were separately seeded into 24-well plates (Nalge Nunc 
International Co., Rochester, NY, USA).  After 24 hrs, these cells were washed three 
times with PBS and equilibrated with pre-warmed HBSS/HEPES incubation medium at 
37°C for 30 min. At the end of incubation, the HBSS/HEPES incubation medium in 
each well was replaced by 300 µl of HBSS/HEPES containing 100 µM of DTT and 0.1 
µCi of 14C AA (Perkin Elmer, Wellesley, MA, USA) and 100 µM of unlabelled AA. 
Incubation was carried out at 37°C for 0.5 to 4 hrs. Following incubation, the cells were 
lysed with 0.1 N NaOH/5% (w/v) SDS. 300 µl of the lysate was mixed with 3 ml of 
scintillation liquid. Intracellular 14C AA was measured using scintillation counter (LS 
3801, Beckman Instruments, Inc., CA, USA). Each experiment was performed in 
triplicates. Parallel culture of cells was prepared and cells in each well of parallel 






 4.2.8 Measurement of Intracellular Arsenic Concentration       
Cells were harvested after drug treatment and washed thoroughly with ice cold PBS 
three times. They were counted and digested in superpure concentrated nitric acid 65% 
(v/v) (Merck, Darmstadt, Germany) using the High Pressure Asher HPA-S (Aston Par, 
Graz, Austria) under the default program with the following conditions (Table 4-1):   
Table 4-1 Parameter for cell digestion using the High Pressure Asher HPA-S 
       Segment             Time (min)  Set Point (°C)  Dwell Time (min) 
1       Step            70   0 
2       20             120   0 
  3       Step            240              60 
  4       Step            0              End 
Arsenic (As) concentrations in the digesates were determined using a quadrupole ICP-
MS Thermo X Series II (Thermo Electron Corporation, Winsford, Cheshire, UK). 
Samples were diluted 1:10 with 1% (v/v) HNO3 prior to measurement. Rhodamine (Rh) 
was added to all samples as the internal standard at 10 ng/ml per sample. Blank and all 
calibration standards were prepared with the same media and internal standard. The 
instrument was operated with the collision cell option enabled, using 8% H2 in helium 
as the collision gas. Kinetic discrimination of 4 volts was used to eliminate the 
interfering species generated in the cell. The high sensitivity Xs interface cones were 







Table 4-2 ICP-MS main instrument settings 
           Parameter Value 
Extraction Voltage (V) +4 
Collision Cell Gas Flow (ml/min) 4 
Hexapole bias voltage (V) -18 
Quadrupole bias voltage (V) -14 
Nebuliser gas flow (L/min) 0.87 
 
A standard single piece quartz torch was used together with a single pass conical spray 
chamber and glass concentric nebuliser. Isotopes measured were As at m/z 75 and Rh 
at m/z 103. As concentration in each sample was quantified from external calibration. 
All sample values were subtracted with the background (matrix blank) of control 
untreated cells. Concentration in each sample was normalized to initial cell count prior 
to sample digestion and expressed as ng per million cells.  
 
4.2.9 Effects of Antioxidants on the Cytotoxicity of Combined Treatments  
Ovarian cancer cells were seeded into 96-well culture plate at a density of 10 000 cells 
per well and allowed to adhere overnight. The medium was removed the next day and 
replaced with either medium without drug or media containing As2O3 alone or media 
containing various combinations of As2O3 with BSO or high dose AA, with or without 
antioxidant supplement. The antioxidants used were NAC (Sigma, MO, St Louis, 
USA), CAT (Sigma, MO, St Louis, USA) and BHA (Sigma, MO, St Louis, USA). 
Cells were incubated for 72 hrs and cell viability at the end of the incubation period 
was determined using FMCA described above.  
4.2.10 Statistics 
Results were presented as the mean ± SD of at least three independent experiments. 





three or more groups (Graphpad Prism 4 Software, Graphpad Software Inc., San Diego, 
CA, USA). A p value of < 0.05 was considered to be statistically significant. 
 
4.3 Results 
4.3.1 Correlation of Intracellular GSH Levels in Ovarian Cancer Cells and 
Normal Fibroblast Cells to their Sensitivity to As2O3 Treatment 
 
It has been widely reported that As2O3 interacts with SH-groups of GSH or proteins 
involved in signal transduction to bring about its cytotoxic effects. The relationship 
between As2O3-induced cell kill and intracellular GSH level was first examined. Basal 
cellular GSH levels obtained in ascending order for the cell lines were as follows: 
OVCAR-3 = OVCAR < JAM < MRC-5 < HF (Figure 4-1). This observation paralleled 
the sensitivities of the ovarian cancer and normal fibroblast cells to the effects of As2O3 
as reflected by their IC50 values as shown previously in Table 2-1. The normal 
fibroblast cells harboured a much higher GSH content and were therefore less 
responsive to the effects of As2O3 than the ovarian tumour cells. Among the ovarian 
cancer cells, JAM cells which were more resistant to As2O3 therapy also contained a 
higher GSH content than the more arsenic responsive OVCAR-3 and OVCAR cells. 
The intracellular GSH levels were subsequently correlated to the respective IC50 values 
of the cells with a r2 value of 0.81. Thus, intracellular GSH level may be a contributing 






































Figure 4-1 Basal GSH level in ovarian cancer and normal fibroblast cell lines 
 
 
4.3.2 BSO and Pharmacological Doses of AA Sensitized Ovarian Tumour Cells to 
the Cytotoxic Effects of As2O3      
 
Since intracellular GSH levels showed a strong correlation to the arsenic sensitivity of 
ovarian cancer cells with the arsenic-responsive ovarian cancer cell showing lower 
GSH levels, the cytotoxic effects of As2O3 after combined treatment with GSH 
modulators, namely, BSO (1 µM, 5 µM and 10 µM) and physiological level of AA 
(100 µM) were evaluated. The BSO concentrations used were minimally toxic to the 
ovarian tumour cell lines tested (Figure 4-2).  


































































Figure 4-2 Effects of BSO on (A) OVCAR, (B) OVCAR-3 and (C) JAM cells 
 
A concentration of as low as 1 µM of BSO was able to sensitize the ovarian cancer 
cells, including the JAM cell line, a cell line less sensitive to the cytotoxic effects of 
As2O3, to the antiproliferative and cytotoxic effects of As2O3 as shown by the dose 
response curves (Figure 4-3). With BSO concentrations of 5 µM or 10 µM, less than 
50% of JAM cells survived the cytotoxic insult brought about by 2 µM of As2O3, 
allowing this arsenic resistant cell line to be killed at a clinically achievable and 
comparable concentration of As2O3 to that used in APL cell lines.       
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Figure 4-3 Effects of As2O3 in combination with BSO on the cytotoxicity and 
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In contrast to previous reports (Dai et al., 1999; Grad et al., 2001), physiological level 
of AA at 100 µM which was minimally toxic to the ovarian cancer cell lines at this 
concentration (Figure 4-4), failed to modulate the cytotoxicity of As2O3 in these cells 
(Figure 4-5).  
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Figure 4-5 Effects of As2O3 in combination with AA at 100 µM on the cytotoxicity and 
proliferation of (A) OVCAR, (B) OVCAR-3 and (C) JAM cells 
 
In order to determine that the negative result was not due to the ineffectiveness of AA, 
a multiple myeloma cell line, U266, was used as a positive control. U266 cells retained 
high viability with SI of 85.03 ± 14.20% when treated with AA 100 µM alone. Upon 
combination treatment of physiological level of AA and As2O3, viability of U266 cells 
was indeed reduced (Figure 4-6) and the percentage of apoptotic cells increased when 
compared to As2O3 treatment alone (Figure 4-7), confirming that physiological level of 
 A) B) 
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AA could enhance the cytotoxic effects of As2O3 in multiple myeloma cells and 
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Figure 4-7 Increased in apoptosis in U266 cells with combined use of As2O3 in 
combination with AA at 100 µM compared with As2O3 alone  
(M1 marker represents the proportion of apoptotic cells) 
                                                    U266  
         As2O3 (µM) 
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AA has been given intravenously at high doses in order to achieve plasma 
concentrations of 1 - 5 mM for the treatment of cancer patients (Riordan et al., 1995). 
Based on this report, the effects of high pharmacological doses of AA, at 500 µM or 
1000 µM, on As2O3-induced ovarian tumour cell death were investigated. AA at 500 




















Figure 4-8 Effects of 500 µM of AA on OVCAR, OVCAR-3 and JAM cells 
 
 
As2O3 in combination with 500 µM of AA caused an enhanced percentage of tumour 
cell death compared to As2O3 treatment alone in OVCAR and OVCAR-3 cells (Figure 
4-9). In JAM cells, only very little augmentation of As2O3-mediated cell kill was 
observed with simultaneous exposure of As2O3 and 500 µM of AA (Figure 4-9). When 
AA concentration was further increased to 1000 µM in JAM cells, AA itself at this 
concentration was again minimally toxic to JAM cells with SI of 95.74 ± 14.20%. 
However, a more pronounced sensitization of the tumour cells to the effects mediated 
by As2O3 was observed, allowing 50% of JAM cells to be killed at about 2 µM of 
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Figure 4-9 Effects of As2O3 in combination with AA at 500 µM on the cytotoxicity and 
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Figure 4-10 Effects of As2O3 in combination with AA at 1000 μM on the cytotoxicity 
and proliferation of JAM cells 
 
 
4.3.3 Selective Kill of Ovarian Cancer Cells Over Normal Fibroblast Cells Using 
Clinically Achievable Concentrations of As2O3 with BSO and Pharmacological 
Doses of AA with As2O3   
 
In order to ascertain the clinical value of the combined treatment of BSO and 
pharmacological doses of AA with As2O3, the effects of these treatments on normal 
cells were tested on HF and MRC-5 cells. MRC-5 and HF cells were less sensitive 
when compared to the ovarian cancer cell lines to the combined use of As2O3 with 
BSO. The IC50 values of As2O3 on HF and MRC-5 cells were higher than that of the 
ovarian cancer cells following combined As2O3 and BSO treatment (Table 4-3), 
indicating the preferential kill of ovarian tumour cells over normal cells. Similarly, for 
combined pharmacologic doses of AA and As2O3 treatments, therapeutic selectivity 
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Table 4-3 IC50 values (mean ± SD) of As2O3 in ovarian cancer cell lines after drug 
treatment with As2O3 alone or in combination with BSO 
 
IC50 values of As2O3 (µM)  
 
Cell Line    OVCAR      OVCAR-3         JAM           MRC-5      HF 
 
As2O3                         1.96 ± 0.67    1.48 ± 0.41    7.89 ± 0.84    9.01 ± 0.10     9.65 ± 0.89                            
 
As2O3 + 1 µM BSO         0.55 ± 0.03    0.45 ± 0.02    3.08 ± 0.18        > 8.00           > 8.00                                  
 
As2O3 + 5 µM BSO         0.12 ± 0.06    0.14 ± 0.01    1.18 ± 0.25    4.07 ± 0.38     2.06 ± 0.57 
 
As2O3 + 10 µM BSO       0.14 ± 0.02    0.12 ± 0.02     0.91 ± 0.05    2.31 ± 0.38    1.20 ± 0.19 
 
Table 4-4 IC50 values (mean ± SD) of As2O3 in ovarian cancer cell lines after drug 
treatment with As2O3 alone or in combination with AA 
 
                     IC50 values of As2O3 (µM) 
 
Cell Line    OVCAR      OVCAR-3         JAM           MRC-5   HF 
 
As2O3                        1.96 ± 0.67    1.48 ± 0.41    7.89 ± 0.84   9.01 ± 0.10   9.65 ± 0.89                               
 
As2O3 + 500 µM AA      0.88 ± 0.02    0.35 ± 0.17    7.95 ± 0.51       > 8.00          > 8.00                                     
 




4.3.4 JAM Cells Were Able to Accumulate AA Better Than OVCAR and OVCAR-
3 Cells   
 
Given that JAM cells required a higher concentration of AA than OVCAR and 
OVCAR-3 cells in order to enhance the cytotoxicity of As2O3, it was possible that this 
may have been due to reduce efficacy of JAM cells in the uptake of AA. Therefore, 
experiments were performed on the uptake of AA by ovarian cancer cells. Incubation of 
each cell line with AA resulted in a time-dependent uptake of AA (Figure 4-11). JAM 
cells were surprisingly able to accumulate more AA than both OVCAR and OVCAR-3 





further suggests that the amount of cellular AA accumulated is not the determinant of 




































Figure 4-11 Intracellular accumulation of AA in ovarian cancer cells 
 
(* p < 0.05 between JAM 2 hr versus OVCAR-3 2 hr; ** p < 0.05 between JAM 4 hr versus OVCAR-3 4 
hr;  *** p < 0.05 between JAM 4 hr versus OVCAR 4 hr; + p < 0.05 OVCAR 4 hr versus OVCAR-3 4 hr 
using ANOVA with Tukey’s Posthoc Test) 
 
4.3.5 Combined As2O3 with BSO But Not Pharmacological Dose of AA Results in 
Increase in Apoptosis Induction    
 
To investigate whether the augmentation of As2O3-induced cytotoxicity by BSO and 
pharmacological doses of AA was mediated by an increase in apoptosis induction, PI 
stained cells were analyzed for any changes in sub-G1 DNA content. Concurrent As2O3 
and BSO treatment resulted in an increase in apoptotic cell kill of all three ovarian 
cancer cells (p < 0.05) (Figure 4-12) while pharmacological doses of AA did not result 
in a significant increase in apoptotic rate after combined treatment (Figure 4-12).    
 
 















































































































































Figure 4-12 Increase in cellular apoptotic rate in (A) OVCAR and (B) 
OVCAR-3 cells after concurrent As2O3 and BSO treatment  
(* p < 0.05 between As2O3 1 µM versus As2O3 1 μM + BSO 5 μM; ** p < 0.05 between 



























































































Figure 4-12  Increase in cellular apoptotic rate in (C) JAM cells after concurrent As2O3 
and BSO treatment (Continued)  
 
 
( + p < 0.05 As2O3 3 μM versus As2O3 3 μM + BSO 5 μM; ++ p < 0.05 between As2O3 3 μM + BSO 5 
μM versus BSO 5 μM using ANOVA with Tukey’s Posthoc Test) 
 
 
4.3.6 Reduction of Intracellular GSH Levels by BSO But Not Pharmacological 
Doses of AA in Ovarian Cancer Cells  
 
The effects of BSO or pharmacological doses of AA alone and in combination with 
As2O3 on intracellular GSH levels were examined. In all the ovarian cancer cell lines 
tested, GSH levels were increased following As2O3 treatment alone (Figure 4-13). 
Treatment with BSO alone resulted in a concentration-dependent reduction in GSH 
levels in OVCAR, OVCAR-3 and JAM cell lines (p < 0.05) (Figure 4-13). Likewise, a 
significant reduction in the intracellular GSH levels was achieved following 
simultaneous exposure of BSO with As2O3 (p < 0.05) (Figure 4-13).  
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Figure 4-13 Effects of As2O3 or BSO alone and their concurrent treatment on 
intracellular GSH levels of (A) OVCAR, (B) OVCAR-3 and (C) JAM cells 
          
                  (* p < 0.05 compared with control using ANOVA with Tukey’s Posthoc Test) 
 
 
 A)       B) 
 C) 
     *     *
   *
     *
    *   *      *     *
  *
   *
  *
 *





It is interesting to note that, contrary to reports in leukaemic (Dai et al., 1999) and 
multiple myeloma cells (Grad et al., 2001), both low physiological and high 
pharmacological doses of AA either alone or in combination with As2O3 failed to cause 
a reduction in the GSH levels in the cell lines tested in this study (Figure 4-14). This 
suggests that an enhanced level of cytotoxicity towards tumour cells with As2O3 
mediated by BSO may have occurred by reduction of intracellular GSH levels, whereas 
pharmacological doses of AA may enhance the effect of As2O3 in ovarian cancer cells 
























































































































































 A)    B) 
Figure 4-14 Effects of As2O3 or AA alone or in combination on intracellular GSH 






































































































Figure 4-14 Effects of As2O3 or AA alone or in combination on intracellular GSH 
levels of (C) JAM cells (Continued) 
 
 
4.3.7 Effects of NAC, CAT and BHA on BSO or AA Augmentation of As2O3-
Mediated Cell Kill  
As GSH is known to protect the cells via its antioxidant properties (Meister, 1994) and 
AA can also act as a pro-oxidant in inducing cell death (Peterkofsky and Prather, 1977; 
Michiels et al., 1990), the effects of several antioxidants on the effects of combined 
As2O3 with BSO or pharmacological doses of AA were investigated. NAC (a general 
free radical scavenger and GSH precursor), BHA (a lipophilic antioxidant with 
superoxide anion radical scavenging activity) and CAT (H2O2 degradation enzyme) 
were used to determine the involvement of ROS in response to simultaneous As2O3 
with BSO or pharmacological doses of AA exposure. For combinations of As2O3 with 
BSO, no protective effect is being conferred by NAC (2 mM), CAT (500 U/ml) or 






ROS is not the main mediator of the enhanced cell death in arsenic-treated ovarian 
cancer cells following GSH depletion by BSO.  







































































































































































































































































  A) 
  B) 
Figure 4-15 Effects of antioxidants on cell death mediated by As2O3 and BSO in    









































































































































Figure 4-15 Effects of antioxidants on cell death mediated by As2O3 and BSO in       
(C) JAM cells (Continued) 
 
In contrast, NAC (2 mM) and CAT (500 U/ml) almost completely protect OVCAR and 
JAM cells and partially defend OVCAR-3 cells against the cytotoxicity induced by 
As2O3 with pharmacological dose of AA, whereas BHA (100 µM) showed little 
protective effect (Figure 4-16). This suggests that augmentation of As2O3-induced cell 
death by high dose AA in ovarian cancer cells may be largely contributed by the 














































































































































































































































































     *    *
   *
   *
Figure 4-16 Effects of antioxidants on (A) OVCAR and OVCAR-3 cell death 
mediated by As2O3 and pharmacological doses of AA 
(* p < 0.05 between As 1 µM + AA 500 µM versus As 1 µM + AA 500 µM + CAT 500 U/ml or 












































































































































4.3.8 Sensitivity of Ovarian Cancer Cells to Pharmacological Doses of AA and 
As2O3 Treatment Was Related to Cellular Antioxidant Enzyme Levels  
 
As JAM cells could more effectively accumulate AA but were less responsive to the 
cytotoxic augmentation by high dose AA, it is postulated that this may be in part 
attributed to its higher antioxidant enzymes levels. Therefore, the intracellular levels of 
GPx and CAT, which are cellular enzymes that are responsible for catalyzing the 
degradation of H2O2, were examined. As shown in Figures 4-17 and 4-18, JAM cells 
that were less sensitive to the modulating effects of AA contained more GPx and CAT 
than OVCAR and OVCAR-3 cells. Together with the findings of higher intracellular 
GSH levels that were shown above (Figure 4-1), the greater antioxidant enzymes and 
GSH antioxidant content within JAM cells than OVCAR and OVCAR-3 cells 
 C) 
 **   ** 
Figure 4-16 Effects of antioxidants on (C) JAM cell death mediated by As2O3 and 
pharmacological doses of AA (Continued) 
( ** p < 0.05 between As 3 µM + AA 1000 µM versus As 3 µM + AA 1000 µM + CAT 500 U/ml or As 3 






contributed to the higher cellular antioxidant threshold. Hence, a larger dose of AA is 
required to generate sufficient oxidative stress to overcome the higher antioxidant 

























         
 





Figure 4-18 Intracellular CAT level in ovarian cancer cell lines 
 
Fold was determined by the band density of CAT normalised to that of actin and expressed as a fraction 
of the CAT/actin band intensity ratio of OVCAR cells. Data shown was representative of 3 independent 
































4.3.9 Increase in Intracellular Arsenic Accumulation Following Concurrent BSO 
and As2O3 Treatment  
 
Next, intracellular arsenic concentration with and without BSO treatment was 
examined. In the ovarian cancer cell lines, 5 µM and 10 µM of BSO only resulted in a 
slight increase in arsenic accumulation. In OVCAR and OVCAR-3 cells, the net 
increase in arsenic accumulation was about approximately two fold (p < 0.05 for 
comparison between As 1 µM versus As 1 µM + BSO 5 µM or As 1 µM + BSO 10 
µM). In JAM cells, an approximate three fold increase in arsenic accumulation was 
observed with concurrent BSO treatment (p < 0.05 for comparison between As 1 µM 
















































































































      *     *
   * 
  * 
  A)   B) 
Figure 4.19 Intracellular arsenic concentration in ovarian cancer cells 
(* p < 0.05 between As 1 µM versus As 1 µM + BSO 5 µM or As 1 µM + BSO 10 µM using ANOVA with 






























































Figure 4.19 Intracellular arsenic concentration in ovarian cancer cells (Continued) 
 
(* p < 0.05 between As 1 µM versus As 1 µM + BSO 5 µM or As 1 µM + BSO 10 µM using ANOVA 




The GSH redox system is known to play a significant role in mediating drug resistance 
against various cytotoxic drugs (Pompella et al., 2003). It is also known to affect the 
activity of arsenicals as As2O3 acts by binding to the thiol group of GSH. In this study, 
the cytotoxic effects of As2O3 in ovarian cancer cell lines and normal fibroblast cells 
showed a strong correlation (r2 = 0.81) to their intracellular GSH levels. While As2O3 is 
likely to exert its cytotoxicity in ovarian cancer through multiple mechanisms, this 
positive association indicates that selective modulation of GSH may be an attractive 
means of enhancing the cytotoxicity of As2O3, particularly in ovarian cancer cells that 
are more resistant to As2O3 therapy.    
 
     *
    *





Numerous agents have been reported to be able to modulate the intracellular level of 
GSH. They include BSO, DEM, bromobenzene and AA. BSO and AA were selected as 
GSH modulating agents as they have low toxic effects when compared to DEM and 
have already been safely used in various clinical settings (Bailey, 1998; Riordan et al., 
2003). In the tested ovarian cancer cell lines, low concentrations of BSO could 
effectively lower intracellular GSH level, sensitizing the ovarian cancer cells, 
particularly the less arsenic responsive JAM cells, to clinically comparable 
concentrations of As2O3 used in APL treatment. More importantly, this augmentation of 
As2O3-medicated cytotoxicity was achieved with greater selectivity for the ovarian 
cancer cells. In addition, the ovarian cancer cells responded to As2O3 treatment alone 
via an up-regulation of intracellular GSH level. Although As2O3 has been reported to 
reduce intracellular GSH levels, different cellular systems react in a dissimilar manner. 
Some showed a reduction in GSH levels (Gupta et al., 2003) while others displayed an 
increase in GSH levels (Ochi, 1997; Jimi et al., 2004). In the ovarian cancer cells, the 
increase in GSH levels is likely attributed to the cellular stress response to confer 
protection against the cytotoxicity of As2O3. This further reinforces that concurrent 
BSO treatment with As2O3 may be an especially useful and attractive chemotherapeutic 
combination for ovarian cancer treatment.  
 
The observed augmentation of As2O3-induced cell kill and increase in cellular 
apoptosis by BSO is consistent with previous reports of the effects of this 
chemotherapeutic combination in leukaemia (Dai et al., 1999), renal cell carcinoma 
(Wu et al., 2004) and prostate cancer cells (Maeda et al., 2004). Notably different from 
the reports by Dai and colleagues in leukaemic cells (Dai et al., 1999) and Maeda et al 





ovarian carcinoma system is not mediated by a net increase in oxidative stress 
generated following GSH depletion. Similar observations were made by Wu et al in 
renal carcinoma cells (Wu et al., 2004). In this study, it has been found that the 
observed augmentation in ovarian cancer cell death is only partially contributed by an 
increase in arsenic accumulation following GSH depletion. This is because GSH 
depletion resulted in about two to three times increase in arsenic accumulation while 
the overall IC50 values for the cells were reduced by at least six-folds in the ovarian 
cancer cell lines tested. This may in turn be attributed to the decrease in drug 
transporter mediated efflux of arsenic-GSH conjugate.  
 
While endogenous GSH depletion alone is not toxic to the tumour cells as evident by 
the lack of loss of cell viability in cells treated with BSO alone, combined treatment 
with arsenic could have pleiotropic deleterious effects owing to the multiplicity of 
cellular GSH functions. It would be difficult to unequivocally identify a single factor 
such as ROS as solely responsible for the increase in toxicity to As2O3 treatment. 
Contribution by other cellular factors such as activation of various cellular kinases 
involved in various signal transduction pathways following GSH depletion remains to 
be investigated. Overall, these results also imply that enhanced As2O3–mediated cell 
kill following concurrent BSO treatment may proceed by different multiple 
mechanisms that again may be cell-type specific.        
 
In this study, it was observed that physiological level of AA did not enhance the 
cytotoxicity of As2O3 in ovarian tumour cells. This differs from reports of this drug 
combination in leukaemia (Dai et al., 1999) and multiple myeloma (Grad et al., 2001) 





pharmacological AA concentrations were used. In particular, with the more arsenic-
resistant JAM cells, an even higher concentration of AA was required to achieve 
significant cell kill at a clinically safe and achievable concentration of As2O3. These 
results suggest that physiological concentration of AA used in conjunction with As2O3 
and other chemotherapeutics for chemotherapy of multiple myeloma (Grad et al., 2001) 
would not have additional beneficial effects if extrapolated directly for the treatment of 
ovarian cancer. Furthermore, careful AA dose titration is required in order to ensure 
optimal response to As2O3 therapy in ovarian carcinoma.  
 
Interestingly, it was found that the augmentation of arsenic-mediated cytotoxicity by 
pharmacological doses of AA was not mediated via an increase in apoptosis. This was 
again disparate to U266 cells, whereby physiological AA was sufficient to result in an 
increase in arsenic-induced apoptosis. Emerging evidence has shown that the ability of 
AA to boost the tumour cell kill of conventional chemotherapeutic agents to be 
complex and may be cell type and drug combination specific (Head, 1998; De Loecker 
et al., 1993; Dai et al., 1999; Grad et al., 2001; Karasavvas et al., 2005; Gokhale et al., 
2006). While enhancement of cancer cell death by increase induction of apoptosis 
(Sane et al., 2004) has been observed, other novel and complex mechanism such as 
autoschizis has been recently reported in various cells including ovarian cancer cells 
(Gilloteaux et al., 1998; 2001; 2003). In AA mediated augmentation of menadione-
induced ovarian cancer cell death, a mixture of cell death phenotypes comprising of 
43% autoschizis, 3% apoptosis and 1.9% onosis was observed (Gilloteaux et al., 2003). 
The dominant mode of cell death is currently unclear. In the present study, the 
enhanced cytotoxicity seen with combined pharmacological doses of AA and As2O3 





contrast to the reports of AA being an effective GSH modulator in leukaemic (Dai et 
al., 1999) and multiple myeloma cells (Grad et al., 2001). The observed differences are 
likely attributed to the different interactions and contributions between multiple 
pathways of GSH synthesis in different cell types. As such, the ability of 
pharmacological doses of ascorbate to increase the cytotoxicity of As2O3 found in the 
present study is likely attributed to other mechanisms.  
 
AA itself has been widely purported to possess cytotoxic activities (Bishun et al., 1978; 
Park et al., 1980; Leung et al., 1993; Sakagami et al., 1996; Maramag et al., 1997). In 
vitro results have reported that high dose ascorbate (1-10 mM) can inhibit cancer cell 
proliferation by a free radical mechanism involving ROS and ascorbate radical 
formation (Bishun et al., 1978; Park et al., 1980; Leung et al., 1993; Sakagami et al., 
1996; Maramag et al., 1997). By using various ROS scavengers, the present study has 
found that the effect of pharmacological dose of ascorbate can be abrogated with CAT 
and NAC but not BHA, suggesting that pharmacological dose of AA acted as a pro-
oxidant in our cellular system to mediate the cytotoxic enhancement of As2O3-induced 
cell kill. This is likely through a H2O2-dependent mechanism. Another key finding was 
that the relative responsiveness among tested ovarian cancer cell lines to this cytotoxic 
drug combination is likely attributed to the composite of intracellular antioxidant 
enzyme levels and independent of the ability of the ovarian cancer cells to uptake 
extracellular AA.  
 
Overall these results suggest that intracellular GSH system may play a role in 





manipulation, may be beneficial in enhancing As2O3-mediated cytotoxicity, as a mode 





Establishment of an Arsenic Resistant OVCAR-3 Cell Line, OVCAR-
3/AsR and Investigations of the Gene Expression Changes After Acute 
and Chronic Arsenic Treatments Using Microarray Analysis    
 
5.1 Introduction 
Chemotherapeutic drug resistance can be classified into intrinsic (de novo) and 
acquired resistance. Intrinsic resistance represents failed response to the effects of the 
chemotherapeutic agents from the onset of the therapy while acquired resistance occurs 
only secondary after initial response to chemotherapy (Kerbel et al., 1994). 
Manifestation of intrinsic resistance is commonly attributed to autocrine or paracrine 
mechanisms governed by tumour–tumour or tumour–stroma interactions (Arlt et al., 
2002).  On the contrary, acquired resistance is a method by which tumour cells obtain 
protection from chemotherapeutic drugs via a multitude of complex mechanisms and 
are generally associated with altered gene expression in the drug-resistant tumour cells 
in relation to their drug-sensitive counterpart. These drug-resistant cells commonly 
show elevated expression of drug efflux pumps, up-regulation of prosurvival proteins, 
increased expression of drug inactivation enzymes and altered expression of drug 
targets (Kerbel et al., 1994).    
 
Identification of these complex genetic interactions and molecular changes leading to 
drug resistance has been tremendously facilitated with the completion of the human 
genome project. The development of new and powerful technology such as 
cDNA/oligonucleotide microarray following the unveiling of the human genome 
provides a powerful platform for characterizing gene expression alterations on a large 





variety of experimental systems for studying chemoresistance development (Chun et 
al., 2004; Auger et al., 2006; L’Esperance et al., 2006; Mahon et al., 2007)  
  
A better understanding of the cellular factors responsible for arsenic-mediated effects in 
ovarian cancer cells and the molecular alterations associated with the development of 
resistance might be particularly valuable for optimizing its possible therapeutic utility 
in ovarian carcinoma treatment. Thus, the aim of this chapter was to establish an 
arsenic resistant OVCAR-3 subline, OVCAR-3/AsR, and to probe the differences 
between the resistant cells and their sensitive parental cells in comparative gene 
expression study using the microarray technology.  
 
5.2 Materials and Methods 
5.2.1 Materials  
As2O3, FDA and RNase A were purchased from Sigma Co. (St Louis, MO, USA). 
Triton X 100 was purchased from Biorad (Hercules, CA, USA). FBS, 
penicillin/streptomycin solution, trypsin, RPMI-1640 medium were from HyClone 
Laboratories Inc. (Logan, UT, USA). PI was from Molecular Probes (Grand Island, 
NY, USA).  As2O3 was dissolved as 1.0 mmol/L stock solutions in PBS, stored at 4C 
and diluted to required concentrations with culture medium before use.   
 
5.2.2 Establishment of Arsenic Resistant OVCAR-3 Cell Line 
The arsenic-resistant cell line, OVCAR-3/AsR, is a variant cell line derived from 
OVCAR-3 parent cell line. It was developed following exposure to increasing doses of 
As2O3 for 12 months. Parental OVCAR-3 cells were first exposed to 0.5 µM of As2O3 





Dead cells were removed and surviving cells were propagated in fresh As2O3 at 0.5 
µM until they reached 80 % confluence. Confluent cells were passage biweekly in 0.5 
µM of As2O3 for 3 months. This process was repeated with 1.0 µM of As2O3 for 
another 3 months and 2.0 µM of As2O3 for the following 6 months until a stable cell 
population demonstrating more than 9 fold IC50 of parental cell line was obtained.  
 
 
5.2.3 Cell Treatment, RNA Isolation, Quality Assessment and Microarray 
Hybridisation and Image Acquisition  
 
Untreated OVCAR-3 cells, OVCAR-3 cells treated with 2 µM of As2O3 for 24 and 48 
hrs and OVCAR-3/AsR cells were harvested. Two independent batches (Batch A and 
Batch B) of RNA samples representing two biological replicates for each of the 
experimental condition were processed. Total RNA from these eight samples was 
isolated using RNeasy Mini Kit (QIAGEN, Valencia, CA) according to the 
manufacturer's protocol. Optical density for each sample of RNA was measured at OD 
260 nm and OD 280 nm using NanoDrop ND-1000 (NanoDrop Technologies, 
Wilmington, DE, USA). All RNA samples isolated have OD260/280 ratio > 2.0. Each 
isolated RNA sample was subjected to further quality check to ensure integrity of RNA 
with Agilent RNA 6000 Nano LabChip® using Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA, USA). All RNA samples were verified to be intact with 
distinct 28S and 18S RNA bands at a ratio of approximately 2:1 and a RIN score > 7 
(Appendix 1).     
 
aRNA for each sample was synthesized using the Amino Allyl MessageAmp II™ 
aRNA Kit from Ambion (Austin, TX, USA). Briefly, 5 µg of total RNA was primed for 





strand cDNA synthesis according to manufacturer’s protocol. The cDNA formed were 
purified and transcribed in vitro with 5-(3-aminoallyl)-UTP to obtain a-UTP labelled 
aRNA. The aRNA synthesized was subsequently purified and 25 µg of it was coupled 
to Cy5 fluorescent dye from Amersham Biosciences (Piscataway, NJ, USA). 
Absorbance of Cy5 labelled aRNA was measured using the NanoDrop ND-1000 
(NanoDrop Technologies, Wilmington, DE, USA) to ensure adequate labelling 
efficiency of the above 10 Cy5 dye molecules per thousand nucleotides. All Cy5 
labelled-aRNA samples were verified to have adequate labelling efficiency of > 10. 
They were fragmented and 10 µg of Cy5 labelled aRNA for each sample was 
hybridized to each of the Human Whole Genome OneArrayTM (Phalanx Biotech Group, 
Hsinchu, Taiwan). This array is made up of 32 050 60-mer sense-strand 
oligonucleotides which can be divided into 30 968 human genome probes and 1082 
experimental control probes. Each oligonucleotide probe is designed to hybridize to a 
specific target gene described in the current public domain contents, such as UniGene, 
Cancer Genome Anatomy Project (CGAP), BioCarta, Kyoto Encyclopedia of Genes 
and Genomes (KEGG), and validated by the Human Genome Sequencing Project 
(HGSP).  Triplicate arrays were performed for each individual RNA sample from each 
batch of cells.  
 
Following hybridization, arrays were washed, dried and scanned using GenePix Axon 
4000B Scanner (Molecular Devices Corporation, Sunnyvale, CA, USA). Images were 








5.2.4 Data Mining For Microarray Study  
 
Genepix Pro 4.1 software (Molecular Devices Corporation, Sunnyvale, CA, USA) was 
used to extract the signal intensity values from each gene chip. Data from each chip 
was first normalized using quantile normalization (Bolstad et al., 2003) to compensate 
for systematic technical differences between different chips with the Matlab® software 
(MathWorks, Natick, MA, USA). It was then filtered to remove signal that was flagged 
absent by the scanner. Next, this normalized data was subjected to per gene 
normalization to the median value for each gene within each sample using the 
Genespring® software (Silicon Genetics, Redwood, CA, USA). For each RNA sample, 
the mean normalized gene intensity was subsequently obtained by averaging the 
normalized gene intensity value of its three technical replicates. The entire data set was 
subjected to statistical analysis using Welch One Way ANOVA (p < 0.05) to identify 
genes that were statistically different between control (untreated) sample versus at least 
one of the three As2O3-treated samples (24 hrs of As2O3 treatment, 48 hrs of As2O3 
treatment and OVCAR-3/AsR cells). The p value obtained was corrected using the false 
discovery rate method of Benjamini and Hochberg at a false discovery rate of 5% 
(Benjamini et al., 1995). This group of genes identified was further filtered for at least 
2-fold differential regulation. Genes common to both batches of RNA after filtering on 
fold change were further subjected to hierarchical clustering. Gene functional analysis 
was subsequently performed using Genespring® and Genecards® (Crown Human 
Genome Center and Weizmann Institute of Science, Israel). 
 
5.3.5 Pathway Analysis of Differentially Expressed Genes in OVCAR-3/AsR Cells 
 
Entrez Gene accession numbers of differentially expressed genes in OVCAR-3/AsR 





Rockville, MD, USA). This is a web-based database consisting of millions of 
individually modelled relationships between proteins, genes, complexes, cells, tissues, 
drugs, and diseases (Nikitin et al., 2003). The data input was queried against the 
Pathway Studio® knowledge base for genetic interactions. Genes mapped to the 
knowledge base are used to build genetic networks. 
 
5.3 Results 
5.3.1 Establishment of Arsenic Resistant OVCAR-3 Cell Line, OVCAR-3/AsR 
 
OVCAR-3 cell line was selected for the development of an arsenic resistant cell line as 
it is a well established ovarian cancer cell line with high sensitivity to As2O3 at 
concentrations of 1-2 µM, which is comparable to the concentrations of As2O3 used in 
APL cell lines. This cell line was grown continuously with increasing concentrations of 
As2O3 as described under materials and methods until it no longer responded to 1-2 
µM of As2O3. This As2O3 resistant subline is designated OVCAR-3/AsR.  
 
Under the phase contrast microscope, little morphological differences were observed 
between the parental OVCAR-3 cell line and its arsenic-resistant counterpart (Figure 5-
1). However, when exposed to increasing concentrations of As2O3, the concentration of 
As2O3 at 2 µM that previous killed more than 50% of parental OVCAR-3 cells had 
little growth inhibitory effect on OVCAR-3/AsR cells (Figure 5-2). At this 
concentration, more than 90% of OVCAR-3/AsR cells survived the cytotoxic insult 
(Figure 5-2). Progressive increase in As2O3 concentrations beyond 5 µM resulted in an 
increasing growth inhibitory effect and cytotoxic cell kill of OVCAR-3/AsR cells. The 





different from that of parental OVCAR-3 cells at 1.48 ± 0.41 µM (p < 0.05). The 
arsenic-resistant OVCAR-3/AsR cell line thus demonstrated a nine-fold resistance to 
As2O3 when compared to parental OVCAR-3 cells. Episodic determinations of IC50 
value confirmed that this arsenic-resistant phenotype was stable for at least 2 months in 
a drug-free medium.  
 
             
                               OVCAR-3                                                             OVCAR-3/AsR 
 
 
Figure 5-1 Morphology of OVCAR-3 and OVCAR-3/AsR cells under the phase 
contrast microscope 
 
Adherent cells were washed once with PBS and visualized using phase contrast microscope. Original 
magnification 400X. 
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As shown in Section 2.3.3, treatment of parental OVCAR-3 cells with 2 µM of As2O3 
for 72 hrs resulted in apoptosis induction. When OVCAR-3/AsR cells were treated 
with 5 µM of As2O3 for 72 hrs, negligible apoptotic cells were observed under 
confocal microscope (Figure 5-3).  
 
                                             
                                      Control                    As2O3 5 µM 
           
              
 
 
                       As2O3 10 µM    As2O3 20 µM 
 
Figure 5-3 Apoptotic morphological changes in OVCAR-3/AsR cells in response to 
high concentrations of As2O3  
 
Original magnification 200X 
 
Progressive increase in apoptotic cells was subsequently observed when As2O3 
concentrations were increased to 10 µM and 20 µM (Figure 5-2). Likewise, when PI 
stained OVCAR-3/AsR cells were analyzed by flow cytometry, only 5.29 ± 0.01% of 
cells were apoptotic after treatment with 5 µM of As2O3 for 72 hrs (Table 5-1). This 





and 20 µM of As2O3, respectively (Table 5-3). In OVCAR-3/AsR cells, As2O3 
treatment also resulted in cell cycle arrest in both the G2/M and S phases of the cell 
cycle (Table 5-1).        
 
Table 5-1 Cell cycle analysis of OVCAR-3/AsR cell after As2O3 treatment 
 
                           Cell Cycle Phase 
                           Sub-G1                G0/G1            S            G2/M    
           Control                  0.63 ± 0.19       50.41 ± 8.40        4.99 ± 0.18  21.54 ± 2.90  
        As2O3 5 µM             5.29 ± 0.01       44.77 ± 2.55        6.15 ± 0.16         25.13 ± 0.36 
       As2O3 10 µM               6.88 ± 0.85       28.61 ± 2.18        6.52 ± 0.49         30.66 ± 0.77     
       As2O3 15 µM             14.56 ± 0.43       21.67 ± 1.62        9.43 ± 0.52         34.21 ± 1.68    




5.3.2 Lack of Cross Resistance of OVCAR-3/AsR to Cddp and Paclitaxel   
 
To ascertain whether OVCAR-3/AsR cells show any cross resistance to Cddp and 
paclitaxel, the responses of these cells in the presence of increasing concentrations of 
the two drugs were separately examined. The IC50 values of OVCAR-3/AsR for both 
cells lines to Cddp and paclitaxel were almost comparable to that in parental OVCAR-3 
cells (Table 5-2). No net increase in the relative resistance value of OVCAR-3/AsR to 
parental cells was observed for both Cddp and paclitaxel while that of As2O3 was 9.31 
(Table 5-3). This result thus confirmed that the arsenic resistant OVCAR-3/AsR cells 










Table 5-2 IC50 values (Mean ± SD) of As2O3, paclitaxel and Cddp in in vitro growth 
inhibition assay in parental OVCAR-3 and OVCAR-3/AsR cells 
 
           
          Cell Line                                             IC50 values 
 
                                            As2O3 (µM)             Paclitaxel (nM)         Cddp (µg/ml)                                
 
            
           OVCAR-3                   1.48 ± 0.41                   4.83 ± 0.43                1.84 ± 0.25#            
       
      OVCAR-3/AsR              13.78 ± 2.21                   3.74 ± 0.74                1.47 ± 0.31                        
  
             
    #Data was obtained from Du and Ho (unpublished data) 
 
 
Table 5-3 Relative resistance value of parental OVCAR-3 and OVCAR-3/AsR cells to 
As2O3, paclitaxel and Cddp  
 
           
                                       Drug                          Relative Resistance                                            
 
            
                                       As2O3                             9.31                 
       
                                   Paclitaxel              0.77 
 
                                    Cddp                                     0.80 
                                                        
 
  Relative resistance = IC50 of OVCAR-3/AsR cells to drug divided by IC50 of OVCAR-3 cells to drug  
 
 
5.3.3 Microarray Profiling of the Gene Expression Changes After Acute and 
Chronic As2O3 Treatment  
 
Microarray experiments were performed to identify genes that were differentially 
expressed between parental untreated OVCAR-3 cells with either cells treated acutely 
(parental OVCAR-3 cells after 24 hrs or 48 hrs of As2O3 treatment) or chronically 
(OVCAR-3/AsR) with As2O3. After initial quantile normalization and flagging out 
probes without signal, a total of 13 257 probes were identified. Each probe was further 
normalized to its median intensity value. This type of normalization process commonly 





that allows for the comparison of gene expression profiles and subsequent clustering of 
genes that may be expressed at very different levels 
 
 
After normalization to the median intensity value of each probe, statistical analysis 
identified probes with intensity values that were statistically significantly different 
between control sample against at least one of the arsenic-treated sample. The probes 
identified were further filtered based on at least two-fold differential expression. In 
Batch A and Batch B, 1206 and 820 probes were identified, respectively. Among these 
differentially regulated genes, 607 probes representing 547 genes were found to be 


















   Batch B 
213 Probes   607 Probes 599 Probes   
 Batch A 
Figure 5-4 Venn diagram showing the number of statistically significant and 
differentially regulated probes with at least a two-fold difference between control 




Next, visualization of the grouping of these 607 probes on the basis of their expression 
profile was obtained using hierarchical clustering. From the clustering figure (Figure 5-





were highly similar between the two batches of RNA processed. With acute As2O3 
treatment (exposure of parental OVCAR-3 cells to As2O3 for 24 and 48 hrs), 
expression pattern of numerous genes represented using this group of 607 probes 
identified showed gradual differential expression levels from that of control (untreated 
parental OVCAR-3 cells) sample. With chronic As2O3 treatment (OVCAR-3/AsR 
cells), a distinct gene expression pattern that differed from that of control cells and cells 


























Figure 5-5 Hierarchical clustering analysis of the 607 differentially expressed probes 





In order to further understand the biological significance of this 607 probes identified, 
the genes represented by these probes that were significantly differentially regulated 
based on ANOVA with at least 2-fold difference in the gene expression values between 
control (untreated) sample against arsenic-treated sample at each individual time-point 
were found. At 24 hr post arsenic treatment, only 16 genes out of the 607 probes 
analyzed were identified to be differentially regulated when compared to control (Table 
5-4). 11 genes were up-regulated while 5 genes were down-regulated. Among them, 
up-regulated genes include those involved in GSH metabolism (GCLM and G6PD), 
protein degradation and apoptosis (SQSTM1), negative regulation of cell growth 
(OKL38) and transcription factor ATF3. For the down-regulated genes, genes such as 
keratin 4 and 15 (KRT 4 and KRT 15), that are components of the cytoskeleton that 
may play a role in cellular communication and matrix Gla protein (MGP) that is 





























































OKL38 4.369 Cell growth and differentiation 
PH_hs_0018184 NM_005952 MT1X 4.297 NO signal transduction; metal ion 
binding 
PH_hs_0000057 NM_001674 ATF3 3.685 Transcription factor 
PH_hs_0010763 NM_003900 SQSTM1 3.129 Apoptosis; protein degradation;  
PH_hs_0001148 NM_024554 PGBD5 2.921 - 















TMEM22 2.343 - 






DSCR1L1 -3.343 Protein phosphatase 2B binding 
PH_hs_0004626 NM_002275 KRT15 -3.752 Cytoskeletal component; cell 
communication 
PH_hs_0024170 NM_002272 KRT4 -4.152 Cytoskeletal component; cell 
communication 
PH_hs_0032872 NM_000900 MGP -4.269 Cell differentiation; extracellular 
matrix component 
 # Average fold change represents the mean fold change value obtained from averaging the fold change for 




When the duration of As2O3 treatment was prolonged to 48 hrs, alteration of the gene 
expression profiles in response to As2O3 became more evident. In total, 145 genes were 
found to be significantly differentially regulated (Table 5-5). This group of genes has 
diverse molecular functions and is involved in a varied number of biological processes. 
They include numerous novel genes with reported functional roles in cellular 
metabolism including GSH metabolism, cellular apoptosis and DNA damage response, 
cell cycle regulation, cell differentiation and proliferation, signal transduction and 





proteolysis as well as those with various solute transporter functions were also 
differentially regulated. Interestingly, among this group of genes, genes such as DDIT3 
(CHOP or GADD153), GADD45A, ATF3, TRIB3, FBXO2, PMAIP (NOXA), 
LEPREL1, CLGN, CYP1A1, MAL, DHRS9, Slc3a2, MGP and HMOX1 (HO-1) have 
been either linked with ER stress response or have association with the ER. 
Furthermore, up-regulation of several oxidative stress-related genes (GCLM, HMOX1, 




















































Summary of Function 
PH_hs_0011943 NM_002133 HMOX1 95.310 Signal transduction; Oxidative stress 
response 
PH_hs_0035466 NM_003739 AKR1C3* 29.620 Electron transport 
PH_hs_0018184 NM_005952 MT1X 7.1620 NO signal transduction; metal ion 
binding 
PH_hs_0005514 NM_032717 MGC11324 5.424 Cellular metabolism 
PH_hs_0004860 NM_004362 CLGN 4.658 Protein unfolding 
PH_hs_0022372 NM_001275 CHGA 4.586 Calcium ion binding 
PH_hs_0000057 NM_001674 ATF3 4.577 Transcription factor 
PH_hs_0001148 NM_024554 PGBD5 4.038 - 
PH_hs_0033101 NM_004083 DDIT3 3.861 DNA damage response; ER overload 
response 
PH_hs_0023764 NM_002061 GCLM 3.814 GSH metabolism, oxidative stress 
response 
PH_hs_0006395 NM_020299 AKR1B10 3.579 Cellular metabolism 
 
PH_hs_0025324 NM_182729 TXNRD1 3.578 Oxidative stress response 
PH_hs_0038876 NM_005953 LOC441019 3.499 Metal ion binding 
PH_hs_0006040 AB018258 ATP10B 3.497 Cation transporter 
PH_hs_0002700 NM_013370 OKL38 3.495 Cell growth and differentiation 
PH_hs_0025826 NM_000904 NQO2 3.424 Oxidative stress response; electron 
transport 
PH_hs_0008141 NM_080725 C20orf139 3.355 Oxidative stress response 
PH_hs_0010763 NM_003900 SQSTM1 3.331 Protein degradation; apoptosis 
PH_hs_0011502 NM_003976 ARTN 3.297 Signal transduction 
PH_hs_0000819 NM_005010 NRCAM 3.094 Neuronal adhesion 
PH_hs_0025078 NM_001394 DUSP4 3.073 Cell cycle; MAPKKK signalling 
cascade 
PH_hs_0037948 AK091102 MGC11082 3.028 - 
PH_hs_0003174 NM_004454 ETV5 3.024 Transcription regulation 
PH_hs_0026045 NM_025130 FLJ22761 2.974 Cellular metabolism 
PH_hs_0000852 NM_031459 SESN2 2.955 Cell cycle arrest 
PH_hs_0017286 AK124426 - 2.939 - 
PH_hs_0023894 NM_021158 TRIB3 2.894 Apoptosis; transcription regulation; 
regulation of MAPK activity 
PH_hs_0025907 NM_000140 FECH 2.877 Cellular metabolism 
PH_hs_0016738 NM_032323 MGC13102 2.853 - 
PH_hs_0004630 NM_001924 GADD45A 2.748 DNA damage response;  apoptosis 
PH_hs_0031749 NM_012168 FBXO2 2.713 Proteolysis; ER related metabolism 
PH_hs_0006542 NM_002729 HHEX 2.699 Transcription regulation 
PH_hs_0000788 NM_002005 FES 2.666 Cell proliferation; cell signalling 
PH_hs_0033390 NM_000690 ALDH2 2.588 Cellular metabolism 
PH_hs_0000354 NM_002220 ITPKA 2.583 Cell signalling 
PH_hs_0005631 NM_025246 TMEM22 2.578 - 
PH_hs_0030119 NM_018357 FLJ11196 2.485 - 
PH_hs_0027158 NM_006756 TCEA1 2.453 Transcription regulation 
PH_hs_0001390 NM_002395 ME1 2.424 Cellular metabolism 
PH_hs_0033599 XM_371429 KIAA1666 2.417 Cellular metabolism 
PH_hs_0006340 NM_003648 DGKD 2.416 Cell growth 




# Average fold change represents the mean fold change value obtained from averaging the fold change for 
Batch A and Batch B   



















Summary of Function 
PH_hs_0003518 NM_012427 KLK5 2.380 Proteolysis 
PH_hs_0006110 NM_019058 DDIT4 2.377 mTOR signalling pathway 
PH_hs_0025490 NM_005269 GLI 2.370 Cell differentiation; transcription 
regulation 
PH_hs_0011430 AL110204 - 2.356 - 
PH_hs_0028187 NM_024692 RSNL2 2.348 - 
PH_hs_0017514 NM_032638 GATA2 2.330 Transcription factor 
PH_hs_0027514 NM_021127 PMAIP1 2.310 Protein binding 
PH_hs_0023967 NM_017786 FLJ20366 2.303 - 




PH_hs_0004621 NM_000402 G6PD 2.275 GSH metabolism; glucose 
metabolism 
PH_hs_0013934 NM_001657 AREG 2.144 Cell proliferation; cell signalling 
PH_hs_0024845 NM_004631 LRP8 2.142 Signal transduction 
PH_hs_0022977 NM_153811 SLC38A6 2.137 - 
PH_hs_0009794 NM_023076 C16orf28 2.129 Protein binding; metal ion binding 
PH_hs_0001888 NM_018420 SLC22A15 2.125 Cation transporter 
PH_hs_0001010 NM_012068 ATF5 2.041 Transciption factor 
PH_hs_0035912 XM_498994 LOC441062 2.016 - 
PH_hs_0010165 NM_153045 C9orf91 2.011 - 
PH_hs_0001024 NM_144713 FLJ32954 -2.048 - 
PH_hs_0000929 NM_004267 CHST2 -2.058 Cellular metabolism 
PH_hs_0032264 NM_003530 HIST1H3D -2.092 - 
PH_hs_0004352 NM_000591 CD14 -2.100 Apoptosis; immune response 
PH_hs_0003688 NM_000888 ITGB6 -2.106 Cell adhesion; inflammatory 
response 
PH_hs_0030157 NM_004815 PARG1 -2.128 Signal transduction 
PH_hs_0037071 CR593560 LOC440934 -2.155 - 
PH_hs_0036464 AK096819 SLC2A9 -2.163 Glucose transporter 
PH_hs_0002304 NM_014112 TRPS1 -2.181 Transcription regulation 
PH_hs_0004398 NM_004105 EFEMP1 -2.233 Protein binding 
PH_hs_0025269 NM_013343 LOH3CR2A -2.235 - 
PH_hs_0000076 NM_000882 IL12A -2.258 -  
PH_hs_0030898 NM_032932 RAB11FIP4 -2.266 Calcium ion binding 
PH_hs_0016124 NM_002231 KAI1 -2.280 Protein binding 
PH_hs_0005146 BX098660 - -2.288 - 
PH_hs_0003822 NM_006557 DMRT2 -2.291 Transcription factor 
PH_hs_0006222 NM_015931 LOC51066 -2.296 - 
PH_hs_0027137 NM_018988 GFOD1 -2.306 Cellular metabolism 
PH_hs_0035772 NM_002982  CCL2* -2.331 Antiapoptosis; signal transduction 
PH_hs_0029983 NM_153699 GSTA5 -2.336 GSH metabolism, oxidative stress 
response 
PH_hs_0018171 NM_003275 TMOD1 -2.341 Cytoskeleton organization 
PH_hs_0027544 NM_000916 OXTR -2.351 Cell signalling 
PH_hs_0002774 NM_004932 CDH6 -2.390 Cell adhesion 
PH_hs_0026662 NM_001955 EDN1 -2.406 Cell signalling 
PH_hs_0026899 NM_014243 ADAMTS3 -2.415 Proteolysis 
PH_hs_0000086 NM_000138 FBN1 -2.449 Extracellular matrix component 
PH_hs_0004186 NM_000499 CYP1A1 -2.453 Detoxification  
 
 
# Average fold change represents the mean fold change value obtained from averaging the fold change for 
Batch A and Batch B   



















Summary of Function 
PH_hs_0031496 NM_003633 ENC1 -2.478 Protein binding 
PH_hs_0004728 NM_002888 RARRES1 -2.489 Cell proliferation 
PH_hs_0005148 NM_016352 CPA4 -2.524 Proteolysis; histone acetylation 




-2.538 Chromosome assembly 
PH_hs_0000953 NM_016267 VGLL1 -2.542 Transcription regulation 
PH_hs_0029016 NM_000227 LAMA3 -2.546 Cell migration; cell adhesion 
PH_hs_0016931 AK055877 LOC151438 -2.560 - 
PH_hs_0034059 NM_033069 C6orf114 -2.563 - 
PH_hs_0005421 NM_153362 PRSS35 -2.567 Proteolysis 
PH_hs_0011690 NM_005458 GPR51 -2.580 Signal transduction 
PH_hs_0000753 NM_003012 SFRP1 -2.613 Antiapoptosis 
PH_hs_0015577 NM_018640 LMO3 -2.643 Transcripton regulation 
PH_hs_0015371 NM_024101 MLPH -2.675 Protein transport 
PH_hs_0003133 NM_018192 LEPREL1 -2.716 Protein metabolism 
PH_hs_0004789 NM_002653 PITX1 -2.716 Transcription regulation 
PH_hs_0004948 NM_020805 KLHL14 -2.754 Protein binding 
PH_hs_0010636 NM_005771 DHRS9 -2.810 Oxidative stress response 
PH_hs_0025869 NM_014883 FAM13A1 -2.831 Signal transduction 
PH_hs_0002227 NM_004633 IL1R2 -2.877 Immune response 
PH_hs_0024437 NM_003810 TNFSF10 -2.903 Apoptosis; cell signalling 
PH_hs_0001026 NM_006350 FST -2.964 Cell differentiation; cell signalling 
PH_hs_0031396 NM_001683 ATP2B2 -3.036 Calcium ion binding; calmodulin 
binding 
PH_hs_0012389 NM_144590 ANKRD22 -3.039 - 
PH_hs_0023550 NM_004665 VNN2 -3.044 Hydrolase 
PH_hs_0037434 AK125888 FBXO32 -3.045 - 
PH_hs_0003145 AK023647 - -3.061 - 




PH_hs_0024961 NM_001565 CXCL10 -3.200 Cell signalling 
PH_hs_0023101 NM_033254 BOC -3.230 Cell adhesion; protein binding 
PH_hs_0004209 NM_020349 ANKRD2 -3.300 Muscle development 
PH_hs_0032398 NM_006952 UPK1B -3.338 Cell differentiation 
PH_hs_0010095 NM_003238 TGFB2 -3.360 Cell growth; cell proliferation; cell 
death 
PH_hs_0000509 XM_033173 PCDH19 -3.389 - 
PH_hs_0007034 AL049227 - -3.405 - 
PH_hs_0009339 NM_000067 CA2* -3.481 Carbon dioxide metabolism; metal 
ion binding 
PH_hs_0010628 BM720103 - -3.556 - 
PH_hs_0004705 NM_012101 TRIM29 -3.647 Transcription regulation; metal ion 
binding; protein binding 
PH_hs_0040800 NM_012338 TM4SF12 -3.784 - 
PH_hs_0002286 NM_015464 SOSTDC1 -3.851 Cell signalling; protein binding 
PH_hs_0036058 NM_000598 IGFBP3 -3.861 Apoptosis; signal transduction 
PH_hs_0024475 NM_001099 ACPP -3.888 Cell cycle 
 
 
# Average fold change represents the mean fold change value obtained from averaging the fold change for 
Batch A and Batch B   



















Summary of Function 
PH_hs_0024094 NM_145035 ADMP -3.973 - 
PH_hs_0004626 NM_002275 KRT15 -3.988 Cytoskeletal component; cell 
communication 
PH_hs_0020156 NM_000424 KRT5 -4.907 Cytoskeletal component; protein 
binding 
PH_hs_0009405 NM_005822 DSCR1L1 -4.976 Protein phosphatase 2B binding 
PH_hs_0023962 NM_052832 SLC26A7 -4.979 Transporter 
PH_hs_0008853 NM_080574 C20orf70 -5.086 - 
PH_hs_0004629 NM_002371 MAL -5.220 Apoptosis; cell differentiation 
PH_hs_0031089 NM_020129 LGALS14 -5.454 Sugar binding 
PH_hs_0024170 NM_002272 KRT4 -5.730 Cytoskeletal component; cell 
communication 
PH_hs_0019619 NM_002964 S100A8 -6.035 Calcium ion binding 
PH_hs_0040930 NM_001874 CPM -6.232 Proteolysis 
PH_hs_0010384 NM_018286 FLJ10970 -8.039 - 
PH_hs_0000305 NM_002425 MMP10 -8.758 Metalloproteinase; cell signalling 








In the comparison between the parental OVCAR-3 cells and resistant OVCAR-3/AsR 
cells, 401 genes showed differential expression between the two groups (Appendix 3). 
Of these genes, 195 genes were more highly expressed in OVCAR-3/AsR cells (2 to 24 
fold) while 206 genes were expressed to lower levels (-2 to -52 fold) (Appendix 3). The 
top 50 overexpressed and underexpressed genes were listed in Tables 5-6 and 5-7, 
respectively. Again, these genes possess a wide variety of cellular functions. A huge 
proportion can be categorized into genes related to cellular metabolism and transport 
and genes involved in signalling pathways for cell cycle regulation, proliferation, or 
apoptosis.  
# Average fold change represents the mean fold change value obtained from averaging the fold change for 
Batch A and Batch B   























Summary of Function 
PH_hs_0035466 NM_003739 AKR1C3* 24.670 Electron transport 
PH_hs_0027536 NM_030754 SAA2 15.865 - 
PH_hs_0005148 NM_016352 CPA4 13.980 Histone acetylation 
PH_hs_0005671 NM_002317 LOX 13.740 Signal transduction 
PH_hs_0004352 NM_000591 CD14 13.490 Apoptosis; immune response 
PH_hs_0011943 NM_002133 HMOX1 12.550 Signal transduction; Oxidative stress 
response 
PH_hs_0032470 XM_292021 LOC341346 12.325 - 
PH_hs_0001558 NM_004753 DHRS3 12.220 Cellular metabolism 
 
PH_hs_0011511 NM_004751 GCNT3 11.485 Cellular metabolism 
 
PH_hs_0004409 NM_000689 ALDH1A1 10.365 Cellular metabolism 
 
PH_hs_0026808 NM_006512 SAA4 10.003 Lipid transporter 
PH_hs_0024170 NM_002272 KRT4 9.748 Cytoskeletal component; cell 
communication 
PH_hs_0004996 NM_002110 HCK 7.912 Kinase 
PH_hs_0038991 NM_021123 GAGE7 7.509 - 
PH_hs_0019619 NM_002964 S100A8 7.344 Calcium ion binding 
 
PH_hs_0022372 NM_001275 CHGA 7.201 Calcium ion binding 
 
PH_hs_0014156 NM_000930 PLAT 7.109 Proteolysis; PDGF signalling 
PH_hs_0035912 XM_498994 LOC441062 6.538 - 
PH_hs_0005514 NM_032717 MGC11324 6.399 Cellular metabolism 
 
PH_hs_0002314 NM_183240 TMEM37 5.971 Ion transporter 
PH_hs_0005421 NM_153362 PRSS35 5.923 Proteolysis 
PH_hs_0000100 NM_002164 INDO 5.826 Metal ion binding 
PH_hs_0008826 NM_001445 FABP6 5.730 Cell proliferation 
PH_hs_0004098 NM_152673 MUC20 5.605 Protein oligomerization 
PH_hs_0000235 NM_000575 IL1A 5.533 Cell growth and proliferation; 
apoptosis 
PH_hs_0024398 NM_004207 SLC16A3 5.509 Anion transporter 
PH_hs_0040800 NM_012338 TM4SF12 5.422 - 
PH_hs_0032478 NM_005574 LMO2 5.322 Metal ion binding 
PH_hs_0032897 NM_003872 NRP2 5.306 Cell differentiation 
PH_hs_0000953 NM_016267 VGLL1 5.299 Transcription regulation 
PH_hs_0002935 NM_001741 CALCA 5.297 Cell signalling 
PH_hs_0024092 NM_007129 ZIC2 5.170 Cell differentiation 
PH_hs_0025524 NM_203447 DOCK8 5.091 GTP and GTPAse binding 
PH_hs_0006947 AK097496 LOC283352 5.065 - 
PH_hs_0007104 NM_022119 PRSS22 5.061 Proteolysis 
PH_hs_0011503 NM_003979 GPCR5A 5.058 Signal transduction 
PH_hs_0011690 NM_005458 GPR51 5.050 Signal transduction 






# Average fold change represents the mean fold change value obtained from averaging the fold change for 
Batch A and Batch B   





















Summary of Function 
PH_hs_0026823 NM_004613 TGM2 4.964 Cell adhesion; cell signalling 
PH_hs_0022469 NM_005715 UST 4.897 Enzyme 
PH_hs_0004577 XM_027236 TTC9 4.883 - 
PH_hs_0034256 XM_211090 LOC283587 4.845 - 
PH_hs_0039790 BC042436 GPCR5A 4.752 Signal transduction 
PH_hs_0027323 NM_024909 C6orf134 4.671 - 
PH_hs_0005870 NM_032034 SLC4A11 4.641 Anion transporter 
PH_hs_0006395 NM_020299 AKR1B10 4.486 Cellular metabolism 
PH_hs_0012806 NM_005725 TSPAN-2 4.374 Cell proliferation; cell adhesion 
PH_hs_0032059 NM_005434 BENE 4.359 Protein binding 
PH_hs_0001536 NM_007150 ZNF185 4.353 - 









# Average fold change represents the mean fold change value obtained from averaging the fold change for 
Batch A and Batch B   














































Summary of Function 
PH_hs_0016036 NM_032539 SLITRK2 -52.540 Protein binding 
PH_hs_0002908 NM_020386 HRASLS -26.365 - 
PH_hs_0016413 NM_018476 BEX1* -16.615 Cell differentiation 
PH_hs_0010088 NM_014289 CAPN6 -15.400 Proteolysis 
PH_hs_0014200 NM_002776 KLK10 -15.260 Cell cycle; proteolysis 
PH_hs_0035772 NM_002982 CCL2* -14.805 Antiapoptosis; signal transduction 
PH_hs_0005998 NM_004626 WNT11 -13.365 Signal transduction 
PH_hs_0031238 NM_002986 CCL11 -12.915 Cell signalling; cell adhesion; 
immune response 
PH_hs_0005801 NM_007196 KLK8 -11.491 Proteolysis 
PH_hs_0005906 NM_000076 CDKN1C -11.060 Cell cycle arrest 
PH_hs_0031396 NM_001683 ATP2B2 -10.631 Calcium ion binding; calmodulin 
binding 
PH_hs_0019248 NM_005302 GPR37 -9.162 Signal transduction 
PH_hs_0037802 BX640888 GPC6 -8.538 - 
PH_hs_0004511 NM_003652 CPZ -8.492 Metal ion binding 
PH_hs_0027279 NM_020698 KIAA1145 -7.961 - 
PH_hs_0018787 NM_004120 GBP2 -7.310 Nucleotide binding 
PH_hs_0000236 NM_002193 INHBB -7.272 Cell growth; cell differentiation 
PH_hs_0028708 NM_000346 SOX9 -6.798 Transcription factor; protein binding 
PH_hs_0022302 NM_001617 ADD2 -6.742 Metalion binding 
PH_hs_0028961 NM_000165 GJA1 -6.439 Gap junction assembly; cell 
signalling 
PH_hs_0024509 NM_006820 IFI44L -6.359 - 
PH_hs_0004276 NM_016083 CNR1 -6.281 Cell signalling 
PH_hs_0003194 NM_021255 PELI2 -6.258 Protein binding 
PH_hs_0005820 NM_018004 FLJ10134 -6.191 - 
PH_hs_0032346 NM_152282 ACPL2* -6.045 - 
PH_hs_0006770 NM_025216 WNT10A -5.874 Cell signalling 
PH_hs_0033196 NM_005823 MSLN -5.768 Cell adhesion 
PH_hs_0025078 NM_001394 DUSP4 -5.744 Cell cycle; MAPKKK signalling 
cascade 
PH_hs_0013028 NM_005725 TIMP3 -5.649 Apoptosis 
PH_hs_0001151 NM_178496 LOC151963 -5.636 - 
PH_hs_0003518 NM_012427 KLK5 -5.375 Proteolysis 
PH_hs_0031572 NM_002237 KCNG1 -5.328 Transporter 
PH_hs_0013732 NM_002430 MN1 -5.293 Cell cycle progression 
PH_hs_0037912 AK124907 TMOD2* -5.092 Cell signalling 
PH_hs_0022217 NM_003317 TITF1 -5.092 Transcription factor 
PH_hs_0001688 XM_378360 LOC400043 -5.055 - 
PH_hs_0026662 NM_001955 EDN1 -4.943 Cell signalling 









# Average fold change represents the mean fold change value obtained from averaging the fold change for 
Batch A and Batch B   






















Summary of Function 
PH_hs_0008565 NM_004429 EFNB1 -4.868 Cell proliferation; cell signalling 
PH_hs_0020111 NM_000597 IGFBP2 -4.849 Cell growth 
PH_hs_0000702 NM_015529 MOXD1 -4.744 Cellular metabolism 
PH_hs_0003752 NM_001448 GPC4 -4.650 Cell proliferation 
PH_hs_0025250 NM_003108 SOX11 -4.633 Transcription factor 
PH_hs_0005583 NM_000044 AR -4.589 Cell growth; cell proliferation; cell 
signalling 
PH_hs_0020546 NM_021219 JAM2 -4.491 Cell adhesion 
PH_hs_0003988 NM_000313 PROS1 -4.484 Blood coagulation 
PH_hs_0003766 NM_145307 PLEKHK1 -4.448 Signal transduction 
PH_hs_0026578 NM_005965 MYLK -4.440 - 
PH_hs_0023602 NM_178012 MGC8685 -4.405 Protein polymerisation 





# Average fold change represents the mean fold change value obtained from averaging the fold change for 
Batch A and Batch B   




5.3.4 Network and Pathway Analysis of Differentially Expressed Genes Between 
Parental OVCAR-3 Cells versus Resistant OVCAR-3/AsR Cells 
 
The presence of any functional relationships and potential interactions of the 401 genes 
identified to show at a least two-fold differential regulation between parental OVCAR-
3 cells and arsenic-resistant OVCAR-3/AsR subline, was further explored using 
Pathway Studio®, a pathway analysis software from Ariadne Genomics Inc. (Rockville, 
MD, USA). 85 of these 401 genes were mapped to a genetic network (Figure 5-6) as 
defined by the Pathway Studio® tool. Within the network, up-regulated genes were 
coloured red while down-regulated genes were coloured green. From this network, a 
unique molecular signature of gene interaction involved in a range of cancer-related 
processes can be observed. They include genes associated with apoptosis, cell growth 
and differentiation, cell cycle arrest, cell adhesion, ECM components and genes 
encoding transporter proteins. Among this network of genes, one main gene cluster was 





at the centre of the hub. Prolonged arsenic treatment up-regulated the gene expression 
of the IL1A gene and its receptor (IL1R1, IL1R2). The increased in IL1A mediated 
signalling in turn led to the down-regulation of the gene expressions of IGFBP4, 
CEBPA, CCL2, FN1, CCL11, SOX9 and up-regulation of LIF, S100A8, PLAT, 
CALCA, SAA2, SZ10 (CXCL10), PTAFR and MMP7 as shown by the genetic 
network created. This group of genes has diverse roles and their gene expression 
changes all led to the development of a more drug resistance phenotype which will be 
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 Figure 5-6 Genetic network of differentially expressed genes between OVCAR-





5.4 Discussion  
 
Acquired platinum chemoresistance is a major determinant of the poor outcome 
associated with advanced ovarian carcinoma. In the quest for suitable agents that can be 
used for the treatment of platinum-resistant ovarian cancer, As2O3 was found to be a 
suitable candidate, owing to its in vitro efficacy against Cddp-resistant tumour cell lines 
(Du and Ho, 2001). In order to improve and optimize the utility of As2O3 for this 
disease, an arsenic-resistant OVCAR-3 cell line, OVCAR-3/AsR, that served as a 
prerequisite to further understand its complex mode of action and to investigate its 
mechanisms of resistance was established. OVCAR-3/AsR is the first ever arsenic-
resistant ovarian tumour cell line developed. It showed a 9-fold stable resistance to 
As2O3 than the parental OVCAR-3 cells at the IC50 value. More importantly, it 
demonstrated no significant cross-resistance with either Cddp or paclitaxel, again re-
inforcing the potential usefulness of As2O3 in platinum-resistant ovarian disease.   
 
A comprehensive analysis of the genes that characterized the response of parental 
OVCAR-3 cells to As2O3 treatment and the As2O3-resistant OVCAR-3/AsR cells were 
investigated using microarray technology. It was observed that As2O3 treatment had 
widespread effects on many genes. In parental OVCAR-3 cells, acute As2O3 exposure 
stimulated a group of ER stress-related genes (DDIT3, GADD45A, ATF3, PMAIP, 
HMOX1) that is of particular interest. The ER is an important organelle involved in 
cellular lipid synthesis, protein folding and trafficking, cellular responses to stress and 
changes to intracellular calcium levels (Rao et al., 2004). It is sensitive to nutrient or 
energy deprivation, disruption of calcium homeostasis, inhibition of N-linked 
glycosylation and oxidative stress (Schroder and Kaufman, 2005; Verkhratsky, 2004). 





accompanied by the accumulation of unfolded protein aggregates, also termed as the 
unfolded protein response (UPR) which could eventually lead to apoptotic induction 
when the ER function is too severely impaired (Rao et al., 2004).   
 
Although the exact signalling mechanisms during ER stress induced cell death are not 
fully understood, ER-induced apoptotic cell death is known to proceed via at least three 
apoptotic pathways. One of them involved the transcriptional up-regulation of the gene 
for C/EBP homologous protein (CHOP), also known as DDIT3 or GADD153. 
Following the transcriptional increase in its gene expression during ER stress, DDIT3 is 
subsequently activated by p38 mitogen-associated protein kinase (Oyadomari and Mori, 
2004). DDIT3 has been reported to negatively regulate cell growth. Its overexpression 
in turn promotes cell death, although the exact mechanism remains unclear. It is 
believed that its function as a transcription factor that directly regulates target genes in 
the nucleus, thereby resulting in cell demise (Oyadomari and Mori, 2004). It has also 
been reported to be able to down-regulate the prosurvival Bcl2 molecule (Barone et al., 
1994; Matsumoto et al., 1996; Maytin et al., 2001; McCullough et al., 2001; 
Oyadomari and Mori, 2004). In parental OVCAR-3 cells after 48 hrs of arsenic 
treatment, DDIT3, a strong marker of ER stress, was one of the top ten most up-
regulated genes.  
 
One more ER stress associated transcription factor that was up-regulated after early 
acute arsenic treatment is ATF3. It is a member of the ATF/CREB subfamily of basic-
region leucine zipper proteins whose expression has been reportedly increased during 
the early stages of ER stress response (Jiang et al., 2004). ATF3 is involved in the 





GADD34 (Wolfgang et al., 1997), another ER stress response marker, that was also 
increased following arsenic treatment of parental OVCAR-3 cells.  
 
Apart from these, PMAIP (NOXA) a Bcl2 family member was up-regulated in this 
study. PMAIP is known to be a p53 regulated gene but has been reported to be induced 
following treatment with ER stress-inducing agent, thapsigargin, in a p53-independent 
fashion (Armstrong et al., 2007). Although its preferred binding partner is Mcl-1, 
PMAIP (NOXA) can also bind Bclxl. This may provide a rationale for the greater 
effectiveness of Bclxl in preventing arsenic-induced cell death as described in Chapter 
3. Although ER stress induced cell death has been reported to be mediated by caspase-
12, the relevance of caspase-12 to ER-induced cell death remains unclear as it is not 
present in most humans (Xu et al., 2005). Furthermore, the ability of broad-spectrum 
caspase inhibitor such as zVAD-fmk in preserving cell survival induced by ER stress is 
not understood. Available evidence showed that non-apoptotic cell death can occur in 
the presence of zVAD-fmk when strong pharmacological inducers of ER stress are used 
(Chae et al., 2004). 
  
In relation to ER stress induced cell death, the cells can respond by up-regulating genes 
encoding ER chaperone proteins, enzymes and ER structural components. In this study, 
gene expression changes for genes such as CLGN, LEPREL1, CYP1A1, DHRS9 and 
HMOX1 that are ER related residents were observed. The induction of HMOX1, with 
antiapoptotic function, served as a mechanism by which the ER regulates cell survival 
(Liu et al., 2005). Additionally, ER stress can lead to an increase in GSH biosynthesis 
as another protective mechanism against oxidative stress. This was evident by the 





net increase in GSH levels is likely brought about by the induction of the glutamate-
cysteine ligase modifier (GCLM) gene after acute As2O3 treatment as exemplified by 
the microarray results. 
 
GCLM is a subunit forming part of the heterodimeric glutamate-cysteine ligase 
enzyme, also known as glutamate-cysteine synthetase. This enzyme is the rate-limiting 
enzyme in GSH synthesis (Lomaestro and Malone, 1995; Deneke and Fanburg, 1989). 
The GSH levels in the liver, lung, pancreas, erythrocytes and plasma of mouse with the 
GCLM knockout gene have been reported to be only 9-16% of that of mouse with the 
functional GCLM gene (Yang et al., 2002), confirming the importance of the GCLM 
subunit in regulating cellular GSH levels. Increased GCLM expression has been 
previously reported under certain oxidative stress conditions (Solis et al., 2002). The 
low level of redox oxidative stress generated by As2O3 treatment (Section 3.3.2) thus 
contributes to ER stress induction and a compensatory increase in cellular GSH 
synthesis as a protective mechanism to enhance cell survival through up-regulation of 
the GCLM gene. This provides the rationale for the effectiveness of BSO in 
augmenting arsenic-induced cell death as discussed in Chapter 4. Concurrent use of 
BSO, a irreversible inhibitor of the glutamate-cysteine ligase enzyme, removes the 
ability of As2O3 treated cells to mount a survival response, hence enhancing the 
efficacy of As2O3 in inducing ovarian cancer cell kill.    
 
Although GSH is traditionally recognized to function as an antioxidant, increasing 
evidence revealed that GSH may function as a reductant (Chakravarthi et al., 2006). In 
the ER, it is now postulated that a potential role of GSH is to reduce the non-native 





2006). This is supported by the continual survival of cell lines with a null mutant of the 
heavy subunit of glutamate-cysteine ligase in NAC containing culture media (Shi et al., 
2000). It also provides a partial explanation for the ineffectiveness of antioxidants in 
conferring any protection against combined As2O3 and BSO treatment (Chapter 4).  
    
Next, the genetic alterations resulting in the development of arsenic-resistant OVCAR-
3/AsR cells was examined. From the microarray results, it can be observed that the 
development of arsenic resistant in OVCAR-3 cells is multi-factorial. It involved an 
altered balance of proapoptotic and antiapoptotic proteins. In this context, the up-
regulation of genes such as BIRC3, HMOX-1, BAG2, CD14 and MGC 18216 that 
encode for antiapoptotic proteins was observed. At the same time, down-regulation of 
genes encoding proapoptotic proteins for example HIP1 and TIMP3 was also seen. The 
prosurvival response of increasing GSH production through up-regulation of GCLM 
gene and HMOX1 continued to be present in OVCAR-3/AsR cells.  
 
In this work, the contribution of the tumour microenvironment and inflammation in 
arsenic chemoresistance development in OVCAR-3 cells was observed. Epithelial 
ovarian cancer exhibits a complex cytokine-chemokine network (Burke et al., 1996). 
The interaction of these factors through an autocrine and/or paracrine fashion in turn 
promotes tumour growth, progression and neovascularization of ovarian cancer. The 
microarray analysis revealed an up-regulation of the gene expressions of IL1A and its 
receptors, suggesting an increase in IL1A-mediated signalling. This can in turn 
stimulate the activation of transcription factors and genes that promote the survival and 
proliferation of cells (Martin and Falk, 1997; Wolf et al., 2001). It can also regulate the 





1998; Dinarello, 1998; Wolf et al., 2001). Accompanying the increased in ILIA 
mediated signalling, gene with tumour suppressor function (CEBPA) was down-
regulated while genes mediating tumour invasion (PLAT) and metastasis (MMP7) were 
up-regulated. Additionally, it was observed that the gene expression of cytokine CCL2 
was down-regulated while that of cytokines such as LIF, S100A8 and SZ10 (CXCL10) 
were up-regulated. Although CCL2 is a cytokine with antiapoptotic properties, it also 
plays an important role in the recruitment of infiltrating macrophages to the ovarian 
tumour cells. Its down-regulation in turn reduces macrophage migration within the 
tumour, thus ensuring continuous production of growth and angiogenic factors (Shih et 
al., 2006). The other cytokines (LIF, S100A8, SZ10) with up-regulated gene expression 
mediate an increase in tumour metastasis (Wysoczynski et al., 2007), angiogenesis 
(Gebhardt et al., 2006) and invasion, respectively (Zipin-Roitman et al., 2007). 
   
Lastly, another interesting finding from the microarray result is the down-regulation of 
the gene encoding the androgen receptor (AR). Androgens can either promote or inhibit 
ovarian cancer cell growth. Androgen production increases in ovarian carcinomas and 
decreases during response to chemotherapy (Mahlck et al., 1986). AR positive 
expression has previously been shown to be associated with lower-stage ovarian 
tumours and better patient survival (Slotman et al., 1990). The down-regulation of AR 
gene expression could possibly imply the chemoresistance status of OVCAR-3/AsR 
cells and the likely androgen independent growth of this cell line. In a similar manner, 
Benbrahim-Tallaa and colleagues reported the development of androgen independence 
during arsenic-induced malignant transformation of the human prostate epithelial cells, 







Overall, the results of this study delineated the ER stress induced pathway as a possibly 
novel mechanism of arsenic-induced cell death in OVCAR-3 cells. Together with the 
results from Chapter 3, it revealed that arsenic-induced cell death of OVCAR-3 cells 
involves a complex cross talk between the ER and the mitochondria. In addition, it 
showed that the progression to arsenic resistance was contributed by numerous factors. 
Among them, IL1A signalling may play an important role in the maintenance of this 









Investigations of Synergistic and Antagonistic Cytotoxic Drug 
Combinations of As2O3 and Cddp with HDACIs, SAHA and MS-275   
 
6.1 Introduction 
Acquired chemoresistance to Cddp has been a major cause of treatment failure in 
ovarian cancer relapse (Kartalou and Essigmann, 2001). The molecular mechanisms 
contributing to platinum resistance in ovarian carcinoma are multi-factorial and 
complex as reviewed in Section 1.3.2. These include the dysregulation of a plethora of 
proapoptotic and antiapoptotic genes via numerous methods. In recent years, aberrant 
epigenetic regulation of these genes has been recognized as an increasingly important 
process contributing to either down-regulation or up-regulation of important tumour 
suppressors and other genes involved in apoptotic pathways. Commonly reported 
epigenetic changes include DNA methylation and histone hypoacetylation (Balch et al., 
2004). Research on the latter has led to the development of a new mechanistic class of 
anticancer agents termed the HDACIs. 
   
HDACIs are made up of several diverse chemical structures, capable of promoting 
histone acetylation, thus favouring the uncoiling and relaxation of the chromatin 
structure (Drummond et al., 2005; Monneret, 2005; Minucci and Pelicci, 2006). 
Chromatin relaxation in turn increases the accessibility of transcriptional factors to the 
DNA structure, permitting the re-expression of silenced genes involved in cell-cycle 
arrest (Ogryzko et al., 1996), DNA repair (Chen et al., 2002) and apoptosis pathways 
(Marks et al., 2000) including those associated with Cddp resistance. Recent emerging 
evidence has also revealed histone acetylation independent actions of HDACIs. They 
consist of activation of apoptosis via the intrinsic mitochondria pathway with caspase 




activation (Marks et al., 2000), apoptosis through ligation of death receptors (Insinga et 
al., 2005), induction of ROS (Ruefli et al., 2001), Akt dephosphorylation (Chen et al., 
2005) and disruption of the HDAC-protein phosphatase 1 complexes (Chen et al., 
2005).      
 
For ovarian cancer, several preclinical studies have shown that various HDACIs were 
able to induce apoptosis in ovarian cancer cell lines in vitro and tumour regression of 
orthotopically implanted ovarian tumours in vivo (Saito et al., 1999; Takai et al., 2004; 
Chobanian et al., 2004; Strait et al., 2005; Cooper et al., 2007). Given these 
encouraging results and the unique mechanism of action of HDACIs, it is possible that 
this novel class of agents may have a potential role in future chemotherapeutic 
combination for ovarian cancer treatment. The focus of this chapter was to study the 
cytotoxic effects of drug combinations of As2O3 and Cddp with two structurally 
different HDACIs, SAHA and MS-275.  
 
6.2 Materials and Methods 
6.2.1 Chemicals  
As2O3, MS-275, FDA and RNase A were acquired from Sigma Co. (St Louis, MO, 
USA). Cddp injection and SAHA were purchased from Pfizer (Bentley, Australia) and 
Alexis Biochemical Corp (San Diego, California, USA), respectively. Triton X 100 was 
supplied by Biorad (Hercules, CA, USA). FBS, penicillin/streptomycin solution, 
trypsin/EDTA, RPMI-1640 medium and DMEM were from HyClone Laboratories Inc. 
(Logan, UT, USA). PI was from Molecular Probes (Grand Island, NY, USA).  As2O3 
was dissolved as 1.0 mmol/L stock solution in PBS. It was stored at 4°C and diluted to 
required working concentration with culture medium before use.   




6.2.2 Cell Lines and Cell Culture  
Two human ovarian cancer cell lines, OVCAR-3 and SKOV-3, and one normal human 
fetal lung fibroblast cell line, MRC-5, were obtained from ATCC (Manassas, VA, 
USA). OVCAR-3 cells were grown as monolayers in RPMI-1640 medium. SKOV-3 
and MRC-5 cells were grown in DMEM.  
 
6.2.3 Analysis of Drug Interaction 
 
The median-drug effect analysis method, described by Chou and Talalay (Chou and 
Talalay, 1984) has been widely used for evaluation of potential synergism between 
different agents (Peters et al., 2000). Drug interaction was assessed by calculating the 
combination index (CI) at a series of values of fraction of the cells affected (fa). Cells 
were seeded into 96-well microtiter plates and allowed to adhere overnight. To evaluate 
the interaction of the drugs, the medium was replaced with either the drugs alone or in 
combination in a fixed IC50-based molar concentration ratio added within a range of 
concentrations for 48 hrs. FMCA assay was used to obtain the IC50 values and the dose 
response curve for subsequent median-drug effect analysis.  
 
For agents that are mutually non-exclusive (having different mechanisms of action or 
are acting independently), the CI is calculated with the following equation:  
    
1 2 1 2
1 2 1 2
(D) (D) (D) (D)CI
(Dx)  (Dx) (Dx) (Dx)
= + +
 
where by (D)1 and (D)2 are doses of Drug 1 and Drug 2 in combination that inhibit x%     
    of cell proliferation 
    (Dx)1 and (Dx)2 are the doses of Drug 1 and Drug 2 alone that also inhibit x%    
of cell proliferation  




CI < 1 indicates synergism, CI = 1 indicates an additive relationship, and CI > 1 
indicates antagonism. By repeating the calculations at various effect levels, a median-
drug-effect plot can be constructed by plotting CI against the fa value.  
 
6.2.4 Sequence Dependent Interaction Between Cddp and HDACIs 
 
Using the OVCAR-3 cells as the ovarian cancer cell prototype cell line, Cddp and 
HDACI were applied in different sequential combinations to determine the effects on 
ovarian cancer cell death. Cppd and HDACI combination were tested in three 
sequences as illustrated in Figure 6-1. These were: (A) pretreatment with SAHA or 
MS-275 for 4 hrs or 24 hrs followed by Cddp for 48 hrs without washing, (B) 
concurrent treatment of either SAHA or MS-275 with Cddp for 48 hrs and (C) 
pretreatment with Cddp for 4 hrs or 24 hrs followed by concurrent treatment of SAHA 
or MS-275 for another 44 hrs or 24 hrs, respectively without washing. Cell survival 
















   
 






















Figure 6-1 Sequence of Cddp and HDACI exposure 
 
6.2.5 Statistical Analysis 
The results were presented as the mean ± SD of three independent experiments. 
Statistical analysis was performed using Graphpad Prism 4 Software (Graphpad 
Software Inc., San Diego, CA, USA). p values were calculated p values were calculated 
according to Student’s t test for comparison between two groups and ANOVA with 
Tukey’s posthoc test for comparison between three or more groups. A p value of < 0.05 
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6.3.1 Evaluation of The Sensitivities of OVCAR-3 and SKOV-3 Cells to Individual 
Drug Treatment After 48 hrs of Incubation  
 
The effects of the individual drugs (As2O3, Cddp, SAHA and MS-275) on the cell 
viability of OVCAR-3 and SKOV-3 cells following 48 hrs of treatment were first 
examined. Exposure to each drug resulted in a significant cytotoxicity and growth 
inhibition of both ovarian cancer cell lines in a concentration-dependent manner 
(Figure 6-2). Cell sensitivities for the individual drugs were further illustrated by their 
















































































           As2O3 (µM)          As2O3 (µM) 
           Cddp (µM)          Cddp (µM) 
Figure 6-2 Dose-dependent cytotoxic cell kill of (A) OVCAR-3 and (B) SKOV-3 cells by 
As2O3, Cddp, SAHA and MS-275 
 





















































































Figure 6-2 Dose-dependent cytotoxic cell kill of (A) OVCAR-3 and (B) SKOV-3 cells 
by As2O3, Cddp, SAHA and MS-275 (Continued) 
 
 
Table 6-1 IC50 values (mean ± SD) of As2O3, Cddp, SAHA and MS-275 in ovarian 
cancer cell lines after 48 hrs of treatment 
 
                 IC50 values (µM) 
 
Treatment     OVCAR-3   SK-OV-3    MRC-5  
 
As2O3        3.05 ± 0.31             13.57 ± 5.83                    14.76 ± 2.90           
 
Cddp        8.75 ± 1.19             16.96 ± 5.28                    32.60 ± 4.20         
 
SAHA        2.06 ± 0.10      8.87 ± 0.99                    81.01 ± 11.83           
 
MS-275   7.72 ± 0.52            139.28 ± 8.00                   65.80 ± 17.42           
 
 
          SAHA (µM)        SAHA (µM) 
          MS-275 (µM)        MS-275  (µM) 




In OVCAR-3 cells, IC50 values for As2O3, Cddp, SAHA and MS-275 were 3.05 ± 0.31 
µM, 8.96 ± 2.00 µM, 2.06 ± 0.10 µM and 7.72 ± 0.52 µM, respectively. In SKOV-3 
cells, the IC50 values for As2O3, Cddp, SAHA and MS-275 were 13.57 ± 5.83 µM, 
16.96 ± 5.28 µM, 8.87 ± 0.99 µM and 139.28 ± 8.00 µM in chronological order. The 
IC50 values for As2O3, Cddp and SAHA in the ovarian cancer cell lines were lesser than 
those of the normal fibroblast control cell line, MRC-5, indicating selectivity of these 
drugs for ovarian cancer cells. MS-275, however, only showed therapeutic selectivity 
for OVCAR-3 cells. For both ovarian tumour cell lines, SAHA was the most potent 
single drug, demonstrating the lowest IC50 value when compared with As2O3, Cddp and 
MS-275. In agreement with previous research (Godwin et al., 1992; Yunmbam et al., 
2004), OVCAR-3 and SKOV-3 exhibited resistance to Cddp treatment. Interestingly, 
SKOV-3 was eighteen times less responsive to the effects of MS-275 when compared 
to OVCAR-3 cells at its IC50 concentration. Overall, SKOV-3 was a more resistant cell 
line to all the drugs tested than OVCAR-3. In the highly resistant SKOV-3 cell line, all 
the IC50 values for the tested drugs were not therapeutically achievable without causing 
significant side effects. 
 
 
6.3.2 As2O3 and HDACIs Combinations Resulted in Antagonism while Cddp and 
HDACIs Combinations Interacted Synergistically in SKOV-3 and OVCAR-3 Cell 
Lines Following Simultaneous Drug Exposure 
 
The combination therapies of As2O3 with SAHA, As2O3 with MS-275, Cddp with 
SAHA, and Cddp with MS-275 were investigated. This involved using median effect 
analysis for synergistic or antagonistic interaction in both ovarian cancer cell lines 
following concurrent treatment. Median effect analysis over a range of SAHA and 
As2O3 concentrations, administered at fixed IC50 ratios of (1:1.48) in OVCAR-3 and 
(1:1.5) in SKOV-3 cells, yielded CI values considerably greater than 1 (Figure 6-3). 




Similarly, median effect analysis over a range of MS-275 and As2O3 concentrations, 
administered at fixed IC50 ratios of (1:0.40) in OVCAR-3 and (1:0.097) in SKOV-3 
cells, again resulted in CI values considerably greater than 1 (Figure 6-3). These 
combinations denoted antagonistic interactions between the drugs used. 
 
Figure 6-3 As2O3 and SAHA and As2O3 and MS-275 combinations resulted in 
antagonism in SKOV-3 and OVCAR-3 cell lines 
 
 
On the contrary, CI values less than 1 for fa greater than 0.40 were obtained for 
OVCAR-3 at fixed IC50 ratios of (1:1.16) for the SAHA with Cddp combination. In 
SKOV-3 cells, CI values less than 1 were obtained for most of the fa values for this 
drug combination at the fixed IC50 ratios of (1:1.5) tested (Figure 6-4). This represents 
synergistic enhancement of the cytotoxic effects of the drugs tested at the respective 
fractional effects. For the drug combination of MS-275 with Cddp administered at fixed 
ratios of (1:0.40) in OVCAR-3 cells and (1:0.12) in SKOV-3 cells, yet again synergism 
was observed in both cell lines. In OVCAR-3 cells, synergistic interaction was 
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0.30-0.90. The representative CI values against fa for all the drug combinations tested 
in OVACR-3 and SKOV-3 cells are listed in Tables 6-2 and 6-3, respectively.  
 
Figure 6-4 Cddp and SAHA and Cddp and MS-275 combinations interacted 
synergistically to induce cell death in SKOV-3 and OVCAR-3 cell lines 
 
 
Table 6-2 Combination indices for the drug combinations in OVCAR-3 cells  
CI values less than 1 indicate synergistic combinations 
 
                 Combination Index 
 
Fractional Effect            As2O3 + SAHA     Cddp + SAHA        As2O3 + MS-275     Cddp + MS-275   
0.1      3.71          2.88            2.83                0.86 
0.2      2.50          1.69                      2.53                        0.69 
0.3      1.98                       1.24                      2.38                        0.61 
0.4      1.66                       0.98                      2.28                        0.55 
0.5      1.43                       0.81                      2.20                        0.51 
0.6      1.25                       0.68                      2.13                        0.48 
0.7      1.09                       0.57                      2.07                        0.45 
0.8      0.93                       0.47                      2.01                        0.42 
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Table 6-3 Combination indices for the drug combinations in SKOV-3 cells 
   CI values less than 1 indicate synergistic combinations 
 
                 Combination Index 
 
Fractional Effect     As2O3 + SAHA          Cddp + SAHA     As2O3 + MS-275     Cddp + MS-275   
0.1  1.53      1.07                     1.59          2.15 
0.2  1.43      0.82                     1.65                     1.33 
0.3  1.37                       0.68                       1.70                     0.98 
0.4  1.34                       0.59                       1.74                     0.76 
0.5  1.31                       0.52                       1.79                     0.60 
0.6  1.28                       0.46                       1.84                     0.48 
0.7  1.26                       0.41                       1.91                     0.38 
0.8  1.25                       0.35                       2.00                     0.28 




6.3.3 Therapeutically Relevant Concentrations of SAHA and MS-275 Achieved       
Synergism with Cddp in Ovarian Tumour Cells  
 
As SAHA and MS-275 have been shown to favourably interact with Cddp from the 
median effect analysis described above, the next investigation was the hypothesis that 
synergistic interactions between these drug combinations were achievable using 
therapeutically relevant concentrations of SAHA and MS-275. In OVCAR-3 cells, 
treatment with 1 µM of SAHA for 48 hrs was minimally toxic to the cells (SI = 88.56 ± 
16.33%). At this concentration, SAHA was able to enhance the cytotoxicity of Cddp 
(Figure 6-5), resulting in a reduction of the IC50 concentration of Cddp from 8.75 ± 
1.91 µM to 3.74 ± 1.13 µM (Table 6-4). When SAHA concentration was further 
increased to 2 µM, SAHA treatment alone resulted only in a marginal decrease in cell 
kill with SI remaining at 70.62 ± 6.14%. However, when combined with Cddp, IC50 
concentration of Cddp was reduced further to 1.79 ± 0.95 µM (Table 6-5). In the 
SKOV-3 cells, SAHA treatment alone at 2 µM and 4 µM was again minimally toxic 
with SI of 83.39 ± 10.00% and 70.58 ± 7.22%, respectively. When combined with 
Cddp, this resulted in an enhancement of cytotoxic cell kill of Cddp (Figure 6-5), 




reducing its IC50 value from 16.96 ± 5.28 µM to 5.89 ± 1.99 µM and 4.43 ± 1.45 µM 
correspondingly (Table 6-4). In OVCAR-3 cells, treatment with MS-275 alone at 1 µM 
and 2 µM, caused little toxicity to the cells (SI = 100.58 ± 5.49% and 85.94 ± 6.07%, 
respectively). When combined with Cddp, IC50 of Cddp was again reduced greatly 
(8.75 ± 1.91 µM to 3.74 ± 1.31 µM and 1.36 ± 0.42 µM, respectively) (Figure 6-6 and 
Table 6-6). In SKOV-3 cells, clinically relevant concentrations of Cddp were not 
achieved when combined with therapeutically achievable concentration of MS-275 at 5 
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Figure 6-5 Therapeutically relevant concentrations of SAHA and MS-275 enhanced 
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Cddp + MS-275 1 µM
Cddp + MS-275 2 µM
 
Figure 6-6 Therapeutically relevant concentrations of MS-275 enhanced the 




Table 6-4 IC50 values (mean ± SD) of Cddp in OVCAR-3 cells after concurrent 
treatment with therapeutically achievable levels of SAHA 
 
          Treatment            IC50 values of Cddp (µM) 
     
       Cddp alone                8.75 ± 1.19 
 
                             Cddp + 1 µM SAHA   3.22 ± 1.50      
 
                             Cddp + 2 µM SAHA      1.79 ± 0.95 
 
 
Table 6-5 IC50 values (mean ± SD) of Cddp in SKOV-3 cells after concurrent treatment 
with therapeutically achievable levels of SAHA 
 
          Treatment            IC50 values of Cddp (µM) 
     
        Cddp alone              16.96 ± 5.28 
 
                             Cddp + 2 µM SAHA   5.89 ± 1.99      
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Table 6-6 IC50 values (mean ± SD) of Cddp in OVCAR-3 cells after concurrent 
treatment with therapeutically achievable levels of MS-275 
 
          Treatment            IC50 values of Cddp (µM) 
     
        Cddp alone    8.75 ± 1.19 
 
                             Cddp + 1 µM MS-275  3.74 ± 1.13      
 




6.3.4 Synergistic Combinations Showed Selectivity for Ovarian Cancer Cells  
 
To further establish the usefulness of Cddp and SAHA and Cddp and MS-275 drug 
combinations, the effects of these combinations on a normal lung fibroblast cell line, 
MRC-5 were evaluated. When treated with Cddp alone for 48 hrs, its IC50 for MRC-5 
cells was greater than 20 µM. When combined with SAHA at 2 µM and 8 µM, IC50 
values of Cddp were reduced to 10.73 ± 1.42 µM and 8.99 ± 1.97 µM, respectively 
(Table 6-7). These IC50 values obtained were however much higher when compared to 
that obtained with concurrent treatment in the ovarian cancer cells, indicating 
preferential kill of ovarian cancer cells over normal cells. With Cddp and MS-275 
combination, IC50 of Cddp remained greater than 20 µM (Table 6-7), again showing 
selective cytotoxicity for ovarian cancer cells responsive to this treatment combination 
at therapeutically relevant concentrations.  
Table 6-7 IC50 values (mean ± SD) of Cddp in MRC-5 Cells after concurrent treatment 
with SAHA or MS-275 
 
          Treatment            IC50 values of Cddp (µM) 
     
        Cddp alone           > 20 
 
   Cddp + 2 µM SAHA               10.73 ± 1.42     
 
                             Cddp + 8 µM SAHA                   8.99 ± 0.42 
 
   Cddp + 2 µM MS-275        > 20  
 
                             Cddp + 8 µM MS-275           > 20 




6.3.5 Effects of Synergistic Combinations on Cell Morphology of OVCAR-3 and 
SKOV-3 Cells 
 
Morphological studies were done to ascertain the observable effects of treatments on 
OVCAR-3 and SKOV-3 cells at relevant drug doses. OVCAR-3 or SKOV-3 cells were 
concurrently treated for 48 hrs with increasing concentrations of Cddp and 1 µM or 2 
µM of SAHA, respectively. Treatment with SAHA alone as observed morphologically 
was minimally toxic to both cell lines with little observable difference in cell numbers 
when compared with control untreated cells. When used concurrently with Cddp, a 
greater reduction in cell numbers was observed in both cell lines than treatment with 
either Cddp or SAHA alone (Figure 6-7 and Figure 6-8). Similarly, treatment with 1 
µM of MS-275 alone in OVCAR-3 caused little cell kill. When used in tandem with 3 
µM of Cddp (Figure 6-9), a much greater decrease in cell number was observed, 
confirming the results obtained for the cell cytotoxicity experiments described under 


















                   
                                Control         Cddp 3 µM  
                    
    Cddp 6 µM                    SAHA 1 µM 
                  
                  Cddp 3 µM + SAHA 1 µM                   Cddp 6 µM + SAHA 1 µM 
 
Figure 6-7 Effects of SAHA and Cddp on the cell morphology of OVCAR-3 cells  
 
Photographs of the adherent cells after washing were taken under a phase-contrast microscope.  
Original magnification 400x 





     
 
                   
          Control         Cddp 3 µM  
                   
                                    Cddp 6 µM         SAHA 2 µM 
                  
                   Cddp 3 µM + SAHA 2 µM                   Cddp 6 µM + SAHA 2 µM 
 
Figure 6-8 Effects of SAHA and Cddp on the cell morphology of SKOV-3 cells 
 
Photographs of the adherent cells after washing were taken under a phase-contrast microscope.  
Original magnification 400x 
 
 




                    
        Control         Cddp 3 µM  
                  
                                MS-275 1 µM                                     Cddp 3 µM + MS-275 1 µM 
 
Figure 6-9 Effects of MS-275 and Cddp on the cell morphology of OVCAR-3 cells  
 
Photographs of the adherent cells after washing were taken under a phase-contrast microscope.  
Original magnification 400x 
 
 
6.3.6 Increased Apoptotic Cell Kill with Cddp and SAHA Combination in 
OVCAR-3 and SKOV-3 Cells and Cddp and MS-275 Combination in OVCAR-3 
Cells 
 
To determine whether the enhancement of cytotoxic kill of Cddp and SAHA or Cddp 
and MS-275 combinations was caused by apoptosis induction, the amount of PI-stained 
cells in sub-G1 phase following different treatments were analysed. In OVCAR-3 cells, 
combined exposure of 1 µM of SAHA with increasing concentrations of Cddp resulted 
in a significant increase in the apoptotic cells (p < 0.05) when compared to treatment 
with either drug alone or that obtained from the sum of the apoptotic effects of 




individual drugs (Figure 6-9). Similar results were obtained for SAHA and Cddp drug 






























































































































































































* p< 0.05 between Cddp 3 µM versus SAHA 1 µM + Cddp 3 µM; ** p <  0.05 between Cddp 6 
µM versus SAHA 1 µM + Cddp 6 µM; *** p <  0.05 between Cddp 8 µM versus SAHA 1 µM + 
Cddp 8 µM; + p < 0.05 between SAHA 1 µM versus SAHA 1 µM + Cddp 3 µM; ++ p < 0.05 
between SAHA 1 µM versus SAHA 1 µM + Cddp 6 µM; +++ p < 0.05 between SAHA 1 µM 




* p < 0.05 between Cddp 3 µM versus SAHA 2 µM/Cddp 3 µM; ** p < 0.05 between Cddp 6 µM 
versus SAHA 2 µM + Cddp 6 µM; *** p < 0.05 between Cddp 8 µM versus SAHA 2 µM + Cddp 
8 µM; + p < 0.05 between SAHA 2 µM versus SAHA 2 µM + Cddp 3 µM; ++ p < 0.05 between 
SAHA 2 µM versus SAHA 2 µM + Cddp 6 µM; +++ p < 0.05 between SAHA 2 µM versus SAHA 
2 µM + Cddp 8 µM using one-way ANOVA with Tukey’s posthoc test 
 
Figure 6-10 Increased in apoptotic cells following co-treatment of Cddp with 
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For lone MS-275 treatment of OVCAR-3 cells, 9.40 ± 1.50% and 13.0 ± 0.10% 
apoptotic cells were found at 1 µM and 2 µM, respectively. Combined treatment of 
Cddp with either 1 µM or 2 µM of MS-275 again resulted in more apoptotic cells (p > 












































































6.3.7 Enhanced Cell Kill with Cddp and SAHA and Cddp and MS-275 
Synergistic Combinations Was Not Attributed to Cell Cycle Arrest  
 
Since HDACIs have been reported to induce G0/G1 cell cycle arrest (Takai et al., 
2004a; Takai et al., 2004b), combined treatments of Cddp with either SAHA or MS-
275 were examined for a possible associated with an alteration in cell cycle 
 + 
 * 
     ++ 
     ** 
* p < 0.05 between Cddp 3 µM versus  MS-275 1 µM + Cddp 3 µM; ** p < 0.05 between Cddp 3 
µM versus  MS-275 2 µM + Cddp 3 µM; + p < 0.05 between MS-275 1 µM versus MS-275 1 µM 
+ Cddp 3 µM; ++ p < 0.05 between MS-275 2 µM versus MS-275 2 µM + Cddp 3 µM using one-
way ANOVA with Tukey’s posthoc test 
 
 




progression. The cell cycle profiles of the untreated cells or drug treated was examined 
by flow cytometry following PI staining. OVCAR-3 and SKOV-3 cells cultured in 3 
µM Cddp alone showed an accumulation of cells in the S and G2/M phases (p < 0.05) 
(Tables 6-8 and 6-9). Increasing concentrations of Cddp in both cell lines were 
accompanied by an increase in sub-G1 phase (p < 0.05) and a reduction in the cell arrest 
at both the S and G2/M phases (Tables 6-8 and 6-9). When used alone, SAHA did not 
affect the proportion of cells in the G0/G1 phase (Tables 6-8 and 6-9). Similarly, when 
used in combination with Cddp, no net increase in the percentage of cells in the G0/G1 
phase was observed (Tables 6-8 and 6-9). Treatment of OVCAR-3 with MS-275 alone 
or in combination with Cddp also did not arrest the cells at the G0/G1 phase (Table 6-
10). Thus, the enhanced cell kill with Cddp and SAHA or Cddp and MS-275 
combination was not associated with cell cycle arrest.  
Table 6-8 Cell cycle analysis of OVCAR-3 cells following treatment with Cddp and 
SAHA alone or combination 
 
Treatment                     Cell Cycle Phase 
 
                            Sub-G1    G0/G1                    S            G2/M   
Control                  4.70 ± 0.50       63.30 ± 1.10       13.70 ± 0.80  16.50 ± 0.30  
SAHA 1 µM alone          14.80 ± 0.90       57.90 ± 0.80       11.50 ± 0.20        14.40 ± 0.70 
Cddp 3 µM alone           12.90 ± 4.10       18.70 ± 1.30       46.60 ± 3.10*      19.70 ± 2.10* 
Cddp 6 µM alone           15.60 ± 3.70       39.30 ± 5.10       25.90 ± 7.20          7.80 ± 1.10       
Cddp 8 µM alone           22.70 ± 0.20       39.80 ± 0.40       27.90 ± 0.60          8.50 ± 0.10 
Cddp 3 µM + SAHA 1 µM   33.50 ± 1.80       25.00 ± 0.70        30.00 ± 1.10   9.60 ± 0.60                          
Cddp 6 µM + SAHA 1 µM   43.50 ± 1.90       30.30.± 0.50        19.10 ± 1.90         6.40 ± 0.40 
Cddp 8 µM + SAHA 1 µM   55.00 ± 5.90       27.90 ± 2.90        12.60 ± 1.90         3.70 ± 1.00 
 
 

















Table 6-9 Cell cycle analysis of SKOV-3 cells following treatment with Cddp and 
SAHA alone or combination 
 
Treatment                     Cell Cycle Phase 
 
                            Sub-G1              G0/G1                 S            G2/M   
Control                         4.50 ± 1.60       78.30 ± 1.90        5.00 ± 0.20        10.70 ± 2.00                    
SAHA 2 µM alone          14.10 ± 2.50       62.40 ± 2.40        8.40 ± 0.50        13.10 ± 0.70 
Cddp 3 µM alone             7.50 ± 2.10       25.50 ± 1.60      40.00 ± 7.70*      23.00 ± 6.90* 
Cddp 6 µM alone           15.10 ± 0.50       42.10 ± 6.60      31.70 ± 4.50          9.10 ± 1.50                   
Cddp 8 µM alone           20.00 ± 0.60       47.40 ± 3.20      21.00 ± 5.70          9.60 ± 1.60 
Cddp 3 µM + SAHA 2 µM   31.60 ± 5.40       32.50 ± 6.30      25.80 ± 1.80  7.50 ± 1.50                           
Cddp 6 µM + SAHA 2 µM    44.50 ± 2.50       39.10.± 2.10      10.00 ± 0.70          5.50 ± 0.50 
Cddp 8 µM + SAHA 2 µM    61.70 ± 3.10       26.90 ± 1.30        7.50 ± 3.00          3.40 ± 0.40 
 
* p < 0.05 compared with control using Student’s t test 
 
 
Table 6-10 Cell cycle analysis of OVCAR-3 cells following treatment with Cddp and 
MS-275 alone or combination 
                
Treatment       Cell Cycle Phase 
 
                           Sub-G1              G0/G1                 S            G2/M   
Control                  4.70 ± 0.50       63.30 ± 1.10       13.70 ± 0.80  16.50 ± 0.30  
MS-275 1 µM alone            9.40 ± 1.50       58.20 ± 0.40       14.70 ± 1.30        15.90 ± 0.70 
MS-275 2 µM alone            13.00 ± 4.10       62.70 ± 1.40       11.90 ± 0.70        11.10 ± 0.90    
Cddp 3 µM alone           12.90 ± 3.70       18.70 ± 1.30       46.60 ± 3.10*      19.70 ± 2.10*     
Cddp 3 µM + MS-275 1 µM 38.10 ± 1.80       25.40 ± 2.90       26.30 ± 0.90   9.00 ± 0.60                          
Cddp 3 µM + MS-275 1 µM 54.10 ± 1.90       20.30 ± 2.90       17.30 ± 2.20          6.20 ± 0.70 
 
 
* p<0.05 compared with control using Student’s t test 
 
 
6.3.8 Optimization of Combination Dosing Schedule Using OVCAR-3 Cells  
 
In order to assess the importance of the sequence of treatment of the SAHA with 
respect to Cddp in ovarian cancer, combinations in three sequences were tested as 
described under materials using OVCAR-3 as the prototype cell line. Pretreatment of 
SAHA or MS-275 for 4 hrs followed by concurrent Cddp treatment for the next 48 hrs 
showed comparable reduction in cell kill compared to concurrent treatment with either 
SAHA or MS-275 and Cddp for 48 hrs (Figure 6-10). On the contrary, pretreatment 
with Cddp for 4 hrs followed by concurrent treatment with either SAHA or MS-275 




resulted in reduced cell death in comparison to the other two sequences of treatment 
(Figure 6-12). When the preincubation time was increased to 24 hrs, pretreatment of 
SAHA or MS-275 for 24 hrs followed by concurrent Cddp treatment for the next 48 hrs 
and concurrent treatment with either SAHA or MS-275 and Cddp for 48 hrs again 
showed greater cell kill than pretreatment with Cddp for 24 hrs followed by concurrent 
treatment with either SAHA or MS-275 (Figure 6-13). Concurrent treatment with the 
Cppd and SAHA combination also showed greater amount of cell kill compared with 
SAHA pretreatment for 24 hrs followed by combined Cddp treatment (Figure 6-13). 
Overall, concurrent treatment has been found to be the preferred treatment sequence 




































































































































Figure 6-12 Comparison of cell death profiles of OVCAR-3 cells following 4 hr 
pretreatment or concurrent treatment sequences 
 
 






































































































































Figure 6-13 Comparison of cell death profiles of OVCAR-3 cells following 24 hr 




6.4 Discussion  
 
Tumour resistance to Cddp and related platinum compounds in relapsed ovarian cancer 
remains one of the important problems in its treatment (Armstrong, 2002). 
Compounded by the lack of sufficiently effective second-line treatment options, new 
combination treatment regimens to improve the outcomes of this illness are urgently 
needed. Successful chemotherapy in general is highly reliant on the identification of 
suitable chemotherapeutic combinations showing efficacy and selectivity against the 
specific tumour cells tested. In this study, the effects of concurrent exposure of p53 
non-functional ovarian cancer cells, OVCAR-3 and SKOV-3, to combinations of As2O3 
or Cddp with selected HDACIs, SAHA and MS-275 were examined.  
 
In the cell lines tested, SAHA is a more potent cell growth inhibitor compared with 
MS-275 as evidenced by the lower IC50 values for the former in both cell lines. 




Although both SAHA and MS-275 are classified as HDACIs, this class of new 
anticancer agents comprises of a range of structurally diverse compounds. SAHA is a 
small molecular weight linear hydroxamic acid derivative while MS-275 is a pyridyl 
carbamate HDACI (Johnstone, 2002). While both are primarily developed based on 
their ability to induce histone hyperacetylation, emerging evidence has shown SAHA to 
be less specific than MS-275 at inhibiting the HDAC enzymes (Richon, 2006; Simonini 
et al., 2006). SAHA is a non-selective inhibitor Class I and II HDACs (Richon, 2006) 
while MS-275 preferentially inhibits HDAC1 over HDAC3 and HDAC8 (Simonini et 
al., 2006). Recently, it has been reported that SAHA and MS-275 regulated different 
sets of genes in breast cancer cells, underscoring the possible importance of non-
histone targets (Glaser et al., 2003). Although the exact mechanism of action is still 
unclear, it is likely that these non-specific activities contribute to the greater tumour cell 
kill effect of SAHA as compared to MS-275 in the cell lines.  
 
Median effect analysis revealed the simultaneous combination treatment of ovarian 
cancer with Cddp and SAHA or Cddp and MS-275, could be potentially effective novel 
therapeutic combinations in the two tested cell lines. The Cddp and SAHA combination 
has been shown to be effective at therapeutically achievable drug concentrations, 
yielding a synergistic growth inhibition with approximately 2-4 fold reduction in the 
IC50 values of Cddp and apoptotic enhancement in both OVCAR-3 and SKOV-3 cells. 
For the Cddp and MS-275 combination, synergistic growth inhibition and apoptosis 
were also achieved with therapeutically relevant drug concentrations in OVCAR-3 
cells. This was however not significantly achieved in SKOV-3 cells at clinically safe 
and useful concentrations of 5 µM of MS-275. This finding may be due to an inherent 
insensitivity of the SKOV-3 cell line to the effects of MS-275 that possibly relates to its 




inability to modulate some of the apoptotic resistance genes in this cell line unlike 
SAHA.  
 
As it has been earlier postulated that cancer therapy may be more effective when cancer 
cells are treated first with HDACIs followed by DNA targeting anticancer drugs (Kim 
et al., 2003). This is because an unfolded chromatin structure after HDACI treatment 
will increase the accessibility to DNA-targeting anticancer agents such as Cddp (Kim et 
al., 2003). Thus, in this study we examined the effects of sequential and concurrent 
used of Cddp with HDACIs. Comparable cell death inhibitory effects were observed 
between pretreatment of HDACIs for 4 hrs before combined Cddp treatment or 
concurrent treatment while concurrent treatment offer greater cell kill than pretreatment 
of HDACIs for 24 hr before combined Cddp treatment. This is in contrast with other 
reports of SAHA with Cddp in squamous cell carcinoma where pretreatment with 
HDACI offered a greater cell kill than concurrent treatment (Sato et al., 2006). It was 
previously thought that pretreatment with HDACIs will loosen the chromatin structure, 
thereby increasing the accessibility of DNA-targeting agents and hence increase the 
cytotoxicity of these traditional chemotherapeutic agents (Kim et al., 2003). This result 
again suggests that in the ovarian cancer cell lines and drug combinations used, 
targeting histone hypoacetylation may not be the only mechanism whereby HDACI 
enhanced the cytotoxic efficacy of Cddp in ovarian cancer cells.    
 
Although the pretreatment of ovarian cancer cells with HDACI followed by Cddp did 
yield significant advantage over concurrent treatment of HDACI with Cddp, these two 
regimens were found to be superior to Cddp pretreatment followed by HDACIs in 
ovarian cancer cells. This further supports the hypothesis that the sequence with which 




the HDACIs are used in relation to conventional chemotherapeutic agents should be 
carefully optimised to ensure maximal ovarian cancer cell kill. It was further supported 
by recent evidence provided by Cooper and colleagues where paclitaxel pretreatment 
followed by SAHA was shown to be more beneficial than SAHA pretreatment followed 
by paclitaxel in prolonging the survival of ovarian carcinoma implanted nude mice 
(Cooper et al., 2007).  
 
In this study, combined exposure of the ovarian cancer cells to HDACIs (SAHA or 
MS-275) with As2O3 was antagonistic. The exact mechanism for this opposing effect is 
still unknown. As such, further research on the effects of HDACIs in ovarian cancer is 
required in order to have a better understanding of the disparate actions of As2O3 and 
HDACIs in these cells.  
 
In conclusion, HDACIs in combination with Cddp exhibited a marked increase in 
cytotoxic cell kill of p53 non-functional Cddp-resistant ovarian cancer cells, OVCAR-3 
and SKOV-3. These drug combinations are promising as they showed therapeutic 
selectivity towards the tumour cells over normal cells. The combination of SAHA and 
Cddp in particular warrants further investigations on in vivo animal models and in 













The work outlined in this thesis evaluated several important aspects of the effects of 
As2O3 in ovarian cancer. As2O3 was found to display a similar pattern of cytotoxic 
effect with paclitaxel against various Cddp-sensitive and resistant ovarian cancer cell 
lines. Its lack of cross-resistance with Cddp and its ability to kill Cddp-resistant ovarian 
tumour cells at clinically achievable As2O3 concentrations of 1-2 µM, further reinforced 
its potential usefulness for the treatment of platinum refractory ovarian carcinoma. 
Investigation into the mechanisms responsible for As2O3-mediated ovarian tumour cell 
kill revealed that the cytotoxic effects of As2O3 were in part mediated via apoptosis 
induction. In OVCAR-3 cells, apoptosis induction was shown to be a late event that 
was time and concentration-dependent. Concurrent with apoptosis induction, OVCAR-
3 cells were also arrested at the G2/M or S phase of the cell cycle. This was again 
dependent on the concentration of As2O3 used.    
 
Cell death induced by As2O3 was found to occur via a caspase-independent and ROS 
independent route. This mode of cell death was accompanied by the dissipation of the 
mitochondrial membrane potential and the mitochondria to nucleus translocation of 
caspase-independent AIF in a fraction of arsenic-treated cells. Additionally, As2O3 
treatment was associated with the down-regulation of Bclxl gene and protein levels. 
With ectopic expression of Bclxl in OVCAR-3 cells, cellular apoptosis in response to 
As2O3 was completely blocked. It was also observed that enforced overexpression of 





suggesting that other complex modes of non-apoptotic cell death process might be 
involved in As2O3-mediated ovarian cancer cell kill.    
 
Intracellular GSH levels were found to be correlated to the arsenic sensitivities of the 
tested ovarian cancer cell lines. Modulation of intracellular GSH levels using BSO 
resulted in an augmentation of arsenic-induced cell death. This occurred in a ROS 
independent manner. It was accompanied by a net increase in cellular arsenic levels, 
suggesting that transporter mediated efflux of arsenic-GSH conjugate played a part in 
determining arsenic sensitivity of ovarian carcinoma cells. In this study, physiological 
level of AA was unable to modulate the intracellular GSH levels of ovarian tumour 
cells, thus failing to bring about an enhancement of arsenic-induced cytotoxicity. 
Likewise, pharmacological levels of AA did not bring about GSH reduction but 
increased arsenic-induced cell kill in part through ROS production.  
 
Gene expression analysis of parental OVCAR-3 cells after acute arsenic treatment 
revealed the role of ER stress in cell death induction. Accompanying the induction of 
ER stress, parental OVCAR-3 cells mounted a survival response involving the increase 
in the GCLM and other antioxidant response genes expressions. The former led to an 
increase in intracellular GSH levels and thus protects the cells from arsenic-induced 
cytotoxic insult. This also formed another rationale with which GSH modulator, BSO, 
was able to effectively enhanced arsenic-induced cell kill by blocking the ability of 
parental OVCAR-3 cells from mounting an important survival response after acute 
As2O3 exposure. A summary of the acute effects of As2O3 in ovarian tumour cells is 




















Figure 7-1 Effects of As2O3 in ovarian tumour cells 
 
In arsenic resistant OVCAR-3/AsR cells, gene expression analysis revealed the 
involvement of multiple factors in mediating As2O3 chemoresistance. These include an 
intricate balance between the expressions of antiapoptotic factors versus proapoptotic 
factors. OVCAR-3/AsR cells also showed an increased in IL1A signalling that could in 
turn modulate the gene expression of other genes, all known to contribute to the 
continual growth and survival of OVCAR-3/AsR cells. Accompanying the 
development of arsenic-resistance, OVCAR-3/AsR cells were observed to acquire an 
AR independent phenotype.           
 


















7.2 Future Studies 
 
7.2.1 Validation of Microarray Results With Real Time Polymerase Chain 
Reaction, Western Blotting and Intracellular GSH Measurement in OVCAR-
3/AsR Cells   
 
The advent of the microarray technology has allowed for convenient large scale gene 
expression profiling that has greatly facilitated the understanding of the working of 
numerous cancer chemotherapeutics (Huang and Sadee, 2003). However, the precision 
of the gene expression measurement is highly dependent on the numerous processing 
steps involved, ranging from RNA preparation, array hybridization and image 
acquisition (Konig et al., 2004). At such, gene expression measurement using the 
microarray platform is at most semi-quantitative. Therefore, validation of the accuracy 
of the gene expression changes on randomly selected genes showing differential 
regulation in the microarray data set using real-time PCR is required. In tandem with 
the real-time PCR experiments, protein expression changes after As2O3 treatment 
should also be performed to show that the gene expression changes is related to 
molecular and functional changes in cells. Additionally, intracellular GSH levels should 
be measured in OVCAR-3 /ASR cells. This helps to further determine if intracellular 
GSH levels play a role in intrinsic and/or acquired chemoresistance in ovarian cancer 
cells.  
 
7.2.2 Investigation of the Mode(s) of Non-Apoptotic PCD Induced by As2O3 in 
Ovarian Tumour Cells          
  
Although apoptosis has been a widely recognized and established mode of cell kill 
following chemotherapy, it has been increasingly documented that anticancer agents 
are capable of inducing non-apoptotic modes of cell death simultaneously with 





2007). In the present study, it was found that As2O3 induced caspase-independent 
apoptosis and possibly other non-apoptotic forms of cell death. As reviewed in Chapter 
1, several non-apoptotic modes of cell death have been identified including autophagy, 
paraptosis, mitotic catastrophy and necrosis. Among them, autophagy is of particular 
relevance to As2O3-induced cell death in ovarian tumour cells as this mode of cell 
demise have been documented to be associated with ER stress induction (Ogata et al., 
2006) and Bclxl protein has been shown to control autophagic PCD depending on the 
autophagic genes activated (Shimizu et al., 2004). Accumulating data have shown that 
when ER stress induced was too extensive such that the function of the ER cannot be 
restored, cells are directed to undergo apoptosis and/or autophagy (Ogata et al., 2006; 
Hoyer-Hansen and Jaattela, 2007). It was further reported that autophagy could in turn 
be a trigger for necrotic cell death following ER stress induction depending on the 
apoptotic competency of the cells involved (Ullman et al., 2007). Thus, the role of 
autophagy and necrotic cell death in relation to autophagy, in the context of As2O3-
mediated ovarian tumour cell kill, should be further examined using electron 
microscopy.   
 
 
7.2.3 Identification of the Mode of Cell Death Induced By Pharmacological 
Concentrations of AA in Combination with As2O3 Using Electron Microscopic 
Study and Translation of the Use of this Drug Combination into an In Vivo 
Animal Model  
 
In this study, the augmentation of As2O3-induced cell kill by pharmacological doses of 
AA was found not to be mediated by apoptosis induction. It has been reported that AA 
alone and in combination with other drugs, induces other unique mode of cell kill of 
ovarian tumour cells such as autoschizis (Gilloteaux et al., 1998; Gilloteaux et al., 





played a role in ovarian tumour cell kill using pharmacological doses of AA in 
combination with As2O3. In this regards, electron microscopic analysis of cell treated 
with this drug combination can be performed.      
 
AA has been shown to act as a pro-oxidant in vitro in this study to synergize with the 
anti-tumour effect of As2O3.  Clement et al reported that the ability of AA to act as a 
pro-oxidant in in vitro cell culture model was due to production of ROS upon 
interaction of AA with a transitional metal ion in cell culture media (Clement et al., 
2001). This implied that the use of AA to augment the cytotoxic effects of other 
chemotherapeutic agents may not be feasible in an in vivo situation. Recently, Chen and 
colleagues revealed that pharmacologic doses of AA could result in H2O2 production in 
human plasma, suggesting that pharmacologic doses of AA could indeed act as a pro-
oxidant in vivo (Chen et al., 2005).  This result was further supported by Duarte and 
colleagues who showed that high dose AA induced DNA strand breakage 
independently of extracellular transition metal ions in culture cells (Duarte et al., 2007). 
Therefore, the merit of combined use of pharmacologic doses of AA with As2O3 for 
ovarian cancer treatment needs to be investigated in a suitable in vivo model. Nude 
mice transplanted subcutaneously with OVCAR-3 cells to generate tumours in the 
logarithmic phase can be used. These mice can be divided into four groups (N = 9) to 
be given 1) saline control alone, 2) As2O3 alone (2 mg/kg/day intraperitoneal), 3) As2O3 
(2 mg/kg/day intraperitoneal) and AA (500 mg/kg/day subcutaneous) 4) AA alone  
(500mg/kg/day subcutaneous). Tumor weight can be measured twice a week and 
animal survival rate in the various groups continuously monitored for three months to 







7.2.4 Targeted Delivery of BSO for Greater Tumour Cell Selectivity of BSO 
During Augmentation of the Drug Activity of As2O3  
 
The results of this work revealed that BSO is a valuable agent for augmenting arsenic-
induced cell kill. Although BSO and As2O3 showed greater selectivity for ovarian 
cancer cell kill, a trend of diminishing selectivity for ovarian tumour cells over normal 
cells was observed with increasing concentration of BSO used (Section 4.3.3). Thus, it 
would be useful to selectively target BSO to ovarian tumour cells to further improve the 
selectivity of BSO and As2O3 drug treatment for tumour eradication.  
 
Numerous drug carriers such as dendrimers, liposomes and nanoparticulate polymeric 
micelles have been explored for targeted delivery of different drug molecules (Yang 
and Alexandridis, 2000). Since BSO is a water soluble amphoteric molecule, the use of 
nanoparticulate polymeric micelles may be useful for its encapsulation. Charges on 
suitable polymeric encapsulation material such as poly(1actic acid)-poly(ethylene 
glycol) and BSO can be carefully manipulated to ensure complimentary electrostatic 
interaction and thus efficient drug encapsulation. Additionally, folic acid can be 
derivatized onto the polyethylene glycol side chain to effect selective tumour targeting 
since ovarian carcinoma cells have be widely reported to overexpress the folate 
receptor (Coney et al., 1991; Weitman et al., 1992; Garin-Chesa et al., 1993; Toffoli et 
al., 1997; Toffoli et al., 1998).  
 
7.2.5 Use of an IL1R Antagonist to Disrupt IL1A Mediated Chemoresistant 
Signalling in OVCAR-3/AsR Cells 
 
Epithelial ovarian cancer is a disease with a rich associated cytokine-chemokine 





network of pro-inflammatory mediators include TNFα, IL1A and interleukin 6. The 
interaction of these factors through an autocrine and/or paracrine fashion has been 
reported to promote tumor growth, progression and neovascularization of ovarian 
cancer (Burke et al., 1996; Negus et al., 1997; Milliken et al., 2002). In this study, an 
increased in IL1A signalling has been observed with acquired chemoresistant 
development to As2O3. IL1A can induce the activation of transcription factors and 
genes to promote cell survival and proliferation (Martin and Falk, 1997; Wolf et al., 
2001). It can also regulate the gene expression of cytokines that mediate inflammation 
and angiogenesis (Auron, 1998; Dinarello, 1998; Wolf et al., 2001). A host of such 
changes have been described previously in Chapter 5, suggesting that the disruption of 
IL1A paracrine signalling could possible reduce the development of acquired 
chemoresistance to As2O3. As IL1A has been known to signal through its receptors 
namely, IL1R1 and IL1R2, the use of an antibody against IL1 receptors or an IL1R1 
receptor antagonist such as Anakinra (Kineret®), previously approved by the FDA for 
the management of rheumatoid arthritis (Cohen, 2004), might be beneficial in reducing 
As2O3-mediated chemoresistance.   
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PH_hs_0000006 NM_000952 PTAFR -1.166 0.467 1.093 0.528 2.698 0.00972 1.188 0.420 -1.092 0.636 3.436 0.0113 
PH_hs_0000057 NM_001674 ATF3 3.983 0.0415 4.173 0.0188 -1.150 0.223 3.386 0.0280 4.981 0.0067 -1.336 0.0807 
PH_hs_0000076 NM_000882 IL12A -2.007 0.0390 -2.248 0.0160 -1.952 0.00936 -1.961 0.0912 -2.268 0.0429 -2.225 0.0328 
PH_hs_0000085 NM_023105 FGFR1 -1.910 0.0190 -2.016 0.0194 -4.098 0.00226 -1.604 0.0561 -1.553 0.0136 -4.353 0.001 
PH_hs_0000086 NM_000138 FBN1 -1.294 0.0933 -2.454 0.00310 -1.034 0.531 -1.618 0.0718 -2.444 0.0140 -1.946 0.0125 
PH_hs_0000100 NM_002164 INDO -1.139 0.290 1.697 0.0440 5.520 0.0132 1.105 0.585 1.352 0.152 6.131 0.0075 
PH_hs_0000113 NM_033554 HLA-DPA1 -2.359 0.0422 -2.255 0.0117 -1.017 0.912 -1.422 0.207 -2.158 0.0522 -1.017 0.905 
PH_hs_0000152 NM_002118 HLA-DMB -1.714 0.209 -1.632 0.0507 3.102 0.00726 -1.458 0.246 -1.821 0.0647 3.387 0.0440 
PH_hs_0000202 NM_001552 IGFBP4 1.194 0.299 1.536 0.0703 -4.205 0.00498 1.000 0.999 1.608 0.0781 -3.862 0.0225 
PH_hs_0000211 NM_000861 HRH1 1.275 0.167 1.379 0.0667 2.439 0.00639 1.193 0.215 1.560 0.0374 2.533 0.00811 
PH_hs_0000235 NM_000575 IL1A 1.443 0.0532 1.254 0.0510 5.877 0.00059 1.214 0.118 1.204 0.0710 5.188 0.00100 
PH_hs_0000236 NM_002193 INHBB -1.571 0.0819 -1.274 0.0473 -5.669 0.0074 -1.590 0.170 -1.817 0.0377 -8.875 0.00716 
PH_hs_0000249 NM_002633 PGM1 -1.208 0.398 -1.282 0.0168 2.303 0.00248 -1.158 0.207 -1.014 0.866 2.770 0.00307 
PH_hs_0000282 NM_004447 EPS8 2.295 0.0193 1.864 0.0133 4.171 0.00302 1.784 0.0561 1.878 0.0167 4.161 0.0115 
PH_hs_0000305 NM_002425 MMP10 -6.214 0.0126 -10.770 0.00383 3.638 0.00248 -3.534 0.0519 -6.745 0.00942 4.434 0.0157 
PH_hs_0000354 NM_002220 ITPKA 2.066 0.0665 3.090 0.0406 2.194 0.0266 1.062 0.509 2.076 0.0235 1.705 0.0245 
PH_hs_0000382 NM_021147 CCNU -1.110 0.729 -1.031 0.701 2.792 0.0035 1.012 0.937 1.003 0.975 2.659 0.0328 
PH_hs_0000400 NM_002155 HSPA6 3.073 0.308 2.181 0.370 9.049 0.0876 1.404 0.121 1.652 0.156 3.031 0.0463 
PH_hs_0000414 NM_015544 TMEM98 -1.185 0.387 1.020 0.895 -3.218 0.0100 1.079 0.460 1.227 0.0815 -2.844 0.0194 
PH_hs_0000415 - - -2.410 0.0211 -2.756 0.00607 -2.979 0.00411 -2.464 0.0912 -2.064 0.0345 -2.497 0.0349 
PH_hs_0000440 NM_014403 - -1.066 0.494 1.053 0.542 2.406 0.00556 1.023 0.877 1.056 0.564 2.446 0.0287 
PH_hs_0000449 NM_006499 LGALS8 1.297 0.299 1.392 0.0117 2.516 0.0311 1.121 0.596 -1.146 0.419 2.177 0.0341 
PH_hs_0000455 NM_014294 TRAM1 1.392 0.113 1.118 0.380 2.140 0.00992 1.129 0.421 1.030 0.768 2.026 0.00740 
PH_hs_0000458 NM_152523 CCNYL1 1.149 0.111 -1.206 0.0434 3.173 0.00172 1.153 0.392 1.255 0.143 5.043 0.0162 
PH_hs_0000490 NM_001262 CDKN2C -1.254 0.135 -1.734 0.0248 2.130 0.0143 -1.262 0.288 -1.531 0.0586 2.051 0.0205 
PH_hs_0000509 XM_033173 - -2.315 0.0269 -3.624 0.00613 -1.136 0.0538 -1.834 0.100 -3.154 0.00334 1.187 0.0648 
PH_hs_0000554 NM_006108 SPON1 -1.268 0.0865 -1.048 0.595 -3.461 0.0046 -1.154 0.411 -1.188 0.223 -3.138 0.0176 
PH_hs_0000598 NM_005476 GNE -1.146 0.464 -1.181 0.107 3.330 0.00148 -1.108 0.560 -1.304 0.218 4.151 0.0225 
PH_hs_0000678 NM_030792 GDPD5 -1.848 0.0423 -1.934 0.0317 -2.634 0.00614 -1.746 0.101 -2.076 0.0527 -2.861 0.0327 
PH_hs_0000691 XM_376018 - -1.180 0.198 -1.595 0.0356 -3.391 0.00333 -1.300 0.208 -1.473 0.0652 -4.132 0.0204 
PH_hs_0000702 NM_015529 MOXD1 -1.125 0.511 -1.219 0.0582 -4.854 0.00152 1.001 0.995 -1.032 0.711 -4.633 0.00384 
PH_hs_0000753 NM_003012 SFRP1 -2.137 0.0569 -2.218 0.0252 -1.432 0.0555 -2.283 0.0973 -3.008 0.0195 -2.531 0.0231 
PH_hs_0000763 NM_022912 C2orf23 -1.460 0.128 -1.573 0.0514 -3.798 0.00872 -1.381 0.201 -1.536 0.0838 -4.649 0.00875 
PH_hs_0000788 NM_002005 FES 3.101 0.0203 2.735 0.00786 1.960 0.00755 2.831 0.109 2.597 0.0261 2.449 0.0438 
PH_hs_0000806 - - 1.143 0.439 1.264 0.182 -2.009 0.0323 1.273 0.235 1.368 0.081 -2.646 0.0154 
PH_hs_0000819 NM_005010 NRCAM 3.331 0.0445 3.096 0.0136 1.801 0.00866 3.026 0.103 3.091 0.0285 2.395 0.0678 
PH_hs_0000852 NM_031459 SESN2 2.710 0.0533 2.794 0.00869 -1.147 0.108 2.245 0.0601 3.115 0.0174 -1.140 0.179 
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PH_hs_0000909 NM_006105 RAPGEF3 -1.403 0.139 -1.725 0.00677 3.099 0.00183 -1.451 0.111 -2.095 0.0148 2.893 0.00360 
PH_hs_0000928 NM_031442 TM4SF10 -1.172 0.164 -1.405 0.0262 -2.202 0.0123 -1.187 0.283 -1.169 0.187 -2.323 0.0109 
PH_hs_0000929 NM_004267 CHST2 -1.286 0.112 -2.057 0.00835 1.264 0.0263 -1.246 0.265 -2.059 0.0215 1.568 0.0494 
PH_hs_0000953 NM_016267 VGLL1 -2.315 0.0672 -2.587 0.0137 5.249 0.00529 -2.205 0.0561 -2.497 0.0153 5.348 0.00302 
PH_hs_0001010 NM_012068 ATF5 1.500 0.179 2.074 0.0125 -1.391 0.0290 1.598 0.169 2.007 0.0444 -2.365 0.0533 
PH_hs_0001024 NM_144713 FLJ32954 -1.260 0.0577 -2.018 0.00180 1.442 0.0139 -1.288 0.116 -2.078 0.0148 1.424 0.0605 
PH_hs_0001026 NM_006350 FST -1.723 0.0269 -2.789 0.0106 -1.946 0.00455 -1.586 0.0906 -3.138 0.0195 -2.434 0.0134 
PH_hs_0001053 - - -2.327 0.0469 -1.949 0.0223 -1.645 0.0396 -2.513 0.0957 -2.213 0.0312 -2.074 0.0461 
PH_hs_0001061 XM_372774 DJ159A19.3 -1.465 0.260 -1.841 0.0548 -2.318 0.0113 -1.397 0.257 -1.179 0.269 -3.273 0.0249 
PH_hs_0001074 NM_014398 LAMP3 2.085 0.121 3.583 0.0226 -1.472 0.113 2.476 0.197 5.788 0.0568 1.140 0.704 
PH_hs_0001148 NM_024554 PGBD5 2.908 0.0113 3.850 0.00385 2.329 0.00170 2.933 0.0332 4.226 0.00942 2.736 0.0141 
PH_hs_0001151 NM_178496 LOC151963 1.109 0.498 1.038 0.766 -4.942 0.00383 1.119 0.470 -1.025 0.831 -6.330 0.00360 
PH_hs_0001244 XM_084578 PPFIBP2 -2.020 0.0451 -1.741 0.0134 -2.470 0.00414 -1.698 0.0561 -1.514 0.0176 -2.258 0.0172 
PH_hs_0001383 NM_006332 IFI30 -1.006 0.951 1.642 0.0232 2.201 0.0156 1.173 0.290 1.779 0.0389 2.179 0.0182 
PH_hs_0001390 NM_002395 ME1 2.158 0.0573 2.473 0.0118 3.281 0.0107 1.884 0.0963 2.375 0.0377 4.041 0.00777 
PH_hs_0001407 NM_002655 PLAG1 1.307 0.411 1.063 0.778 4.587 0.0245 -1.367 0.230 -1.041 0.762 2.799 0.0189 
PH_hs_0001495 BC016962 - 2.083 0.0452 1.559 0.0592 -1.514 0.0381 2.130 0.107 2.120 0.0289 -1.283 0.223 
PH_hs_0001536 NM_007150 ZNF185 -1.014 0.919 1.018 0.821 3.927 0.00308 -1.006 0.974 1.192 0.119 4.779 0.00903 
PH_hs_0001558 NM_004753 DHRS3 2.148 0.0374 1.947 0.0331 10.750 0.00609 1.999 0.136 1.467 0.124 13.69 0.00131 
PH_hs_0001591 - - 1.690 0.0692 1.635 0.0505 3.417 0.00584 1.131 0.255 1.073 0.247 2.506 0.00478 
PH_hs_0001684 NM_012305 AP2A2 -1.176 0.391 1.007 0.854 -2.846 0.00916 -1.000 1.000 1.221 0.168 -2.374 0.0121 
PH_hs_0001688 XM_378360 LOC400043 -1.062 0.305 -1.101 0.143 -5.223 0.00111 -1.255 0.133 -1.236 0.121 -4.886 0.0148 
PH_hs_0001733 NM_001902 CTH 2.594 0.0193 1.714 0.0136 2.283 0.00657 1.881 0.118 2.303 0.0377 2.860 0.0176 
PH_hs_0001767 - - 1.136 0.119 1.211 0.0327 -2.599 0.00201 -1.372 0.221 -1.505 0.0819 -2.449 0.0160 
PH_hs_0001803 NM_022126 LHPP 1.383 0.336 2.119 0.018 -1.191 0.151 1.003 0.992 1.206 0.367 -2.095 0.0541 
PH_hs_0001811 NM_004086 COCH 1.558 0.108 1.497 0.0838 -4.144 0.00577 1.378 0.217 1.623 0.0743 -3.347 0.0114 
PH_hs_0001854 NM_020168 PAK6 1.293 0.325 1.370 0.0598 3.482 0.000756 1.023 0.856 1.147 0.149 2.415 0.00479 
PH_hs_0001888 NM_018420 SLC22A15 1.744 0.0277 2.217 0.0211 -1.088 0.376 1.371 0.116 2.032 0.0166 1.068 0.468 
PH_hs_0001947 NM_152314 MGC34830 -1.177 0.521 1.093 0.451 3.815 0.00402 -1.965 0.170 -2.125 0.0904 1.833 0.0883 
PH_hs_0002058 NM_030817 DKFZP434F
0318 
1.388 0.124 1.265 0.161 -2.568 0.00926 1.378 0.165 1.243 0.141 -2.348 0.0117 
PH_hs_0002061 NM_152400 C4orf32 1.208 0.320 1.198 0.271 -3.008 0.00930 -1.104 0.318 -1.093 0.265 -3.749 0.0507 
PH_hs_0002179 NM_020925 KIAA1573 -1.342 0.0431 -1.681 0.0423 -3.889 0.00427 -1.241 0.180 -1.215 0.0970 -3.311 0.00847 
PH_hs_0002227 NM_004633 IL1R2 -2.598 0.0626 -3.067 0.00577 2.959 0.00164 -1.962 0.0645 -2.686 0.0197 4.143 0.0112 
PH_hs_0002286 NM_015464 SOSTDC1 -2.784 0.0451 -4.174 0.0128 -1.962 0.0189 -2.554 0.082 -3.527 0.0280 -1.971 0.0261 
PH_hs_0002304 NM_014112 TRPS1 -1.815 0.0713 -2.360 0.0256 -1.914 0.0265 -1.677 0.108 -2.001 0.045 -2.024 0.0360 
PH_hs_0002314 NM_183240 TMEM37 -1.086 0.430 -1.186 0.0435 5.545 0.00335 1.156 0.157 1.071 0.271 6.397 0.000887 
PH_hs_0002362  - - -1.043 0.644 -1.078 0.224 2.112 0.00425 -1.008 0.973 -1.093 0.543 2.169 0.0454 
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PH_hs_0002434 BM709175 HSU79275 -1.639 0.0902 -1.870 0.0223 4.388 0.00512 -1.350 0.158 -2.007 0.0995 3.875 0.000979 
PH_hs_0002484 NM_023935 C20orf116 1.337 0.232 1.479 0.0392 2.229 0.00598 1.357 0.117 1.180 0.109 2.082 0.0186 
PH_hs_0002532 NM_024610 HSPBAP1 -1.060 0.452 1.118 0.0180 -2.404 0.00243 -1.044 0.496 1.289 0.0732 -2.125 0.00649 
PH_hs_0002640 NM_004093 EFNB2 -1.661 0.243 -1.889 0.0249 -2.732 0.00695 -1.794 0.123 -2.109 0.0505 -3.191 0.0133 
PH_hs_0002700 NM_013370 OKL38 3.897 0.0283 3.382 0.00755 2.926 0.00412 4.840 0.0192 3.607 0.00638 2.583 0.00307 
PH_hs_0002730 NM_173672 PPIL6 -1.188 0.270 1.215 0.0671 -2.323 0.00877 -1.129 0.474 1.150 0.310 -2.239 0.0187 
PH_hs_0002731 NM_002194 INPP1 -1.013 0.910 1.099 0.305 3.934 0.00271 -1.040 0.747 1.083 0.111 3.436 0.000887 
PH_hs_0002774 NM_004932 CDH6 -1.741 0.0340 -2.570 0.00677 -1.106 0.166 -1.564 0.0561 -2.210 0.0295 -1.113 0.153 
PH_hs_0002908 NM_020386 HRASLS -1.022 0.594 1.088 0.190 -23.430 0.00350 -1.132 0.292 -1.319 0.0906 -29.300 0.00251 
PH_hs_0002910 NM_024628 SLC12A8 2.076 0.0283 1.481 0.0288 -1.087 0.364 1.857 0.118 2.450 0.0454 1.234 0.345 
PH_hs_0002935 NM_001741 CALCA -1.016 0.945 1.170 0.325 6.496 0.00400 1.056 0.793 1.031 0.850 4.097 0.0108 
PH_hs_0002958 AK055969 - 1.252 0.336 1.759 0.0334 -2.786 0.0103 -1.052 0.803 1.922 0.081 -2.118 0.0370 
PH_hs_0003007 NM_005727 TSPAN-1 -1.693 0.0672 -1.385 0.0846 2.951 0.00931 -1.123 0.308 1.078 0.401 4.644 0.00182 
PH_hs_0003032 NM_003916 AP1S2 1.112 0.554 -1.224 0.220 -2.021 0.0211 -1.119 0.550 -1.418 0.103 -2.136 0.0247 
PH_hs_0003133 NM_018192 LEPREL1 -1.198 0.205 -2.550 0.00589 1.011 0.811 -1.119 0.481 -2.882 0.0296 -1.423 0.0694 
PH_hs_0003145 AK023647 - -1.376 0.137 -2.772 0.0329 1.084 0.100 -1.702 0.093 -3.349 0.0140 -1.391 0.0966 
PH_hs_0003174 NM_004454 ETV5 1.622 0.163 3.842 0.00786 1.523 0.0285 1.770 0.136 2.205 0.0423 1.336 0.167 
PH_hs_0003194 NM_021255 PELI2 -1.189 0.168 -1.186 0.0536 -6.991 0.00400 -1.203 0.394 -1.175 0.201 -5.524 0.00251 
PH_hs_0003316 NM_017549 UCC1 1.686 0.0666 1.361 0.0807 -9.455 0.0667 1.505 0.160 1.597 0.0794 -5.892 0.00676 
PH_hs_0003342 NM_001248 ENTPD3 -1.425 0.134 -1.583 0.0617 3.189 0.00691 -1.738 0.0504 -1.465 0.0580 2.546 0.0218 
PH_hs_0003443 NM_015187 KIAA0746 2.865 0.0126 2.571 0.0116 1.906 0.00148 2.156 0.0805 1.857 0.0560 1.902 0.0117 
PH_hs_0003518 NM_012427 KLK5 1.210 0.205 2.464 0.0212 -5.013 0.00271 1.514 0.116 2.295 0.0421 -5.736 0.0457 
PH_hs_0003660 NM_003149 STAC 1.261 0.205 1.478 0.0240 -3.204 0.00219 1.146 0.238 1.503 0.0531 -2.658 0.0299 
PH_hs_0003661 NM_021992 TMSNB 1.041 0.429 -1.070 0.131 -2.644 0.00168 -1.024 0.635 -1.254 0.0502 -3.495 0.00132 
PH_hs_0003688 NM_000888 ITGB6 -1.085 0.558 -2.080 0.0409 -2.480 0.00160 -1.392 0.132 -2.132 0.0272 -1.877 0.0545 
PH_hs_0003705 NM_152332 MTAC2D1 -1.315 0.149 -1.437 0.0415 -2.665 0.00313 -1.344 0.161 -1.281 0.0971 -2.094 0.00231 
PH_hs_0003752 NM_001448 GPC4 1.235 0.490 1.610 0.0302 -2.951 0.00384 -1.038 0.861 -1.273 0.197 -6.348 0.0160 
PH_hs_0003766 NM_145307 PLEKHK1 -1.127 0.419 -1.232 0.0180 -4.079 0.00377 -1.108 0.612 -1.072 0.622 -4.817 0.00875 
PH_hs_0003767 NM_023915 GPR87 1.307 0.0723 -1.092 0.408 2.768 0.00823 1.059 0.757 -1.334 0.124 2.370 0.0255 
PH_hs_0003822 NM_006557 DMRT2 -1.893 0.209 -2.606 0.0154 2.406 0.00903 -1.825 0.0477 -1.975 0.0133 3.071 0.0075 
PH_hs_0003852 BX093084 - 1.089 0.528 -1.042 0.806 3.397 0.000590 1.249 0.313 1.287 0.163 5.906 0.0132 
PH_hs_0003897 NM_018987 SEMA5B -3.136 0.0844 -3.271 0.0114 -1.435 0.0488 -2.723 0.0607 -2.998 0.0467 -2.503 0.0431 
PH_hs_0003912 AK127315 - 1.092 0.448 1.058 0.103 -2.498 0.00824 -1.085 0.613 -1.346 0.0783 -2.789 0.00875 
PH_hs_0003939 NM_001993 F3 2.788 0.0845 1.800 0.111 2.690 0.0307 1.788 0.0879 1.915 0.0610 3.234 0.00901 
PH_hs_0003982 NM_003227 TFR2 1.762 0.0366 1.571 0.0211 3.181 0.00300 1.212 0.177 1.181 0.108 2.361 0.0296 
PH_hs_0003985 NM_004392 DACH1 1.140 0.236 1.197 0.124 2.702 0.00353 -1.048 0.747 -1.205 0.188 2.094 0.0180 
PH_hs_0003988 NM_000313 PROS1 1.380 0.0862 1.783 0.00607 -4.472 0.00460 1.163 0.286 1.378 0.0688 -4.496 0.00339 
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PH_hs_0004004 NM_002048 GAS1 -2.835 0.0190 -2.934 0.00755 -2.391 0.00874 -2.114 0.0601 -1.657 0.0309 -1.931 0.0305 
PH_hs_0004062 NM_000474 TWIST1 -1.300 0.0552 -1.097 0.0603 3.614 0.00171 -1.613 0.0924 -1.362 0.0605 2.569 0.00945 
PH_hs_0004098 NM_152673 MUC20 -1.520 0.0757 -1.165 0.214 5.316 0.00933 -1.281 0.243 -1.121 0.271 5.894 0.00676 
PH_hs_0004099 NM_015364 LY96 5.346 0.0393 5.741 0.0143 3.654 0.00748 4.722 0.134 4.141 0.0627 4.536 0.0545 
PH_hs_0004186 NM_000499 CYP1A1 -1.094 0.557 -2.038 0.0216 1.487 0.0242 -1.079 0.583 -2.867 0.00975 -1.474 0.0445 
PH_hs_0004209 NM_020349 ANKRD2 -2.217 0.0599 -2.743 0.0177 1.586 0.0564 -2.181 0.0862 -3.856 0.0195 1.316 0.0532 
PH_hs_0004265 NM_023009 MARCKSL1 -1.030 0.302 -1.130 0.0162 -2.316 0.000590 1.039 0.593 1.004 0.902 -2.041 0.00165 
PH_hs_0004276 NM_016083 CNR1 -2.452 0.0573 -2.286 0.00854 -6.489 0.000902 -1.900 0.119 -1.771 0.0512 -6.072 0.00726 
PH_hs_0004307 NM_006026 H1FX -1.701 0.102 -1.744 0.0461 -3.244 0.00891 -1.225 0.283 -1.094 0.559 -2.477 0.00726 
PH_hs_0004352 NM_000591 CD14 -2.322 0.0584 -1.999 0.0338 14.39 0.00576 -1.768 0.141 -2.194 0.0290 12.590 0.000887 
PH_hs_0004394 NM_004364 CEBPA 1.282 0.138 1.237 0.117 -2.482 0.0101 1.120 0.329 1.435 0.0522 -2.310 0.00726 
PH_hs_0004398 NM_004105 EFEMP1 -2.025 0.0346 -2.464 0.0128 2.110 0.0112 -1.949 0.0415 -2.002 0.0113 2.140 0.00556 
PH_hs_0004409 NM_000689 ALDH1A1 -1.096 0.574 -1.580 0.0314 10.36 0.00697 -1.552 0.150 -1.756 0.0511 10.370 0.0181 
PH_hs_0004441 NM_000345 SNCA 1.220 0.213 -1.254 0.117 -2.983 0.0314 -1.029 0.929 -1.165 0.218 -2.452 0.0341 
PH_hs_0004472 NM_015158 ANKRD15 -1.081 0.304 -1.215 0.0194 2.575 0.00170 -1.167 0.0911 -1.227 0.190 2.856 0.0109 
PH_hs_0004511 NM_003652 CPZ -1.721 0.0286 -1.564 0.0150 -8.254 0.00359 -1.253 0.308 -1.077 0.518 -8.729 0.00726 
PH_hs_0004577 XM_027236 TTC9 -1.071 0.274 1.030 0.495 5.351 0.000756 -1.197 0.102 -1.025 0.838 4.415 0.000887 
PH_hs_0004598 NM_006159 NELL2 2.448 0.0493 1.840 0.0141 -1.434 0.0501 1.281 0.330 1.215 0.271 -2.134 0.0445 
PH_hs_0004621 NM_000402 G6PD 2.275 0.0283 2.103 0.00611 1.305 0.0181 2.510 0.0427 2.446 0.0195 1.655 0.0448 
PH_hs_0004626 NM_002275 KRT15 -4.678 0.0128 -4.334 0.00650 2.071 0.00529 -2.826 0.0477 -3.642 0.0176 2.999 0.0118 
PH_hs_0004629 NM_002371 MAL -4.298 0.0119 -5.597 0.00607 1.913 0.0159 -2.952 0.0561 -4.842 0.0113 3.260 0.0151 
PH_hs_0004630 NM_001924 GADD45A 2.354 0.0408 2.678 0.0152 1.122 0.195 2.098 0.0561 2.817 0.0141 1.176 0.166 
PH_hs_0004661 NM_002961 S100A4 -1.452 0.103 -1.299 0.0350 2.505 0.00292 -1.149 0.432 -1.099 0.467 2.942 0.0357 
PH_hs_0004694 NM_000877 IL1R1 -1.175 0.395 1.121 0.333 3.740 0.00996 -1.102 0.585 -1.254 0.196 2.763 0.0188 
PH_hs_0004705 NM_012101 TRIM29 -3.448 0.0190 -3.847 0.00607 1.617 0.0105 -2.817 0.0718 -3.446 0.0133 1.576 0.0541 
PH_hs_0004728 NM_002888 RARRES1 -1.737 0.0349 -2.768 0.00981 -1.722 0.00383 -1.459 0.158 -2.210 0.0319 -1.417 0.0765 
PH_hs_0004786 - - -1.007 0.967 1.188 0.0697 2.949 0.0127 -1.124 0.485 -1.232 0.189 2.267 0.0219 
PH_hs_0004789 NM_002653 PITX1 -2.443 0.0190 -2.850 0.0197 1.162 0.0676 -2.032 0.0860 -2.582 0.0301 1.284 0.107 
PH_hs_0004817 NM_022443 MLF1 1.053 0.714 1.017 0.844 -2.805 0.00180 1.203 0.338 1.128 0.403 -2.157 0.0386 
PH_hs_0004860 NM_004362 CLGN 2.980 0.0357 3.832 0.0273 -2.844 0.00863 2.724 0.0601 5.484 0.0234 1.018 0.855 
PH_hs_0004948 NM_020805 KLHL14 -2.561 0.0445 -3.421 0.0117 -1.605 0.00636 -1.926 0.0822 -2.086 0.0294 -1.036 0.774 
PH_hs_0004982 NM_004395 DBN1 -1.079 0.518 -1.140 0.136 -2.241 0.00384 1.126 0.512 1.077 0.399 -2.007 0.0206 
PH_hs_0004996 NM_002110 HCK -1.664 0.0968 1.018 0.885 7.743 0.00371 -1.412 0.144 1.144 0.193 8.080 0.00359 
PH_hs_0005005 NM_002820 PTHLH -1.144 0.875 1.212 0.632 3.044 0.0838 1.647 0.216 1.369 0.182 2.571 0.0171 
PH_hs_0005010 NM_000120 EPHX1 1.121 0.120 -1.029 0.489 2.130 0.00226 1.278 0.0884 1.314 0.0377 2.315 0.00575 
PH_hs_0005058 NM_003786 ABCC3 1.873 0.0269 1.912 0.00939 2.451 0.00269 1.675 0.0822 1.582 0.0451 2.221 0.0284 
PH_hs_0005065 NM_004695 SLC16A5 -1.107 0.574 1.829 0.0215 3.417 0.00359 1.295 0.250 1.792 0.0559 4.643 0.00823 
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PH_hs_0005123 NM_032512 PDZK4 1.047 0.872 1.343 0.0175 -2.455 0.0217 1.029 0.911 -1.073 0.669 -3.186 0.0197 
PH_hs_0005127 NM_004598 SPOCK 1.142 0.229 1.160 0.0429 2.418 0.00308 1.196 0.195 1.447 0.0360 2.218 0.0197 
PH_hs_0005146 BX098660 - -2.240 0.0535 -2.567 0.0191 1.105 0.245 -1.870 0.0561 -2.008 0.0222 1.087 0.278 
PH_hs_0005148 NM_016352 CPA4 -1.418 0.0431 -2.685 0.00768 11.02 0.000590 1.191 0.195 -2.362 0.0257 16.94 0.000887 
PH_hs_0005182 NM_021809 TGIF2 -1.173 0.165 -1.077 0.315 -2.552 0.00415 -1.045 0.528 -1.021 0.734 -2.712 0.00338 
PH_hs_0005421 NM_153362 PRSS35 -1.954 0.114 -2.518 0.00911 4.828 0.00507 -1.585 0.0653 -2.615 0.0420 7.017 0.00152 
PH_hs_0005514 NM_032717 MGC11324 5.778 0.0134 5.225 0.00946 6.840 0.00112 4.275 0.0311 5.622 0.0113 5.958 0.00932 
PH_hs_0005573 - - 1.412 0.0822 1.338 0.0651 4.791 0.00194 1.504 0.156 1.334 0.0957 5.180 0.0162 
PH_hs_0005583 NM_000044 AR 1.407 0.0770 1.144 0.258 -4.248 0.00209 -1.032 0.806 -1.066 0.539 -4.929 0.0241 
PH_hs_0005587 NM_021136 RTN1 1.336 0.196 1.055 0.721 -2.282 0.0134 1.406 0.0913 1.022 0.759 -3.525 0.128 
PH_hs_0005631 NM_025246 TMEM22 2.537 0.0325 2.791 0.00881 1.408 0.0218 2.148 0.0491 2.364 0.0148 1.208 0.125 
PH_hs_0005671 NM_002317 LOX 2.509 0.0666 2.660 0.00740 15.510 0.00094 1.634 0.202 1.487 0.141 11.970 0.000887 
PH_hs_0005744 NM_032438 L3MBTL3 1.227 0.118 1.588 0.0150 -2.305 0.00444 -1.131 0.251 1.601 0.0301 -2.161 0.0427 
PH_hs_0005789 NM_007152 ZNF195 1.291 0.243 1.054 0.288 -2.548 0.00752 1.306 0.219 1.287 0.187 -2.053 0.0351 
PH_hs_0005801 NM_007196 KLK8 -1.049 0.673 1.316 0.0805 -13.610 0.00574 1.188 0.273 1.277 0.123 -9.371 0.0155 
PH_hs_0005820 NM_018004 FLJ10134 -1.138 0.241 -1.707 0.0127 -7.843 0.0101 -1.173 0.338 -1.350 0.0883 -4.538 0.0132 
PH_hs_0005870 NM_032034 SLC4A11 -1.447 0.0683 -1.136 0.111 4.550 0.00331 -1.162 0.439 -1.046 0.370 4.731 0.00203 
PH_hs_0005900 NM_017436 A4GALT -1.769 0.0996 -2.577 0.0560 -2.287 0.0375 -1.402 0.204 -2.017 0.0369 -1.573 0.0173 
PH_hs_0005906 NM_000076 CDKN1C -1.164 0.202 1.096 0.342 -10.240 0.00102 -1.103 0.445 1.029 0.680 -11.880 0.00389 
PH_hs_0005930 NM_014141 CNTNAP2 1.356 0.174 1.198 0.181 -2.890 0.00916 1.260 0.212 1.143 0.236 -3.969 0.0112 
PH_hs_0005961 NM_031455 CCDC3 -1.613 0.0431 -1.251 0.121 -4.155 0.000902 -1.391 0.101 -1.196 0.146 -4.490 0.00251 
PH_hs_0005969 NM_006476 ATP5L -1.169 0.468 1.117 0.135 2.735 0.0147 -1.387 0.237 -2.122 0.0386 1.758 0.0492 
PH_hs_0005972 NM_145244 DDIT4L -1.146 0.448 -1.156 0.273 -2.805 0.00635 -1.159 0.334 1.032 0.746 -3.002 0.0233 
PH_hs_0005982 NM_005689 ABCB6 1.898 0.103 2.116 0.0146 2.852 0.00971 1.994 0.163 1.857 0.0983 2.285 0.0247 
PH_hs_0005998 NM_004626 WNT11 -1.165 0.229 -2.619 0.00965 -11.880 0.00430 1.032 0.810 -1.900 0.0195 -14.850 0.00676 
PH_hs_0006015 NM_006963 ZNF22 1.049 0.861 1.058 0.381 -2.673 0.0121 -1.127 0.518 1.002 0.988 -2.013 0.0363 
PH_hs_0006040 AB018258 ATP10B 2.523 0.0340 3.950 0.00892 -1.788 0.0215 2.675 0.0340 3.043 0.0113 -1.489 0.0803 
PH_hs_0006110 NM_019058 DDIT4 2.270 0.0190 2.023 0.00692 1.217 0.0266 2.192 0.0601 2.731 0.0148 1.677 0.0289 
PH_hs_0006124 NM_003890 FCGBP -1.524 0.142 -1.803 0.0352 2.172 0.00136 -1.282 0.110 -1.515 0.0214 2.523 0.0133 
PH_hs_0006160 NM_002965 S100A9 -1.375 0.293 -1.943 0.0216 3.658 0.00109 -1.230 0.316 -2.244 0.0538 3.627 0.00945 
PH_hs_0006222 NM_015931 LOC51066 -2.687 0.0865 -2.513 0.0143 -1.251 0.0262 -1.917 0.0404 -2.079 0.0346 -1.031 0.752 
PH_hs_0006340 NM_003648 DGKD 2.453 0.0217 2.622 0.00613 1.696 0.00709 1.858 0.0312 2.210 0.0148 1.399 0.0768 
PH_hs_0006395 NM_020299 AKR1B10 5.605 0.0283 3.809 0.0185 3.677 0.00962 4.590 0.0513 3.349 0.0148 5.295 0.0176 
PH_hs_0006423 NM_181785 LOC283537 1.373 0.277 1.185 0.473 3.739 0.0155 1.523 0.136 1.462 0.0882 3.290 0.0125 
PH_hs_0006542 NM_002729 HHEX 2.450 0.0143 2.995 0.00577 1.479 0.0196 1.739 0.0427 2.403 0.00942 1.385 0.0175 
PH_hs_0006549 NM_004480 FUT8 -1.059 0.823 -1.012 0.909 2.957 0.00726 -1.313 0.176 -1.339 0.0898 2.990 0.0189 
PH_hs_0006770 NM_025216 WNT10A -1.703 0.0312 -1.688 0.0205 -5.776 0.00362 -1.280 0.148 -1.830 0.0301 -5.971 0.00251 
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PH_hs_0006823 NM_173660 FLJ33718 1.095 0.571 1.230 0.172 2.566 0.0146 1.259 0.343 -1.009 0.963 2.359 0.0246 
PH_hs_0006947 AK097496 LOC283352 -1.127 0.790 1.244 0.414 5.733 0.0223 -1.038 0.899 1.304 0.223 4.397 0.0269 
PH_hs_0007034 AL049227 - -2.611 0.0296 -3.916 0.0117 -2.558 0.00391 -2.078 0.0698 -2.894 0.0104 -2.282 0.00649 
PH_hs_0007104 NM_022119 PRSS22 -1.101 0.695 1.222 0.341 5.350 0.0123 -1.093 0.681 1.104 0.515 4.772 0.0261 
PH_hs_0007227 NM_025045 FLJ22582 -1.332 0.146 1.464 0.0601 2.340 0.0102 -1.140 0.659 1.105 0.475 2.039 0.0225 
PH_hs_0007344 NM_018431 DOK5 -1.174 0.180 -1.466 0.0249 -3.380 0.00271 -1.273 0.119 -1.498 0.0377 -2.582 0.0446 
PH_hs_0007351 NM_001165 BIRC3 1.074 0.780 -1.177 0.436 2.866 0.00333 -1.329 0.406 -1.775 0.114 3.152 0.0301 
PH_hs_0007483 NM_016240 SCARA3 -1.162 0.182 -1.182 0.0294 2.127 0.00608 -1.078 0.262 -1.070 0.263 2.043 0.000887 
PH_hs_0007485 NM_022089 HSA9947 1.206 0.541 1.280 0.170 2.846 0.0163 1.101 0.536 1.276 0.155 2.114 0.0181 
PH_hs_0007492 NM_024761 MOBKL2B -1.038 0.900 -1.072 0.579 -2.002 0.0280 -1.429 0.117 -1.170 0.181 -2.451 0.0513 
PH_hs_0007520 NM_152461 ERN1 1.652 0.274 2.588 0.0540 1.401 0.187 1.605 0.146 3.036 0.0432 1.300 0.163 
PH_hs_0007590 NM_001195 BFSP1 1.078 0.290 -1.122 0.104 -3.137 0.00856 -1.026 0.774 -1.178 0.111 -3.150 0.00955 
PH_hs_0007951 - - 1.614 0.345 2.364 0.143 1.207 0.586 1.663 0.0756 2.506 0.0113 1.558 0.0297 
PH_hs_0008141 NM_080725 C20orf139 3.964 0.0460 3.665 0.00740 2.178 0.00225 2.610 0.0693 3.045 0.0113 -1.929 0.765 
PH_hs_0008291 NM_053276 VIT 1.126 0.422 -1.075 0.288 2.809 0.00803 1.031 0.877 -1.200 0.250 2.207 0.0241 
PH_hs_0008298 XM_049695 VANGL2 1.611 0.103 2.203 0.0180 -1.419 0.0122 1.359 0.277 1.374 0.157 -2.156 0.0787 
PH_hs_0008565 NM_004429 EFNB1 -1.422 0.136 -1.563 0.0768 -4.307 0.00936 -1.308 0.207 -1.528 0.0433 -5.429 0.0145 
PH_hs_0008826 NM_001445 FABP6 1.210 0.354 2.086 0.0107 6.876 0.000902 1.154 0.440 1.364 0.132 4.583 0.0125 
PH_hs_0008853 NM_080574 C20orf70 -3.526 0.0195 -5.030 0.00677 1.346 0.0468 -2.929 0.0653 -5.141 0.0148 1.332 0.102 
PH_hs_0008975 BG546536 - -1.269 0.292 -2.050 0.0115 -4.834 0.00269 -1.041 0.815 -1.645 0.0838 -2.770 0.00875 
PH_hs_0009153 NM_005923 MAP3K5 -1.281 0.160 -1.423 0.0154 2.399 0.00248 -1.308 0.175 -1.389 0.0650 2.205 0.0292 
PH_hs_0009236 NM_014677 RIMS2 2.618 0.0573 3.352 0.0286 -1.010 0.958 1.900 0.168 2.679 0.0589 -1.117 0.512 
PH_hs_0009300 NM_001236 CBR3 1.977 0.0296 1.398 0.0298 3.296 0.00579 1.686 0.0934 1.092 0.388 2.475 0.0132 
PH_hs_0009339 NM_000067 CA2 -3.402 0.0511 -4.166 0.0156 -1.794 0.00863 -2.640 0.0230 -2.795 0.00975 -1.215 0.0533 
PH_hs_0009353 NM_005165 ALDOC -1.438 0.220 -1.329 0.00692 2.016 0.0136 -1.099 0.339 -1.139 0.0824 2.754 0.00359 
PH_hs_0009360 NM_021643 TRIB2 -1.050 0.752 -1.141 0.292 -4.278 0.00400 1.029 0.838 1.150 0.228 -3.591 0.00787 
PH_hs_0009362 NM_001134 AFP 2.719 0.0431 1.471 0.0294 2.008 0.00657 2.617 0.0519 1.253 0.0499 1.420 0.0368 
PH_hs_0009405 NM_005822 DSCR1L1 -3.459 0.0314 -4.875 0.00910 -1.560 0.0144 -3.226 0.0311 -5.077 0.0113 -1.630 0.0518 
PH_hs_0009600 NM_003857 GALR2 1.153 0.244 -1.091 0.522 2.730 0.00712 1.347 0.263 1.202 0.0533 2.920 0.00620 
PH_hs_0009661 AL157504 - -1.721 0.196 -2.265 0.0161 1.434 0.0199 -2.140 0.0519 -1.961 0.0218 1.264 0.184 
PH_hs_0009662 XM_499250 LFNG -1.374 0.228 -1.855 0.00742 -2.418 0.00576 -1.238 0.268 -1.914 0.0411 -2.587 0.0323 
PH_hs_0009730 NM_001490 GCNT1 -1.097 0.665 -1.716 0.0835 2.042 0.0177 -1.345 0.311 -2.759 0.0547 1.847 0.0618 
PH_hs_0009794 NM_023076 C16orf28 2.496 0.0666 2.298 0.00535 2.514 0.00209 2.224 0.0542 1.959 0.0272 2.003 0.0736 
PH_hs_0009802 BM930757 - -1.318 0.312 -1.314 0.0395 2.932 0.00248 -1.461 0.0706 -1.287 0.0515 2.744 0.00644 
PH_hs_0009841 NM_007064 TRAD 1.390 0.151 -1.172 0.229 -4.293 0.00590 1.298 0.219 -1.222 0.125 -4.098 0.00945 
PH_hs_0010006 NM_004029 IRF7 -1.032 0.879 -1.153 0.173 -2.239 0.0119 -1.135 0.589 -1.233 0.130 -2.624 0.0614 
PH_hs_0010061 NM_013314 BLNK -2.032 0.0878 -1.893 0.0128 1.720 0.00943 -2.058 0.0997 -1.440 0.0387 2.116 0.00964 
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PH_hs_0010088 NM_014289 CAPN6 -1.647 0.0847 -1.930 0.00607 -12.820 0.00710 -1.561 0.0591 -1.840 0.0235 -17.980 0.000887 
PH_hs_0010092 NM_000149 FUT3 -1.116 0.527 -1.056 0.731 2.847 0.0159 1.000 0.999 1.057 0.622 3.337 0.00715 
PH_hs_0010095 NM_003238 TGFB2 -2.339 0.0385 -3.050 0.00735 -2.412 0.0141 -2.451 0.129 -3.669 0.0386 -2.368 0.0493 
PH_hs_0010138 AK023631 - 1.270 0.0847 -1.173 0.128 -2.526 0.0132 -1.012 0.954 -1.112 0.426 -2.508 0.0451 
PH_hs_0010165 NM_153045 C9orf91 2.124 0.00800 2.002 0.0120 1.226 0.0107 1.640 0.116 2.020 0.0199 1.132 0.140 
PH_hs_0010267 NM_173549 FLJ39553 1.624 0.109 1.495 0.0303 -2.428 0.00475 1.285 0.115 1.257 0.0686 -2.287 0.0449 
PH_hs_0010369 AK091332 - -1.250 0.137 -1.084 0.330 -2.888 0.0220 -1.363 0.283 -1.802 0.0874 -3.547 0.0151 
PH_hs_0010384 NM_018286 FLJ10970 -5.342 0.0542 -10.470 0.00613 1.254 0.0347 -2.941 0.0649 -5.608 0.0146 1.992 0.00649 
PH_hs_0010628 BM720103 - -1.985 0.0665 -3.204 0.0129 -1.535 0.0407 -1.798 0.171 -3.908 0.0195 -1.889 0.0407 
PH_hs_0010636 NM_005771 DHRS9 -2.179 0.0672 -2.711 0.00768 -1.712 0.00781 -1.585 0.0561 -2.908 0.00522 -1.281 0.0628 
PH_hs_0010698 NM_138720 HIST1H2BD -2.567 0.0779 -1.852 0.0235 -1.207 0.105 -2.428 0.0934 -2.977 0.0493 -1.349 0.191 
PH_hs_0010725 - - 1.186 0.142 -1.068 0.419 -2.259 0.0114 1.076 0.550 1.447 0.0486 -2.054 0.00901 
PH_hs_0010763 NM_003900 SQSTM1 3.009 0.00831 3.139 0.0100 1.085 0.407 3.249 0.0477 3.523 0.0133 1.362 0.00705 
PH_hs_0010807 NM_001661 ARF4L -2.210 0.034 -2.863 0.00972 -3.922 0.00313 -1.987 0.0889 -1.795 0.0148 -4.148 0.0011 
PH_hs_0010879 NM_001835 CLTCL1 -1.414 0.217 -1.492 0.0841 2.116 0.0301 -1.069 0.698 -1.102 0.276 2.135 0.0133 
PH_hs_0010944 NM_013396 USP25 -1.041 0.724 -1.076 0.287 -2.448 0.00386 -1.122 0.334 -1.333 0.0584 -3.280 0.0229 
PH_hs_0011430 AL110204 - 1.646 0.0393 2.025 0.0112 1.023 0.794 2.096 0.0733 2.687 0.0401 -1.020 0.914 
PH_hs_0011493 NM_001839 CNN3 -1.022 0.899 -1.399 0.0192 -4.608 0.00122 -1.079 0.512 -1.038 0.727 -2.872 0.0133 
PH_hs_0011502 NM_003976 ARTN 3.042 0.0314 3.200 0.0184 2.473 0.0181 2.835 0.0561 3.393 0.0197 2.265 0.0445 
PH_hs_0011503 NM_003979 GPCR5A 1.763 0.0297 1.285 0.0454 4.157 0.00168 1.715 0.0683 1.324 0.0933 5.958 0.00649 
PH_hs_0011511 NM_004751 GCNT3 -1.755 0.0628 -1.843 0.0387 10.090 0.00263 -1.583 0.0963 -1.372 0.0678 12.880 0.00357 
PH_hs_0011690 NM_005458 GPR51 -1.101 0.516 -2.102 0.00755 5.657 0.00180 -1.336 0.174 -3.057 0.0193 4.442 0.00240 
PH_hs_0011706 NM_005467 NAALAD2 1.311 0.161 1.204 0.287 -2.609 0.00927 -1.047 0.723 -1.067 0.490 -3.771 0.0180 
PH_hs_0011943 NM_002133 HMOX1 69.990 0.0193 73.02 0.00804 11.060 0.00391 65.490 0.0718 117.6 0.0293 14.040 0.0385 
PH_hs_0012041 NM_020467 LOC57228 -1.141 0.609 1.199 0.0228 2.246 0.0222 1.084 0.547 -1.001 0.996 2.229 0.0156 
PH_hs_0012283 NM_152742 GPC2 -1.225 0.148 -1.124 0.235 -2.328 0.00495 1.093 0.554 -1.001 0.995 -2.513 0.0297 
PH_hs_0012389 NM_144590 ANKRD22 -3.154 0.0528 -3.240 0.0421 2.470 0.00384 -2.693 0.0645 -2.837 0.0179 2.968 0.00977 
PH_hs_0012708 NM_031422 CHST9 -1.084 0.573 -1.211 0.0778 3.657 0.00150 -1.344 0.163 -1.377 0.0823 3.336 0.0232 
PH_hs_0012784 NM_017805 RASIP1 1.041 0.753 1.072 0.567 -2.663 0.0068 1.192 0.359 1.259 0.0999 -2.510 0.0655 
PH_hs_0012796 NM_004925 AQP3 -1.357 0.408 -1.515 0.0499 2.548 0.0107 -1.160 0.537 -1.239 0.187 2.041 0.0210 
PH_hs_0012806 NM_005725 TSPAN-2 1.222 0.560 1.289 0.127 5.045 0.00210 -1.169 0.366 -1.067 0.528 3.702 0.0183 
PH_hs_0012818 NM_023926 FLJ12895 1.014 0.868 1.126 0.0959 -2.420 0.00748 1.108 0.544 1.236 0.0523 -2.203 0.00582 
PH_hs_0012825 NM_016354 SLCO4A1 1.484 0.0297 1.530 0.0123 2.058 0.00613 1.320 0.214 1.513 0.0501 2.319 0.0212 
PH_hs_0012868 NM_052942 GBP5 1.407 0.134 1.587 0.0188 -2.600 0.00325 1.279 0.153 1.628 0.0850 -2.148 0.0748 
PH_hs_0012930 NM_000627 LTBP1 -1.769 0.0479 -1.801 0.0254 -2.410 0.00685 -1.664 0.0601 -1.562 0.0136 -3.152 0.00189 
PH_hs_0013028 NM_000362 TIMP3 -1.401 0.0791 -1.240 0.0559 -5.290 0.00269 -1.260 0.0653 -1.096 0.226 -6.008 0.00286 
PH_hs_0013167 NM_005958 MTNR1A 1.035 0.915 -1.071 0.587 4.316 0.00209 -1.196 0.197 -1.415 0.0713 2.483 0.0241 
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PH_hs_0013274 NM_003304 TRPC1 1.192 0.215 1.087 0.265 -2.255 0.0151 1.099 0.646 -1.089 0.180 -2.912 0.0124 
PH_hs_0013301 NM_006580 CLDN16 -1.021 0.859 -1.908 0.0133 -4.754 0.00705 -1.218 0.195 -1.078 0.298 -3.186 0.00352 
PH_hs_0013732 NM_002430 MN1 -1.196 0.352 -1.381 0.146 -4.505 0.00799 -1.551 0.127 -1.550 0.0159 -6.080 0.0164 
PH_hs_0013934 NM_001657 AREG 1.963 0.0738 2.164 0.0342 -1.663 0.0451 1.215 0.173 2.124 0.0148 -2.073 0.0788 
PH_hs_0014044 NM_017581 CHRNA9 1.117 0.709 1.293 0.314 -2.383 0.0399 1.129 0.660 1.482 0.162 -2.340 0.0451 
PH_hs_0014077 NM_000944 PPP3CA -1.479 0.121 -1.678 0.0198 -2.611 0.00778 -1.589 0.101 -1.653 0.0415 -2.230 0.0320 
PH_hs_0014078 NM_182908 DHRS2 2.774 0.0447 1.455 0.0399 1.842 0.0142 3.131 0.0562 1.656 0.0777 2.011 0.0662 
PH_hs_0014156 NM_000930 PLAT 1.015 0.933 -1.321 0.0599 8.691 0.00353 -1.220 0.341 -1.718 0.0493 5.526 0.0188 
PH_hs_0014200 NM_002776 KLK10 1.484 0.0888 1.254 0.0710 -16.450 0.00210 1.251 0.188 -1.038 0.613 -14.070 0.00251 
PH_hs_0014290 NM_000611 CD59 -1.006 0.926 -1.006 0.952 4.141 0.000756 -1.047 0.774 -1.359 0.0533 3.601 0.00347 
PH_hs_0014372 BG200096 C9orf70 1.138 0.684 1.294 0.383 2.332 0.0745 1.251 0.542 1.581 0.0950 2.065 0.0457 
PH_hs_0014431 NM_014583 LMCD1 -1.872 0.063 -1.759 0.0105 -2.965 0.00059 -1.403 0.0822 -1.394 0.0377 -2.571 0.00359 
PH_hs_0014556 NM_032383 HPS3 -1.335 0.131 -2.273 0.00804 -2.336 0.00748 -1.185 0.427 -1.709 0.0474 -2.649 0.0261 
PH_hs_0014783 NM_015894 STMN3 -1.369 0.208 -1.300 0.194 3.592 0.0132 -1.033 0.882 -1.475 0.0893 2.963 0.0151 
PH_hs_0014918 NM_147204 TRPV4 -1.356 0.203 1.015 0.890 2.069 0.0347 1.020 0.959 -1.439 0.167 2.018 0.0633 
PH_hs_0015034 - - -1.339 0.113 1.138 0.192 -2.505 0.00455 -1.158 0.442 -1.282 0.161 -2.886 0.0354 
PH_hs_0015041 NM_023067 FOXL2 1.065 0.817 1.448 0.0589 -2.113 0.00202 1.207 0.450 1.122 0.510 -2.186 0.0392 
PH_hs_0015371 NM_024101 MLPH -1.803 0.0977 -2.854 0.0222 -1.575 0.00894 -2.314 0.0973 -2.496 0.0271 -1.677 0.150 
PH_hs_0015559 NM_207376 LOC387882 -1.197 0.119 -1.485 0.0699 -2.357 0.000902 -1.209 0.239 -1.364 0.0523 -2.333 0.00837 
PH_hs_0015577 NM_018640 LMO3 -2.760 0.0306 -3.057 0.00514 -3.595 0.00194 -2.114 0.0666 -2.228 0.00942 -3.303 0.00261 
PH_hs_0015584 NM_019558 HOXD8 -1.068 0.352 1.115 0.220 -2.474 0.00194 -1.193 0.163 1.135 0.151 -2.402 0.00839 
PH_hs_0015664 NM_002982 CCL2 -1.572 0.0519 -2.051 0.0127 -9.374 0.000739 -1.131 0.134 -1.997 0.0218 -13.590 0.000887 
PH_hs_0016000 NM_182920 ADAMTS9 -1.267 0.323 -1.250 0.276 2.397 0.0264 -1.235 0.0561 -1.872 0.0176 2.100 0.0396 
PH_hs_0016017 NM_182704 SELV -1.130 0.252 1.160 0.0819 -2.108 0.0190 1.089 0.504 1.158 0.167 -2.197 0.0178 
PH_hs_0016036 NM_032539 SLITRK2 -1.501 0.142 -1.062 0.304 -51.190 0.00444 -1.241 0.201 -1.031 0.782 -53.890 0.00526 
PH_hs_0016124 NM_002231 KAI1 -2.083 0.0190 -2.535 0.0140 3.853 0.00160 -1.541 0.0683 -2.024 0.0269 4.138 0.0116 
PH_hs_0016413 NM_018476 BEX1 1.092 0.252 1.014 0.747 -13.66 0.000651 1.039 0.787 -1.353 0.105 -19.57 0.00705 
PH_hs_0016489 NM_138287 DTX3L 1.107 0.0875 -1.021 0.771 -3.259 0.00271 -1.146 0.184 -1.031 0.682 -2.904 0.0208 
PH_hs_0016654 - - -2.191 0.0431 -2.373 0.00892 -2.514 0.00498 -1.775 0.0520 -1.862 0.0195 -2.034 0.0112 
PH_hs_0016738 NM_032323 MGC13102 2.692 0.0326 2.964 0.00786 1.508 0.0233 2.088 0.0340 2.741 0.0222 1.270 0.0801 
PH_hs_0016853 NM_012219 MRAS 1.170 0.267 1.025 0.746 -3.373 0.00269 1.064 0.628 1.239 0.142 -3.498 0.00676 
PH_hs_0016931 AK055877 LOC151438 -2.284 0.0502 -3.016 0.0245 1.970 0.0187 -1.512 0.106 -2.103 0.00942 2.247 0.0737 
PH_hs_0017058 NM_145280 LOC151194 -1.294 0.226 -1.048 0.545 2.511 0.00133 -1.092 0.384 -1.268 0.0473 2.197 0.0176 
PH_hs_0017206 NM_003586 DOC2A -1.372 0.111 -1.075 0.509 -2.762 0.00459 -1.091 0.618 1.198 0.150 -2.006 0.0317 
PH_hs_0017286 AK124426 - 2.235 0.0269 2.745 0.00687 -1.159 0.108 2.049 0.0913 3.133 0.0067 1.040 0.667 
PH_hs_0017514 NM_032638 GATA2 2.763 0.0486 2.335 0.0415 -1.941 0.0387 2.090 0.0718 2.325 0.0218 -1.293 0.143 
PH_hs_0018171 NM_003275 TMOD1 -1.553 0.154 -2.119 0.00835 1.817 0.00567 -1.567 0.143 -2.563 0.0216 1.314 0.111 
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PH_hs_0018184 NM_005952 MT1X 4.134 0.0127 6.289 0.00804 -1.028 0.604 4.459 0.0173 8.034 0.0141 -1.074 0.456 
PH_hs_0018787 NM_004120 GBP2 -2.265 0.0467 -1.485 0.0719 -8.219 0.00936 -1.651 0.149 -1.370 0.150 -6.401 0.00945 
PH_hs_0019248 NM_005302 GPR37 -1.232 0.332 -1.079 0.700 -6.684 0.0109 -1.487 0.157 -1.197 0.128 -11.640 0.00359 
PH_hs_0019583 NM_024430 PSTPIP2 -1.652 0.235 -1.369 0.0601 -2.129 0.0234 -1.563 0.0973 -1.729 0.0355 -3.240 0.00696 
PH_hs_0019591 NM_019894 TMPRSS4 -1.400 0.144 1.217 0.105 3.869 0.00271 -1.197 0.341 1.017 0.900 3.089 0.0132 
PH_hs_0019618 CR602569  -1.359 0.143 -1.381 0.0920 -2.710 0.0125 -1.275 0.338 -1.022 0.896 -2.251 0.0295 
PH_hs_0019619 NM_002964 S100A8 -2.637 0.0665 -5.414 0.00411 7.185 0.000651 -2.034 0.133 -6.655 0.0176 7.502 0.0112 
PH_hs_0019710 NM_001849 COL6A2 -1.275 0.369 1.089 0.566 -2.528 0.0133 1.087 0.660 1.054 0.480 -2.015 0.0399 
PH_hs_0019818 NM_003662 PIR 2.422 0.0665 2.632 0.0174 2.910 0.0233 1.952 0.131 1.648 0.0585 2.474 0.00402 
PH_hs_0019988 XM_039515
3 
G2 -1.469 0.0635 -1.572 0.144 2.594 0.000651 -1.746 0.0340 -1.703 0.0547 2.077 0.00402 
PH_hs_0020084 NM_018413 CHST11 1.712 0.041 1.621 0.0314 3.474 0.00756 1.591 0.0973 1.652 0.0207 3.308 0.00534 
PH_hs_0020111 NM_000597 IGFBP2 -1.078 0.213 -1.097 0.160 -5.162 0.000898 1.054 0.394 -1.196 0.0288 -4.536 0.00478 
PH_hs_0020151 NM_002885 RAP1GA1 1.142 0.593 1.411 0.0791 2.033 0.0271 1.045 0.857 1.154 0.443 2.066 0.0694 
PH_hs_0020156 NM_000424 KRT5 -2.669 0.0564 -3.365 0.00180 -2.542 0.00286 -3.811 0.0561 -6.449 0.0197 -5.082 0.0253 
PH_hs_0020166 NM_138284 IL17D 1.709 0.0455 1.547 0.0136 -2.162 0.00995 1.350 0.217 1.293 0.0530 -2.469 0.0610 
PH_hs_0020300 NM_004385 CSPG2 1.010 0.960 -1.062 0.666 -2.105 0.0269 -1.083 0.474 -1.156 0.170 -3.415 0.0133 
PH_hs_0020408 XM_086879 LOC150371 -2.063 0.0226 -1.485 0.0487 -2.697 0.00589 -1.488 0.00676 -1.668 0.0210 -3.716 0.0245 
PH_hs_0020427 AL831898 LOC285812 -2.346 0.105 -2.052 0.0286 -1.015 0.857 -2.121 0.152 -2.572 0.0618 -1.274 0.276 
PH_hs_0020456 NM_138768 MYEOV -1.120 0.216 -1.019 0.790 2.650 0.00269 -1.038 0.847 -1.047 0.631 2.024 0.0162 
PH_hs_0020546 NM_021219 JAM2 1.342 0.220 1.612 0.0481 -4.881 0.0276 1.353 0.263 1.183 0.302 -4.101 0.0137 
PH_hs_0020591 NM_153233 FLJ36445 -1.101 0.804 1.409 0.126 2.367 0.0160 1.019 0.912 1.386 0.0674 2.649 0.00964 
PH_hs_0020618 NM_000228 LAMB3 1.313 0.147 1.233 0.0452 2.364 0.00646 1.235 0.0519 1.254 0.0216 2.414 0.000887 
PH_hs_0020829 NM_018494 LRDD -1.347 0.0899 -1.278 0.0772 -2.325 0.00475 -1.124 0.521 -1.208 0.184 -2.513 0.0128 
PH_hs_0021015   -1.451 0.335 -1.931 0.0316 -2.352 0.0241 -1.461 0.254 -1.755 0.0319 -2.184 0.0142 
PH_hs_0021087 NM_207436 FLJ42957 -2.990 0.0412 -1.592 0.0722 -2.358 0.0116 -1.771 0.0926 -1.568 0.0799 -2.089 0.0192 
PH_hs_0022133 NM_003956 CH25H -2.109 0.0314 -1.945 0.0107 2.814 0.0102 -1.449 0.519 -1.606 0.326 2.817 0.142 
PH_hs_0022138 NM_014548 TMOD2 1.064 0.778 1.268 0.113 -2.698 0.00644 -1.477 0.290 -1.313 0.305 -3.269 0.0216 
PH_hs_0022217 NM_003317 TITF1 -1.730 0.0431 -1.893 0.0228 -5.584 0.00201 -1.445 0.176 -1.468 0.0907 -4.599 0.00905 
PH_hs_0022233 NM_022454 SOX17 -1.449 0.0262 -1.373 0.0223 -4.439 0.00122 -1.238 0.101 -1.266 0.0386 -4.075 0.00141 
PH_hs_0022302 NM_001617 ADD2 1.095 0.571 1.108 0.298 -7.807 0.00521 1.317 0.306 1.545 0.111 -5.676 0.0207 
PH_hs_0022310 NM_004390 CTSH -1.095 0.228 1.010 0.913 -2.704 0.00900 1.058 0.768 1.149 0.356 -2.317 0.0464 
PH_hs_0022320 NM_000187 HGD 1.987 0.0389 2.156 0.0141 1.249 0.101 2.100 0.0957 2.658 0.0179 1.730 0.0449 
PH_hs_0022370 NM_172373 ELF1 1.896 0.0918 1.634 0.0176 2.572 0.00971 1.767 0.0519 1.404 0.0745 2.469 0.0133 
PH_hs_0022372 NM_001275 CHGA 6.251 0.0127 5.103 0.0160 7.888 0.00152 5.496 0.0913 4.068 0.0377 6.514 0.0302 
PH_hs_0022374 NM_020169 LXN 1.112 0.190 -1.054 0.651 3.447 0.000590 1.145 0.539 -1.004 0.980 2.955 0.0193 
PH_hs_0022409 NM_032867 FLJ14966 -1.757 0.0349 -1.846 0.0133 -3.094 0.00316 -1.731 0.0607 -1.189 0.128 -2.759 0.00916 
PH_hs_0022465 NM_031458 PARP9 -1.064 0.761 -1.129 0.0758 -4.440 0.00104 -1.082 0.0797 1.005 0.894 -3.120 0.0339 
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PH_hs_0022469 NM_005715 UST 1.226 0.216 1.189 0.0721 4.697 0.00122 1.158 0.397 1.573 0.0217 5.096 0.00631 
PH_hs_0022539 NM_006384 CIB1 -1.073 0.636 -1.014 0.906 2.134 0.0161 1.046 0.778 1.074 0.371 2.197 0.00933 
PH_hs_0022560 NM_005862 STAG1 1.218 0.105 -1.350 0.0211 -2.268 0.0118 -1.146 0.197 -1.223 0.0432 -2.137 0.0628 
PH_hs_0022589 NM_003986 BBOX1 -1.559 0.0341 -1.586 0.00687 -4.296 0.000651 -1.411 0.174 -1.246 0.0165 -3.565 0.0297 
PH_hs_0022632 NM_007361 NID2 1.267 0.242 1.215 0.295 2.337 0.00406 -1.056 0.740 1.256 0.0664 5.901 0.0160 
PH_hs_0022734 NM_016339 RAPGEFL1 1.048 0.705 1.421 0.0841 2.148 0.0169 1.164 0.223 1.310 0.0560 2.191 0.00711 
PH_hs_0022739 XM_114303 FRMD4B -1.034 0.757 -1.288 0.0429 -2.846 0.0136 -1.050 0.823 -1.116 0.379 -2.391 0.0375 
PH_hs_0022779 NM_017664 ANKRD10 -1.202 0.0880 -1.274 0.0242 -2.219 0.0407 -1.123 0.430 -1.088 0.401 -2.015 0.0200 
PH_hs_0022919 NM_013246 CLC 1.826 0.0493 1.400 0.0105 3.007 0.00271 2.115 0.0519 2.083 0.0180 3.351 0.00911 
PH_hs_0022944 NM_006867 RBPMS 1.011 0.963 1.333 0.0509 2.608 0.0101 1.172 0.485 1.259 0.208 2.408 0.00945 
PH_hs_0022977 NM_153811 SLC38A6 2.144 0.0676 2.104 0.0311 2.077 0.0236 1.781 0.0562 2.169 0.0133 2.305 0.00649 
PH_hs_0022999 NM_003567 BCAR3 1.928 0.0431 1.620 0.0508 2.522 0.0133 1.544 0.0936 1.469 0.0222 2.268 0.00359 
PH_hs_0023101 NM_033254 BOC -3.841 0.00792 -4.380 0.00418 -1.019 0.631 -2.366 0.0519 -2.079 0.0317 1.250 0.0967 
PH_hs_0023398 NM_006714 SMPDL3A 1.477 0.0629 1.214 0.0204 -3.717 0.0214 1.208 0.149 1.127 0.229 -3.222 0.0512 
PH_hs_0023411 NM_138451 IQCD -1.022 0.916 -1.229 0.156 2.859 0.0126 1.108 0.425 1.219 0.128 3.186 0.0138 
PH_hs_0023504 NM_014432 IL20RA -1.403 0.362 -3.820 0.116 1.723 0.0135 -1.746 0.143 -2.266 0.0296 1.847 0.0318 
PH_hs_0023550 NM_004665 VNN2 -1.856 0.116 -3.316 0.0120 3.319 0.00626 -1.629 0.180 -2.772 0.0469 4.680 0.0084 
PH_hs_0023568 NM_015570 AUTS2 -1.112 0.305 -1.082 0.155 -2.112 0.000689 -1.105 0.273 -1.013 0.835 -2.422 0.00677 
PH_hs_0023584 NM_001946 DUSP6 2.221 0.0283 2.194 0.0210 1.937 0.00685 1.485 0.148 2.022 0.0597 1.407 0.0799 
PH_hs_0023602 NM_178012 MGC8685 1.092 0.703 1.201 0.333 -4.489 0.00109 -1.000 1.000 1.078 0.689 -4.321 0.0160 
PH_hs_0023636 NM_001751 CARS 1.217 0.135 1.164 0.055 -2.948 0.00311 1.349 0.252 1.698 0.0740 -2.159 0.0466 
PH_hs_0023739 NM_152282 ACPL2 -1.256 0.135 -1.298 0.0679 -5.893 0.00248 -1.313 0.139 -1.331 0.0617 -4.396 0.00307 
PH_hs_0023764 NM_002061 GCLM 4.939 0.0230 3.817 0.00835 3.817 0.00697 4.008 0.0265 3.810 0.00942 4.523 0.00412 
PH_hs_0023894 NM_021158 TRIB3 2.012 0.0411 2.399 0.00239 -1.213 0.0231 2.150 0.0519 3.389 0.00670 -1.003 0.951 
PH_hs_0023937 NM_006120 HLA-DMA -2.098 0.0266 -1.753 0.0477 1.817 0.0130 -1.221 0.290 -1.065 0.517 2.398 0.0152 
PH_hs_0023962 NM_052832 SLC26A7 -3.503 0.0101 -4.992 0.00141 -3.634 0.00775 -2.996 0.0520 -4.965 0.0107 -6.112 0.0112 
PH_hs_0023967 NM_017786 FLJ20366 1.920 0.0570 2.148 0.0268 1.382 0.0620 1.446 0.0718 2.457 0.0194 1.373 0.0368 
PH_hs_0024008 NM_182487 OLFML2A -1.503 0.0368 -1.519 0.0267 -2.245 0.00936 -1.382 0.188 -1.353 0.0216 -2.746 0.00970 
PH_hs_0024009 NM_002604 PDE7A -1.559 0.0826 -1.862 0.00729 -2.224 0.00353 -1.187 0.180 -1.743 0.0148 -2.731 0.00478 
PH_hs_0024014 NM_003199 TCF4 -1.412 0.295 -1.430 0.0278 -3.580 0.00824 -1.952 0.134 -2.043 0.0846 -3.553 0.0178 
PH_hs_0024015 AL832164 LOC283666 1.157 0.189 1.564 0.0344 -3.196 0.00268 1.062 0.126 2.000 0.0291 -3.695 0.0349 
PH_hs_0024092 NM_007129 ZIC2 1.260 0.335 1.906 0.0257 6.229 0.00573 1.028 0.770 1.309 0.0414 4.111 0.0228 
PH_hs_0024094 NM_145035 ADMP -2.579 0.0269 -4.333 0.0120 -3.868 0.00308 -2.461 0.0913 -3.613 0.00638 -3.298 0.0247 
PH_hs_0024164 XM_031553 SR140 -1.112 0.408 -1.186 0.0479 -2.172 0.00697 -1.064 0.594 -1.251 0.0544 -2.121 0.00945 
PH_hs_0024170 NM_002272 KRT4 -4.266 0.0249 -6.642 0.00266 6.936 0.00211 -4.038 0.0311 -4.817 0.00377 12.560 0.000887 
PH_hs_0024307 NM_014857 RABGAP1L 1.312 0.225 1.221 0.0309 2.661 0.0101 -1.197 0.308 -1.656 0.0473 -3.003 0.638 
PH_hs_0024364 - - -1.609 0.394 -1.369 0.137 6.962 0.00409 -1.864 0.150 -2.631 0.0664 5.244 0.000887 











  Batch A     Batch  B   
   0 vs 24 
hrs 
0 vs 24 
hrs 
0 vs 48 
hrs 
0 vs 48 
hrs 
0 vs R 0 vs R 0 vs 24 
hrs 
0 vs 24 
hrs 
0 vs 48 
hrs 
0 vs 48 
hrs 
0 vs R 0 vs R 
   Fold p-value Fold p-value Fold p-value Fold p-value Fold p-value Fold p-value 
               
PH_hs_0024398 NM_004207 SLC16A3 1.072 0.568 1.066 0.552 5.350 0.00301 1.243 0.428 -1.214 0.349 5.667 0.0212 
PH_hs_0024437 NM_003810 TNFSF10 -1.765 0.0383 -2.801 0.0107 1.061 0.183 -1.468 0.111 -3.004 0.0101 1.189 0.0791 
PH_hs_0024448 NM_003730 RNASET2 1.056 0.734 1.413 0.0179 2.677 0.00122 1.039 0.268 1.277 0.0165 2.501 0.00964 
PH_hs_0024475 NM_001099 ACPP -3.865 0.0393 -4.435 0.0107 1.252 0.101 -2.512 0.0612 -3.340 0.00942 1.025 0.785 
PH_hs_0024509 NM_006820 IFI44L -2.066 0.0393 -2.372 0.0292 -7.283 0.0114 -2.332 0.118 -1.830 0.0752 -5.435 0.0104 
PH_hs_0024531 NM_002037 FYN 1.677 0.0269 1.490 0.0339 -2.538 0.0161 1.479 0.186 2.170 0.0345 -1.653 0.0532 
PH_hs_0024685 - - -1.093 0.214 -1.287 0.0245 2.406 0.00202 -1.278 0.188 1.078 0.437 3.292 0.00714 
PH_hs_0024713 NM_001846 COL4A2 -1.122 0.386 -1.164 0.0699 -2.883 0.00248 1.112 0.503 1.377 0.0944 -2.481 0.0258 
PH_hs_0024752 - - -1.344 0.192 -1.210 0.0850 -2.924 0.0034 -1.093 0.552 1.095 0.414 -2.862 0.0197 
PH_hs_0024758 NM_003034 SIAT8A 1.062 0.714 -1.266 0.129 -2.678 0.00705 -1.236 0.287 -1.785 0.0289 -3.058 0.0297 
PH_hs_0024812 NM_052941 GBP4 -2.387 0.0412 -2.354 0.00899 -3.259 0.00655 -1.678 0.0913 -1.873 0.0250 -3.928 0.00499 
PH_hs_0024827 NM_016105 FKBP7 -1.339 0.114 -1.522 0.0179 -3.171 0.00819 -1.165 0.347 -1.373 0.0612 -3.034 0.0338 
PH_hs_0024837 NM_004304 ALK -1.401 0.152 -1.179 0.113 2.448 0.00819 -1.066 0.293 1.035 0.640 2.553 0.00677 
PH_hs_0024839 NM_022817 PER2 -2.114 0.123 -1.781 0.0351 1.688 0.0212 -2.258 0.0196 -2.234 0.00767 -1.078 0.575 
PH_hs_0024845 NM_004631 LRP8 2.092 0.0492 2.073 0.0205 2.308 0.00598 1.824 0.0630 2.210 0.0148 2.068 0.0151 
PH_hs_0024930 NM_000132 F8 1.144 0.299 -1.124 0.213 -3.295 0.0286 -1.117 0.553 -1.133 0.416 -2.623 0.0170 
PH_hs_0024953 NM_032466 ASPH 3.100 0.0953 2.936 0.0245 3.826 0.000651 2.328 0.136 2.225 0.0611 2.656 0.0259 
PH_hs_0024961 NM_001565 CXCL10 -1.876 0.072 -1.994 0.00607 5.196 0.00449 -2.246 0.0519 -4.406 0.0132 3.434 0.00471 
PH_hs_0024978 - - 2.339 0.0383 1.883 0.0143 1.461 0.0174 2.063 0.0210 1.996 0.00789 1.668 0.00723 
PH_hs_0025004 NM_014234 HSD17B8 -1.126 0.257 -1.188 0.228 -3.018 0.00608 -1.084 0.733 -1.328 0.233 -2.929 0.0426 
PH_hs_0025057 NM_000350 ABCA4 -1.603 0.112 -1.605 0.0184 2.446 0.00433 -1.391 0.121 -1.410 0.0673 3.241 0.00726 
PH_hs_0025078 NM_001394 DUSP4 3.012 0.0269 3.183 0.00577 -5.686 0.00755 2.217 0.0653 2.963 0.0251 -5.801 0.0125 
PH_hs_0025081 NM_016831 PER3 -1.965 0.0283 -1.237 0.0635 -2.459 0.00450 -2.139 0.0311 -1.306 0.0703 -2.486 0.0237 
PH_hs_0025088 NM_212474 FN1 -1.201 0.0436 -2.218 0.00786 -1.984 0.00425 -1.119 0.186 -1.508 0.018 -2.055 0.00523 
PH_hs_0025139 NM_001449 FHL1 1.238 0.169 1.406 0.0525 -2.569 0.0102 1.126 0.252 1.327 0.0251 -2.567 0.0209 
PH_hs_0025184 NM_024907 FBXO17 1.149 0.118 1.365 0.0629 -3.031 0.00383 1.066 0.241 1.318 0.0301 -3.116 0.0211 
PH_hs_0025212 NM_015993 TM4SF11 -2.001 0.0408 -1.934 0.0154 -2.594 0.00995 -1.677 0.120 -1.709 0.0315 -2.148 0.0148 
PH_hs_0025250 NM_003108 SOX11 -1.141 0.210 1.172 0.116 -4.750 0.00521 -1.033 0.851 1.191 0.0957 -4.515 0.00237 
PH_hs_0025269 NM_013343 LOH3CR2A -2.388 0.0851 -2.156 0.0230 -3.171 0.0122 -1.760 0.082 -2.313 0.0218 -3.129 0.00853 
PH_hs_0025272 NM_025080 ASRGL1 1.226 0.250 1.024 0.860 -3.718 0.00657 -1.058 0.841 -1.138 0.541 -4.191 0.0209 
PH_hs_0025293 NM_006097 MYL9 1.121 0.567 1.450 0.0863 -2.808 0.0104 1.013 0.961 1.115 0.537 -4.913 0.0124 
PH_hs_0025324 NM_182729 TXNRD1 4.035 0.0314 3.716 0.0105 2.297 0.0229 2.945 0.0999 3.439 0.0176 2.108 0.0151 
PH_hs_0025342 NM_153365 FLJ90013 1.390 0.0535 1.343 0.0563 2.265 0.00521 1.236 0.211 1.036 0.746 2.218 0.00365 
PH_hs_0025406 - - 1.108 0.547 1.210 0.264 3.600 0.00689 1.139 0.286 1.166 0.00975 4.150 0.0123 
PH_hs_0025490 NM_005269 GLI 1.553 0.101 2.002 0.0454 -1.427 0.0835 1.357 0.129 2.738 0.0315 -1.674 0.0375 
PH_hs_0025524 NM_203447 DOCK8 -1.134 0.483 -3.232 0.0487 4.804 0.00809 -1.290 0.393 -2.479 0.0642 5.378 0.0241 
PH_hs_0025581 NM_001845 COL4A1 1.086 0.506 -1.082 0.247 -2.795 0.00624 1.077 0.624 -1.032 0.763 -2.965 0.0162 
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PH_hs_0025588 NM_020453 ATP10D 1.272 0.0246 -1.044 0.587 3.968 0.00983 -1.021 0.927 -1.555 0.101 3.817 0.0171 
PH_hs_0025607 NM_004998 MYO1E 1.265 0.0564 1.112 0.192 2.658 0.00245 1.239 0.303 1.323 0.120 2.264 0.0434 
PH_hs_0025690 - - -1.166 0.704 -1.090 0.139 -2.408 0.00383 -1.273 0.304 -1.239 0.211 -2.523 0.0173 
PH_hs_0025701 NM_017842 FLJ20489 1.576 0.210 1.281 0.0212 2.189 0.00248 1.323 0.197 1.082 0.420 2.434 0.0155 
PH_hs_0025782 NM_001431 EPB41L2 -1.166 0.0566 -1.443 0.0107 -2.065 0.00516 -1.228 0.199 -1.512 0.0333 -2.230 0.0274 
PH_hs_0025799 NM_001744 CAMK4 -1.308 0.159 -1.867 0.0074 -3.325 0.00438 -1.303 0.186 -1.660 0.0673 -2.460 0.0121 
PH_hs_0025826 NM_000904 NQO2 3.704 0.0101 3.894 0.0046 3.414 0.00276 2.785 0.0822 2.953 0.0287 2.567 0.0124 
PH_hs_0025862 NM_002065 GLUL 1.201 0.0569 1.054 0.191 -3.211 0.00145 -1.049 0.582 -1.063 0.617 -2.364 0.00359 
PH_hs_0025869 NM_014883 FAM13A1 -1.656 0.0493 -2.973 0.0120 -2.856 0.000651 -1.441 0.145 -2.689 0.0287 -2.210 0.0141 
PH_hs_0025875 NM_002589 PCDH7 1.118 0.689 1.249 0.114 4.469 0.00717 1.056 0.678 1.187 0.157 3.971 0.00523 
PH_hs_0025907 NM_000140 FECH 3.336 0.0372 3.502 0.0127 1.958 0.00771 2.144 0.0731 2.252 0.0166 1.563 0.0317 
PH_hs_0025925 NM_033138 CALD1 1.218 0.452 -1.360 0.0168 -3.336 0.00384 -1.022 0.542 1.024 0.425 -3.066 0.0613 
PH_hs_0025967 NM_003937 KYNU 3.227 0.0283 2.148 0.0131 2.076 0.00809 1.618 0.108 1.317 0.101 2.335 0.0297 
PH_hs_0026045 NM_025130 FLJ22761 2.448 0.0440 3.037 0.0120 1.697 0.0108 1.612 0.0913 2.910 0.0155 1.706 0.0349 
PH_hs_0026095 NM_022036 GPRC5C 1.387 0.0312 1.148 0.122 2.068 0.00986 1.507 0.0860 1.387 0.0523 2.871 0.00677 
PH_hs_0026211 NM_014391 ANKRD1 -1.276 0.177 -1.763 0.071 -4.543 0.0141 -1.198 0.425 -1.680 0.0497 -3.728 0.0939 
PH_hs_0026354 - - 1.189 0.134 1.343 0.0262 2.173 0.00481 1.363 0.103 1.300 0.192 2.273 0.0139 
PH_hs_0026357 NM_023938 SARG -1.455 0.431 -1.414 0.133 3.001 0.0120 -1.665 0.188 -2.085 0.0555 3.200 0.0211 
PH_hs_0026522 NM_002627 PFKP 1.350 0.179 1.505 0.0344 4.018 0.00934 1.269 0.134 1.263 0.0549 3.649 0.00238 
PH_hs_0026578 NM_005965 MYLK -1.895 0.0665 -2.069 0.0254 -4.474 0.00402 -1.887 0.0973 -1.509 0.0414 -4.406 0.0218 
PH_hs_0026589 NM_145909 ZNF323 1.732 0.0668 1.921 0.00892 -2.920 0.00481 1.744 0.0890 1.830 0.0289 -2.967 0.0287 
PH_hs_0026600 NM_006500 MCAM 1.173 0.169 1.184 0.116 -3.010 0.00269 1.079 0.493 1.009 0.880 -4.086 0.00384 
PH_hs_0026605 NM_006317 BASP1 -1.213 0.196 -1.009 0.950 -3.443 0.00611 1.042 0.873 1.049 0.793 -2.46 0.0440 
PH_hs_0026662 NM_001955 EDN1 -1.682 0.0597 -2.319 0.0161 -3.539 0.0112 -1.757 0.0913 -2.493 0.0141 -6.346 0.0267 
PH_hs_0026765 NM_016356 DCDC2 -1.074 0.820 -1.496 0.0333 -2.237 0.00455 -1.614 0.123 -1.735 0.0478 -2.343 0.0415 
PH_hs_0026808 NM_006512 SAA4 1.355 0.184 1.842 0.0379 10.820 0.00867 1.223 0.583 1.259 0.433 9.186 0.018 
PH_hs_0026823 NM_004613 TGM2 -1.356 0.169 -1.774 0.0524 4.013 0.00614 -1.214 0.483 -1.301 0.292 5.914 0.0286 
PH_hs_0026843 NM_024896 KIAA1815 1.464 0.147 1.535 0.0845 3.590 0.00763 1.412 0.111 1.904 0.0216 5.031 0.0114 
PH_hs_0026899 NM_014243 ADAMTS3 -1.141 0.429 -2.328 0.0228 -1.170 0.258 -1.220 0.372 -2.502 0.0468 -1.193 0.284 
PH_hs_0027024 NM_000359 TGM1 -1.281 0.310 -1.079 0.348 2.731 0.00269 -1.438 0.188 -1.022 0.849 2.359 0.0115 
PH_hs_0027041 NM_002423 MMP7 1.501 0.0941 -1.352 0.0245 2.568 0.00675 1.232 0.0822 -1.692 0.0751 2.729 0.0226 
PH_hs_0027066 NM_001550 IFRD1 2.152 0.0227 1.678 0.0141 -1.907 0.00806 2.000 0.0769 2.245 0.0359 -1.181 0.0823 
PH_hs_0027088 NM_031430 RILP 1.100 0.778 1.383 0.0980 2.588 0.00383 -1.120 0.354 1.038 0.429 2.310 0.0431 
PH_hs_0027090 NM_020770 CGN -1.964 0.0661 -2.435 0.0154 -1.378 0.0768 -1.657 0.118 -2.257 0.0280 -1.328 0.114 
PH_hs_0027093 NM_005704 PTPRU 1.026 0.630 1.927 0.00786 3.352 0.0129 -1.013 0.935 -1.096 0.341 2.361 0.00653 
PH_hs_0027127 NM_004282 BAG2 1.829 0.0283 1.560 0.0120 2.574 0.00225 1.565 0.115 1.270 0.160 2.266 0.0154 
PH_hs_0027137 NM_018988 GFOD1 -2.326 0.0481 -2.543 0.00468 -1.227 0.0139 -1.771 0.0693 -2.069 0.0291 -1.419 0.0253 
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PH_hs_0027158 NM_006756 TCEA1 2.074 0.0428 2.337 0.0114 -1.154 0.0521 1.531 0.0973 2.568 0.0251 -1.114 0.253 
PH_hs_0027161 NM_015149 RGL1 -1.602 0.0977 -1.445 0.0452 -2.006 0.0162 -1.552 0.0666 -1.495 0.0357 -2.632 0.0122 
PH_hs_0027162 NM_002394 SLC3A2 2.333 0.0649 2.417 0.0217 3.743 0.00308 1.999 0.0820 2.155 0.0288 2.793 0.0324 
PH_hs_0027200 BC010607 MGC18216 1.318 0.216 1.497 0.0150 3.853 0.00128 1.065 0.643 1.333 0.0761 3.855 0.00309 
PH_hs_0027214 NM_003843 SCEL -1.066 0.653 1.081 0.264 3.888 0.00764 1.123 0.357 -1.259 0.0742 3.951 0.0118 
PH_hs_0027279 NM_020698 KIAA1145 -1.650 0.0477 -1.842 0.0133 -9.601 0.000926 -1.282 0.115 -1.126 0.180 -6.321 0.00175 
PH_hs_0027301 - - -1.224 0.269 -1.389 0.0107 3.190 0.00104 1.008 0.966 -1.302 0.139 3.592 0.00901 
PH_hs_0027323 NM_024909 C6orf134 1.320 0.0542 1.366 0.0490 4.277 0.00269 1.369 0.0690 1.091 0.444 5.065 0.00979 
PH_hs_0027514 NM_021127 PMAIP1 2.498 0.0386 2.164 0.0150 1.483 0.0181 1.789 0.0477 2.456 0.0148 1.552 0.0292 
PH_hs_0027536 NM_030754 SAA2 -1.454 0.136 -1.685 0.0116 14.240 0.000756 -1.267 0.289 -2.086 0.0624 17.49 0.00240 
PH_hs_0027544 NM_000916 OXTR -1.807 0.253 -2.535 0.00742 -2.473 0.00854 -1.996 0.0561 -2.166 0.0296 -2.072 0.0505 
PH_hs_0027715 - - -1.077 0.283 -1.195 0.142 -3.255 0.000790 -1.043 0.737 -1.345 0.0957 -3.815 0.00901 
PH_hs_0027908 NM_002264 KPNA1 1.102 0.457 -1.126 0.249 -3.588 0.00880 1.019 0.932 -1.200 0.317 -2.682 0.0115 
PH_hs_0028098 NM_000096 CP -1.451 0.0902 -2.763 0.00942 -4.869 0.00400 -1.450 0.0822 -1.633 0.0218 -2.199 0.00750 
PH_hs_0028187 NM_024692 RSNL2 3.151 0.0312 2.409 0.0367 1.149 0.312 1.839 0.112 2.286 0.0362 1.350 0.212 
PH_hs_0028196 NM_021105 PLSCR1 -1.042 0.763 1.281 0.0744 -2.664 0.00383 1.206 0.348 2.264 0.00670 -1.401 0.0229 
PH_hs_0028696 NM_001735 C5 -1.059 0.652 -1.252 0.0487 -2.564 0.0542 -1.040 0.817 1.011 0.888 -2.145 0.0510 
PH_hs_0028708 NM_000346 SOX9 -1.421 0.0396 -1.538 0.0242 -5.303 0.00820 -1.428 0.0519 -1.453 0.0386 -8.293 0.00147 
PH_hs_0028763 NM_018389 SLC35C1 -1.087 0.619 1.144 0.149 3.492 0.00880 1.052 0.659 -1.013 0.898 3.019 0.0124 
PH_hs_0028818 - - 2.622 0.0875 4.018 0.00607 1.441 0.105 1.705 0.0842 2.104 0.0368 -1.256 0.246 
PH_hs_0028833 NM_003512 HIST1H2AC -3.665 0.0266 -3.073 0.00687 -1.685 0.0146 -2.486 0.0519 -2.003 0.0322 -1.163 0.173 
PH_hs_0028850 NM_016262 TUBE1 2.315 0.0366 1.881 0.0349 -1.347 0.0601 1.387 0.121 2.060 0.0207 -1.381 0.121 
PH_hs_0028931 - - -1.549 0.246 -2.370 0.0180 -3.941 0.000902 -1.614 0.180 -1.699 0.0390 -3.629 0.0188 
PH_hs_0028942 NM_003551 NME5 -1.310 0.0706 -1.002 0.980 -3.197 0.0125 -1.175 0.491 -1.343 0.196 -2.567 0.0432 
PH_hs_0028961 NM_000165 GJA1 -1.043 0.797 -1.272 0.0768 -4.295 0.00300 -1.506 0.170 -1.908 0.0500 -8.582 0.00600 
PH_hs_0028988 NM_003739 AKR1C3 12.560 0.00732 20.810 0.00126 14.200 0.000601 10.06 0.0513 15.330 0.00522 13.980 0.00289 
PH_hs_0029016 NM_000227 LAMA3 -1.523 0.238 -1.969 0.0223 2.966 0.00824 -1.452 0.230 -3.122 0.0218 3.609 0.0153 
PH_hs_0029204 NM_001233 CAV2 1.099 0.599 -1.158 0.273 2.108 0.0100 -1.099 0.426 -1.036 0.784 2.004 0.0119 
PH_hs_0029218 NM_144684 ZNF480 1.165 0.320 -1.082 0.282 -2.202 0.00613 1.097 0.563 -1.048 0.664 -2.088 0.0224 
PH_hs_0029236 - - -1.301 0.209 -1.987 0.0249 -2.550 0.0163 -1.878 0.183 -2.001 0.0148 1.025 0.887 
PH_hs_0029418 NM_018159 NUDT11 1.197 0.417 -1.181 0.384 -2.030 0.0404 -1.008 0.950 -1.268 0.0538 -2.705 0.0147 
PH_hs_0029660 - - 21.380 0.0127 33.250 0.0117 31.380 0.00438 11.890 0.0784 21.850 0.0211 25.84 0.000887 
PH_hs_0029732 NM_006096 NDRG1 -2.003 0.157 -1.359 0.0367 1.827 0.0178 -1.729 0.133 -1.621 0.0732 2.017 0.0358 
PH_hs_0029926 - - -1.291 0.137 1.163 0.0174 -2.181 0.0185 -1.181 0.429 -1.194 0.296 -3.247 0.0150 
PH_hs_0029946 NM_000846 GSTA2 -1.893 0.0424 -2.450 0.00607 1.324 0.0102 -1.518 0.0973 -2.623 0.0195 1.034 0.724 
PH_hs_0029964 - - 1.403 0.146 1.324 0.0167 2.821 0.0352 1.664 0.0491 1.701 0.0270 3.607 0.00194 
PH_hs_0029983 NM_153699 GSTA5 -1.829 0.185 -2.523 0.0188 1.204 0.234 -1.448 0.0930 -2.149 0.0176 1.501 0.241 
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PH_hs_0030079 - - 1.253 0.196 1.109 0.269 -2.537 0.00406 1.048 0.539 -1.256 0.0386 -3.891 0.00849 
PH_hs_0030089 NM_019111 HLA-DRA -1.962 0.0383 -1.355 0.0324 2.164 0.00475 -1.230 0.0962 -1.318 0.0326 2.034 0.0249 
PH_hs_0030119 NM_018357 FLJ11196 1.311 0.243 2.338 0.0402 -1.375 0.108 1.445 0.120 2.631 0.0155 -1.146 0.236 
PH_hs_0030157 NM_004815 PARG1 -1.347 0.205 -2.022 0.0193 -1.513 0.0574 -1.172 0.581 -2.233 0.0377 -1.052 0.739 
PH_hs_0030211   2.689 0.106 3.338 0.0640 1.498 0.204 2.022 0.0879 2.903 0.039 1.027 0.946 
PH_hs_0030239 NM_001332 CTNND2 1.258 0.147 -1.142 0.204 -2.865 0.00705 -1.047 0.731 -1.083 0.414 -2.970 0.0126 
PH_hs_0030259 NM_005504 BCAT1 1.516 0.0497 1.897 0.0114 -2.702 0.0219 1.216 0.388 1.166 0.355 -2.441 0.0355 
PH_hs_0030302 NM_005338 HIP1 1.240 0.231 1.021 0.471 -3.509 0.0105 -1.008 0.845 1.364 0.0432 -2.518 0.0295 
PH_hs_0030600   -2.259 0.0548 -2.300 0.00696 -2.704 0.000790 -1.709 0.0822 -1.684 0.0550 -2.449 0.00945 
PH_hs_0030754 NM_000187 HGD 2.666 0.0696 3.596 0.0135 1.925 0.0186 2.258 0.101 3.139 0.0545 1.755 0.0788 
PH_hs_0030871 NM_005130 FGFBP1 -1.520 0.0434 -1.886 0.0131 3.020 0.00933 -1.335 0.0561 -1.969 0.00670 3.506 0.000887 
PH_hs_0030881 NM_002309 LIF -1.318 0.395 -1.754 0.0936 3.153 0.0149 -1.066 0.808 -1.230 0.335 3.086 0.0374 
PH_hs_0030898 NM_032932 RAB11FIP4 -1.785 0.0126 -2.104 0.0159 -2.379 0.0153 -1.991 0.0561 -2.428 0.0175 -2.265 0.0819 
PH_hs_0030903 NM_012121 CDC42EP4 1.116 0.428 -1.076 0.527 -2.064 0.0136 -1.219 0.276 -1.062 0.547 -2.088 0.0132 
PH_hs_0030926 NM_015892 GALNAC4S
-6ST 
-1.062 0.573 1.569 0.0223 2.583 0.0174 -1.035 0.908 1.172 0.437 2.065 0.0545 
PH_hs_0031064 NM_018393 FLJ11336 -1.053 0.784 -1.397 0.0297 2.190 0.00622 -1.313 0.304 -1.308 0.1480 2.328 0.0200 
PH_hs_0031078 XM_378178 MGC9913 -1.279 0.233 -1.030 0.792 -2.026 0.00772 -1.190 0.223 -1.007 0.933 -2.226 0.0821 
PH_hs_0031089 NM_020129 LGALS14 -3.614 0.0611 -5.705 0.00789 -3.045 0.00645 -2.712 0.0173 -5.202 0.0165 -5.014 0.0112 
PH_hs_0031096 NM_207387 FLJ35696 1.561 0.125 1.680 0.0204 -2.083 0.00697 1.359 0.193 1.941 0.0301 -2.243 0.0199 
PH_hs_0031238 NM_002986 CCL11 -1.792 0.0567 -2.287 0.0127 -12.21 0.00229 -1.357 0.393 -3.337 0.0742 -13.62 0.000887 
PH_hs_0031245 NM_030913 SEMA6C -1.176 0.101 -1.095 0.223 -2.441 0.00670 -1.165 0.271 -1.117 0.167 -3.071 0.0132 
PH_hs_0031365 NM_002925 RGS10 -1.328 0.193 -1.075 0.465 -3.078 0.00935 -1.251 0.304 -1.644 0.0591 -3.901 0.00964 
PH_hs_0031396 NM_001683 ATP2B2 -3.611 0.0193 -3.663 0.0116 -9.902 0.00292 -2.786 0.0820 -2.409 0.0101 -11.360 0.000887 
PH_hs_0031496 NM_003633 ENC1 -1.391 0.0408 -2.776 0.0143 1.044 0.462 -1.595 0.113 -2.180 0.0141 1.326 0.0337 
PH_hs_0031510 NM_198147 LOC116236 1.155 0.503 1.191 0.194 2.135 0.0141 1.078 0.403 1.331 0.148 2.359 0.0198 
PH_hs_0031568 NM_003088 FSCN1 1.402 0.0749 1.823 0.0228 -2.171 0.0139 1.441 0.216 1.496 0.0681 -3.317 0.00945 
PH_hs_0031572 NM_002237 KCNG1 1.268 0.133 1.710 0.0119 -6.467 0.00726 1.522 0.0415 2.489 0.0133 -4.188 0.00151 
PH_hs_0031600 NM_003116 SPAG4 1.214 0.313 1.529 0.0230 2.301 0.00446 1.164 0.233 1.456 0.0166 2.200 0.00286 
PH_hs_0031608 NM_014474 SMPDL3B -1.382 0.148 -1.402 0.103 -2.420 0.0113 -1.241 0.269 -1.161 0.200 -2.250 0.0150 
PH_hs_0031658 NM_024605 ARHGAP10 1.032 0.804 1.061 0.151 2.795 0.00109 -1.029 0.692 -1.009 0.885 2.089 0.0119 
PH_hs_0031712 NM_013253 RIG 1.314 0.291 1.877 0.0343 -2.124 0.0298 -1.097 0.485 1.376 0.0580 -2.806 0.00455 
PH_hs_0031749 NM_012168 FBXO2 1.603 0.0523 3.340 0.00371 1.966 0.0331 1.553 0.156 2.086 0.0323 1.401 0.0913 
PH_hs_0031870 NM_015385 SORBS1 1.353 0.129 1.122 0.354 -4.333 0.00438 1.290 0.214 1.294 0.107 -3.026 0.0199 
PH_hs_0031884 NM_000067 CA2 -2.111 0.0344 -2.576 0.0143 -1.252 0.0450 -2.926 0.0165 -2.120 0.0113 -1.094 0.0908 
PH_hs_0031932 NM_002264 KPNA1 1.165 0.231 -1.172 0.138 -3.475 0.00763 1.014 0.782 1.195 0.0900 -2.476 0.0124 
PH_hs_0032059 NM_005434 BENE 1.123 0.213 -1.298 0.0707 3.210 0.00124 1.318 0.126 1.249 0.0386 5.507 0.000887 
PH_hs_0032109 NM_004566 PFKFB3 -1.087 0.442 -1.282 0.0975 2.845 0.00940 1.018 0.937 -1.226 0.225 3.227 0.0149 
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PH_hs_0032238 NM_152305 MDS010 -1.031 0.773 -1.469 0.0263 -3.329 0.00609 -1.347 0.153 -1.123 0.0694 -2.711 0.0434 
PH_hs_0032260 NM_052942 GBP5      1.374 0.0899      1.522 0.0136     -2.844 0.000590      1.432      0.120      2.321  0.0113    -1.876 0.0249 
PH_hs_0032264 NM_003530 HIST1H3D -1.706 0.0431 -2.177 0.0179 -1.497 0.0347 -1.520 0.317 -2.006 0.0071 -1.147 0.190 
PH_hs_0032279 NM_201535 NDRG2 -1.203 0.248 -1.146 0.132 2.557 0.00583 -1.188 0.195 -1.014 0.852 2.006 0.00955 
PH_hs_0032346 NM_152282 ACPL2 -1.146 0.179 -1.649 0.0256 -7.768 0.0110 -1.178 0.144 1.005 0.950 -4.322 0.0198 
PH_hs_0032385 NM_005969 NAP1L4 1.081 0.573 -1.404 0.105 -3.825 0.00444 -1.026 0.877 1.149 0.0900 -2.215 0.0254 
PH_hs_0032398 NM_006952 UPK1B -1.363 0.0447 -3.571 0.00468 1.629 0.00639 -1.658 0.084 -3.105 0.00942 1.543 0.0139 
PH_hs_0032470 XM_292021 LOC341346 1.290 0.111 1.335 0.0243 13.170 0.000651 1.273 0.0519 1.250 0.0560 11.48 0.000767 
PH_hs_0032478 NM_005574 LMO2 -1.625 0.0746 -1.560 0.00650 4.586 0.00101 -1.540 0.108 -1.244 0.136 6.057 0.0124 
PH_hs_0032525 NM_133455 EMID1 -1.378 0.332 -1.000 0.999 -3.923 0.0133 -1.623 0.0561 -1.336 0.102 -4.347 0.0232 
PH_hs_0032565 NM_000699 AMY2A -1.143 0.706 -1.027 0.801 -2.201 0.00755 -1.768 0.211 -2.121 0.0900 -4.670 0.0200 
PH_hs_0032566 NM_014431 KIAA1274 -2.242 0.0570 -1.875 0.0268 -1.783 0.0199 -2.026 0.130 -1.890 0.0155 -2.014 0.0396 
PH_hs_0032595 NM_000610 CD44 2.022 0.158 1.642 0.0129 3.059 0.00609 1.295 0.314 1.327 0.0824 2.214 0.0677 
PH_hs_0032710 NM_018476 BEX1 1.010 0.878 1.109 0.199 -2.738 0.00202 -1.052 0.692 -1.009 0.776 -3.123 0.0153 
PH_hs_0032764 NM_033445 HIST3H2A -2.884 0.0436 -2.589 0.0126 -2.174 0.00318 -2.086 0.0561 -1.886 0.0291 -1.545 0.0345 
PH_hs_0032872 NM_000900 MGP -5.607 0.0298 -15.120 0.000692 2.268 0.00152 -2.930 0.0196 -13.840 0.00334 2.129 0.00831 
PH_hs_0032879 NR_001296 PRSS2 -1.157 0.491 -1.060 0.665 -3.247 0.00732 -1.045 0.934 -1.231 0.569 -3.620 0.0915 
PH_hs_0032897 NM_003872 NRP2 -1.213 0.393 -1.636 0.0537 5.176 0.00313 -1.125 0.667 -1.557 0.150 5.435 0.0201 
PH_hs_0032959 NM_021034 IFITM3 -1.273 0.142 1.008 0.934 -2.307 0.00863 -1.176 0.268 1.042 0.561 -2.621 0.00589 
PH_hs_0032990 XM_370724 C13orf21 1.384 0.0687 1.415 0.0519 -2.108 0.00726 1.207 0.271 1.145 0.353 -2.180 0.0458 
PH_hs_0033042 NM_015286 DMN 2.310 0.0961 1.941 0.00607 4.558 0.000902 1.420 0.205 1.493 0.0304 2.572 0.0786 
PH_hs_0033092 NM_002510 GPNMB 1.298 0.0703 1.736 0.0349 2.574 0.00710 1.252 0.202 1.853 0.0443 3.372 0.00676 
PH_hs_0033096 NM_002037 FYN 1.633 0.0772 1.874 0.0525 -2.369 0.0155 1.164 0.282 2.201 0.0176 -1.926 0.148 
PH_hs_0033101 NM_004083 DDIT3 2.126 0.0855 3.928 0.00607 1.286 0.0468 2.309 0.0519 3.794 0.0214 1.073 0.449 
PH_hs_0033119 XM_171078 LOC255324 -1.058 0.754 1.010 0.819 3.595 0.00494 1.129 0.428 1.317 0.0629 2.702 0.0119 
PH_hs_0033196 NM_005823 MSLN -1.362 0.179 -1.235 0.0548 -6.842 0.00301 -1.140 0.144 -1.150 0.0888 -4.694 0.0167 
PH_hs_0033323 NM_006271 S100A1 -1.144 0.483 -1.261 0.235 2.885 0.0219 -1.276 0.0939 -1.063 0.450 2.911 0.00556 
PH_hs_0033367 NM_021199 SQRDL 1.456 0.250 1.448 0.0366 3.882 0.00333 1.187 0.271 1.129 0.0717 4.072 0.00719 
PH_hs_0033374 NM_002771 PRSS3 -1.095 0.516 -1.220 0.145 -3.109 0.0100 -1.095 0.594 -1.172 0.274 -4.105 0.0197 
PH_hs_0033390 NM_000690 ALDH2 1.948 0.0875 2.511 0.0105 1.348 0.0189 1.943 0.0384 2.665 0.0184 1.344 0.0279 
PH_hs_0033480 NM_003613 CILP -2.919 0.0245 -3.614 0.0074 2.190 0.0171 -1.869 0.0230 -1.943 0.0260 2.746 0.00526 
PH_hs_0033599 XM_371429 KIAA1666 1.579 0.157 2.684 0.0235 1.870 0.0605 1.253 0.432 2.150 0.0176 1.497 0.136 
PH_hs_0033908 NM_003681 PDXK 1.238 0.0686 1.474 0.0368 2.454 0.00541 1.328 0.205 1.568 0.0271 2.198 0.00359 
PH_hs_0034019 NM_030758 OSBP2 -1.718 0.182 -1.853 0.0127 4.144 0.00611 -2.252 0.105 -3.294 0.0433 2.955 0.0243 
PH_hs_0034059 NM_033069 C6orf114 -1.769 0.244 -2.409 0.0207 1.093 0.119 -1.646 0.180 -2.717 0.0293 1.068 0.692 
PH_hs_0034096 XM_379623 LOC401492 -1.082 0.478 -1.294 0.0796 -4.782 0.00308 -1.145 0.159 -1.136 0.186 -3.565 0.0438 
PH_hs_0034256 XM_211090 LOC283587 -1.214 0.380 1.041 0.813 3.508 0.0189 1.274 0.563 1.017 0.962 6.182 0.0294 
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PH_hs_0034360 XM_371141 LOC388508 1.298 0.217 1.284 0.138 2.731 0.00798 1.150 0.478 1.083 0.571 2.233 0.0236 
PH_hs_0034471 NM_001004
441 
DP58 -1.280 0.0283 -1.745 0.0193 -3.797 0.00477 -1.341 0.186 -1.369 0.0280 -3.439 0.00534 
PH_hs_0034684 NM_003518 HIST1H2BG -3.916 0.0665 -3.785 0.00755 -2.815 0.00821 -2.389 0.0519 -2.486 0.0235 -2.221 0.0445 
PH_hs_0034753 XM_498675 LOC440449 -2.238 0.0312 -1.911 0.00924 5.068 0.00059 -1.450 0.0666 -1.595 0.0195 4.997 0.000887 
PH_hs_0035407 NM_024610 HSPBAP1 1.099 0.186 -1.006 0.887 -2.761 0.00194 -1.041 0.802 1.105 0.110 -2.284 0.00324 
PH_hs_0035435 NM_021194 SLC30A1 2.048 0.0383 1.679 0.0117 2.255 0.0109 1.852 0.0934 1.570 0.0552 2.615 0.0151 
PH_hs_0035466 NM_003739 AKR1C3 22.34 0.0397 35.99 0.00607 29.39 0.00059 14.23 0.0519 23.250 0.00942 19.950 0.00324 
PH_hs_0035585 NM_052813 CARD9 1.256 0.434 -1.055 0.718 3.524 0.0108 1.417 0.255 1.080 0.654 3.451 0.0154 
PH_hs_0035694 NM_152663 RALGPS2 2.145 0.0766 2.230 0.0387 2.040 0.0319 1.479 0.115 1.684 0.0300 2.627 0.0255 
PH_hs_0035772 NM_002982 CCL2 -1.801 0.0245 -2.334 0.00608 -11.470 0.000651 -1.318 0.162 -2.328 0.0148 -18.140 0.000887 
PH_hs_0035781 NM_002276 KRT19 -2.453 0.0720 -1.905 0.0180 2.044 0.00992 -2.145 0.140 -2.405 0.0352 1.615 0.0657 
PH_hs_0035830 XM_047499 LOC149603 1.202 0.133 1.016 0.755 -2.146 0.00647 1.305 0.138 2.079 0.0148 1.105 0.249 
PH_hs_0035877 NM_138373 MYADM 1.179 0.227 1.155 0.154 2.421 0.00598 1.205 0.493 1.856 0.0777 2.717 0.0519 
PH_hs_0035912 XM_498994 LOC441062 1.378 0.199 2.046 0.0133 6.399 0.00109 1.682 0.185 1.986 0.0413 6.676 0.00726 
PH_hs_0035989 NM_005241 EVI1 -1.523 0.0605 -1.273 0.0806 2.593 0.00394 -1.764 0.153 -1.767 0.0817 2.149 0.0280 
PH_hs_0036005 NM_003153 STAT6 1.209 0.245 1.234 0.0807 2.240 0.00691 1.395 0.281 1.678 0.106 2.311 0.0413 
PH_hs_0036058 NM_000598 IGFBP3 -2.392 0.0495 -4.327 0.0091 1.277 0.127 -2.187 0.0718 -3.395 0.0155 1.618 0.0704 
PH_hs_0036148 XM_044166 LOC92312 1.013 0.922 -1.204 0.0683 -2.094 0.00350 1.104 0.233 -1.158 0.0140 -2.431 0.0813 
PH_hs_0036211 NM_003983 SLC7A6 1.824 0.176 1.355 0.317 2.143 0.0761 1.358 0.161 1.435 0.0587 2.558 0.0198 
PH_hs_0036464 AK096819 SLC2A9 -2.220 0.0447 -2.157 0.0230 -1.855 0.0295 -1.949 0.0728 -2.168 0.0238 -1.518 0.0485 
PH_hs_0036468 AK096267 LOC90525 1.497 0.0787 1.739 0.0338 -2.033 0.0100 1.314 0.165 1.287 0.237 -2.484 0.0742 
PH_hs_0036576 BC028572 DKFZp761A
132 
1.851 0.179 2.301 0.0349 1.522 0.0437 1.704 0.133 2.251 0.0285 2.020 0.0460 
PH_hs_0036714 AK123310 GA17 -1.083 0.623 -2.389 0.289 2.141 0.0200 -1.284 0.354 -2.180 0.0250 1.231 0.138 
PH_hs_0036776 AK097245 CLC 1.927 0.0952 1.756 0.0135 3.790 0.00598 2.307 0.0519 1.650 0.0282 2.951 0.00365 
PH_hs_0036845 BC040486 ZFP90 1.065 0.657 1.317 0.034 -2.214 0.00726 1.037 0.830 1.255 0.0757 -2.439 0.00584 
PH_hs_0037071 CR593560 LOC440934 -1.711 0.0572 -2.132 0.0136 1.000 0.996 -1.482 0.153 -2.178 0.0205 -1.015 0.901 
PH_hs_0037182 AF131784 RAB27B -1.628 0.235 -2.060 0.0383 1.307 0.0375 -1.798 0.221 -2.233 0.0845 1.330 0.329 
PH_hs_0037318 BG354579 CBX2 -1.048 0.516 1.051 0.371 -2.051 0.00331 -1.050 0.454 1.093 0.159 -2.130 0.00419 
PH_hs_0037434 AK125888 FBXO32 -1.962 0.0829 -3.150 0.00468 -1.383 0.0457 -1.595 0.101 -2.940 0.0385 -1.077 0.656 
PH_hs_0037781 NM_016577 RAB6B -1.063 0.402 1.644 0.0126 -2.169 0.0470 -1.369 0.330 -1.092 0.632 -4.515 0.0206 
PH_hs_0037802 BX640888 GPC6 1.461 0.164 1.896 0.0450 -6.335 0.0148 1.009 0.956 1.171 0.118 -10.740 0.00556 
PH_hs_0037912 AK124907 TMOD2 -1.142 0.698 -1.001 0.995 -4.233 0.00675 -1.973 0.134 -2.531 0.0454 -5.951 0.0125 
PH_hs_0037948 AK091102 MGC11082 2.615 0.0262 3.300 0.0105 1.188 0.0945 2.277 0.0519 2.755 0.0127 1.267 0.281 
PH_hs_0038086 AL355708 LOC388134 -1.379 0.0312 -1.144 0.103 -2.638 0.00209 -1.104 0.205 -1.028 0.677 -2.642 0.00359 
PH_hs_0038111 AK098422 FLJ36031 1.048 0.672 -1.139 0.201 -2.754 0.00398 -1.022 0.922 -1.057 0.662 -2.352 0.0251 
PH_hs_0038263 BC022980 LOC202451 1.500 0.0257 1.852 0.0228 3.447 0.00263 1.269 0.263 1.513 0.0477 2.682 0.0226 
PH_hs_0038290 AB028952 SYNPO -1.819 0.0611 -2.101 0.0127 -2.540 0.00978 -1.626 0.0906 -1.773 0.0509 -2.239 0.0124 
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PH_hs_0038537 XM_375747 LOC400759 -1.416 0.183 -2.372 0.0135 -4.986 0.00459 -1.638 0.222 -2.232 0.101 -3.321 0.0121 
PH_hs_0038844 XM_499353 LOC401330 -1.305 0.254 -1.650 0.0116 3.524 0.00672 -1.126 0.176 1.010 0.876 4.791 0.00251 
PH_hs_0038876 NM_005953 LOC441019 3.066 0.0257 3.649 0.0105 1.370 0.0349 2.759 0.0862 3.348 0.0418 1.183 0.296 
PH_hs_0038883 BX649128 SESN3 -2.321 0.142 -1.817 0.0162 -1.061 0.539 -2.299 0.0912 -2.254 0.0355 -1.242 0.210 
PH_hs_0038919 BC030694 MYCL1 -1.835 0.0953 -1.975 0.0271 -2.139 0.0190 -2.278 0.0718 -1.776 0.0287 -2.297 0.0466 
PH_hs_0038991 NM_021123 GAGE7 1.029 0.867 1.002 0.977 8.032 0.000902 -1.027 0.882 -1.102 0.425 6.986 0.0132 
PH_hs_0039790 BC042436 GPCR5A 1.551 0.0209 1.691 0.0333 4.503 0.00824 1.449 0.233 1.569 0.113 5.000 0.0234 
PH_hs_0040130 NM_002958 RYK 1.086 0.374 -1.349 0.0141 -5.643 0.00059 -1.058 0.607 1.216 0.0686 -2.642 0.0132 
PH_hs_0040288 NM_005165 ALDOC -1.037 0.854 -1.307 0.0886 2.223 0.00730 -1.267 0.309 -1.032 0.806 3.396 0.0115 
PH_hs_0040625 NM_203481 MGC70870 1.107 0.272 -1.729 0.0292 -4.082 0.00170 -1.216 0.219 1.291 0.0527 -2.662 0.255 
PH_hs_0040710 NM_002053 GBP1 -1.378 0.190 -2.983 0.00607 -4.166 0.00350 -1.712 0.0891 -1.230 0.0301 -3.751 0.00212 
PH_hs_0040800 NM_012338 TM4SF12 -2.381 0.0629 -3.318 0.00854 6.694 0.00444 -2.413 0.0666 -4.249 0.00670 4.149 0.00794 
PH_hs_0040823 AK091558 LIPA 1.313 0.520 2.570 0.0813 3.075 0.0480 2.211 0.257 3.139 0.104 3.965 0.0778 
PH_hs_0040930 NM_001874 CPM -3.562 0.0665 -8.712 0.0327 -1.130 0.0546 -3.466 0.0520 -3.752 0.0101 -1.103 0.291 
PH_hs_0041072 NM_016577 RAB6B 1.229 0.270 1.138 0.359 -2.985 0.0171 -1.075 0.718 1.212 0.0816 -2.696 0.0182 


















Summary of Function 
PH_hs_0035466 NM_003739 AKR1C3* 24.670 Electron transport 
PH_hs_0027536 NM_030754 SAA2 15.865 - 
PH_hs_0005148 NM_016352 CPA4 13.980 Histone acetylation 
PH_hs_0005671 NM_002317 LOX 13.740 Signal transduction 
PH_hs_0004352 NM_000591 CD14 13.490 Apoptosis; immune response 
PH_hs_0011943 NM_002133 HMOX1 12.550 Oxidative Stress response 
PH_hs_0032470 XM_292021 LOC341346 12.325 - 
PH_hs_0001558 NM_004753 DHRS3 12.220 Cellular metabolism 
PH_hs_0011511 NM_004751 GCNT3 11.485 Cellular metabolism 
PH_hs_0004409 NM_000689 ALDH1A1 10.365 Cellular metabolism 
PH_hs_0026808 NM_006512 SAA4 10.003 Lipid transporter 
PH_hs_0024170 NM_002272 KRT4 9.748 Cytoskeleton; cell communication 
PH_hs_0004996 NM_002110 HCK 7.912 Kinase 
PH_hs_0038991 NM_021123 GAGE7 7.509 - 
PH_hs_0019619 NM_002964 S100A8 7.344 Calcium ion binding 
PH_hs_0022372 NM_001275 CHGA 7.201 Calcium ion binding 
PH_hs_0014156 NM_000930 PLAT 7.109 Proteolysis; PDGF signalling 
PH_hs_0035912 XM_498994 LOC441062 6.538 - 
PH_hs_0005514 NM_032717 MGC11324 6.399 Cellular metabolism 
PH_hs_0002314 NM_183240 TMEM37 5.971 Ion transporter 
PH_hs_0005421 NM_153362 PRSS35 5.923 Proteolysis 
PH_hs_0000100 NM_002164 INDO 5.826 Metal ion binding 
PH_hs_0008826 NM_001445 FABP6 5.730 Cell proliferation 
PH_hs_0004098 NM_152673 MUC20 5.605 Protein oligomerization 
PH_hs_0000235 NM_000575 IL1A 5.533 Cell growth; apoptosis 
PH_hs_0024398 NM_004207 SLC16A3 5.509 Anion transporter 
PH_hs_0040800 NM_012338 TM4SF12 5.422 - 
PH_hs_0032478 NM_005574 LMO2 5.322 Metal ion binding 
PH_hs_0032897 NM_003872 NRP2 5.306 Cell differentiation 
PH_hs_0000953 NM_016267 VGLL1 5.299 Transcription regulation 
PH_hs_0002935 NM_001741 CALCA 5.297 Cell signalling 
PH_hs_0024092 NM_007129 ZIC2 5.170 Cell differentiation 
PH_hs_0025524 NM_203447 DOCK8 5.091 GTP and GTPAse binding 
PH_hs_0006947 AK097496 LOC283352 5.065 - 
PH_hs_0007104 NM_022119 PRSS22 5.061 Proteolysis 
PH_hs_0011503 NM_003979 GPCR5A 5.058 Signal transduction 
PH_hs_0011690 NM_005458 GPR51 5.050 Signal transduction 
PH_hs_0034753 XM_498675 LOC440449 5.033 - 
PH_hs_0026823 NM_004613 TGM2 4.964 Cell adhesion; cell signalling 
PH_hs_0022469 NM_005715 UST 4.897 Enzyme 
PH_hs_0004577 XM_027236 TTC9 4.883 - 
PH_hs_0034256 XM_211090 LOC283587 4.845 - 
PH_hs_0039790 BC042436 GPCR5A 4.752 Signal transduction 
PH_hs_0027323 NM_024909 C6orf134 4.671 - 
PH_hs_0005870 NM_032034 SLC4A11 4.641 Anion transporter 
PH_hs_0006395 NM_020299 AKR1B10 4.486 Cellular metabolism 
PH_hs_0012806 NM_005725 TSPAN-2 4.374 Cell proliferation; cell adhesion 
PH_hs_0032059 NM_005434 BENE 4.359 Protein binding 
PH_hs_0001536 NM_007150 ZNF185 4.353 - 
PH_hs_0024961 NM_001565 CXCL10 4.315 Cell signalling 
PH_hs_0026843 NM_024896 KIAA1815 4.311 Proteolysis; metal ion binding 
PH_hs_0025875 NM_002589 PCDH7 4.220 Cell adhesion 
PH_hs_0023764 NM_002061 GCLM 4.170 Glutathione metabolism, oxidative stress 
response 




# Average fold change represents the mean fold change value obtained from averaging the fold change for 
Batch A and Batch B   
 















Summary of Function 
PH_hs_0038844 XM_499353 LOC401330 4.158 - 
PH_hs_0002434 BM709175 HSU79275 4.132 - 
PH_hs_0022632 NM_007361 NID2 4.119 Cell adhesion 
PH_hs_0000458 NM_152523 FLJ40432 4.108 Cell cycle 
PH_hs_0000305 NM_002425 MMP10 4.036 Metalloproteinase; cell signalling 
PH_hs_0005065 NM_004695 SLC16A5 4.030 Anion transporter 
PH_hs_0023550 NM_004665 VNN2 3.999 Hydrolase 
PH_hs_0016124 NM_002231 KAI1 3.996 Protein binding 
PH_hs_0033367 NM_021199 SQRDL 3.977 - 
PH_hs_0027214 NM_003843 SCEL 3.920 Metal ion binding; protein binding 
PH_hs_0025588 NM_020453 ATP10D 3.893 Cation transporter 
PH_hs_0014290 NM_000611 CD59 3.871 Immune response 
PH_hs_0027200 BC010607 MGC18216 3.854 Antiapoptosis; insulin receptor signalling 
PH_hs_0026522 NM_002627 PFKP 3.834 Cellular metabolism 
PH_hs_0003007 NM_005727 TSPAN-1 3.798 Cell proliferation 
PH_hs_0000598 NM_005476 GNE 3.741 Cell adhesion; cell metabolism 
PH_hs_0001407 NM_002655 PLAG1 3.693 Metal ion binding 
PH_hs_0002731 NM_002194 INPP1 3.685 Signal transduction 
PH_hs_0001390 NM_002395 ME1 3.661 Cellular metabolism 
PH_hs_0006160 NM_002965 S100A9 3.643 Cell signalling 
PH_hs_0002227 NM_004633 IL1R2 3.551 Immune response 
PH_hs_0034019 NM_030758 OSBP2 3.549 Lipid transport 
PH_hs_0006423 NM_181785 LOC283537 3.515 - 
PH_hs_0012708 NM_031422 CHST9 3.597 Proteolysis 
PH_hs_0035585 NM_052813 CARD9 3.488 Apoptosis; cell signalling 
PH_hs_0019591 NM_019894 TMPRSS4 3.479 Proteolysis 
PH_hs_0013167 NM_023926 MTNR1A 3.399 Signal transduction 
PH_hs_0020084 NM_018413 CHST11 3.391 Carbohydrate metabolism 
PH_hs_0036776 AK097245 CLC* 3.371 Apoptosis; cell signaling; cell 
differentiation 
PH_hs_0029016 NM_000227 LAMA3 3.288 Cell migration; cell adhesion 
PH_hs_0014783 NM_015894 STMN3 3.278 Signal transduction 
PH_hs_0027162 NM_002394 SLC3A2 3.268 Transporter 
PH_hs_0030871 NM_005130 FGFBP1 3.263 Cell proliferation; signal transduction 
PH_hs_0028763 NM_018389 SLC35C1 3.256 Transporter 
PH_hs_0004694 NM_000877 IL1R1 3.252 Cytokine signaling; immune response 
PH_hs_0000152 NM_002118 HLA-DMB 3.245 Immune response 
PH_hs_0024953 NM_032466 ASPH 3.241 Calcium ion binding 
PH_hs_0022374 NM_020169 LXN 3.201 Carboxypeptidase inhibitor 
PH_hs_0033119 XM_171078 LOC255324 3.149 - 
PH_hs_0030881 NM_002309 LIF 3.119 Cell signalling; immune response 
PH_hs_0026357 NM_023938 SARG 3.100 - 
PH_hs_0010092 NM_000149 FUT3 3.092 Cellular metabolism 
PH_hs_0004062 NM_000474 TWIST1 3.092 Cell differentiation 
PH_hs_0000006 NM_000952 PTAFR 3.067 Cell signalling 
PH_hs_0038263 BC022980 LOC202451 3.065 - 
PH_hs_0032109 NM_004566 PFKFB3 3.036 Cellular metabolism 
PH_hs_0023411 NM_138451 IQCD 3.023 Glycolysis 
PH_hs_0007351 NM_001165 BIRC3 3.001 Antiapoptosis 
PH_hs_0000909 NM_006105 RAPGEF3  2.996 Cell proliferation 
PH_hs_0025826 NM_000904 NQO2 2.991 Oxidative stress response; electron 
transport 
PH_hs_0006549 NM_004480 FUT8 2.974 Cellular metabolism 
PH_hs_0033092 NM_002510 GPNMB 2.973 Cell adhesion; cell proliferation 
PH_hs_0003939 NM_001993 F3 2.962 Blood coagulation; immune response 




# Average fold change represents the mean fold change value obtained from averaging the fold change for 
Batch A and Batch B   















Summary of Function 
PH_hs_0033323 NM_006271 S100A1 2.898 Cell signalling 
PH_hs_0009300 NM_001236 CBR3 2.886 Cellular metabolism 
PH_hs_0003342 NM_001248 ENTPD3 2.868 Cellular metabolism 
PH_hs_0027093 NM_005704 PTPRU 2.857 Cell adhesion; signal transduction 
PH_hs_0025057 NM_000350 ABCA4 2.844 Transporter 
PH_hs_0009600 NM_003857 GALR2 2.825 Signal transduction 
PH_hs_0040288 NM_005165 ALDOC* 2.809 Cellular metabolism 
PH_hs_0003982 NM_003227 TFR2 2.771 Metal transport 
PH_hs_0002700 NM_013370 OKL38 2.756 Cell growth and differentiation 
PH_hs_0003822 NM_006557 DMRT2 2.739 Transcription factor 
PH_hs_0000382 NM_021147 UNG2 2.726 Cell cycle 
PH_hs_0004661 NM_002961 S100A4 2.724 Calcium binding; protein binding 
PH_hs_0012389 NM_144590 ANKRD22 2.719 - 
PH_hs_0004472 NM_015158 ANKRD15 2.716 Cell cycle 
PH_hs_0019818 NM_003662 PIR 2.692 Cellular transcription 
PH_hs_0027041 NM_002423 MMP7 2.649 Metalloproteinase; tumor progression and 
metastasis 
PH_hs_0024448 NM_003730 RNASET2 2.589 RNA catabolism 
PH_hs_0004629 NM_002371 MAL 2.587 Apoptosis; cell differentiation 
PH_hs_0001733 NM_001902 CTH 2.572 Amino acid synthesis 
PH_hs_0005982 NM_005689 ABCB6 2.569 Transporter 
PH_hs_0003767 NM_023915 GPR87 2.569 Signal transduction 
PH_hs_0027024 NM_000359 TGM1 2.545 Protein binding;  
calcium ion binding 
PH_hs_0000249 NM_002633 PGM1 2.537 Cellular metabolism 
PH_hs_0004626 NM_002275 KRT15 2.535 Cytoskeletal component; cell 
communication 
PH_hs_0001148 NM_024554 PGBD5 2.533 - 
PH_hs_0022370 NM_172373 ELF1 2.521 Transcription factor 
PH_hs_0020591 NM_153233 FLJ36445 2.508 - 
PH_hs_0022944 NM_006867 RBPMS 2.508 Protein binding; RNA binding 
PH_hs_0008291 NM_053276 VIT 2.508 - 
PH_hs_0024837 NM_004304 ALK 2.501 Cell signalling 
PH_hs_0000211 NM_000861 HRH1 2.486 Cell signalling; inflammatory response 
PH_hs_0034360 XM_371141 LOC388508 2.482 - 
PH_hs_0007485 NM_022089 HSA9947 2.480 Transporter 
PH_hs_0026095 NM_022036 GPRC5C 2.469 Signal transduction 
PH_hs_0033480 NM_003613 CILP 2.468 Nucleoside metabolism 
PH_hs_0006823 NM_173660 FLJ33718 2.463 Protein binding 
PH_hs_0025607 NM_004998 MYO1E 2.461 Calmodulin binding ; nucleotide binding 
PH_hs_0027088 NM_031430 RILP 2.449 Protein transport 
PH_hs_0031658 NM_024605 ARHGAP10 2.442 Signal transduction 
PH_hs_0035435 NM_021194 SLC30A1 2.435 Cation transporter 
PH_hs_0000440 NM_014403 SIAT7D 2.426 - 
PH_hs_0027127 NM_004282 BAG2 2.420 Antiapoptosis; protein binding 
PH_hs_0003985 NM_004392 DACH1 2.398 Transcription factor 
PH_hs_0022999 NM_003567 BCAR3 2.395 Cell cycle 
PH_hs_0020618 NM_000228 LAMB3 2.389 Cell adhesion; protein binding 
PH_hs_0035989 NM_005241 EVI1 2.371 Cell proliferation; transcription 
regulation 
PH_hs_0011502 NM_003976 ARTN 2.369 Signal transduction 
PH_hs_0017058 NM_145280 LOC151194 2.354 - 
PH_hs_0006124 NM_003890 FCGBP 2.348 Cell adhesion 
PH_hs_0000449 NM_006499 LGALS8 2.347 Sugar binding 
PH_hs_0020456 NM_138768 MYEOV 2.337 - 




# Average fold change represents the mean fold change value obtained from averaging the fold change for 
Batch A and Batch B   














Summary of Function 
PH_hs_0019988 XM_0395153 G2 2.336 - 
PH_hs_0035694 NM_152663 RALGPS2 2.334 Signal transduction 
PH_hs_0033908 NM_003681 PDXK 2.326 Metal ion binding 
PH_hs_0005127 NM_004598 SPOCK 2.318 Cell proliferation; cell adhesion 
PH_hs_0025701 NM_017842 FLJ20489 2.312 - 
PH_hs_0009153 NM_005923 MAP3K5 2.302 Apoptosis; Mapkkk signalling  
PH_hs_0012796 NM_004925 AQP3 2.295 Transporter 
PH_hs_0032279 NM_201535 NDRG2 2.282 Cell differentiation 
PH_hs_0036005 NM_003153 STAT6 2.276 Apoptosis; signal transduction 
PH_hs_0031064 NM_018393 FLJ11336 2.259 - 
PH_hs_0031600 NM_003116 SPAG4 2.251 Cytoskeletal component 
PH_hs_0016000 NM_182920 ADAMTS9 2.249 Proteolysis 
PH_hs_0031510 NM_198147 LOC116236 2.247 - 
PH_hs_0025342 NM_153365 FLJ90013 2.242 - 
PH_hs_0012041 NM_020467 LOC57228 2.238 - 
PH_hs_0005010 NM_000120 EPHX1 2.223 Detoxification 
PH_hs_0025967 NM_003937 KYNU 2.206 Cellular metabolism 
PH_hs_0000788 NM_002005 FES 2.205 Cell proliferation; cell signalling 
PH_hs_0025324 NM_182729 TXNRD1 2.203 Oxidative stress response 
PH_hs_0032872 NM_000900 MGP 2.199 Cell differentiation; ECM component 
PH_hs_0022977 NM_153811 SLC38A6 2.191 - 
PH_hs_0001383 NM_006332 IFI30 2.190 Immune response 
PH_hs_0007227 NM_025045 FLJ22582 2.189 - 
PH_hs_0012825 NM_016354 SLCO4A1 2.189 Transporter 
PH_hs_0024845 NM_004631 LRP8 2.188 Signal transduction 
PH_hs_0022734 NM_016339 RAPGEFL1 2.169 Signal transduction 
PH_hs_0022539 NM_006384 CIB1 2.166 Apoptosis; DNA damage response 
PH_hs_0002484 NM_023935 C20orf116 2.156 - 
PH_hs_0010879 NM_001835 CLTCL1 2.126 - 
PH_hs_0004398 NM_004105 EFEMP1 2.125 Protein binding 
PH_hs_0023937 NM_006120 HLA-DMA 2.108 Immune response 
PH_hs_0030089 NM_019111 HLA-DRA 2.099 Immune response 
PH_hs_0000490 NM_001262 CDKN2C 2.091 Cell cycle 
PH_hs_0007483 NM_016240 SCARA3 2.085 Oxidative stress response 
PH_hs_0000455 NM_014294 TRAM1 2.083 Protein transport 
PH_hs_0029204 NM_001233 CAV2 2.056 Cell proliferation; protein binding 
PH_hs_0003443 NM_015187 KIAA0746 1.904 KIAA0746 protein 
PH_hs_0002286 NM_015464 SOSTDC1 -1.967 Sclerostin domain containing 1 
PH_hs_0002304 NM_014112 TRPS1 -1.969 Trichorhinophalangeal syndrome I 
PH_hs_0025088 NM_212474 FN1 -2.019 Cell signalling; cell adhesion 
PH_hs_0030903 NM_012121 CDC42EP4 -2.076 Regulation of cell shape; signal 
transduction; protein binding 
PH_hs_0003032 NM_003916 AP1S2 -2.079 Protein transport 
PH_hs_0000076 NM_000882 IL12A -2.089 -  
PH_hs_0037318 BG354579 CBX2 -2.091 Chromatin assembly 
PH_hs_0022779 NM_017664 ANKRD10 -2.117 - 
PH_hs_0004982 NM_004395 DBN1 -2.124 Cell differentiation 
PH_hs_0032990 XM_370724 C13orf21 -2.144 - 
PH_hs_0029218 NM_144684 ZNF480 -2.145 Transcription regulation 
PH_hs_0024164 XM_031553 SR140 -2.147 Nucleotide binding 
PH_hs_0025782 NM_001431 EPB41L2 -2.148 Cytosekleton organisation 
PH_hs_0015041 NM_023067 FOXL2 -2.149 Apoptosis; cell differentiation 
PH_hs_0016017 NM_182704 SELV -2.153 Oxidative stress response 
PH_hs_0004004 NM_002048 GAS1 -2.161 Cell cycle arrest 
PH_hs_0031096 NM_207387 FLJ35696 -2.163 - 
PH_hs_0004265 NM_023009 MARCKSL1 -2.179 Calmodulin binding 
PH_hs_0001026 NM_006350 FST -2.190 Cell differentiation; cell signalling 
PH_hs_0038919 BC030694 MYCL1 -2.218 Transcription regulation 
  Average fold change represents the mean fold change value obtained from averaging the fold change for 
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Batch A and Batch B   













Summary of Function 
PH_hs_0021087 NM_207436 FLJ42957 -2.224 - 
PH_hs_0005744 NM_032438 L3MBTL3 -2.233 Transcription regulation 
PH_hs_0002532 NM_024610 HSPBAP1* -2.265 HSPB associated protein 1 
PH_hs_0023568 NM_015570 AUTS2 -2.267 Endopeptidase inhibitor 
PH_hs_0019710 NM_001849 COL6A2 -2.272 Extracellular matrix component 
PH_hs_0000928 NM_031442 TM4SF10 -2.272 - 
PH_hs_0002730 NM_173672 PPIL6 -2.281 Protein folding 
PH_hs_0026765 NM_016356 DCDC2 -2.290 Cell signalling 
PH_hs_0005789 NM_007152 ZNF195 -2.301 Transcription regulation 
PH_hs_0012818 NM_023926 FLJ12895 -2.312 Transcription regulation 
PH_hs_0027161 NM_015149 RGL1 -2.319 Signal transduction 
PH_hs_0036845 BC040486 ZFP90 -2.327 Transcription regulation 
PH_hs_0031608 NM_014474 SMPDL3B -2.335 Cellular metabolism 
PH_hs_0006015 NM_006963 ZNF22 -2.343 Transcription regulation 
PH_hs_0015559 NM_207376 LOC387882 -2.345 - 
PH_hs_0010267 NM_173549 FLJ39553 -2.358 - 
PH_hs_0032260 NM_052942 GBP5 -2.360 Adaptor molecule; immunity 
PH_hs_0014044 NM_017581 CHRNA9 -2.362 Transporter 
PH_hs_0001244 XM_084578 PPFIBP2 -2.364 Adaptor protein 
PH_hs_0029418 NM_018159 NUDT11 -2.368 Signal transduction 
PH_hs_0025212 NM_015993 TM4SF11 -2.371 Transporter 
PH_hs_0003705 NM_152332 MTAC2D1 -2.379 - 
PH_hs_0017206 NM_003586 DOC2A -2.384 Transporter 
PH_hs_0038290 AB028952 SYNPO -2.389 Cytoskeleton organisation 
PH_hs_0010095 NM_003238 TGFB2 -2.390 Cell growth; cell death 
PH_hs_0004394 NM_004364 CEBPA -2.396 Transcription factor 
PH_hs_0020829 NM_018494 LRDD -2.419 Apoptosis; signal transuction 
PH_hs_0012283 NM_152742 GPC2 -2.421 - 
PH_hs_0014077 NM_000944 PPP3CA -2.421 Cell cycle 
PH_hs_0015584 NM_019558 HOXD8 -2.438 Transcription regulation 





PH_hs_0032959 NM_021034 IFITM3 -2.464 Immune response  
PH_hs_0031712 NM_013253 RIG -2.465 Signal transduction 
PH_hs_0025081 NM_016831 PER3 -2.473 - 
PH_hs_0024009 NM_002604 PDE7A -2.478 Transcription; signal transduction 
PH_hs_0019618 CR602569  - -2.481 ‐ 
PH_hs_0004817 NM_022443 MLF1 -2.481 Cell cycle arrest; cell differentiation 
PH_hs_0014556 NM_032383 HPS3 -2.493 - 
PH_hs_0024008 NM_182487 OLFML2A -2.496 - 
PH_hs_0009662 XM_499250 LFNG -2.503 - 
PH_hs_0022310 NM_004390 CTSH -2.511 Proteolysis 
PH_hs_0010138 AK023631  - -2.517 ‐ 
PH_hs_0010138 AK023631  - -2.517 ‐ 
PH_hs_0034684 NM_003518 HIST1H2BG -2.518 - 
PH_hs_0035407 NM_024610 HSPBAP1* -2.523 Protein folding and unfolding 
PH_hs_0025869 NM_014883 FAM13A1 -2.533 Signal transduction 
PH_hs_0038111 AK098422 FLJ36031 -2.553 - 
PH_hs_0023636 NM_001751 CARS -2.554 Metal ion binding 
PH_hs_0025139 NM_001449 FHL1 -2.568 Cell growth; cell differentiation 
PH_hs_0030259 NM_005504 BCAT1 -2.572 Cell cycle 
PH_hs_0013274 NM_016354 TRPC1 -2.584 Transporter 





# Average fold change represents the mean fold change value obtained from averaging the fold change for 
Batch A and Batch B   














Summary of Function 
PH_hs_0022739 XM_114303 FRMD4B -2.619 Protein binding 
PH_hs_0005182 NM_021809 TGIF2 -2.632 Transcription regulation 
PH_hs_0038086 AL355708 LOC388134 -2.640 - 
PH_hs_0003912 AK127315  - -2.644 ‐ 
PH_hs_0024713 NM_001846 COL4A2 -2.682 Extracellular matrix component 
PH_hs_0019583 NM_024430 PSTPIP2 -2.685 - 
PH_hs_0004441 NM_000345 SNCA -2.718 Antiapoptosis 
PH_hs_0031568 NM_003088 FSCN1 -2.744 Cell proliferation; cytoskeleton  
PH_hs_0000678 NM_030792 PP1665 -2.748 Cellular metabolism 
PH_hs_0031245 NM_030913 SEMA6C -2.756 Cell differentiation 
PH_hs_0020300 NM_004385 CSPG2 -2.760 Cell adhesion 
PH_hs_0014431 NM_014583 LMCD1 -2.768 Transcription regulation 
PH_hs_0012930 NM_004925 LTBP1 -2.781 TGFb singalling 
PH_hs_0025862 NM_002065 GLUL -2.788 Cellular metabolism 
PH_hs_0001061 XM_372774 DJ159A19.3 -2.796 - 
PH_hs_0005123 NM_032512 PDZK4 -2.821 Protein binding 
PH_hs_0041072 NM_016577 RAB6B -2.841 Signal transduction; vesicle transport 
PH_hs_0004307 NM_006026 H1FX -2.861 Chromosone organisation 
PH_hs_0010944 NM_013396 USP25 -2.864 Proteolysis 
PH_hs_0024758 NM_003034 SIAT8A -2.868 Metabolism; cell proliferation;  
PH_hs_0025581 NM_001845 COL4A1 -2.880 Extracellular matrix component 
PH_hs_0028942 NM_003551 NME5 -2.882 Oxidative stress response 
PH_hs_0025799 NM_001744 CAMK4 -2.893 Signal transduction 
PH_hs_0005972 NM_145244 DDIT4L -2.904 - 
PH_hs_0030239 NM_001332 CTNND2 -2.918 Signal transduction; transcription  
PH_hs_0022409 NM_032867 FLJ14966 -2.927 - 
PH_hs_0032710 NM_018476 BEX1* -2.931 Brain expressed, X-linked 1 
PH_hs_0003660 NM_003149 STAC -2.931 Cell signalling 
PH_hs_0026589 NM_145909 ZNF323 -2.944 Transcription regulation 
PH_hs_0026605 NM_006317 BASP1 -2.952 - 
PH_hs_0024930 NM_000132 F8 -2.959 Blood coagulation; cell adhesion 
PH_hs_0002640 NM_004093 EFNB2 -2.962 Cell differentiation; cell signalling 
PH_hs_0025004 NM_014234 HSD17B8 -2.975 Cellular metabolism 
PH_hs_0031932 NM_002264 KPNA1 -2.976 Karyopherin alpha 1  
PH_hs_0007344 NM_018431 DOK5 -2.981 Mapkkk signalling cascade 
PH_hs_0022138 NM_014548 TMOD2 -2.984 Tropomodulin 2 (neuronal) 
PH_hs_0030302 NM_005338 HIP1 -3.014 Apoptosis 
PH_hs_0032238 NM_152305 MDS010 -3.020 - 





PH_hs_0003661 NM_021992 TMSNB -3.069 Cytoskeleton organisation 
PH_hs_0025184 NM_024907 FBXO17 -3.074 Protein degradation 
PH_hs_0016489 NM_138287 DTX3L -3.082 Protein binding; metal ion binding 
PH_hs_0024827 NM_016105 FKBP7 -3.103 - 
PH_hs_0027908 NM_002264 KPNA1* -3.135 Protein transport; protein binding 
PH_hs_0007590 NM_001195 BFSP1 -3.144 Cytoskeleton; protein binding 
PH_hs_0025269 NM_013343 LOH3CR2A -3.150 - 
PH_hs_0011706 NM_005467 NAALAD2 -3.190 Peptidase 
PH_hs_0020408 XM_086879 LOC150371 -3.207 - 
PH_hs_0010369 AK091332  - -3.218 ‐ 
PH_hs_0000554 NM_006108 SPON1 -3.299 Cell adhesion 
PH_hs_0037781 NM_016577 RAB6B -3.342 Signal transduction; vesicle transport 





# Average fold change represents the mean fold change value obtained from averaging the fold change for 
Batch A and Batch B   















Summary of Function 
PH_hs_0016853 NM_012219 MRAS -3.436 Cell signalling 
PH_hs_0032565 NM_000699 AMY2A -3.436 Cellular metabolism 
PH_hs_0024015 AL832164 LOC283666 -3.446 - 
PH_hs_0015577 NM_018640 LMO3 -3.449 Transcription regulation 
PH_hs_0031365 NM_002925 RGS10 -3.489 Signal transduction 
PH_hs_0028098 NM_000096 CP -3.534 Transporter 
PH_hs_0026600 NM_006500 MCAM -3.548 Cell adhesion 
PH_hs_0024014 NM_003199 TCF4 -3.567 Transcription factor 
PH_hs_0024094 NM_145035 ADMP -3.583 - 
PH_hs_0024812 NM_052941 GBP4 -3.594 - 
PH_hs_0002179 NM_020925 KIAA1573 -3.600 - 
PH_hs_0033374 NM_002771 PRSS3 -3.607 Proteolysis 
PH_hs_0034471 
NM_0010044
41 DP58 -3.618 
- 
PH_hs_0031870 NM_015385 SORBS1 -3.679 Insulin receptor signalling 
PH_hs_0011493 NM_001839 CNN3 -3.740 Calmodulin binding 
PH_hs_0001811 NM_004086 COCH -3.746 Perception of sound 
PH_hs_0000691 XM_376018 KIAA1644 -3.762 - 
PH_hs_0022465 NM_031458 PARP9 -3.780 Enzyme; cell migration 
PH_hs_0008975 BG546536  - -3.802 - 
PH_hs_0020156 NM_000424 KRT5 -3.812 Cytoskeleton; protein binding 
PH_hs_0025293 NM_006097 MYL9 -3.861 Calcium ion binding 
PH_hs_0022589 NM_003986 BBOX1 -3.931 Electron transport 
PH_hs_0009360 NM_021643 TRIB2 -3.935 Regulation of MAPK activity 
PH_hs_0025272 NM_025080 ASRGL1 -3.955 Cellular metabolism 
PH_hs_0040710 NM_002053 GBP1 -3.959 Immune response 
PH_hs_0013301 NM_006580 CLDN16 -3.970 Cell adhesion; ion transport 
PH_hs_0031089 NM_020129 LGALS14 -4.029 Sugar binding 
PH_hs_0000202 NM_001552 IGFBP4 -4.034 Cell growth; cell proliferation 
PH_hs_0010807 NM_001661 ARF4L -4.035 Signal transduction 
PH_hs_0032525 NM_133455 EMID1 -4.135 Protein binding 
PH_hs_0040130 NM_002958 RYK -4.143 Signal transduction 
PH_hs_0038537 XM_375747 LOC400759 -4.154 - 
PH_hs_0034096 XM_379623 LOC401492 -4.174 - 
PH_hs_0009841 NM_007064 TRAD -4.196 Signal transduction 
PH_hs_0000763 NM_022912 C2orf23 -4.224 - 
PH_hs_0000085 NM_023105 FGFR1 -4.226 MAPKKK signalling cascade 
PH_hs_0022233 NM_022454 SOX17 -4.257 Transcription regulation 
PH_hs_0005961 NM_031455 CCDC3 -4.323 - 
PH_hs_0023602 NM_178012 MGC8685 -4.405 Protein polymerisation 
PH_hs_0026578 NM_005965 MYLK -4.440 - 
PH_hs_0003766 NM_145307 PLEKHK1 -4.448 Signal transduction 
PH_hs_0003988 NM_000313 PROS1 -4.484 Blood coagulation 
PH_hs_0020546 NM_021219 JAM2 -4.491 Cell adhesion 
PH_hs_0005583 NM_000044 AR -4.589 Cell growth; cell signalling 
PH_hs_0025250 NM_003108 SOX11 -4.633 Transcription factor 
PH_hs_0003752 NM_001448 GPC4 -4.649 Cell proliferation 
PH_hs_0000702 NM_015529 MOXD1 -4.744 Cellular metabolism 
PH_hs_0020111 NM_000597 IGFBP2 -4.849 Cell growth 
PH_hs_0008565 NM_004429 EFNB1 -4.868 Cell proliferation; cell signalling 
PH_hs_0023962 NM_052832 SLC26A7 -4.873 Transporter 
PH_hs_0026662 NM_001955 EDN1 -4.943 Cell signalling 
PH_hs_0001688 XM_378360 LOC400043 -5.055 - 
PH_hs_0022217 NM_003317 TITF1 -5.092 Transcription factor 





# Average fold change represents the mean fold change value obtained from averaging the fold change for 
Batch A and Batch B   
















Summary of Function 
PH_hs_0023739 NM_152282 ACPL2* -5.145 acid phosphatase-like 2 
PH_hs_0013732 NM_002430 MN1 -5.293 Cell cycle progression 
PH_hs_0031572 NM_002237 KCNG1 -5.328 Transporter 
PH_hs_0003518 NM_012427 KLK5 -5.375 Proteolysis 
PH_hs_0001151 NM_178496 LOC151963 -5.636 - 
PH_hs_0013028 NM_005725 TIMP3 -5.649 Apoptosis 
PH_hs_0025078 NM_001394 DUSP4 -5.744 Cell cycle; MAPKKK signalling  
PH_hs_0033196 NM_005823 MSLN -5.768 Cell adhesion 
PH_hs_0006770 NM_025216 WNT10A -5.874 Cell signalling 
PH_hs_0032346 NM_152282 ACPL2* -6.045 - 
PH_hs_0005820 NM_018004 FLJ10134 -6.191 - 
PH_hs_0003194 NM_021255 PELI2 -6.258 Protein binding 
PH_hs_0004276 NM_016083 CNR1 -6.281 Cell signalling 
PH_hs_0024509 NM_006820 IFI44L -6.359 - 
PH_hs_0028961 NM_000165 GJA1 -6.439 Cell signalling; gap junction 
PH_hs_0022302 NM_001617 ADD2 -6.742 Metalion binding 
PH_hs_0028708 NM_000346 SOX9 -6.798 Transcription factor; protein binding 
PH_hs_0000236 NM_002193 INHBB -7.272 Cell growth; cell differentiation 
PH_hs_0018787 NM_004120 GBP2 -7.310 Nucleotide binding 
PH_hs_0027279 NM_020698 KIAA1145 -7.961 - 
PH_hs_0004511 NM_003652 CPZ -8.492 Metal ion binding 
PH_hs_0037802 BX640888 GPC6 -8.538 - 
PH_hs_0019248 NM_005302 GPR37 -9.162 Signal transduction 
PH_hs_0031396 NM_001683 ATP2B2 -10.631 Calcium ion  and calmodulin binding 
PH_hs_0005906 NM_000076 CDKN1C -11.060 Cell cycle arrest 
PH_hs_0015664 NM_002982 CCL2* -11.482 Chemokine (C-C motif) ligand 2 
PH_hs_0005801 NM_007196 KLK8 -11.491 Proteolysis 
PH_hs_0031238 NM_002986 CCL11 -12.915 Immune response; cell signalling 
PH_hs_0005998 NM_004626 WNT11 -13.365 Signal transduction 
PH_hs_0035772 NM_002982 CCL2* -14.805 Antiapoptosis; signal transduction 
PH_hs_0014200 NM_002776 KLK10 -15.260 Cell cycle; proteolysis 
PH_hs_0010088 NM_014289 CAPN6 -15.400 Proteolysis 
PH_hs_0016413 NM_018476 BEX1* -16.615 Cell differentiation 
PH_hs_0002908 NM_020386 HRASLS -26.365 - 





# Average fold change represents the mean fold change value obtained from averaging the fold change for 
Batch A and Batch B   
* Gene with duplicated probe 
 
 
